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The book Renal Failure – The Facts consists of some facts about diagnosis, 
etiopathogenis and treatment of acute and chronic renal failure. Acute, as well as 
chronic renal failure is great medical problems and their treatment is a burden for the 
budget of each government.  
Acute kidney injury (AKI), previously termed acute renal failure, is a frequent clinical 
condition in critically ill patients especially, in intensive care units (ICU). Its incidence 
varies from 1-7 % of all hospitalized patients to 30-50 % of patients in ICU. Irrespective 
of the progress being made in the understanding of the pathophysiology of AKI and 
its underlying processes and the advances in critical care medicine, mortality rate 
associated with AKI remains high especially in ICU patients at more than 50 %. In 
addition, a significant proportion of surviving patients (20 %) develops CKD and 
end-stage renal disease, requiring chronic renal replacement therapy. Long-term 
outcome is worse for patients after recovery from AKI, further impacting health care 
cost and quality of life. In developing countries, AKI is more common in young and 
pediatric patients, while in developed countries elderly patients are predominant. In 
critically ill patients the most common cause of AKI is sepsis, accounting for 50 % of 
all cases. 
Chronic kidney disease (CKD) is a long-term condition which can arise from the 
damage to the kidneys from a variety of diseases. Patients with CKD are frequently 
asymptomatic until the disease is advanced. In 2002 the K/DOQI Clinical Practice 
Guidelines provided a definition of CKD which is now widely used around the world. 
Generally, cross-sectional population studies in a number of countries suggests an 
overall prevalence of CKD 1-5 of >10%. CKD appears to be an independent and 
significant risk factor for progressive cardio vascular disease (CVD). CVD accounts for 
≈ 50% of the death in patients with CKD. 
The purpose of the chapters is to present some important issues of diagnosis and 
causes of AKI, as well as caused by snakes and arthropods, after cardiac surgery,  
as well as some therapeutic achievements in AKI. Well presented are the 
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Risk Factors for Renal Failure:  
From Infancy to Adulthood 
Silvio Maringhini*, Vitalba Azzolina, Rosa Cusumano and Ciro Corrado 
Pediatric Nephrology Unit. U.O.C.  Nefrologia Pediatrica, Ospedale dei Bambini  
“G. Di Cristina” A.R.N.A.S. “Civico, Di Cristina e Benfratelli”, Palermo 
 Italy 
1. Introduction 
Abnormal development of the kidneys and the urinary tract, genetic factors, acquired  
disease during infancy and childhood, wrong dietary habits and environmental factors  may 
produce renal damage and cause renal insufficiency which may become clinically evident in 
adulthood. Prevention of renal insufficiency relies on early recognition of risk factors 
recognizable in childhood.   
2. Risk factors for kidney disease  
The incidence and progression of renal injury vary substantially among individuals who are 
at risk for kidney disease. Variability of risk for the occurrence and progression of Chronic 
Kidney Disease (CKD) suggests that biologically relevant characteristics may influence the 
occurrence or course of the renal disease. Prediction of increased risk of occurrence or 
progression of CKD may enable clinicians to identify individuals who may benefit from 
closer supervision of care or more intensive disease modifying interventions. Risk factors 
can be used to define at risk population that can be targeted for education and early 
intervention programs. These factors include familiarity of CKD, genetic factors, nephron 
number, low birth weight, perinatal programming, nutritional setting, hypertension and 
congenital abnormalities of the kidney and urinary tract (CAKUT) (Table 1). 
 
Risk factors for Chronic Kidney Disease detectable in childhood 
Family history of hypertension and kidney disease 
Low birth weight 
Perinatal kidney injury 
Congenital injury 
Hematuria and/or proteinuria 
Urinary tract infection 
High blood pressure 
Overweight 
Table 1. 
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2.1 Familiarity of CKD 
A family history of kidney disease (FAM)  has been associated with an increased risk of end 
stage renal disease (ESRD). In a recent report FAM was identified as an independent risk 
factor for ESRD [1]. In 1998 Lei at al in large population case-control study found a 
correlation between FAM and ESRD, especially in patients with a strong FAM with an odds 
ratio of 7.4.[2]. In the same year Freedman et al. found a high prevalence (20%) of FAM in 
dialysis patients. The prevalence decreased with age, was higher among African-Americans 
than Caucasians [3].  Satko et al documented a three- to nine-fold greater risk of ESRD in 
individuals with a FAM of ESRD. He noted a marked racial variation in the familial 
aggregation of kidney disease, with high rates in African American [4]. Other authors 
documented a stronger association in blacks than whites, indicating specific ethnic 
differences [5-6]. Recently in USA it has been proposed the ESRD Networks Family History 
Project as a national CKD surveillance system for patients with stage 5 CKD to identify 
relatives of incident patients with ESRD who are 2 to 3 times as likely to have ESRD [7].   
2.2 Genetic factors 
It is well known that genetic factors play a crucial role in CKD and ESRD [8] More recently, 
genome-wide association studies have yielded highly promising results suggesting a 
number of potential candidate genes and genomic regions that may contribute to the 
pathogenesis of CKD [8].  For example, common variants in the UMOD and PRKAG2 genes 
are associated with risk of chronic kidney disease [9]. Genome-wide association studies of 
CKD are beginning to define the genomic architecture of kidney disease and will impact our 
understanding of how genetic variation influences susceptibility to this condition. 
The expression of genes is defined by their epigenetic state; prenatal factors may produce 
stable changes in expression of genes as documented in several studies. DNA methylation 
[10], oxidative stress in response to low protein diet in pregnancy [11], telomere length [12] 
which is regulated by telomerase enzymatic activity during fetal life have been implicated in 
fetal renal development and disesase, excess glucocorticoids in early life can permanently 
alter tissue glucocorticoid signalling. All these studies show that the mechanism involved in 
developmental programming are likely epigenetic rather than due to DNA sequence 
mutations. It is important to note that changes produced by epigenetic factors, differently 
from genetic changes, are potentially reversible. 
2.3 Nephron number 
The number of nephrons in humans ranges from 250.000 to 2.5 million with an average of 
about 1 million per kidney; this high variability is due to various causes. Nephrogenesis 
ends at 36 weeks of gestation, for this reason premature newborns may have a reduced 
nephron number; the same condition is observed in patients with kidney disease and in 
older patients due to age–related glomerulosclerosis. In the  last 20 years many authors 
analyzed the association between nephron number and onset of renal disease later in life; 
most of these studies have been conducted in animals since it is difficult to determinate the 
number of glomeruli as measure of nephrons’  number in humans. Nyengaard and Bendtsen 
performed in 1992 the first study that calculated the number of glomeruli in the kidneys of 37 
Danes obtained at autopsy; they found a significant negative correlation between  glomerular 
number and age [13]. Successively Keller et al. documented a significant reduced number of 
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glomeruli in patients with hypertension compared to those who were normotensive [14]. More 
recently Zhang et al have documented a wide 4.5-fold variability in the number of glomeruli in 
children  younger than 3  months ranging from 246,181 to 1,106,062 [15]. 
2.4 Prematurity and low birth weight  
Low birth weight (LBW) is defined by the World Health Organization as a birth weight of 
<2500 g.  Intrauterine growth retardation (IUGR) is  defined as weight below the tenth decile 
for birth weight. 
 Fetal growth is conditioned by multiple factors which include the composition of maternal 
body,  alimentary habits during pregnancy, transport of nutrients through the placenta and 
others. The final consequence of the alteration of this factors determinate a fetal-growth 
reduction. The IUGR can be related to maternal undernutrition and/or placental insufficiency 
[16]. Placental insufficiency, usually associated with preeclampsia and maternal cardiovascular 
risk factors, is due to poor placentation. Maternal malnutrition is often related to wromg 
dietaty composition more than total calorie intake. In rats Langley-Evans et al have 
demonstrated that even short periods of maternal protein restriction during gestation in rats 
are associated with LBW and subsequent hypertension [17]. In humans, increased  protein 
turnover at 18 weeks of gestation is associated with increased length of babies at birth [18]. 
In humans, the causes of LBW are multifactorial: demographic factors, socio-economics 
status, poor maternal weight especially during pregnancy, shorter maternal height, maternal 
gestational weight gain below 7 kg, maternal hypertension, chronic infections, glucose 
intolerance or DM during pregnancy, maternal smoking or alcohol abuse, genetics, etc. 
Irving et al demonstrated that premature children, independently of birth weight, have an 
high risk of cardiovascular disease in adult age, thus making it very difficult to separate the 
effects of gestational age and birth weight [19]. However, the growth retardation for a given 
gestational age has greater relevance than the effect of prematurity on subsequent 
cardiovascular disease in adult age, as was demonstrated by Whincup et al [20]. The 
correlation between low birth weight  and number of nephrons was reported by Ma˜ nalich et 
al.; they observed a mean reduction of 20% of the nephrons in children with LBW. [21]. The 
same observations was obtained by Hughson et al who documented that LBW is accompanied 
by fewer large-volume nephrons than in individuals with normal birth weights [22]. 
Multiple animal models have demonstrated the association of LBW with later development 
of hypertension. The link between adult hypertension and LBW in these animal models 
appears to be mediated by a congenital nephron deficit showed by Vehaskari et al [23]. In 
humans many studies have reported higher blood pressures in those who had been of LBW. 
Barker et al first reported the association between hypertension in adult life and birth 
weight [24]. A study in Swedish children by Nilsson et al found a significant relation 
between birth weight and systolic arterial pressure [25]. Similar observations was done by 
Huxley et al [26]. In several studies, the relationship was more significant in girls than boys 
[27] and in woman than man [28]. The relationship between birth weight and blood pressure 
is also increased by accelerated postnatal growth [29] . Hoy et al in 1999 reported an 
association between low birth weight and CKD, observing increased rates of 
microalbuminuria in Australian Aborigines, a population with high rates of low birth 
weight [30]. In the last years many studies have documented that low birth weights 
contribute to high rates of early-onset chronic renal failure in United States patients, in 
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ducth adolescents, and in young and adult Norwegians [31-34].  In a meta-analysis, White et 
al. found that the combined odds ratio (OR) for risk of albuminuria associated with low 
birth weight was 1.81 (1.19–2.77) and for ESRD 1.58 (1.33-1.88). They concluded that existing 
data indicate that low birth weight is associated with subsequent risk of CKD  [35]. Recently, 
Hodgin et al. described an association between focal segmental glomerular sclerosis (FSGS) 
and prematurity and very low birth weight [36].  
2.5 Perinatal programming 
The processes of development and maturation of organs occur continuously throughout the 
pre- and postnatal periods. Intrauterine growth is generally regulated by intrinsic growth 
potential, genetic endowment, and support of nutrients from the materno-uteroplacental 
unit. However, during the postnatal period growth may be affected by environmental 
conditions and genetic background. The environmental impact on a genetic program 
determine the renal perinatal programming of each individual. The term “fetal 
programming” describes the structural and functional adaptive phenomena in response to 
critical periods during fetal life and early postnatal growth. Perinatal programming may 
produce a reduced nephron number leading to the development of chronic kidney disease 
[37]. Several environmental stressors may act on specific genetic programming of low 
nephron number. The time at which an adverse factor is involved during gestation before 
completion of nephrogenesis may affect kidney growth [38]. A history of LBW and IUGR, 
vitamin A deficiency, urinary tract malformations, administration of nephrotoxic drugs may 
interact to increase potential nephron damage. Maternal nutrition may have an important 
influence on renal programming [39]. In rats, a restricted supply of nutrients to the 
mother during nephrogenesis contributed to a reduced number of glomeruli per kidney, 
activation of the renin-angiotensin system, glomerular enlargement, and hypertension in 
adult life [40]. 
2.6 Hypertension 
Maternal hypertension is a significant risk factor for LBW and is more prevalent among 
black than white women, making the population-attributable risk of LBW highest among 
babies of hypertensive black mothers [41]. Taittonen et al found that a history of mother’s 
high blood pressure during pregnancy predicted future blood pressure more eminently than 
birth weight [42]. 
Hypertension is one of the major causes of renal insufficiency in adults. It has been proven 
that children with higher blood pressure develop hypertension, cardiovascular diseases and 
renal failure as adults. The first study that found a correlation of adult blood pressure with 
childhood blood pressure was the Muscatine study in 1989 [43]. Successively the Bogalusa 
Heart study documented that childhood blood pressure predicts adult microalbuminuria in 
African Americans, but not in whites [44]. In the same group of patients it was found that 
diastolic blood pressure in children and increased blood pressure variability in children are 
significantly correlated with adult hypertension [45-47]. 
2.7 Obesity 
Obesity is a recognized risk factor for end-stage renal disease (ESRD) [48]. The increased 
blood pressure associated with obesity is accompanied by impaired pressure natriuresis. 
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The volume expansion is related to activation of the sympathetic nervous system and renin-
angiotensin system. Obesity also causes renal vasodilation and glomerular hyperfiltration as 
compensatory mechanisms. In the long-term, these changes, along with the increased 
systemic arterial pressure, causes glomerular injury. Moreover obesity causes an increase of 
urinary protein excretion and gradual loss of nephron function that worsens with time and 
exacerbates hypertension. Overweight and obesity are associated with the metabolic 
syndrome and  type II diabetes, a major cause of kidney disease; in obese patients renal 
failure progresses much more rapidly [49].  
2.8 CAKUT 
Congenital abnormalities of the kidney and urinary tract in most cases apparently are not 
associated with a reduced glomerular filtration rate (GFR) but the renal reserve may be 
reduced to the point that an increased demand by a growing body produces a drop in GFR.  
A recent review of Sanna-Cherchi et al evaluated the renal outcome in patients with CAKUT 
[50]. They found that patients with solitar kidney, usually considered to have good 
prognosis, have a higher risk for dialysis  with an HR of 2.43 compared to patients with 
hypodysplasia or multicystic kidney. These data are in contrast to precedent studies that 
found a good prognosis of renal function in patients with unilateral agenesis [51]. In the last 
years many authors have looked for a correlation of CAKUT with genetic disorders [52].  
2.9 Hematuria and proteinuria  
Iseki et al in 1996 in a community mass screening found that proteinuria was the most 
useful predictor of ESRD (adjusted odds ratio 14.9, 95% confidence interval 10.9 to 20.2), and 
the next most potent predictor was hematuria (adjusted odds ratio 2.30, 95% confidence 
interval 1.62 to 3.28) [53]. In a recent paper Vivante A et Al found an increase of incidence of 
ESRD in patients (aged 16 to 25 year) with persistent asymptomatic isolated microscopic 
hematuria [54]. In 2011 a meta-analysis found that albuminuria is a  risk factor for all-cause 
and cardiovascular mortality in high-risk populations [55].  
2.10 Urinary tract infections and vesico-ureteral reflux 
Vesicoureteral reflux (VUR) is a frequent condition  in pediatric patients. Approximately 
1/3 of patients who have had a urinary tract infection (UTI) have VUR and 9–20% of 
patients with prenatal hydronephrosis have VUR [56].  Children affected by VUR may 
develop reflux nephropathy (RN) and  some of them  chronic kidney  disease (CKD). In a 
recent review Brakeman identifies the principal risk factors of progression of VUR to CKD: 
reduced glomerular filtration rate (GFR), bilateral VUR and/or renal scarring, grade V VUR, 
proteinuria, and hypertension. [57]. Ardissino et al found an estimated risk of end stage 
renal disease (ESRD) of  56%  in italian children by age 20 years [58] 
3. Evolution of renal damage 
The pathogenesis of progressive renal functional deterioration is certainly multifactorial, 
and the decline in glomerular filtration rate varies in groups of patients with different 
nephropathies, but also in patients with the same disease. Some of these factors may be 
modifiable, particularly in children,  and therapeutic interventions may result in a reduced 
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rate of deterioration of renal function. The persistent deterioration of renal function may be 
a result of repeated and chronic insults to the renal parenchyma leading to permanent 
damage and/or to the adaptive hyperfiltration response of the kidney. The reduced 
glomerular filtration area due to congenital or acquired nephron deficit, according with the 
Brenner’s hypothesis of “glomerular hyperfiltration”, could expose to a higher risk of 
cardiovascular and renal disease in adulthood since the increased workload produces 
proteinuria with glomerulosclerosis, tubulointerstitial inflammation and fibrosis [59]. In 
addition to hyperfiltration and proteinuria, there is evidence that chronic renal hypoxia 
could be directly involved in the progression of CKD, particularly in progression of 
tubulointerstitial fibrosis. Chronic renal hypoxia could be elicited by several factors such as 
loss of peritubular capillaries (PTCs), decreased PTC flow, decreased nitric oxide production 
and/or bioavailability and activation of the renin-angiotensin system. With regard to this, 
Kang et al previously demonstrated that the inhibition of NOS accelerated renal damage in a 
remnant kidney model by eliciting PTC loss [60]. Recent evidence suggests that overweight 
and obesity play a role in renal-pressure natriuresis. Excessive weight gain increases renal 
tubular reabsorption and impairs pressure natriuresis, in part, through activation of the 
sympathetic and renin-angiotensin system as well as physical compression of the kidney. 
With prolonged obesity, there are also structural changes in the kidney (including 
enlargement of Bowman’s space, increased glomerular cell proliferation, increased 
mesangial matrix, and thicker basement membranes, increased expression of glomerular 
transforming growth factor) that eventually cause loss of nephron function, further 
impairment of pressure natriuresis, and further increases in arterial pressure [61].  Finally, a 
number of genetic factors (eg, single nucleotide polymorphisms and modifier genes) may 
influence the immune response, inflammation, fibrosis, and atherosclerosis, possibly 
contributing to accelerated progression of CKD [62]. With respect to specific genes, 
apolipoprotein E (ApoE) polymorphisms may alter the risk of atherosclerotic disease, and 
therefore progression of CKD. The ApoE epsilon-2 allele is associated with elevated 
lipoprotein and triglyceride levels, whereas the ApoE epsilon-4 allele is associated with 
elevated levels of high density lipoprotein and lower triglycerides. In a secondary analysis 
of the Atherosclerosis Risk in Communities Study of 14,520 patients with a median follow-
up of 14 years, individuals with an ApoE epsilon-4 allele (present in 30 percent) had a 15 
percent reduction in risk of progression of CKD compared to individuals with ApoE 
epsilon-3 allele (present in 90 percent). The risk with the ApoE epsilon-2 allele was not 
significantly different compared with ApoE epsilon-3 [63]. Gene expression profiles within 
the kidney may help identify molecular prognostic factors in chronic renal disease. In the 
future, genetic testing and molecular analysis of renal biopsy specimens (and/or urine) may 
provide useful prognostic information. 
The rate of progression to ESRD in childhood is inversely proportional to the baseline CrCl 
at presentation. In addition, genetic, familial, or ethnic predisposition may influence the rate 
of renal decline. As an example, African-Americans are more susceptible to CKD, and the 
rate of progression of CKD is higher among African-American males than other ethnic 
groups. The rate of progression of CKD is usually greatest during the two periods of rapid 
growth, infancy and puberty, when the sudden increase in body mass results in a rise in the 
filtration demands of the remaining nephrons [64]. Therefore children may have a normal 
glomerular filtration rate which sharply reduces in young adulthood. These events place 
increased demands upon the preexistent compromised kidney function. As a result, children 
with CKD should be closely monitored during these two periods for an accelerated 
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progression of CKD. In addition to the increase in body mass, hormonal changes during 
puberty may also contribute to the rapid decline in renal function seen in adolescence. 
4. Causes of renal injury and renal failure in children 
Genetic and environmental factors are traditionally considered causes of human disease. 
Many genetic disorders may cause renal disease in childhood or in adults (Table 2) but also 
prenatal factors may produce stable changes in expression of genes. Studies from diverse 
populations suggest that fetal programming may be the origin of several intrauterine events 
that ultimately manifests as overt disease such as hypertension, type 2 diabetes, obesity, and 
chronic kidney disease (CKD) [65]. 
 
GENETIC KIDNEY DISEASE 
Cystic disease 
Polycistic Disease (ARPKD, ADPKD) 
Tuberous Sclerosis 
Von Hippel Lindau Syndrome 
Glomerulocystic Disease 




Family Focal Glomerulosclerosis 






Distal tubular acidosis 





In addition to prenatal conditions, adverse postnatal events must be taken in consideration: 
infections, drugs, trauma, systemic diseases etc. In fact, CKD in children, which has a much 
lower prevalence than in adults,  is the result of a heterogeneous group of disorders (Figure 
1). Congenital disease accounts for almost 60 percent of CKD cases and includes obstructive 
uropathy, renal hypoplasia, and renal dysplasia. Glomerular disorders are the second 
largest cause of childhood CKD and are present in 7 to 17 percent of children with CKD. 
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Glomerular disease is more common in children greater than 12 years of age. Focal 
segmental glomerulosclerosis (FSGS) is the most common glomerular disorder occurring in 
9 percent of all CKD cases. Other causes account for approximately 25 percent of cases. In 18 
percent of all cases of CKD, the underlying primary diagnosis is not identified (15 percent) 
or is unknown (3 percent). Other more uncommon causes of CKD in children include 
hemolytic-uremic syndrome, genetic disorders (eg, cystinosis, oxalosis, and hereditary 
nephritis), and interstitial nephritis. 
 
Fig. 1. FSGS: focal segmental glomerulosclerosis; GN: glomerulonephritis; Structural: 
structural anomalies of the kidney and urinary tract. 
Adapted from: NAPRTCS: 2007 Annual Report, Rockville, MD, EMMES, 2007. Available at 
https://web.emmes.com/study/ped/announce.htm.  
5. Prevention of renal diseases and kidney injury 
Preventing renal impairment is an urgent challenge for medical practitioners. Several 
studies indicate that earlier stages of CKD can be detected through laboratory testing, and 
that early therapeutic interventions in the course of CKD are effective in slowing or 
preventing the progression toward ESRD and its associated complications [66]. Pediatricians 
and General Practioners should closely follow these infants, Health Care and Education 
providers should prioritize programs to stress the importance of preventive care and 
continuity of care especially for children of mothers with evidence of low propensity toward 
health promotion. 
The NKF-K/DOQI guidelines for CKD, reviewed in Kidney Disease Improving Global 
Outcomes (KDIGO), recommend that all individuals should be assessed, as routine health 
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for developing CKD should be screened for hematuria with a urinalysis and with a urine 
test for proteinuria and a blood test for creatinine to estimate GFR. Depending upon the 
presence of particular risk factors, additional testing such as renal ultrasonography may be 
required, for example in patients with a family history of polycystic kidney disease. A 
formidable task for paediatricians is to prevent renal diseases that may develop in adult life. 
In order to achieve such goal, they should identify children at risk, counsel families to 
minimize any further renal risk factors such as smoking, obesity, and hypertension, and, in 
some cases together with a nephrologist, to institute pharmacologic therapy [67].  
Strict blood pressure control has been shown to slow the progression of kidney disease and 
reduce the risk of cardiovascular disease. The National High Blood Pressure Education 
Program Working Group (NHBPEP) established guidelines for the definition of normal and 
elevated blood pressures (BP) in children by developing blood pressure percentiles based on 
gender, age, and height [68]. Hypertension (HTN) is defined as either systolic and/or 
diastolic BP ≥95th percentile measured upon three or more occasions. Therapy includes both 
nonpharmacologic and pharmacologic interventions. Treatment should be initiated with 
conservative measures such as weight reduction, exercise, and dietary salt reduction. 
Pharmacologic therapy may be started in non responders;  ACE inhibitors or angiotensin II 
receptor blockers (ARBs), that are the preferred antihypertensive agents as they reduce 
proteinuria and appear to be more beneficial in slowing the progression of CKD compared 
to other agents in patients with CKD [69-70].  
Additional interventions that have been studied in adults with CKD include dietary protein 
restriction, lipid lowering therapy, and correction of anemia. However, results are 
inconclusive with respect to the impact of these interventions upon delaying the progression 
of CKD. In children, data have not shown a benefit of a low protein diet upon the 
progression of kidney disease CKD [71]. The current consensus by pediatric nephrology 
experts is to provide children with CKD the age appropriate recommended daily allowance 
for protein. 
6. Treatment  
The management of patients with CKD varies upon the severity of CKD. In the early stage it 
is important to treat reversible kidney dysfunction and prevent or slow the progression of 
kidney disease. In advanced stages (Stage 3 to 5) the management is focused on preventing 
and treating the complications of CKD, that include disorders of fluid and electrolytes, renal 
osteodystrophy, anemia, hypertension, dyslipidemia, growth impairment. The most 
common conditions with potentially recoverable kidney function are primarily due to 
decreased kidney perfusion or to the administration of nephrotoxic agents. Kidney 
hypoperfusion is produced by systemic hypotension, volume depletion from vomiting, 
diarrhea, diuretic use, or bleeding, and the administration of drugs that lower the kidney 
perfusion (such as nonsteroidal anti-inflammatory drugs, angiotensin converting enzyme 
[ACE] inhibitors, angiotensin II receptor blockers [ARBs]). Common nephrotoxic drugs 
include nonsteroidal anti-inflammatory agents, diagnostic agents (eg, radiographic contrast 
materials), and others (eg, aminoglycosides, amphotericin B, cyclosporine, and tacrolimus). 
The administration of such drugs, therefore, should be avoided or used with caution in 
patients with underlying CKD, with the assistance of therapeutic drug level monitoring. [72]  
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6.1 CKD complications  
Major Problems in children with CKD  
• Water and sodium retection 
• Hyperkalemia 
• Metabolic acidosis 




Table 3.  
6.1.1 Water and sodium retention 
It’s present as GFR becomes severely decreased (ie, stages 4 and 5 disease), and it may result 
in volume overload. In general, a combination of dietary sodium restriction and diuretic 
therapy may correct the increased water balance. Dietary sodium intake should be 
decreased to 2 to 3 g/day and diuretic therapy includes loop diuretics such as 
furosemide given at a dose of 0.5 to 2 mg/kg per day [73].  
6.1.2 Hyperkalemia  
Hyperkalemia develops primarily because of inadequate potassium excretion due to a 
reduced GFR. Other factors that can contribute to elevated potassium levels include a high 
dietary potassium intake, metabolic acidosis, hypoaldosteronism (due in some cases to 
administration of an ACE inhibitor or an ARB), or an impaired cellular uptake of potassium. 
Management to prevent hyperkalemia in children with CKD consists in low potassium diet, 
administration of a loop diuretic (eg, furosemide) to increase urinary potassium loss, 
correction of acidosis with oral sodium bicarbonate [73].  
6.1.3 Metabolic acidosis 
Metabolic acidosis is characteristically present when the estimated GFR is less than 30 
mL/min per 1.73 m2 (ie, stage 4 disease). Acidosis is associated with growth impairment 
because the body utilizes bone buffering to bind some of the excess hydrogen ions. Current 
guidelines by the K/DOQI working group are to maintain the serum bicarbonate level at or 
above 22 mEq/L . Sodium bicarbonate therapy is started at 1 to 2 mEq/kg per day in two to 
three divided doses, and the dose is titrated to the clinical target [74].  
6.1.4 Mineral metabolism and bone disease  
Alterations of mineral metabolism are an almost universal finding with progressive CKD 
due to abnormalities in the metabolism of calcium, phosphate, vitamin D, and parathyroid 
hormone (PTH) levels. If these abnormalities are not addressed, these changes result in 
kidney bone disease, referred to as renal osteodystrophy. The management and prevention 
of secondary hyperparathyroidism is complex and requires frequent monitoring and 
adjustment of therapy. The initial step is to correct phosphate retention by dietary restriction 
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usually combined with either calcium-containing phosphate binders and/or sevelamer. The 
KDOQI guidelines recommend that treatment with calcitriol should be started when the 
serum 25-hydroxyvitamin D is <30 ng/mL (75 nmol/L), or when serum PTH is above the 
target range [75]. In adults, calcimimetics have been increasingly used to suppress PTH 
secretion and decrease the risk of hypercalcemia associated with calcitriol. These agents, 
which increase the sensitivity of the calcium-sensing receptor (CaSR) in the parathyroid 
gland to calcium, have not been adequately studied in the pediatric population.  
6.1.5 Anemia  
Anemia in CKD is due to reduced kidney erythropoietin production and generally develops 
when the GFR is below 30 mL/min per 1.73 m2. The treatment of anemia in children with 
CKD often includes iron supplementation and erythropoiesis stimulating agent (ESA). The 
K/DOQI guidelines recommend a target Hgb between 11 and 12 g/dL based upon consensus 
expert opinion. The initial ESA dose in older children not receiving dialysis is 80 to 120 u/kg 
per week, administered in two to three divided doses. Children younger than five years of age 
or children receiving dialysis frequently require higher doses (300 u/kg per week) [76-77].   
6.1.6 Nutrition 
Malnutrition is common in children with CKD because of poor appetite, decreased intestinal 
absorption of nutrients, and metabolic acidosis. Attention to nutrition is critical as it affects 
both the physical growth and neurocognitive development of children [78].  
6.1.7 Growth  
Growth failure has been long recognized in children with CKD. While the institution of 
recombinant human growth hormone (rHuGH) therapy can have a profound effect on the 
height velocity of children with CKD who are growing poorly, early recognition and 
management of malnutrition, renal osteodystrophy, acid-base abnormalities and electrolyte 
disturbances should take place prior to considering the institution of rHuGH. [79].  
6.1.8 Renal replacement therapy  
Once the estimated GFR declines to less than 30 mL/min per 1.73 m2 (stage 4 CKD), it is 
time to start preparing the child and the family for renal replacement therapy. The family 
should be provided with information related to preemptive kidney transplantation, 
peritoneal dialysis, and hemodialysis. As in adults, some form of renal replacement therapy 
will generally be needed when the GFR falls below 15 mL/min per 1.73 m2 (stage 5 CKD). 
However, renal replacement therapy is often initiated before children reach these levels.  
7. References 
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The Pathogenesis of Acute Kidney Injury 
Nicholas A. Barrett and Marlies Ostermann 
Department of Critical Care,  
Guy’s and St Thomas’ NHS Foundation Trust, London 
UK 
1. Introduction 
Acute kidney injury (AKI) is common in critically ill patients affecting 20 - 60% of patients 
(Chertow, et al., 2005; de Mendonca, et al., 2000; Mehta, et al., 2005; Ostermann & Chang, 
2008; Silvester, et al., 2001; Uchino, et al., 2005). The exact incidence varies depending on 
patient population, associated comorbid factors and criteria used to define AKI. Sepsis 
induced AKI accounts for approximately 50% of cases and AKI is commonly a manifestation 
of multiple organ dysfunction (Chertow, et al., 2005; de Mendonca, et al., 2000; Mehta, et al., 
2005; Ostermann & Chang, 2008; Silvester, et al., 2001; Uchino, et al., 2005). Many patients 
with AKI have a mixed aetiology where the presence of sepsis, ischaemia and 
nephrotoxicity co-exist. Current management of AKI is supportive, ensuring adequate 
perfusion pressures, correction of fluid depletion, avoidance of nephrotoxins and when 
required institution of renal replacement therapy (RRT). Despite the widespread use of RRT 
in the intensive care unit (ICU), AKI is associated with an associated mortality risk of 40 – 
90% depending on patient population (Chertow, et al., 2005; Ostermann & Chang, 2008; 
Silvester, et al., 2001). Furthermore, evidence has emerged that AKI survivors have an 
increased risk of chronic kidney disease, long-term dialysis, increased mortality and 
reduced quality of life (Johansen, et al., 2010; Lo, et al., 2009; Lopes, et al., 2010; Wald, et al., 
2009). AKI is no longer viewed as a reversible bystander of critical illness but a significant 
contributor to short and long-term morbidity and mortality.   
2. Renal physiology 
2.1 Renal blood supply and oxygenation 
The chief function of the kidneys (ie. filtration of plasma and formation of urine) dictates the 
renal flow to be much higher than necessary to meet the metabolic needs. The kidneys 
receive blood via the renal arteries which supply them with approximately 25% of cardiac 
output. The vascular supply of nephrons consists of glomerular afferent and efferent 
arterioles which branch into the peritubular arteries and vasa recta. Oxygen tensions in the 
kidney are low, decreasing from 70 mmHg in the cortex to 20 mmHg in the medulla. The 
unique microvasculature of the kidneys coupled with high oxygen demand from the tubular 
salt-water reabsorption make the kidneys, in particular the medulla highly sensitive to 
hypoxia (Brezis & Rosen, 1995; Evans, et al., 2008). As a result, the renal microcirculation is 
recognised as a key actor in the initiation and development of AKI.  
 
Renal Failure – The Facts 
 
16
Chloride, and Sulfate. National Academic Press, Washington, DC 2004. Available at 
www.nap.edu/books/0309091691/html.  
[74] National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in 
chronic renal failure: 2008 Update. Am J Kidney Dis; 53(Suppl 2):S1, 2009. 
[75] National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism 
and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 
46(Suppl1):S, 2005   
[76] K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia 
in chronic kidney disease. Am J Kidney Dis; 47(Suppl 3):S1, 2006. 
[77] NKF-K/DOQI Clinical Practice Guidelines and Clinical practice recommendations for 
anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney 
Dis; 50:474, 2007.  
[78] National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in 
chronic renal failure: 2008 Update. Am J Kidney Dis; 53(Suppl 2):S1, 2009. 
[79] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and 
treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). 
Kidney Int Suppl 2009.  
2 
The Pathogenesis of Acute Kidney Injury 
Nicholas A. Barrett and Marlies Ostermann 
Department of Critical Care,  
Guy’s and St Thomas’ NHS Foundation Trust, London 
UK 
1. Introduction 
Acute kidney injury (AKI) is common in critically ill patients affecting 20 - 60% of patients 
(Chertow, et al., 2005; de Mendonca, et al., 2000; Mehta, et al., 2005; Ostermann & Chang, 
2008; Silvester, et al., 2001; Uchino, et al., 2005). The exact incidence varies depending on 
patient population, associated comorbid factors and criteria used to define AKI. Sepsis 
induced AKI accounts for approximately 50% of cases and AKI is commonly a manifestation 
of multiple organ dysfunction (Chertow, et al., 2005; de Mendonca, et al., 2000; Mehta, et al., 
2005; Ostermann & Chang, 2008; Silvester, et al., 2001; Uchino, et al., 2005). Many patients 
with AKI have a mixed aetiology where the presence of sepsis, ischaemia and 
nephrotoxicity co-exist. Current management of AKI is supportive, ensuring adequate 
perfusion pressures, correction of fluid depletion, avoidance of nephrotoxins and when 
required institution of renal replacement therapy (RRT). Despite the widespread use of RRT 
in the intensive care unit (ICU), AKI is associated with an associated mortality risk of 40 – 
90% depending on patient population (Chertow, et al., 2005; Ostermann & Chang, 2008; 
Silvester, et al., 2001). Furthermore, evidence has emerged that AKI survivors have an 
increased risk of chronic kidney disease, long-term dialysis, increased mortality and 
reduced quality of life (Johansen, et al., 2010; Lo, et al., 2009; Lopes, et al., 2010; Wald, et al., 
2009). AKI is no longer viewed as a reversible bystander of critical illness but a significant 
contributor to short and long-term morbidity and mortality.   
2. Renal physiology 
2.1 Renal blood supply and oxygenation 
The chief function of the kidneys (ie. filtration of plasma and formation of urine) dictates the 
renal flow to be much higher than necessary to meet the metabolic needs. The kidneys 
receive blood via the renal arteries which supply them with approximately 25% of cardiac 
output. The vascular supply of nephrons consists of glomerular afferent and efferent 
arterioles which branch into the peritubular arteries and vasa recta. Oxygen tensions in the 
kidney are low, decreasing from 70 mmHg in the cortex to 20 mmHg in the medulla. The 
unique microvasculature of the kidneys coupled with high oxygen demand from the tubular 
salt-water reabsorption make the kidneys, in particular the medulla highly sensitive to 
hypoxia (Brezis & Rosen, 1995; Evans, et al., 2008). As a result, the renal microcirculation is 
recognised as a key actor in the initiation and development of AKI.  
 
Renal Failure – The Facts 
 
18
Basal renal oxygen consumption is approximately 400mmol/min/100g. Due to the high 
renal blood flow, there is a low oxygen extraction (Valtin & Schafer, 1995). Energy 
dependent processes in the kidney are those related to basal cellular metabolism and those 
related to filtration and reabsorption of solutes. In conditions associated with decreased 
renal blood flow, there is a reduction in both glomerular filtration and tubular reabsorption 
followed by a reduction in oxygen consumption. This relationship holds until the threshold 
of approximately 150mL/min/100g blood flow at which point oxygen extraction increases. 
At a blood flow of approximately 75mL/min/100g tissue the capacity for increased oxygen 
extraction is exceeded and anaerobic metabolism and cellular ischaemia occur (Schlichtig, et 
al., 1991). 
2.2 Renal energy utilisation 
Aside from basal metabolic requirements the major energy dependent process in the kidney 
is the reabsorption of solute, especially sodium. From animal studies, it is well established 
that there is a linear relationship between the reabsorption of sodium and oxygen 
consumption within the kidney (Gullans & Mandel, 1992). The predominant method of ATP 
production within the kidney is oxidative metabolism. In the cortex, oxidative metabolism 
accounts for over 97% of ATP production whereas in the medulla, up to 33% of energy 
comes from glycolysis (Bernanke & Epstein, 1965). In the presence of renal cortical 
hypoxia, the predominant form of energy production changes to glycolysis, however, this 
can not sustain significant function of the renal cells above homeostasis (Gullans & 
Mandel, 1992). 
3. Ischaemic Acute Kidney Injury 
Ischaemic AKI can occur in several clinical settings ranging from hypotension due to fluid 
depletion, blood loss, sepsis or reduced cardiac output to the use of vasoactive drugs. 
Following a reduction in effective kidney perfusion, tubular cells are unable to maintain 
adequate intracellular ATP. This depletion of ATP leads to rapid disorganization of the 
cytoskeletal structure and disruption of tight intercellular junctions (Sharfuddin & Molitoris, 
2011). in case of severe depletion, apoptosis or necrosis occur and cells die. All segments of 
the nephron can be affected during an ischaemic insult but the most commonly injured sites 
are the proximal and distal tubular cells. Sloughed tubular cells and cellular debris can 
obstruct the tubule lumen and ultimately cease glomerular filtration in that functional 
nephron.  
A marked decrease in total kidney perfusion may cause global ischaemia, but more often, 
ischaemic injury occurs due to decreased regional perfusion without major change in global 
perfusion. Both ischaemia and sepsis can have profound effects on renal endothelial cells, 
resulting in microvascular dysregulation and continued ischaemia and further injury. 
Ischaemic injury results in endothelial cell activation, endothelial swelling, up-regulation of 
adhesion molecules and shedding of components of the glycocalyx. This, in combination 
with leucocyte activation, platelet aggregation, red cell trapping and activation of the 
coagulation pathway serve as the basis for vascular congestion of the microvasculature (Le 
Dorze, et al., 2009). In response, a range of inflammatory mediators are being released, 
including prostaglandins, endothelin and nitric oxide, that alter the balance of 
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vasodilatation and constriction within the renal vasculature (Bonventre, 2004; Le Dorze, et 
al., 2009). Although the ultimate aim is to control intrarenal damage and to promote repair, 
these activated leucocytes and proinflammatory mediators are also thought to be 
responsible for distant effects in non-renal organs, in particular lungs, heart and brain (ie. 
principle of organ cross-talk).  
4. Septic Acute Kidney Injury 
Sepsis is a pathological state characterised by a systemic inflammatory response to infective 
agents. Septic shock is characterised by inadequate tissue perfusion and significant 
hypotension is usually present. There are a number of proposed mechanisms regarding the 
pathogenesis of septic AKI, including hypoperfusion at the systemic and/or microcirculatory 
level, apoptosis mediated by either the infective agents or cytokines released in response to 
infection as well as renal mitochondrial hibernation triggered by sepsis.  
4.1 Histopathology 
Our progress in understanding the pathogenesis of AKI in sepsis has been limited due to the 
paucity of histopathological studies performed in well-defined patient populations with 
sepsis. Results from studies have been inconsistent with varying reports of cellular necrosis, 
glomerular infiltration and microvascular thrombosis (Solez, et al., 1979). 
Autopsy studies have similarly reported variable and inconsistent findings in sepsis-
induced AKI including interstitial oedema, swelling of the tubular cells, tubular cell 
apoptosis and regeneration, as well as focal necrosis and micro-abscess formation (Lucas, 
2007). Part of the difficulty with autopsy series is that autolysis of the kidney occurs rapidly 
after death which leads to difficulties in interpreting findings. In one study reporting on 
rapid autopsies (within 6 hours) of 20 patients who died from sepsis and multiple organ 
dysfunction, there was no evidence of cellular necrosis or apoptosis (Hotchkiss, et al., 1999). 
However, a more recent study of immediate (within 30 minutes) post-mortem renal 
histology in patients with septic shock demonstrated acute tubular lesions, glomerular 
leukocyte infiltration and tubular cell apoptosis which affected 2.9% of tubular cells (Lerolle, 
et al., 2010). In this study these patients had died in states of profound shock. Hypovolaemia 
and hyperlactataemia, suggestive of poor tissue perfusion correlated with the degree of 
histological change seen and it is not clear that the changes seen were due to shock and 
hypoperfusion or sepsis per se. 
Animal models of sepsis-induced AKI exist and have also demonstrated inconsistent 
changes in renal histopathology (Heyman, et al., 2002; Rosen & Heyman, 2001). 
Furthermore, the microvasculature of the rat kidney is markedly different from that of 
humans (Rosen & Heyman, 2001) and none of the models adequately account for the 
resuscitation and supportive management seen in critically ill patients, making data difficult 
to extrapolate (Heyman, et al., 2002). 
4.2 Haemodynamic changes 
Experimental evidence for renal haemodynamic changes due to sepsis is inconsistent. 
Animal models variably demonstrate that with preserved systemic blood pressures there is 
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either a reduction in renal blood flow causing decreased glomerular flow (Badr, et al., 1986; 
Kikeri, et al., 1986) or renovascular vasodilatation with a consequent increase in renal blood 
flow (Langenberg, et al., 2006; Ravikant & Lucas, 1977). In humans, techniques measuring 
renal blood flow using para-aminohippurate extraction and renal vein catheter 
thermodilution have demonstrated that renal blood flow is preserved in sepsis (Brenner, et 
al., 1990). A systematic review of human and animal trials found that the primary 
determinant of renal blood flow during sepsis was cardiac output and that even in the 
presence of preserved renal blood flow, there is a reduction in glomerular filtration and AKI 
continues to progress (Langenberg, et al., 2005). It remains unclear as to whether there is 
significant relative reduction in medullary blood flow in humans with sepsis but given that 
the renal medulla is normally exposed to relative hypoxia, it has been hypothesised that this 
may be exacerbated during sepsis leading to tubular cell dysfunction or death (Brezis & 
Rosen, 1995; Eckardt, et al., 2005). Sepsis also leads to damage of the endothelial glycocalyx 
which aggravates a breakdown of the vascular barrier and contributes to microcirculatory 
changes in septic AKI (Chappell, et al., 2009). 
4.3 Apoptosis 
Apoptosis has been demonstrated to occur in animal models of AKI (Bonegio & Lieberthal, 
2002; Sharfuddin & Molitoris, 2011; Wan, et al., 2003). Apoptosis is thought to occur in 
response to a variety of insults including sepsis, ischaemia, inflammatory cytokines and 
bacterial lipo-polysaccharide. However, there is inconsistent evidence for the presence of 
significant apoptosis in kidneys from patients with sepsis at autopsy (Hotchkiss, et al., 1999; 
Lerolle, et al., 2010; Lucas, 2007). It remains uncertain that apoptosis, estimated at less than 
3% in a recent study (Lerolle, et al., 2010), is occurring on a scale that would result in 
significant organ dysfunction and failure. 
4.4 Bioenergetics 
A recent hypothesis is that the organ dysfunction including AKI observed in sepsis is 
secondary to bioenergetic changes with mitochondrial down-regulation and hibernation 
(Singer, 2007a, 2007b; Singer, et al., 2004). There is some evidence that there is reversible 
mitochondrial dysfunction resulting in inadequate ATP generation and that this may 
underlie the organ dysfunction seen in sepsis (Singer, et al., 2004). Although not 
conclusively demonstrated in humans, there is evidence of decreased ATP and a reduction 
in activity of respiratory chain complexes associated with sepsis and septic shock (Brealey, 
et al., 2002). 
4.5 Immune mechanisms 
Another mechanism of renal failure associated with infection is that of immune-mediated 
glomerulonephritis (Naicker, et al., 2007). This occurs as a post-infectious condition and is 
usually related to streptococcal or viral diseases. The pathophysiological mechanism is 
immune-complex deposition leading to inflammation within the glomerulus and 
glomerulonephritis. Although well characterised following infection, there is no evidence 
that this mechanism is responsible for AKI associated with acute sepsis. 
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5. Repair of AKI 
Renal tubular epithelial cells have high potential to regenerate after an ischaemic, septic or 
toxic insult. Minimally injured cells are repaired when blood flow is re-established. Viable 
cells proliferate and spread across denuded basement membrane and later regain their 
characteristics as tubular epithelial cells (Sharfuddin & Molitoris, 2011). There is evidence 
that progenitor cells, stem cells and mesenchymal stem cells have an important role in 
promoting tubular epithelial repair but also lead to chronic fibrosis. The benefit of infusions 
of mesenchymal cells to promote recovery of renal function in humans is currently under 
investigation (Humphreys & Bonventre, 2008). Endothelial cells have less regenerative 
capability. Decrease of peritubular capillary density has been observed several months after 
an episode of AKI (Basile, et al., 2001). 
6. Conclusion 
AKI is a common manifestation of multiple organ dysfunction observed in critically ill 
patients, especially in relation to sepsis and ischaemia.  There is increasing evidence that 
independent of the exact aetiology, AKI should be regarded as an inflammatory condition 
with secondary effects on other organs. However, the exact underlying pathophysiology 
and pathology of human AKI remains incompletely understood. 
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1. Introduction  
Ischemic injury to the kidney is the most common cause of acute kidney injury. Despite 
intensive basic research and in critical care for decades it is still associated with high 
mortality rates of ~50% in the intensive care unit. It is observed in a variety of clinical 
situations such as cardiac arrest with recovery, organ transplantation, or heminephrectomy. 
Postischemic acute kidney injury is characterized by an abrupt decrease in glomerular 
filtration rate (GFR) (the hallmark feature of acute kidney injury), and increased renal 
vascular resistance that determines a persistent reduction in renal blood flow (RBF) and 
tubular injury. However, the pathophysiological mechanisms responsible for the 
postischemic renal injury and the profoundly depressed renal function remain incompletely 
understood.  The accumulated data in the literature are compatible with the hypothesis that 
ischemic acute kidney injury is essentially a phenomenon of altered renal hemodynamics 
linked critically to endothelial cell dysfunction caused by the production of high levels of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS), leading to decreased 
nitric oxide availability as a consequence of its destruction to form peroxynitrite, associated 
with an intracellular energy store depletion. The oxidative and nitrosative stress will 
produce lipid peroxidation, oxidative DNA damage and modification and inactivation of 
proteins that originates an inflammatory reaction characterized by endothelial activation 
and injury, enhanced endothelial cell-leukocyte adhesion, leukocyte entrapment, and a 
reduction in microvascular blood flow mainly affecting the renal outer medulla as indicated 
by the marked vascular congestion typically observed in this zone of the kidney. On the 
other hand, and depending on the severity of renal ischemia, tubular epithelial cells will 
undergo a varying degree of necrosis or apoptosis with tubular obstruction followed by 
both an anatomical and functional recovery. The way in which vascular and tubular 
epithelium recover determines the final status of the renal function, ranging from full 
recovery to chronic renal failure and ultimately to end-stage renal disease. Because of the 
importance of endothelial cells in this process, emphasis will be placed on the involvement 
of oxidative and nitrosative stress in causing endothelial dysfunction, the sources of oxygen 
and nitrogen reactive species, and the interactions between them, specially superoxide anion 
and nitric oxide because together they form peroxynitrite, a potent oxidant and nitrosant 
agent. Among other factors, the severity of acute kidney injury is mainly determined by the 
duration of the ischemia.  Special attention will be paid to the vascular and hemodynamic 
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changes produced in the outer medulla during renal ischemia/reperfusion, because this 
renal zone is physiologically nearly hypoxic. The role of heme oxygenase system and the 
gender differences in the susceptibility to ischemic acute renal failure will be also be revised 
2. Morphologic and hemodynamic changes in ischemic acute kidney injury 
In apparent disagreement with the severe impairment of renal function, histologic changes 
in acute kidney injury are relatively subtle, and necrosis (if present) is restricted to the outer 
medullary region of the kidney. Morphologic changes include effacement and loss of 
proximal tubule brush border, patchy loss of tubule cells with apoptosis limited to both 
proximal and distal tubules, focal areas of tubular dilation with distal tubular casts 
(consisting of Tamm-Horsfall protein and cellular debris) and areas of regeneration. 
Peritubular capillaries present endothelial injury with enhanced expression of adhesion 
molecules (e.g. intercellular adhesion molecule-1, E-selectin, P-selectin) and cell swelling 
that promote adhesion of platelets to endothelium, with subsequent leukocyte adhesion and 
adhesion of platelets to neutrophils which are then aggregated and trapped in narrow 
peritubular capillaries causing vascular congestion, with cessation and even reversal of 
blood flow (Brodsky et al, 2002; Yamamoto et al, 2002). Endothelial injury also iniciates an 
inflammatory response that can be enhanced by tubular cells through the generation of 
proinflammatory cytokines and chemotactic cytokines (Bonventre & Zuk, 2004; Friedewald 
& Rabb, 2004; Schrier et al, 2004; Devarajan, 2006).  
Functionally, the ischemic insult is followed by an intense and persistent renal 
vasoconstriction that significantly reduces renal blood flow to ~50% of normal (Cristol et al, 
1993; Lieberthal et al, 1989), and has dramatic consequences in the renal outer medulla due 
to the fact that it is physiologically on the verge of hypoxia. Through a poorly understood 
mechanism, this acute reduction in outer medullary blood flow is followed later by a 
situation of chronic hypoxia (Basile et al, 2001; López Conesa et al, 2001). The increased 
basal vascular tone is also accompanied by increased reactivity to vasoconstrictors and a 
decreased response of arterioles to vasodilators, with loss of autoregulation of renal blood 
flow and abnormal vascular reactivity characteristic of postischemic acute kidney injury 
(Bonventre & Weinberg, 2003). These changes have been attributed to altered prostaglandins 
synthesis, to the generation of reactive oxygen and nitrogen species, and/or to activation of 
inflammatory responses to ischemia and it seems to be critically linked to endothelial 
dysfunction and to the increased generation of reactive oxygen and nitrogen species 
(oxidative and nitrosative stress) with a decrease in nitric oxide availability. 
3. Temporal course of ischemic acute renal failure 
Clinically, ischemic acute renal failure has classically been divided into the “Initiation”, 
“Maintenance” and “Recovery” phases (Sutton et al, 2002; Devarajan et al, 2006). Sutton et al 
(2002) proposed a fourth phase, the “Extension” phase. 
The “Initiation” phase begins when cellular ATP content becomes depleted as a 
consequence of anoxia, with the resultant tubular epithelial, smooth muscle and endothelial 
cell injuries characterized by disruption of actin cytoskeleton that produces structural and 
functional tubular alterations, and renal vasculature abnormalities. The severity and extent 
of these injuries will be determined by the degree and duration of ischemia. From a 
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functional point of view epithelial and endothelial cells become “activated” up-regulating a 
number of cytokines and chemokines such as interleukins -1, -6, and -8, monocyte 
chemoatractant protein-1, and tumor necrosis factor alpha, thus triggering the inflammatory 
cascade. A key event in the “activation” of endothelial cells is a decrease in nitric oxide 
production. 
The “Extension” phase is determined by two major events, a state of continued hypoxia 
with decreased blood flow, stasis and red and white blood cells accumulation mainly 
affecting outer medulla, and an inflammatory response. Thus, endothelial dysfunction in 
this phase plays a key role in the continued ischemia of tubular cells as well as in the 
inflammatory response observed in ischemic acute renal failure. As a consequence of these 
changes, apoptosis and necrosis of tubular cells (mainly affecting outer medulla) is observed 
and glomerular filtration rate continues falling. 
During the “Maintenance” phase cells undergo repair (with apoptosis, proliferation and 
migration of cells) to re-establish and maintain cell and structure integrity with a slow 
improving in cellular and tubular function. Glomerular filtration rate is maintained to a 
level determined by the severity and duration of ischemia. Renal blood flow recovers 
approaching preischemic levels. During the “Recovery” phase a slowly and progressive 
improvement towards normality is taking place. 
During all these phases the initial endothelium dysfunction and its posterior recuperation 
are of key importance to overall recovery. 
4. Importance of renal medulla in the renal response to ischemia 
4.1 Susceptibility of renal medulla to hypoxia 
Many studies indicate that the severity of post-ischemic renal injury depends on the state of 
persistent hypo-perfusion of the renal outer medulla. The susceptibility of renal medulla to 
hypoxia lies in the fact that: a) renal arteries and veins run strictly parallel and in close 
contact with each other over long distances, allowing oxygen to diffuse from the arterial to 
the venous system before it has entered the capillary bed; b) tubular segments of the outer 
medulla have a limited capacity for anaerobic energy generation and, thus, depend on its 
oxygen supply to maintain active transtubular sodium and the reabsorption and secretion of 
solutes. These facts are particularly relevant in the tubular segments of the outer medulla (S3 
segment of proximal tubules and medullary thick ascending loop of Henle) where the 
combination of limited oxygen supply (pO2 < 25 mmHg) and a high oxygen demand makes 
the outer medulla to be physiologically on the verge of hypoxia (Brezis & Rosen, 1995; 
Zhang & Edwards, 2002).  A variety of physiologic mechanisms are involved in protecting 
the outer medulla against hypoxic injury, including nitric oxide, prostaglandins, heme 
oxygenase-1 and adenosine, all of which enhance medullary blood flow while down-
regulate active tubular transport of sodium and solutes (Brezis et al, 1989; Brezis et al, 1991; 
Knight & Johns, 2005; Rosenberger et al, 2006). A number of studies have shown that nitric 
oxide is a main regulator of medullary blood flow. Inhibition of nitric oxide production is 
followed by a decrease in medullary pO2 in control animals and medullary blood flow 
(Cowley et al, 2003; Fenoy et al, 1995; López-Conesa et al, 2001; Nakanishi et al, 1995; 
O´Connor et al, 2006; Rodríguez et al, 2010; Rosenberger et al, 2006). Therefore, the 
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functional point of view epithelial and endothelial cells become “activated” up-regulating a 
number of cytokines and chemokines such as interleukins -1, -6, and -8, monocyte 
chemoatractant protein-1, and tumor necrosis factor alpha, thus triggering the inflammatory 
cascade. A key event in the “activation” of endothelial cells is a decrease in nitric oxide 
production. 
The “Extension” phase is determined by two major events, a state of continued hypoxia 
with decreased blood flow, stasis and red and white blood cells accumulation mainly 
affecting outer medulla, and an inflammatory response. Thus, endothelial dysfunction in 
this phase plays a key role in the continued ischemia of tubular cells as well as in the 
inflammatory response observed in ischemic acute renal failure. As a consequence of these 
changes, apoptosis and necrosis of tubular cells (mainly affecting outer medulla) is observed 
and glomerular filtration rate continues falling. 
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level determined by the severity and duration of ischemia. Renal blood flow recovers 
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improvement towards normality is taking place. 
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are of key importance to overall recovery. 
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hypoxia lies in the fact that: a) renal arteries and veins run strictly parallel and in close 
contact with each other over long distances, allowing oxygen to diffuse from the arterial to 
the venous system before it has entered the capillary bed; b) tubular segments of the outer 
medulla have a limited capacity for anaerobic energy generation and, thus, depend on its 
oxygen supply to maintain active transtubular sodium and the reabsorption and secretion of 
solutes. These facts are particularly relevant in the tubular segments of the outer medulla (S3 
segment of proximal tubules and medullary thick ascending loop of Henle) where the 
combination of limited oxygen supply (pO2 < 25 mmHg) and a high oxygen demand makes 
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functional status of the renal medullary nitric oxide system after the ischemia-reperfusion 
injury is believed to be a major determinant in the development of renal failure. 
4.2 Outer medulla and ischemia-reperfusion 
The importance of outer medulla in the renal response to an ischemic event has been 
demonstrated by several studies. Basile et al (2001) observed that renal ischemia results in 
permanent damage to peritubular capillaries and influences long-term function. They 
measured a 30-50% reduction in peritubular capillary density in the outer medulla at 4, 8 
and 40 weeks after ischemia and tubulointerstitial fibrosis with increased transforming 
growth factor-1 expression at 40 weeks. Moreover, they also demonstrated an increase in 2- 
pimonidazole staining (a hypoxia-sensitive marker) in outer medulla accompanied by 
proteinuria, interstitial fibrosis and renal functional loss. They also observed that chronic L-
arginine administration in drinking water increased total renal blood flow, decreased 2- 
pimonidazole staining and attenuated or delayed the progression of chronic renal 
insufficiency after recovery from acute ischemic injury (Basile et al, 2003). On the other 
hand, López-Conesa et al (2001) reported that an antioxidant ameliorated the renal failure 
and prevented the outer medullary vasoconstriction observed after 45 min of renal ischemia, 
effects that seem to be dependent on the presence of nitric oxide and the scavenging of 
peroxynitrite. Taken together, data from these studies strongly suggest that the renal failure 
that follows an ischemic event is directly related to alterations in outer medullary blood 
flow and that these changes seems to be dependent on free radical production and nitric 
oxide bioavailability. 
5. Free radicals in acute renal injury 
Free radicals are small, diffusible molecules that have an unpaired electron and tend to be 
reactive and can participate in chain reactions in which a single free radical event can be 
propagated to damage multiple molecules. The generation of oxygen free radicals is mainly 
restricted to mitochondria. In a controlled process 4 electrons from the electron transport 
chain are added to molecular oxygen yielding two water molecules. These electrons 
additions generate sequentially superoxide anion, hydrogen peroxide and the hydroxyl 
radical before the addition of the final electron to produce water.  Reactive oxygen species 
can be also endogenously generated from other enzymes such as NAD(P)H-oxidases, 
xanthine oxidases, cyclooxigenases, lipooxygenases, myeloperoxidases, or uncoupled nitric 
oxide synthases. Each of these free radicals is able of oxidizing surrounding biomolecules 
thus generating other potent oxidants such as hypochlorous acid (harnessed by phagocytes 
for bacterial killing) or peroxynitrite anion (formed by the reaction of equimolecular 
amounts of nitric oxide and superoxide). However, the idea that the effects of reactive 
oxygen species on cellular functions are always deleterious is no longer valid because a 
number of studies have demonstrated that under physiological conditions low 
concentrations of reactive oxygen species play an important role in the normal regulation of 
cell and organ function. In this regard Ignarro et al (1988) demonstrated that superoxide 
dismutase enhanced arterial relaxation induced by the infusion of acetylcholine, indicating 
that there is a physiological production of a small amount of superoxide that is normally 
counteracting the vasodilatory effect of nitric oxide.  In the kidney, Zou & Cowley (2001) 
demonstrated a basal generation of superoxide anion in all renal zones with the highest 
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production in the outer medulla. Nitric oxide is a known renal vasodilator and acts as a 
natriuretic agent; superoxide has been shown to decrease renal blood flow and sodium 
excretion (Majid & Nishiyama, 2002; Majid et al, 2004, 2005; López et al, 2003; Makino et al, 
2002; Zou & Cowley, 2001). Thus, there is evidence suggesting that superoxide is an 
important physiologic modulator of endogenous NO activity, counteracting the effects of 
nitric oxide in the kidney, and that superoxide exerts a tonic regulatory action on renal 
medullary blood flow.   
Under steady-state conditions free radicals are effectively eliminated by antioxidant defense 
mechanisms that include free radical scavenging enzymes (superoxide dismutase, catalase, 
or glutathione peroxidase) and abundant radical scavenging chemicals (reduced 
glutathione, cysteine, vitamins C and E) that prevent almost completely radical chain 
reactions. However, when present in excess, a condition known as oxidative stress, they 
exert deleterious effects including lipid peroxidation, oxidative DNA damage and protein 
oxidation and nitration that collectively lead to progressive endothelial and tubular cells 
damage described in the precedent section. Generation of high levels of reactive oxygen 
species during renal ischemia/reperfusion have been confirmed directly (Zweier et al, 1994; 
Salom et al, 2007) and indirectly by measuring the effects of oxidants on lipids, proteins and 
DNA and by determining the beneficial effects of free radicals scavenging with antioxidant 
enzymes like superoxide dismutase or catalase or with antioxidants allopurinol (a xanthine 
oxidase inhibitor), tempol (an superoxide dismutase mimetic), N-acetyl-L-cysteine (an 
antioxidant), or dimethylthiourea (a hydroxyl radical scavenger)(Chatterjee et al, 2000; 
López-Conesa et al, 2001; Nitescu et al, 2006; Noiri et al, 2001; Tsuji et al, 2009). However, 
these compounds also scavenge or inhibit the formation of peroxynitrite (ONOO¯) a highly 
reactive chemical specie derived from nitric oxide and superoxide. Peroxynitrite and other 
reactive nitrogen species act together with other reactive oxygen species to damage cells, 
causing what is known as nitrosative stress. 
6. Renal vascular endothelium, nitric oxide and acute renal failure 
6.1 Vascular endothelium and nitric oxide in renal function regulation  
The endothelium is the thin layer of cells that lines the interior surface of blood vessels, 
forming an interface between circulating blood in the lumen and the rest of the vessel wall. 
The vascular endothelium regulates vascular permeability, and modulates vasomotor, 
inflammatory, and haemostatic responses and nitric oxide appears to play a key role in these 
regulatory functions (Bird, 2011; Michel, & Vanhoutte, 2010). Nitric oxide regulates vascular 
tone preventing abnormal constriction, inhibits platelet aggregation, the expression of 
adhesion molecules at the surface of endothelial cells thus inhibiting the adhesion and 
penetration of white blood cells, and the release and action of endothelin-1 (Michel & 
Vanhoutte, 2010).  
6.1.1 Nitric Oxide System  
Nitric oxide is a diatomic free-radical gas synthesized from L-arginine by a family of 
enzymes called nitric oxide synthases. There are three mammalian nitric oxide synthases 
isoforms: neuronal (nNOS), inducible (iNOS) and endothelial (eNOS). They share 50–60% 
homology at the amino acid level and have an N-terminal oxygenase domain with heme-, L-
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functional status of the renal medullary nitric oxide system after the ischemia-reperfusion 
injury is believed to be a major determinant in the development of renal failure. 
4.2 Outer medulla and ischemia-reperfusion 
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permanent damage to peritubular capillaries and influences long-term function. They 
measured a 30-50% reduction in peritubular capillary density in the outer medulla at 4, 8 
and 40 weeks after ischemia and tubulointerstitial fibrosis with increased transforming 
growth factor-1 expression at 40 weeks. Moreover, they also demonstrated an increase in 2- 
pimonidazole staining (a hypoxia-sensitive marker) in outer medulla accompanied by 
proteinuria, interstitial fibrosis and renal functional loss. They also observed that chronic L-
arginine administration in drinking water increased total renal blood flow, decreased 2- 
pimonidazole staining and attenuated or delayed the progression of chronic renal 
insufficiency after recovery from acute ischemic injury (Basile et al, 2003). On the other 
hand, López-Conesa et al (2001) reported that an antioxidant ameliorated the renal failure 
and prevented the outer medullary vasoconstriction observed after 45 min of renal ischemia, 
effects that seem to be dependent on the presence of nitric oxide and the scavenging of 
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flow and that these changes seems to be dependent on free radical production and nitric 
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can be also endogenously generated from other enzymes such as NAD(P)H-oxidases, 
xanthine oxidases, cyclooxigenases, lipooxygenases, myeloperoxidases, or uncoupled nitric 
oxide synthases. Each of these free radicals is able of oxidizing surrounding biomolecules 
thus generating other potent oxidants such as hypochlorous acid (harnessed by phagocytes 
for bacterial killing) or peroxynitrite anion (formed by the reaction of equimolecular 
amounts of nitric oxide and superoxide). However, the idea that the effects of reactive 
oxygen species on cellular functions are always deleterious is no longer valid because a 
number of studies have demonstrated that under physiological conditions low 
concentrations of reactive oxygen species play an important role in the normal regulation of 
cell and organ function. In this regard Ignarro et al (1988) demonstrated that superoxide 
dismutase enhanced arterial relaxation induced by the infusion of acetylcholine, indicating 
that there is a physiological production of a small amount of superoxide that is normally 
counteracting the vasodilatory effect of nitric oxide.  In the kidney, Zou & Cowley (2001) 
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damage described in the precedent section. Generation of high levels of reactive oxygen 
species during renal ischemia/reperfusion have been confirmed directly (Zweier et al, 1994; 
Salom et al, 2007) and indirectly by measuring the effects of oxidants on lipids, proteins and 
DNA and by determining the beneficial effects of free radicals scavenging with antioxidant 
enzymes like superoxide dismutase or catalase or with antioxidants allopurinol (a xanthine 
oxidase inhibitor), tempol (an superoxide dismutase mimetic), N-acetyl-L-cysteine (an 
antioxidant), or dimethylthiourea (a hydroxyl radical scavenger)(Chatterjee et al, 2000; 
López-Conesa et al, 2001; Nitescu et al, 2006; Noiri et al, 2001; Tsuji et al, 2009). However, 
these compounds also scavenge or inhibit the formation of peroxynitrite (ONOO¯) a highly 
reactive chemical specie derived from nitric oxide and superoxide. Peroxynitrite and other 
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arginine-, tetrahydrobiopterin (BH4)-binding domains, a central calmodulin (CaM)-binding 
region, and a C-terminal reductase domain with NADPH, FAD, and FMN binding sites 
(Stuehr, 1997). Under physiological conditions, the dominant nitric oxide synthase isoform 
in the vasculature is endothelial nitric oxide synthase, which is dynamically regulated at the 
transcriptional, posttranscriptional, and posttranslational levels (see Rafikov R et al, 2011 for 
a comprehensible review of the posttranslational control of endothelial nitric oxide 
synthase). Nitric oxide synthesis requires binding of the Ca2+/calmodulin complex, but also 
requires dimerization of endothelial nitric oxide synthase and cofactors binding for activity. 
In the inactive state, endothelial nitric oxide synthase is located in plasma membrane 
caveolae bound to inhibitory protein caveolin-1. When activated the increase in Ca2+/CaM 
releases and dimerizes endothelial nitric oxide synthase and interacts with its associated 
proteins heat shock protein 90 and Akt, and cofactors in an active complex. This activation 
process requires phosphorylation/dephosphorylation of the enzyme at different sites of 
tyrosine (Tyr-81 and Tyr-657), serine (Ser-114, Ser-615, Ser-633, and Ser-1177), and threonine 
(Thr495). The enzymes cycles between the inactive state bound to caveolin-1 in caveolae to 
cytoplasma in the activated state. The production of nitric oxide in endothelium cells is 
induced by mechanical action (shear stress) and by agonists such as acetylcholine, 
bradykinin, or histamine. Nitric oxide freely diffuses through plasma membrane to the 
underlying smooth muscles and triggers their relaxation by stimulating soluble guanylate 
cyclase that increases cyclic guanosine monophosphate levels. Nitric oxide also diffuses to 
the endothelium surface where inhibits adhesion and aggregation of platelets, modulates 
the permeability of endothelium, and inhibits endothelium-leukocytes interaction by 
reducing the expression of adhesion molecules.  
Nitric oxide also plays an important role in the regulation of the renal hemodynamic and 
excretory functions (Romero et al, 1992). Inhibition of nitric oxide synthesis has shown to 
worsen both cortical and medullary blood flow and oxygenation (Cowley et al, 2003; Brezis 
et al, 1991)., indicating that nitric oxide is important for the maintenance of renal blood flow 
after ischemia-reperfusion injury of the renal vascular bed. 
6.2 Endothelial dysfunction and acute renal failure – Role of nitric oxide 
Ischemia/reperfusion of the kidney is followed by endothelium dysfunction and injury that 
contribute to the impairment of renal perfusion and chronic hypoxia, with the subsequent 
epithelial cell injury and decrease in the glomerular filtration rate that are the hallmarks of 
acute renal failure. Endothelial dysfunction, defined as impaired vasorelaxation in response 
to endothelium-dependent vasodilators, has been observed during renal ischemia-
reperfusion (Brezis & Rosen, 1995; Cristol et al, 1993; Erdely et al, 2003; Kher et al, 2005; 
Lieberthal et al, 1989; Salom et al, 1998). Cristol et al (1993) and Salom et al (1998) reported 
renal vasoconstriction and impairment of the vasodilator effect of acetylcholine after acute 
renal ischemia. They also found that the recovery of renal blood flow observed on 
reperfusion was prevented by the previous nitric oxide synthesis inhibition. Renal 
ischemia/reperfusion is accompanied by a persistent reduction in renal blood flow of 
greater magnitude in the outer medulla. Mechanisms involved in this persistent reduction in 
renal perfusion are incompletely understood, but it has been observed endothelial cell 
swelling and detachment with trapping of red blood cells and leukocytes that produce 
vascular congestion of renal microcirculation especially in outer medulla (Olof et al, 1991; 
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Hellberg et al, 1990a, 1990b; Mason et al, 1984; Solez et al, 1974). Endothelial dysfunction in 
the outer medulla could contribute to the tubular epithelial cell injury thus determining a 
progressive fall in glomerular filtration rate in the initial and extending phases of acute renal 
failure. The key role of endothelial dysfunction in acute renal ischemia was demonstrated 
by studies of Brodsky et al, (2002) who transplanted endothelial cells or surrogate cells 
expressing endothelial nitric oxide synthase into rats subjected to renal artery clamping. 
Implantation of endothelial cells or their surrogates in the renal microvasculature resulted 
in a dramatic functional protection of ischemic kidneys. These observations strongly 
suggest that endothelial cell dysfunction is the primary cause of the no-reflow 
phenomenon, which, when ameliorated, results in prevention of renal injury seen in acute 
renal failure. 
 
Fig. 1. Outer medullary blood flow during renal ischemia/reperfusion in SD rats. 
% Change from the basal period in outer medullary blood flow during renal 
ischemia/reperfusion (45 min occlusion of renal artery) in Sprague-Dawley rats infused 
(Treat.) with saline (Control), N-acetyl-L-cysteine (150 mg/kg, as a bolus, plus 715 
µg/kg/min) or L-Name (10 µg/kg/min), or L-Name + N-acetyl-L-cysteine).† Significant 
difference from the same experimental period of the control group (López-Conesa et al, 2001) 
Endothelial dysfunction is an early event that is produced when oxygen free radicals are 
produced on reflow. Tsao et al (1990), Tsao & Lefer (1990) and Lefer & Ma (1991) in cardiac 
and splanchnic ischemia-reperfusion experiments demonstrated that endothelial 
dysfunction was related to reoxygenation and not to reflow and that this noxious effect can 
be prevented when free radical scavengers are infused before reperfusion. In the kidney, an 
increased free radical production has been demonstrated during reperfusion in in vitro 
(Kadkhodaee et al, 1995; Paller & Neumann, 1991) and in vivo experiments (Haraldsson et al, 
1992; Nilsson et al, 1993). There is indirect evidence showing that endothelial dysfunction 
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arginine-, tetrahydrobiopterin (BH4)-binding domains, a central calmodulin (CaM)-binding 
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in the vasculature is endothelial nitric oxide synthase, which is dynamically regulated at the 
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a comprehensible review of the posttranslational control of endothelial nitric oxide 
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In the inactive state, endothelial nitric oxide synthase is located in plasma membrane 
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releases and dimerizes endothelial nitric oxide synthase and interacts with its associated 
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process requires phosphorylation/dephosphorylation of the enzyme at different sites of 
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(Thr495). The enzymes cycles between the inactive state bound to caveolin-1 in caveolae to 
cytoplasma in the activated state. The production of nitric oxide in endothelium cells is 
induced by mechanical action (shear stress) and by agonists such as acetylcholine, 
bradykinin, or histamine. Nitric oxide freely diffuses through plasma membrane to the 
underlying smooth muscles and triggers their relaxation by stimulating soluble guanylate 
cyclase that increases cyclic guanosine monophosphate levels. Nitric oxide also diffuses to 
the endothelium surface where inhibits adhesion and aggregation of platelets, modulates 
the permeability of endothelium, and inhibits endothelium-leukocytes interaction by 
reducing the expression of adhesion molecules.  
Nitric oxide also plays an important role in the regulation of the renal hemodynamic and 
excretory functions (Romero et al, 1992). Inhibition of nitric oxide synthesis has shown to 
worsen both cortical and medullary blood flow and oxygenation (Cowley et al, 2003; Brezis 
et al, 1991)., indicating that nitric oxide is important for the maintenance of renal blood flow 
after ischemia-reperfusion injury of the renal vascular bed. 
6.2 Endothelial dysfunction and acute renal failure – Role of nitric oxide 
Ischemia/reperfusion of the kidney is followed by endothelium dysfunction and injury that 
contribute to the impairment of renal perfusion and chronic hypoxia, with the subsequent 
epithelial cell injury and decrease in the glomerular filtration rate that are the hallmarks of 
acute renal failure. Endothelial dysfunction, defined as impaired vasorelaxation in response 
to endothelium-dependent vasodilators, has been observed during renal ischemia-
reperfusion (Brezis & Rosen, 1995; Cristol et al, 1993; Erdely et al, 2003; Kher et al, 2005; 
Lieberthal et al, 1989; Salom et al, 1998). Cristol et al (1993) and Salom et al (1998) reported 
renal vasoconstriction and impairment of the vasodilator effect of acetylcholine after acute 
renal ischemia. They also found that the recovery of renal blood flow observed on 
reperfusion was prevented by the previous nitric oxide synthesis inhibition. Renal 
ischemia/reperfusion is accompanied by a persistent reduction in renal blood flow of 
greater magnitude in the outer medulla. Mechanisms involved in this persistent reduction in 
renal perfusion are incompletely understood, but it has been observed endothelial cell 
swelling and detachment with trapping of red blood cells and leukocytes that produce 
vascular congestion of renal microcirculation especially in outer medulla (Olof et al, 1991; 
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the outer medulla could contribute to the tubular epithelial cell injury thus determining a 
progressive fall in glomerular filtration rate in the initial and extending phases of acute renal 
failure. The key role of endothelial dysfunction in acute renal ischemia was demonstrated 
by studies of Brodsky et al, (2002) who transplanted endothelial cells or surrogate cells 
expressing endothelial nitric oxide synthase into rats subjected to renal artery clamping. 
Implantation of endothelial cells or their surrogates in the renal microvasculature resulted 
in a dramatic functional protection of ischemic kidneys. These observations strongly 
suggest that endothelial cell dysfunction is the primary cause of the no-reflow 
phenomenon, which, when ameliorated, results in prevention of renal injury seen in acute 
renal failure. 
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difference from the same experimental period of the control group (López-Conesa et al, 2001) 
Endothelial dysfunction is an early event that is produced when oxygen free radicals are 
produced on reflow. Tsao et al (1990), Tsao & Lefer (1990) and Lefer & Ma (1991) in cardiac 
and splanchnic ischemia-reperfusion experiments demonstrated that endothelial 
dysfunction was related to reoxygenation and not to reflow and that this noxious effect can 
be prevented when free radical scavengers are infused before reperfusion. In the kidney, an 
increased free radical production has been demonstrated during reperfusion in in vitro 
(Kadkhodaee et al, 1995; Paller & Neumann, 1991) and in vivo experiments (Haraldsson et al, 
1992; Nilsson et al, 1993). There is indirect evidence showing that endothelial dysfunction 
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appears to be due to the generation of oxygen free radicals during reperfusion (Lieberthal, 
1997; Salom et al, 1998). When infused before reperfusion, oxygen free radical scavengers 
exert a beneficial effect by preventing oxygen free radical production during reoxygenation 
(Baker et al, 1985; Hansson et al, 1990; Nilsson et al, 1993; Salom et al, 1998). In addition, the 
beneficial effect of some scavengers has been attributed to nitric oxide potentiation 
(Caramelo et al, 1996; López-Neblina et al, 1996; Salom et al, 1998), suggesting that the 
inactivation of nitric oxide by free radical is an important factor contributing to postischemic 
acute renal failure. This hypothesis was tested by López-Conesa et al, (2001) who found that 
N-acetyl-L-cysteine, a free radical scavenger, ameliorated the renal failure, and prevented 
the outer medullary vasoconstriction and the increase in plasma concentration of rhodamine 
123 (index of peroxynitrite production) induced by renal ischemia. These results suggest 
that beneficial effects of N-acetyl-L-cysteine seem to be dependent on the presence of nitric 
oxide and the scavenging of peroxynitrite.  
6.3 Ischemic preconditioning 
Ischemic preconditioning is a phenomenon induced by brief ischemia and reperfusion 
periods that renders an organ more tolerant to subsequent sustained ischemia/reperfusion. 
In preconditioned kidneys, the sustained ischemia produces only small increases in plasma 
creatinine and in fractional sodium excretion, accompanied by markedly attenuated outer 
medullary congestion and leukocyte infiltration (Park et al, 2001, 2002). The mechanisms 
underlying this protective effect against injury are not well known. However, several 
candidates that could potentially serve as mediators of the preconditioning phenomenon 
have been identified. One of them, the nitric oxide synthase pathway, seems to be of 
importance. Park et al (2003) observed that prior ischemia results in prolonged increase in 
endothelial and inducible nitric oxide synthases (eNOS and iNOS). Torras et al (2002) 
observed that the protection afforded by ischemic preconditioning is abrogated by the 
inhibition of iNOS, and reproduced by a nitric oxide donor. Park et al (2003) showed that 
gene deletion of inducible (but not endothelial) nitric oxide synthase increases the kidney 
susceptibility to ischemia. In apparent contradiction, Yamasowa et al (2005) found that 
preconditioning in eNOS+/+ mice markedly attenuated the renal dysfunction and improved 
the histological renal damage that follow ischemia/reperfusion (medullary congestion, 
intratubular casts or tubular necrosis). Preconditioning also prevented the marked decrease 
in endothelial nitric oxide synthase activity observed 6 hours after ischemia. (Yamasowa et 
al, 2005). The effects of preconditioning were abolished by a non-selective inhibitor of nitric 
oxide synthases, whereas aminoguanidine (a selective inhibitor of the inducible isoform) 
had no effect. A role for nitric oxide has also been reported by Jefayri et al (2000). 
Differences in the length of time between the first (preconditioning) and the second ischemic 
episode may explain differences observed between these studies. Park et al (2003) 
performed the second ischemia 1, 3, 4, 6, 10, or 12 weeks after the first (preconditioning) 
ischemia and at that time the expression of inducible but not endothelial nitric oxide 
synthase was significantly increased and nitric oxide levels before the second ischemia were 
high due to inducible isoform of the enzyme. In the study of Yamasowa et al (2005) the 
second ischemia was performed immediately after the preconditioning was finished (5 min). 
Yamasowa et al found that preconditioning prevents the decrease in endothelial nitric oxide 
synthase activity and prevented the increase in inducible nitric oxide synthase activity 
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observed after 6 h of reperfusion. As Nakajima et al (2006) observed an increased 
production of superoxide in the first day after the ischemia, the inhibition of inducible nitric 
oxide synthase could theoretically prevent the formation of high levels of peroxynitrite. This 
could explain why inhibition of inducible nitric oxide synthase before the ischemia reduces 
renal ischemia/reperfusion injury (Chatterjee et al, 2002; Walker et al, 2000) and why 
inhibition of inducible nitric oxide synthase before the ischemia prevents renal 
microvascular hypoxia and inhibition of endothelial isoform aggravates renal function 
(Legrand et al, 2009). The data of these studies indicate that preconditioning protects the 
kidney partly by increasing nitric oxide levels due to the increase in endothelial (early 
protecting effect) or in the inducible nitric oxide synthase activity (long lasting protective 
effect). The studies of Nakajima et al (2006) who observed a significant attenuation of 
nitrotyrosine formation, neutrophil infiltration into renal tissues, and renal superoxide 
production, that were significantly attenuated by the preischemic treatment with a nitric 
oxide donor. Thus, a better understanding of ischemic preconditioning may help to unravel 
the underlying mechanisms of protection that mediate this tolerance against injury.  
7. Oxidative and nitrosative stress and endothelial dysfunction in ischemic 
acute kidney injury  
Endothelial dysfunction and oxidative stress are the main pathophysiological mechanisms 
of several diseases such as hypertension, atherosclerosis, dyslipidemia, diabetes mellitus, 
cardiovascular disease, renal failure and ischemia-reperfusion injury. Reactive oxygen 
species can modulate cellular function, receptor signals and immune responses in 
physiological conditions, but when present in excess, they mediate progressive endothelial 
damage through growth and migration of vascular smooth muscle and inflammatory cells, 
alteration of extracellular matrix, apoptosis of endothelial cells, activation of transcription 
factors (NFkB, AP-1), and over-expression of inflammatory cytokines and adhesion 
molecules (ICAM-1, VCAM-1 , E-selectin). Recent evidences suggest that the major source of 
reactive oxygen species is the NADPH-oxidase, especially activated by angiotensin II, shear 
stress and hyperglycemia. The unbalance between production of free radicals and the ability 
to neutralize them by antioxidant systems causes a condition of "oxidative stress". Reactive 
oxygen species alter vascular tone by increasing concentration of cytosolic calcium and 
especially causing a decreased availability of nitric oxide, the principal agent of endothelial 
function with vasodilating action (Urso & Caimi, 2011). 
Ischemia/reperfusion is accompanied by an increase in radical oxygen species, a situation 
known as oxidative stress. The superoxide anion formed reacts with nitric oxide and 
inactivates nitric oxide (endothelial dysfunction) producing peroxynitrite, a highly reactive 
oxidant specie that exerts profound deleterious effects on renal function. The amount of 
peroxynitrite and, thus, the severity of postischemic acute kidney injury will depend on the 
relative concentration of both nitric oxide and superoxide (Miles et al, 1996) in such a way 
that the higher the nitric oxide concentration, the lower peroxynitrite will be formed and 
less renal damage will take place after ischemia. Renal nitric oxide levels increase 
dramatically during ischemia decreasing to near preischemic levels on reperfusion (Figure 
1). The increase in nitric oxide concentration seems to be independent of nitric oxide 
synthases and appears to originate in tissue nitric oxide stores that release nitric oxide 
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appears to be due to the generation of oxygen free radicals during reperfusion (Lieberthal, 
1997; Salom et al, 1998). When infused before reperfusion, oxygen free radical scavengers 
exert a beneficial effect by preventing oxygen free radical production during reoxygenation 
(Baker et al, 1985; Hansson et al, 1990; Nilsson et al, 1993; Salom et al, 1998). In addition, the 
beneficial effect of some scavengers has been attributed to nitric oxide potentiation 
(Caramelo et al, 1996; López-Neblina et al, 1996; Salom et al, 1998), suggesting that the 
inactivation of nitric oxide by free radical is an important factor contributing to postischemic 
acute renal failure. This hypothesis was tested by López-Conesa et al, (2001) who found that 
N-acetyl-L-cysteine, a free radical scavenger, ameliorated the renal failure, and prevented 
the outer medullary vasoconstriction and the increase in plasma concentration of rhodamine 
123 (index of peroxynitrite production) induced by renal ischemia. These results suggest 
that beneficial effects of N-acetyl-L-cysteine seem to be dependent on the presence of nitric 
oxide and the scavenging of peroxynitrite.  
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Ischemic preconditioning is a phenomenon induced by brief ischemia and reperfusion 
periods that renders an organ more tolerant to subsequent sustained ischemia/reperfusion. 
In preconditioned kidneys, the sustained ischemia produces only small increases in plasma 
creatinine and in fractional sodium excretion, accompanied by markedly attenuated outer 
medullary congestion and leukocyte infiltration (Park et al, 2001, 2002). The mechanisms 
underlying this protective effect against injury are not well known. However, several 
candidates that could potentially serve as mediators of the preconditioning phenomenon 
have been identified. One of them, the nitric oxide synthase pathway, seems to be of 
importance. Park et al (2003) observed that prior ischemia results in prolonged increase in 
endothelial and inducible nitric oxide synthases (eNOS and iNOS). Torras et al (2002) 
observed that the protection afforded by ischemic preconditioning is abrogated by the 
inhibition of iNOS, and reproduced by a nitric oxide donor. Park et al (2003) showed that 
gene deletion of inducible (but not endothelial) nitric oxide synthase increases the kidney 
susceptibility to ischemia. In apparent contradiction, Yamasowa et al (2005) found that 
preconditioning in eNOS+/+ mice markedly attenuated the renal dysfunction and improved 
the histological renal damage that follow ischemia/reperfusion (medullary congestion, 
intratubular casts or tubular necrosis). Preconditioning also prevented the marked decrease 
in endothelial nitric oxide synthase activity observed 6 hours after ischemia. (Yamasowa et 
al, 2005). The effects of preconditioning were abolished by a non-selective inhibitor of nitric 
oxide synthases, whereas aminoguanidine (a selective inhibitor of the inducible isoform) 
had no effect. A role for nitric oxide has also been reported by Jefayri et al (2000). 
Differences in the length of time between the first (preconditioning) and the second ischemic 
episode may explain differences observed between these studies. Park et al (2003) 
performed the second ischemia 1, 3, 4, 6, 10, or 12 weeks after the first (preconditioning) 
ischemia and at that time the expression of inducible but not endothelial nitric oxide 
synthase was significantly increased and nitric oxide levels before the second ischemia were 
high due to inducible isoform of the enzyme. In the study of Yamasowa et al (2005) the 
second ischemia was performed immediately after the preconditioning was finished (5 min). 
Yamasowa et al found that preconditioning prevents the decrease in endothelial nitric oxide 
synthase activity and prevented the increase in inducible nitric oxide synthase activity 
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observed after 6 h of reperfusion. As Nakajima et al (2006) observed an increased 
production of superoxide in the first day after the ischemia, the inhibition of inducible nitric 
oxide synthase could theoretically prevent the formation of high levels of peroxynitrite. This 
could explain why inhibition of inducible nitric oxide synthase before the ischemia reduces 
renal ischemia/reperfusion injury (Chatterjee et al, 2002; Walker et al, 2000) and why 
inhibition of inducible nitric oxide synthase before the ischemia prevents renal 
microvascular hypoxia and inhibition of endothelial isoform aggravates renal function 
(Legrand et al, 2009). The data of these studies indicate that preconditioning protects the 
kidney partly by increasing nitric oxide levels due to the increase in endothelial (early 
protecting effect) or in the inducible nitric oxide synthase activity (long lasting protective 
effect). The studies of Nakajima et al (2006) who observed a significant attenuation of 
nitrotyrosine formation, neutrophil infiltration into renal tissues, and renal superoxide 
production, that were significantly attenuated by the preischemic treatment with a nitric 
oxide donor. Thus, a better understanding of ischemic preconditioning may help to unravel 
the underlying mechanisms of protection that mediate this tolerance against injury.  
7. Oxidative and nitrosative stress and endothelial dysfunction in ischemic 
acute kidney injury  
Endothelial dysfunction and oxidative stress are the main pathophysiological mechanisms 
of several diseases such as hypertension, atherosclerosis, dyslipidemia, diabetes mellitus, 
cardiovascular disease, renal failure and ischemia-reperfusion injury. Reactive oxygen 
species can modulate cellular function, receptor signals and immune responses in 
physiological conditions, but when present in excess, they mediate progressive endothelial 
damage through growth and migration of vascular smooth muscle and inflammatory cells, 
alteration of extracellular matrix, apoptosis of endothelial cells, activation of transcription 
factors (NFkB, AP-1), and over-expression of inflammatory cytokines and adhesion 
molecules (ICAM-1, VCAM-1 , E-selectin). Recent evidences suggest that the major source of 
reactive oxygen species is the NADPH-oxidase, especially activated by angiotensin II, shear 
stress and hyperglycemia. The unbalance between production of free radicals and the ability 
to neutralize them by antioxidant systems causes a condition of "oxidative stress". Reactive 
oxygen species alter vascular tone by increasing concentration of cytosolic calcium and 
especially causing a decreased availability of nitric oxide, the principal agent of endothelial 
function with vasodilating action (Urso & Caimi, 2011). 
Ischemia/reperfusion is accompanied by an increase in radical oxygen species, a situation 
known as oxidative stress. The superoxide anion formed reacts with nitric oxide and 
inactivates nitric oxide (endothelial dysfunction) producing peroxynitrite, a highly reactive 
oxidant specie that exerts profound deleterious effects on renal function. The amount of 
peroxynitrite and, thus, the severity of postischemic acute kidney injury will depend on the 
relative concentration of both nitric oxide and superoxide (Miles et al, 1996) in such a way 
that the higher the nitric oxide concentration, the lower peroxynitrite will be formed and 
less renal damage will take place after ischemia. Renal nitric oxide levels increase 
dramatically during ischemia decreasing to near preischemic levels on reperfusion (Figure 
1). The increase in nitric oxide concentration seems to be independent of nitric oxide 
synthases and appears to originate in tissue nitric oxide stores that release nitric oxide 
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during ischemia (Salom et al, 2005). Combined with superoxide produced during ischemia, 
the nitric oxide increase appears to be responsible for an important part of the ensuing renal 
damage.  
It has been reported that arterial ischemia produces an abrupt and significant increase in 
tissue nitric oxide concentration, which can last as long as ischemia is maintained and 
returns to preischemic levels during reperfusion. This phenomenon has been observed in 
kidney (Saito & Miyawaga, 2000) as well as in other organs (Lhuillier et al, 2003; Zweier et 
al, 1999). Although its physiological relevance is unclear, it may generate the high levels of 
peroxynitrite anion formed during reperfusion when a burst of superoxide anion reacts with 
the high levels of nitric oxide accumulated during ischemia (Miles et al, 1996), thus 
contributing to reperfusion damage. The mechanism responsible for these increased nitric 
oxide levels during renal ischemia is unknown, although it seems to be partially insensitive 
to nitric oxide synthesis inhibition, at least in liver and kidney (Lhuillier et al, 2003; Saito & 
Miyawaga, 2000). This is not surprising because nitric oxide synthase requires molecular 
oxygen. Therefore, during ischemia, nitric oxide must be released from other sources, such 
as tissue nitric oxide stores (Muller et al, 1996; Rodriguez et al, 2003; Sogo et al, 2000). 
In the presence of oxygen, nitric oxide is synthesized from L-arginine through the action of 
nitric oxide synthase, and this gaseous hormone acts in the kidney by stimulating guanylyl 
cyclase and by inhibiting cytochrome P-450 (López et al, 2003). However, as soon as it is 
synthesized, nitric oxide avidly reacts with molecular oxygen, superoxide anion, and heme 
groups. The wide availability of these nitric oxide scavengers in all tissues argues against 
the simple diffusion-limited transport of free nitric oxide from synthase to cyclase or 
cytochrome. This implies that nitric oxide must be stabilized in vivo by reacting with carrier 
molecules that prolong its half-life and preserve its biological activity. This role may be 
subserved by biological molecules containing sulfhydryl groups that readily react with 
nitric oxide to form S-nitrosothiols (Stamler et al, 1992b), which are significantly more stable 
than nitric oxide itself and have been shown to be long-lasting and potent vasodilators. 
These compounds have been postulated to be biologically active intermediates in the 
mechanism of action of nitric oxide (Stamler 1992a). From this point of view, it has been 
shown that, at physiological concentrations, nitric oxide reacts with thiols in the presence of 
oxygen to form S-nitrosoglutathione (Kharitonov et al, 1995) and that nitric oxide circulates 
in mammalian plasma as nitrosothiols, mainly S-nitroso-serum albumin (Stamler et al, 
1992a). The abundance of S-nitrosothiols in plasma compared with that of nitric oxide (3- to 
4-fold) (Stamler et al, 1992a) suggests that plasma S-nitrosothiols may serve as a reservoir of 
nitric oxide, acting as an effective buffer (Lhuillier et al, 2003). This has also been shown in 
vascular tissue (Muller et al, 1996), where S-nitrosothiols are known to cause a prolonged 
nitric oxide-dependent relaxation (Sogo et al, 2000). These facts led us to hypothesize that 
renal ischemia induces an increase in tissue nitric oxide levels likely coming from tissue 
nitrosothiol stores and therefore that this phenomenon should be dependent on the presence 
of thiol groups in the tissue. In a study performed in our laboratories (Salom et al, 2005) we 
found that renal ischemia is followed by a rapid increase in intrarenal nitric oxide 
concentration that is maintained until reperfusion, when a fast drop in nitric oxide levels 
near preischemic values is observed. The increased nitric oxide concentration observed 
seems to be independent of nitric oxide synthase and appears to originate in tissue nitric 
oxide stores that release nitric oxide during ischemia. 
 




Fig. 2. Changes in nitric oxide levels in Outer Medulla during renal ischemia/reperfusion 
Changes in nitric oxide levels in outer medulla before, during and after a 45 min renal artery 
occlusion in SD rats infused with either saline (Ischemia) or L-Name (10 µg/kg/min, 
Ischemia + L-Name). ).† Significant difference from the control period (-30 min) (Salom MG 
et al, 2005) 
8. Sex differences in renal response to AKI 
Females are known to suffer less severe renal I/R injury than males (Hutchens et al, 2008; 
Kang et al, 2004; Kher et al, 2005; Si et al, 2009; Wei et al, 2005; Xue et al, 2006) being the 
incidence of end stage renal disease approximately 50% higher in men than women. 
However, the mechanisms explaining this difference remain to be determined. It has been 
hypotethized that sex differences could be due to a higher renal constitutive nitric oxide 
synthase activity and/or increased nitric oxide bioavailability in females that protects the 
kidney against I/R injury (Chambliss & Shaul, 2002). However, lower, higher, or similar 
levels of endothelial and neuronal nitric oxide synthase expression in renal homogenates, 
cortex, and medulla of males and females have been reported (Erdely et al, 2003; Ji et al, 
2005; Reckelhoff et al, 1998; Rodriguez et al, 2010; Wang et al, 2006; Wangensteen et al, 
2004).  However, the physiological meaning of nitric oxide synthase expression alone is 
uncertain, because dissociation between nitric oxide synthase expression and activity has 
been reported (Reckelhoff et al, 1998). The fact that nitric oxide availability depends not only 
on nitric oxide synthase expression and activity but also on the production of reactive 
oxygen species (because they inactivate nitric oxide in a concentration-dependent manner) 
also implies that sex differences could be due to a lower oxidative stress in females leading 
to increased nitric oxide levels (Arnal et al, 1996; Barbacanne et al, 1999) compared with 
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during ischemia (Salom et al, 2005). Combined with superoxide produced during ischemia, 
the nitric oxide increase appears to be responsible for an important part of the ensuing renal 
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peroxynitrite anion formed during reperfusion when a burst of superoxide anion reacts with 
the high levels of nitric oxide accumulated during ischemia (Miles et al, 1996), thus 
contributing to reperfusion damage. The mechanism responsible for these increased nitric 
oxide levels during renal ischemia is unknown, although it seems to be partially insensitive 
to nitric oxide synthesis inhibition, at least in liver and kidney (Lhuillier et al, 2003; Saito & 
Miyawaga, 2000). This is not surprising because nitric oxide synthase requires molecular 
oxygen. Therefore, during ischemia, nitric oxide must be released from other sources, such 
as tissue nitric oxide stores (Muller et al, 1996; Rodriguez et al, 2003; Sogo et al, 2000). 
In the presence of oxygen, nitric oxide is synthesized from L-arginine through the action of 
nitric oxide synthase, and this gaseous hormone acts in the kidney by stimulating guanylyl 
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Fig. 2. Changes in nitric oxide levels in Outer Medulla during renal ischemia/reperfusion 
Changes in nitric oxide levels in outer medulla before, during and after a 45 min renal artery 
occlusion in SD rats infused with either saline (Ischemia) or L-Name (10 µg/kg/min, 
Ischemia + L-Name). ).† Significant difference from the control period (-30 min) (Salom MG 
et al, 2005) 
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incidence of end stage renal disease approximately 50% higher in men than women. 
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hypotethized that sex differences could be due to a higher renal constitutive nitric oxide 
synthase activity and/or increased nitric oxide bioavailability in females that protects the 
kidney against I/R injury (Chambliss & Shaul, 2002). However, lower, higher, or similar 
levels of endothelial and neuronal nitric oxide synthase expression in renal homogenates, 
cortex, and medulla of males and females have been reported (Erdely et al, 2003; Ji et al, 
2005; Reckelhoff et al, 1998; Rodriguez et al, 2010; Wang et al, 2006; Wangensteen et al, 
2004).  However, the physiological meaning of nitric oxide synthase expression alone is 
uncertain, because dissociation between nitric oxide synthase expression and activity has 
been reported (Reckelhoff et al, 1998). The fact that nitric oxide availability depends not only 
on nitric oxide synthase expression and activity but also on the production of reactive 
oxygen species (because they inactivate nitric oxide in a concentration-dependent manner) 
also implies that sex differences could be due to a lower oxidative stress in females leading 
to increased nitric oxide levels (Arnal et al, 1996; Barbacanne et al, 1999) compared with 
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males (Brandes & Mügge, 1997).  Thus, the reduced susceptibility of females to I/R injury 
may be due to a greater nitric oxide synthase activation, nitric oxide bioavailability, and/or 
lower free radicals formation during ischemia and early reperfusion, resulting in a less 
severe acute renal failure. In a recent study performed in our laboratory (Rodríguez et al 
2010) we evaluated sex differences in outer medullary changes of nitric oxide and 
peroxynitrite levels during 45 min of ischemia and 60 min of reperfusion in SD rats.  No sex 
differences were observed in endothelial and neuronal nitric oxide synthases nor in nitric 
oxide and peroxynitrite levels. We also found that a 45-min ischemia was followed after 24 h 
of reperfusion by a postischemic renal failure in males but not in females. This sex difference 
was associated with lower nitric oxide and greater peroxynitrite and 3-nitrotyrosine levels in 
males during ischemia, indicating increased oxidative and nitrosative stress. Pretreatment 
with the antioxidants N-acetyl-L-cysteine or ebselen abolished sex differences in 
peroxynitrite, nitrotyrosine, and glomerular filtration rate, suggesting that a greater 
oxidative and nitrosative stress worsens renal damage in males. Taken together, the data in 
the present study strongly suggest that the resistance of females to renal failure may be 
related to a greater renal tissular antioxidant capacity that could blunt the conversion of  
nitric oxide to peroxynitrite during ischemia. 
9. Role of heme oxygenase system in renal I/R 
Heme is a ubiquitous molecule with an active iron center with high affinity for oxygen 
which allows for transport of oxygen in hemoglobin and myoglobin. Heme also serves as 
the catalytic site in a variety of proteins involved in cell metabolism including respiratory 
chain cytochromes and numerous cytochrome P450 isoenzymes (Maines, 1997). Oxidative 
stress destabilizes heme proteins, leading to free heme release, which has prooxidant and 
toxic effects through free radical formation, and lipid peroxidation in renal tissues,  (Akagi 
et al, 2002). 
Intracellular free levels are tightly controlled in most cells and tissues by heme oxigenases 
(HO) which catalyze the initial and rate limiting step in heme catabolism (Tenhunen et al, 
1968). Oxidative cleavage of heme molecules by HO yields equimolar quantities of 
biliverdin (BV), carbon monoxide (CO), and Fe+2.  Biliverdin undergoes further degradation 
to bilirubin (BR) by the cytosolic biliverdin reductase. All HO-derived products are 
biologically active substances: biliverdin and iron are believe to subserve antioxidant and 
prooxidant mechanisms, respectively (Abraham et al, 1997), whereas HO-derived CO exerts 
exerts vasorelaxant (Zhang et al, 2001), antiapoptotic, and anti-inflammatory effects.  
Oxidative stress promotes the upregulation of the inducible isoform of heme oxygenase 
(HO-1) (Motterlini et al, 2002), which is expressed, along with the constitutive HO-2 isoform, 
in renal vascular and tubular structures in renal cortex and medulla (Abraham et al, 2009).  
HO-1 and HO-2 catalyze the same reaction and have similar cofactors requirements, but 
they differ with respect to the regulation and expression pattern.  HO-2 accounts for the 
bulk of renal HO activity in normal conditions, whereas HO-1 operates as an inducible 
enzyme with low renal levels in the healthy kidney (Da Silva, 2001), but markedly increased 
in pathological conditions associated to hypoxia and inflammation (Otterbein et al, 2003). 
Ischemia compromises organ function, which is further aggravated upon reperfusion, as a 
consequence of endothelial dysfunction, high levels of oxidative stress, altered renal 
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hemodynamic,  and activation of the immune response. HO-1 prior to the induction of I/R 
results in functional protection in ischemic renal failure (Maines, 1999), which is partially 
mediated by reduction of oxidative and nitrosative stress during ischemia (Salom et al, 
2007). Moreover, in the same way that HO metabolites maintain renal medullary perfusion 
(Zou et al, 2000), glomerular filtration rate and renal blood flow (Arregui B, 2004) in 
physiological conditions, HO-1 induction preserved postischemic medullary blood flow and 
GFR, in ischemic renal failure, (Salom et al, 2007). Overall, HO-1 induction might have 
multiple beneficial functions in I/R injury a) by reducing oxidative stress insults b) by 
preserving alteration of renal hemodynamic which contributes greatly to the subsequent 
renal failure and c) via suppression of the immune response through its anti-inflammatory 
actions, (Kotsch et al, 2007). 
The molecular mechanisms underlying the protective role of HO induction in I/R injury are 
complex and likely multifactorial. Increased HO-1 activity in acute renal ischemia would 
result in the removal of the potent cell stressor heme (Akagi et al, 2005), but protection is 
also a consequence of the production of biologically active metabolites, i.e, CO, and BV. In 
this regard, the preadministration of exogenous CO donors in vivo have demonstrated 
functional protection comparable to HO-1 induction, pointing out to CO as a key component 
of the protection associated with HO-1 induction (Vera et al, 2005). Moreover, studies 
combining inhaled CO and infused bilirubin in rat renal transplantation demonstrated 
synergistic effects on glomerular filtration rate and renal blood flow  (Nakao et al, 2005) 
suggesting also a role of bilirubin production in cytoprotection against 
ischemia/reperfusion injury. Finally, HO induction, through a variety of mechanisms, can 
reduce NO synthesis and, consequently, diminish augmented peroxynitrite formation 
during ischemia (Salom MG, 2007). 
10. Concluding remarks, perspectives and significance 
Ischemic injury to the renal vasculature may play an important role in the pathogenesis of 
both early and chronic ischemic acute kidney injury (AKI). Established and new data 
support the suggestion that vascular injury, in particular endothelial cell injury, participates 
in the extent and maintenance of AKI. Early alterations in peritubular capillary blood flow 
during reperfusion has been documented and associated with loss of normal endothelial cell 
function, which can be replaced pharmacologically or with cell replacement interventions. 
Distorted peritubular capillary morphology is associated with loss of barrier function that 
may contribute to early alterations in vascular stasis. In addition, ischemia induces 
alterations in endothelial cells that may promote inflammation and procoagulant activity, 
thus contributing to vascular congestion. Reductions in microvasculature density may play 
a critical part in the progression of chronic kidney disease following initial recovery from 
ischemia/reperfusion-induced AKI. The exact nature of how capillary loss alters renal 
function and predisposes renal disease is thought to be due at least in part to oxidative and 
nitrosative stress causing an endothelial balance between nitric oxide and peroxynitrite. 
Restoring the imbalance between nitric oxide and peroxynitrite will ameliorate endothelial 
dysfunction thus improving renal function. Finally, the loss of endothelial cell function may 
represent an important therapeutic target in which nitric oxide, vascular trophic support, 
and/or endothelial progenitor cells may show potential importance in ameliorating the 
acute and/or chronic effects of ischemic AKI. The use of drugs like statins that increase 
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hemodynamic,  and activation of the immune response. HO-1 prior to the induction of I/R 
results in functional protection in ischemic renal failure (Maines, 1999), which is partially 
mediated by reduction of oxidative and nitrosative stress during ischemia (Salom et al, 
2007). Moreover, in the same way that HO metabolites maintain renal medullary perfusion 
(Zou et al, 2000), glomerular filtration rate and renal blood flow (Arregui B, 2004) in 
physiological conditions, HO-1 induction preserved postischemic medullary blood flow and 
GFR, in ischemic renal failure, (Salom et al, 2007). Overall, HO-1 induction might have 
multiple beneficial functions in I/R injury a) by reducing oxidative stress insults b) by 
preserving alteration of renal hemodynamic which contributes greatly to the subsequent 
renal failure and c) via suppression of the immune response through its anti-inflammatory 
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this regard, the preadministration of exogenous CO donors in vivo have demonstrated 
functional protection comparable to HO-1 induction, pointing out to CO as a key component 
of the protection associated with HO-1 induction (Vera et al, 2005). Moreover, studies 
combining inhaled CO and infused bilirubin in rat renal transplantation demonstrated 
synergistic effects on glomerular filtration rate and renal blood flow  (Nakao et al, 2005) 
suggesting also a role of bilirubin production in cytoprotection against 
ischemia/reperfusion injury. Finally, HO induction, through a variety of mechanisms, can 
reduce NO synthesis and, consequently, diminish augmented peroxynitrite formation 
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support the suggestion that vascular injury, in particular endothelial cell injury, participates 
in the extent and maintenance of AKI. Early alterations in peritubular capillary blood flow 
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hemo oxygenase-1 expression, and restores the normal imbalance beween nitric oxide and 
peroxynitrite (Heeba et al, 2009) and reduce postischemic renal failure (Gueler et al, 2002) 
seem to be promissory. 
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1. Introduction 
There are about quarter of million patients on chronic renal replacement therapy in Europe, 
and the estimated number of patients with chronic kidney disease, stages 1-4 is about 
tenfold higher. Interestingly, regardless of the initiating cause (infection, autoimmune 
response, chemical insult, radiation or tissue injury etc.), the mechanism of fibrosis is similar 
in the different chronic kidney diseases and characterized by inflammation. In general, the 
damaged glomerular or tubular cells release danger signals (Anders, 2010; McDonald et al., 
2010) and produce chemotactic stimuli, which trigger the rapid recruitment of leukocytes.  
The infiltrating immune and the damaged renal cells then produce high levels of 
proinflammatory cytokines, growth factors, chemokines and adhesion molecules which 
contribute to glomerular/tubular injury, accumulation of further leukocytes and 
myofibroblasts, which are the effector cells of renal fibrosis. However the origin of the 
myofibroblasts is still controversial recent hypotheses suggest that myofibroblasts can 
originate from different renal cells, such as epithelial and endothelial cells, pericytes or the 
bone marrow derived fibrocytes. The thus generated myofibroblasts then serves as the key 
cellular mediator of renal fibrosis. Myofibroblasts have migratory capacity, are resistant to 
apoptosis, produce several growth factors and cytokines and according to our present 
knowledge these cells are the main source of the collagen-I and collagen-III rich extracellular 
matrix in the fibrous tissue. Organ fibrosis is characterized by excessive deposit of 
extracellular matrix (ECM) leading to glomerular sclerosis and renal tubule-interstitium 
fibrosis. The excessive deposition of fibrous tissue replaces healthy kidney tissue; the 
nephrons disappear and the kidney function gradually declines. In this chapter we will 
summarize our knowledge about the role of immune cells and molecular changes leading to 
generation of renal myofibroblasts. 
2. Role of immune system 
Progressive renal diseases always have an inflammatory component, characterized by the 
infiltration of different leukocytes, overexpression of inflammatory genes and release of pro-
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The infiltrating immune and the damaged renal cells then produce high levels of 
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contribute to glomerular/tubular injury, accumulation of further leukocytes and 
myofibroblasts, which are the effector cells of renal fibrosis. However the origin of the 
myofibroblasts is still controversial recent hypotheses suggest that myofibroblasts can 
originate from different renal cells, such as epithelial and endothelial cells, pericytes or the 
bone marrow derived fibrocytes. The thus generated myofibroblasts then serves as the key 
cellular mediator of renal fibrosis. Myofibroblasts have migratory capacity, are resistant to 
apoptosis, produce several growth factors and cytokines and according to our present 
knowledge these cells are the main source of the collagen-I and collagen-III rich extracellular 
matrix in the fibrous tissue. Organ fibrosis is characterized by excessive deposit of 
extracellular matrix (ECM) leading to glomerular sclerosis and renal tubule-interstitium 
fibrosis. The excessive deposition of fibrous tissue replaces healthy kidney tissue; the 
nephrons disappear and the kidney function gradually declines. In this chapter we will 
summarize our knowledge about the role of immune cells and molecular changes leading to 
generation of renal myofibroblasts. 
2. Role of immune system 
Progressive renal diseases always have an inflammatory component, characterized by the 
infiltration of different leukocytes, overexpression of inflammatory genes and release of pro-
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inflammatory cytokines. In the following paragraphs we will summarise the role of the 
different immune cells in the pathomechanism of renal fibrosis. 
2.1 Neutrophil granulocytes 
Neutrophil granulocytes are polymorphonuclear cells, which constitute the majority of 
circulating leukocytes and respond quickly to chemotactic stimuli. They are the first 
immune cells, which migrate to the inflamed tissue and eliminate the pathogens and tissue 
debris by enzymatic degradation or by reactive oxygen species; moreover, they attract and 
activate further immune cells by producing different chemokines and cytokines. These cells 
are generally regarded as short-lived and terminally differentiated leukocytes. Kidney 
injury leads to the rapid influx of neutrophils and subsequent monocyte and other leukocyte 
recruitment (Machida et al., 2010). Damaged renal cells produce different cytokines and 
chemokines (e.g.: interleukin (IL)-8 (Hang et al., 2000; Topley et al., 2005), IL-17 (Kitching et 
al., 2011) macrophage inflammatory protein (MIP)-1, monocyte chemoattractant protein 
(MCP)-1 (Li et al., 2005)) which - among other leukocytes – efficiently attract neutrophils. 
Neutrophils become activated by immune complexes became trapped in the glomerulus or 
through pattern recognition receptors by damage associated or pathogen-associated 
molecular patterns (DAMP/PAMP) signals (like macrophages, see in details later). In 
response to specific stimuli, neutrophils have the capacity to synthesize several factors such 
as extracellular matrix and antimicrobial proteins (defensins), reactive oxygen species, 
cytokines (IL-1-β, tumor necrosis factor (TNF)-α) and chemokines (IL-8, MIPs) that can 
contribute in regulating the inflammatory response (Cassatella, 1999; Sawyer et al., 1989;  
Fantone & Ward, 1985). Neutrophils are able to generate arachidonic acid-derived lipid 
mediators, such as leukotriene B4, which is also a potent chemoattractant for leukocytes 
(Busse, 1998). Neutrophils have been shown to generate prostaglandin E2 and tromboxane 
via the inducible cyclooxigenase 2 pathway (Maloney et al, 1998). Prostaglandine E2 has 
both pro-and anti-inflammatory properties, for example it regulates vascular permeability, 
so contribute the accumulation of immune cells to the target tissue. Many of these cytokine-, 
lipid- and oxygen-derived mediators are regulated by nuclear factor (NF)-κB activation, 
which supports neutrophils in direct pathogen killing (Blackwell et al., 1997). Although 
these important host defense functions, neutrophils also have an destructive capacity and 
can elicit significant tissue damage. For example, in antineutrophil cytoplasmic antibody -
associated diseases immune complexes became trapped on the endothelial surface in the 
vasculature of glomerulus, and the local activation of neutrophils and monocytes may 
disrupt the integrity of tissue architecture (Weidner et al., 2004). Human 
polymorphonuclear cells may be activated by particulate uromodulin (also known as: 
Tamm-Horsfall glycoprotein), which is the most abundant protein excreted in the urine 
under physiological conditions, but its biological function is still not fully understood 
(Rampoldi et al., 2011). Neutrophil-uromodulin interaction in the renal interstitium is 
characterized by the activation of the respiratory burst, as well as by comprehensive 
polymorphonuclear cell degranulations, which lead to marked tissue damage and 
eventually result in interstitial fibrosis (Horton et al., 1990). Ichino et al has been detected a 
marked upregulation of neutrophil-gelatinase associated lipocalin at the mRNA and protein 
levels in a rat model of renal scarring. This molecule has been proposed over the past years 
as emergent biomarkers for the early and accurate diagnosis and monitoring of acute kidney 
injury (Ichino et al., 2010). After they completed their role in the damaged kidney, 
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neutrophils undergo apoptotic cell death. The phagocytic uptake of apoptotic neutrophils 
(and other cells) and other anti-inflammatory signals favor macrophage polarization toward 
anti-inflammatory (M2c) or profibrotic (M2a) M2 phenotypes (Swaminathan & Griffin, 
2008). Furthermore, tumor-conditioned granulocytes may play a role in priming 
macrophages toward either an M1 or M2 phenotype (Tsuda et al., 2004). 
2.2 Monocytes and macrophages  
Cells of monocyte/macrophage lineage are always present and are the predominant 
infiltrating cell type both in experimental models and in human chronic kidney diseases 
(CKDs). Macrophages produce a wide variety of different cytokines, chemokines and 
growth factors, reactive oxygen and nitrogen species, matrix metalloproteinases and 
component of the extracellular matrix. Thus, the presence of macrophages often correlates 
with the degree of fibrosis, so infiltrated macrophages has been considered to be key effector 
cells by modulating inflammatory response and subsequent proliferation of myofibroblasts, 
extracellular matrix deposition and other fibrotic processes (Eddy, 1995). However, a 
significant number of reports noted an inverse correlation between the number of interstitial 
macrophages and the degree of fibrosis, especially at the later stage of the CKD. Therefore 
macrophages are also assumed to have a role in the repair processes of the injured kidney 
(Kushiyama et al., 2010; Cochrane et al., 2005). How is it possible that macrophages have 
functions, which are so different from each other? Recent works indicates that recruited 
monocytes may differentiate into at least two different types of tissue macrophages (Anders 
& Riu, 2011). Renal infection (bacterial or fungal cell wall components, viruses), degraded 
ECM or cell necrosis induces the differentiation of proinflammatory, “classically activated” 
M1 macrophages that may exacerbate renal cell damage. In contrast, uptake of apoptotic 
cells induces “alternatively activated” M2 macrophages, which have anti-inflammatory 
(M2c/suppressor), profibrotic (M2a/wound healing) or fibrolytic (M2b) properties (Gordon 
& Taylor, 2005; Mosser & Edwards, 2008; Mantovani et al., 2004). In renal fibrosis, classically 
and alternatively activated macrophage functions are not always sharply separated from 
each other, since some factors are required in the development and functions of both types. 
2.2.1 Classically activated ‘M1’ macrophages 
Tissue injury triggers a rapid influx of neutrophils that is followed by an increased adhesion 
of circulating monocytes to the activated endothelial surfaces and their subsequent 
extravasation into the renal interstitium (Muller, 2009). In obstructive nephropathy, flow 
cytometric analysis revealed a marked increase in cell counts of macrophages in the 
obstructed kidney. The depletion of Mac-1/CD11b+ monocyte lineages including 
macrophages and dendritic cells attenuated renal fibrosis, thus suggesting the importance of 
monocyte lineage in the development of the early phase of renal fibrotic diseases (Machida 
et al., 2010). Duffield et al. also showed that macrophage depletion reduced the number of 
interstitial myofibroblasts and CD4+ T lymhocytes, and attenuated the degree of fibrosis in 
the diseased kidney (Duffield et al., 2005). Renal epithelial, capillary endothelial cells and 
infiltrated leukocytes produce various chemokines, which are responsible for the early 
recruitment of macrophages into the injured tissue (Crisman et al., 2001). For example the 
levels of CC chemokines (MCP-1/CCL-2, macrophage inhibitory protein (MIP)-1α/CCL-3, 
“regulated on activation normal T cell expressed and secreted” (RANTES/CCL-5)) are 
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inflammatory cytokines. In the following paragraphs we will summarise the role of the 
different immune cells in the pathomechanism of renal fibrosis. 
2.1 Neutrophil granulocytes 
Neutrophil granulocytes are polymorphonuclear cells, which constitute the majority of 
circulating leukocytes and respond quickly to chemotactic stimuli. They are the first 
immune cells, which migrate to the inflamed tissue and eliminate the pathogens and tissue 
debris by enzymatic degradation or by reactive oxygen species; moreover, they attract and 
activate further immune cells by producing different chemokines and cytokines. These cells 
are generally regarded as short-lived and terminally differentiated leukocytes. Kidney 
injury leads to the rapid influx of neutrophils and subsequent monocyte and other leukocyte 
recruitment (Machida et al., 2010). Damaged renal cells produce different cytokines and 
chemokines (e.g.: interleukin (IL)-8 (Hang et al., 2000; Topley et al., 2005), IL-17 (Kitching et 
al., 2011) macrophage inflammatory protein (MIP)-1, monocyte chemoattractant protein 
(MCP)-1 (Li et al., 2005)) which - among other leukocytes – efficiently attract neutrophils. 
Neutrophils become activated by immune complexes became trapped in the glomerulus or 
through pattern recognition receptors by damage associated or pathogen-associated 
molecular patterns (DAMP/PAMP) signals (like macrophages, see in details later). In 
response to specific stimuli, neutrophils have the capacity to synthesize several factors such 
as extracellular matrix and antimicrobial proteins (defensins), reactive oxygen species, 
cytokines (IL-1-β, tumor necrosis factor (TNF)-α) and chemokines (IL-8, MIPs) that can 
contribute in regulating the inflammatory response (Cassatella, 1999; Sawyer et al., 1989;  
Fantone & Ward, 1985). Neutrophils are able to generate arachidonic acid-derived lipid 
mediators, such as leukotriene B4, which is also a potent chemoattractant for leukocytes 
(Busse, 1998). Neutrophils have been shown to generate prostaglandin E2 and tromboxane 
via the inducible cyclooxigenase 2 pathway (Maloney et al, 1998). Prostaglandine E2 has 
both pro-and anti-inflammatory properties, for example it regulates vascular permeability, 
so contribute the accumulation of immune cells to the target tissue. Many of these cytokine-, 
lipid- and oxygen-derived mediators are regulated by nuclear factor (NF)-κB activation, 
which supports neutrophils in direct pathogen killing (Blackwell et al., 1997). Although 
these important host defense functions, neutrophils also have an destructive capacity and 
can elicit significant tissue damage. For example, in antineutrophil cytoplasmic antibody -
associated diseases immune complexes became trapped on the endothelial surface in the 
vasculature of glomerulus, and the local activation of neutrophils and monocytes may 
disrupt the integrity of tissue architecture (Weidner et al., 2004). Human 
polymorphonuclear cells may be activated by particulate uromodulin (also known as: 
Tamm-Horsfall glycoprotein), which is the most abundant protein excreted in the urine 
under physiological conditions, but its biological function is still not fully understood 
(Rampoldi et al., 2011). Neutrophil-uromodulin interaction in the renal interstitium is 
characterized by the activation of the respiratory burst, as well as by comprehensive 
polymorphonuclear cell degranulations, which lead to marked tissue damage and 
eventually result in interstitial fibrosis (Horton et al., 1990). Ichino et al has been detected a 
marked upregulation of neutrophil-gelatinase associated lipocalin at the mRNA and protein 
levels in a rat model of renal scarring. This molecule has been proposed over the past years 
as emergent biomarkers for the early and accurate diagnosis and monitoring of acute kidney 
injury (Ichino et al., 2010). After they completed their role in the damaged kidney, 
Immunological and Molecular Mechanisms  
Leading to Fibrosis: Origin of Renal Myofibroblasts 
 
49 
neutrophils undergo apoptotic cell death. The phagocytic uptake of apoptotic neutrophils 
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with the degree of fibrosis, so infiltrated macrophages has been considered to be key effector 
cells by modulating inflammatory response and subsequent proliferation of myofibroblasts, 
extracellular matrix deposition and other fibrotic processes (Eddy, 1995). However, a 
significant number of reports noted an inverse correlation between the number of interstitial 
macrophages and the degree of fibrosis, especially at the later stage of the CKD. Therefore 
macrophages are also assumed to have a role in the repair processes of the injured kidney 
(Kushiyama et al., 2010; Cochrane et al., 2005). How is it possible that macrophages have 
functions, which are so different from each other? Recent works indicates that recruited 
monocytes may differentiate into at least two different types of tissue macrophages (Anders 
& Riu, 2011). Renal infection (bacterial or fungal cell wall components, viruses), degraded 
ECM or cell necrosis induces the differentiation of proinflammatory, “classically activated” 
M1 macrophages that may exacerbate renal cell damage. In contrast, uptake of apoptotic 
cells induces “alternatively activated” M2 macrophages, which have anti-inflammatory 
(M2c/suppressor), profibrotic (M2a/wound healing) or fibrolytic (M2b) properties (Gordon 
& Taylor, 2005; Mosser & Edwards, 2008; Mantovani et al., 2004). In renal fibrosis, classically 
and alternatively activated macrophage functions are not always sharply separated from 
each other, since some factors are required in the development and functions of both types. 
2.2.1 Classically activated ‘M1’ macrophages 
Tissue injury triggers a rapid influx of neutrophils that is followed by an increased adhesion 
of circulating monocytes to the activated endothelial surfaces and their subsequent 
extravasation into the renal interstitium (Muller, 2009). In obstructive nephropathy, flow 
cytometric analysis revealed a marked increase in cell counts of macrophages in the 
obstructed kidney. The depletion of Mac-1/CD11b+ monocyte lineages including 
macrophages and dendritic cells attenuated renal fibrosis, thus suggesting the importance of 
monocyte lineage in the development of the early phase of renal fibrotic diseases (Machida 
et al., 2010). Duffield et al. also showed that macrophage depletion reduced the number of 
interstitial myofibroblasts and CD4+ T lymhocytes, and attenuated the degree of fibrosis in 
the diseased kidney (Duffield et al., 2005). Renal epithelial, capillary endothelial cells and 
infiltrated leukocytes produce various chemokines, which are responsible for the early 
recruitment of macrophages into the injured tissue (Crisman et al., 2001). For example the 
levels of CC chemokines (MCP-1/CCL-2, macrophage inhibitory protein (MIP)-1α/CCL-3, 
“regulated on activation normal T cell expressed and secreted” (RANTES/CCL-5)) are 
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quickly increased after unilateral ureteral obstruction (UUO) (Vielhauer et al., 2001). 
Targeted deletion or blockade of these chemokines (Wada et al., 2004; Li et al., 2005) or 
chemokine receptors (Kitagawa et al., 2004; Eis et al., 2004) primarily interrupted the initial 
phase of macrophage infiltration and resulted in reduced inflammation and subsequent 
renal fibrosis. Also at the early stage of inflammation, DAMP (such as ATP, uric acid, 
hypomethylated DNA) or PAMP (such as bacterial lipopolysaccharide), lipoteichoic acid, 
peptidoglycan, double-stranded RNA, unmethylated CpG motifs) activate Toll-like (TLR) 
and other pattern recognition receptors of leukocytes and inherent renal cells. TLR 
activation on the monocytes and the presence of interferon (IFN)-γ are essential for the 
expression of interferon-related factor 5. It is required for the complete activation of NF-κB 
signaling and thus for the maturation of the proinflammatory M1 macrophage phenotype 
(Krausgruber et al., 2011). However, after the early inflammation response, in the 
progressive fibrotic stage macrophage activation may occur in TLR-independent pathways 
as well (Chowdhury et al., 2010). In addition, in the most types of glomerulonephritis, 
immune complexes can deposit in the glomerulus and bind leukocyte receptors including 
activating immunoglobulin Fc receptors and complement receptors to activate macrophages 
with similar activation and cytokine release pattern that described for DAMP/PAMP 
signals (Ravetch et al., 2001). The mature proinflammatory M1 macrophages then release 
matrix-metalloproteases (MMPs), which may induce the destruction of vascular and tubular 
basement membranes and further migration of inflammatory and fibrotic cells into the 
interstitial space (Song et al., 2000; Gibbs et al., 1999). MMPs also promote the degradation 
of ECM that results small ECM fragments, which can serve as immunstimulatory DAMP 
signals to maintain M1 macrophage phenotype (Sorokin, 2004). Stimulation of the 
production of MMPs by M1 macrophages during the later stages of fibrosis may shift the 
equilibrium towards ECM degradation and play an important anti-fibrotic role (see below). 
In M1 macrophages NF-κB is activated early after renal damage and controls the expression 
of multiple proinflammatory factors, such as chemokines (to recruit additional immune 
cells), adhesion molecules (to help the leukocyte adhesion and extravasation into the tissue), 
proinflammatory cytokines (to activate tissue or accumulated immune cells), lipid mediators 
and reactive oxygen species that support neutrophils in direct pathogen killing (Blackwell & 
Christman 1997). Furthermore, in M1 macrophages the synthesis of inducible nitric oxide 
synthase is also triggered by NF-κB proinflammatory pathway (Musial & Eissa, 2001). Nitric 
oxide (NO) produced by inducible nitric oxide synthase has a well known protective 
function against renal fibrosis (Hochberg et al., 2000; Morrissey et al., 1996). M1 
macrophages express Major Histocompatibility Complex (MHC) class II molecules on their 
cell surface, so have antigen-presenting capacity to activate naive T cells by antigen-specific 
manner. In this process macrophage IL-12 and IL-18 as a cofactor play an important role, 
because they promote the generation of T helper (Th)1 cell phenotype and potentially 
maintenance of proinflammatory Th1 responses (Kitching et al., 2005). M1 macrophages 
produce one of the most important proinflammatory cytokine IL-6, which have a significant 
role in releasing acute phase proteins from the liver, which is an early sign of inflammation. 
Elevated levels of the acute phase C-reactive protein may promote early renal inflammation 
and fibrosis by the activation of both proinflammatory NF-κB and profibrotic transforming 
growth factor (TGF)-β/Smad signaling pathways (Li et al., 2011). Following renal damage, 
renal epithelial cells, denditic cells and M1 macrophages release large amount of TNF-α, 
which has a paracrine/autocrine effect on macrophage activation. TNF-α mediates 
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proapoptotic effects to limit the survival of activated immune cells (Wajant et al., 2003), but 
also induces activation and apoptosis of renal mesangial cells (Misseri et al., 2005; Duffield 
et al., 2000). NF-κB regulates the expression of TNF-α, which in turn may activate NF-κB 
(Ozes et al., 1999). Like TNF-α, after renal injury IL-1 cytokine levels are also upregulated. 
IL-1 may contribute to the development of renal interstitial injury and fibrosis, because IL-1 
receptor blockade decreases the number of infiltrated macrophages and alpha smooth 
muscle actin (α-SMA)+ myofibroblasts (Yamagishi et al., 2001).  
2.2.2 Alternatively activated ‘M2’ macrophages 
Apoptotic cells of the injured kidney are rapidly recognized and phagocytosed by 
macrophages. This process effectively promotes their differentiation into alternatively 
activated M2 macrophages (Ricardo et al., 2008; Fadok et al., 1998). M2 macrophages express 
typically high-level of scavenger and mannose receptors, which may promote macrophage 
activation and phagocytosis by a TLR-independent manner. Besides the phagocytosis of 
apoptotic cells, the induction of M2 macrophages requires other anti-inflammatory signals 
favor macrophage polarization, like Th2 or regulatory T (Treg) cytokines and other anti-
inflammatory agents such as corticosteroids (Goerdt & Orfanos, 1999). Like M1 
macrophages, M2 macrophages are also characterized by expression of MHC class II 
molecules, and have antigen-presenting capacity to activate naive T cells towards Th2 or 
Treg phenotype (Gordon, 2003). The phagocytosis of the apoptotic cells that generated 
during the early immune response especially promotes the differentiation of anti-
inflammatory M2c/supressor phenotype (Swaminathan & Griffin, 2008). Regulatory T cells 
via release of IL-10 and TGF-β are also required to the polarization of macrophages towards 
type M2c. M2c macrophages attenuate organ injury by downregulating inflammation, 
predominantly the Th1 response (Herbert et al., 2004). They secrete anti-inflammatory 
mediators, such as IL-10, TGF-β and other immune suppressive factors (Mosser & Edwards, 
2008). Furthermore, M2c macrophages play a positive role in epithelial (tubular 
reepithelization) and vascular (angiogenesis) repair and tissue remodeling. Insufficient 
tissue repair lead to increased secretion of different profibrotic cytokines and growth factors 
such as TGF-β (Kaneto et al., 1993) or platelet derived growth factor receptor (PDGF) 
(Fellström et al., 1989), which promote the differentiation of macrophages into M2a/wound 
healing macrophages that accelerate fibrogenesis (Gurtner et al., 2008). This process is 
supported by Th2 cells that release IL-4 and IL-13 cytokines, which further promote the 
polarization of M2a macrophage phenotype (Mantovani et al., 2004). M2a macrophages 
preferentially express the macrophage scavenger receptor (CD204), the mannose receptor 
(CD206) and fibronectin-1 which provide signals for tissue repair and proliferation. M2a 
macrophages are characterized  by the generation of arginase-1, which may enhance 
collagen biosynthesis by supressing proinflammatory NO production (Bronte & Zanovello, 
2005). Interestingly organ fibrosis may be reversible. Recently the role of fibrolytic M2b 
macrophages was demonstrated in this process. Actually M2b macrophages have the 
potential to limit or reverse fibrogenesis by the secretion of different matrix 
metalloproteinases (Ronco & Chatziantoniou, 2008). MMPs have a digestive capacity against 
ECM proteins (especially against collagen IV and denatured collagen I) without concomitant 
secretion of proinflammatory cytokines. Indeed MMPs have dual role in renal inflammation 
and fibrosis (Zeisberg et al., 2006). During UUO the expression of tissue inhibitor of 
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quickly increased after unilateral ureteral obstruction (UUO) (Vielhauer et al., 2001). 
Targeted deletion or blockade of these chemokines (Wada et al., 2004; Li et al., 2005) or 
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phase of macrophage infiltration and resulted in reduced inflammation and subsequent 
renal fibrosis. Also at the early stage of inflammation, DAMP (such as ATP, uric acid, 
hypomethylated DNA) or PAMP (such as bacterial lipopolysaccharide), lipoteichoic acid, 
peptidoglycan, double-stranded RNA, unmethylated CpG motifs) activate Toll-like (TLR) 
and other pattern recognition receptors of leukocytes and inherent renal cells. TLR 
activation on the monocytes and the presence of interferon (IFN)-γ are essential for the 
expression of interferon-related factor 5. It is required for the complete activation of NF-κB 
signaling and thus for the maturation of the proinflammatory M1 macrophage phenotype 
(Krausgruber et al., 2011). However, after the early inflammation response, in the 
progressive fibrotic stage macrophage activation may occur in TLR-independent pathways 
as well (Chowdhury et al., 2010). In addition, in the most types of glomerulonephritis, 
immune complexes can deposit in the glomerulus and bind leukocyte receptors including 
activating immunoglobulin Fc receptors and complement receptors to activate macrophages 
with similar activation and cytokine release pattern that described for DAMP/PAMP 
signals (Ravetch et al., 2001). The mature proinflammatory M1 macrophages then release 
matrix-metalloproteases (MMPs), which may induce the destruction of vascular and tubular 
basement membranes and further migration of inflammatory and fibrotic cells into the 
interstitial space (Song et al., 2000; Gibbs et al., 1999). MMPs also promote the degradation 
of ECM that results small ECM fragments, which can serve as immunstimulatory DAMP 
signals to maintain M1 macrophage phenotype (Sorokin, 2004). Stimulation of the 
production of MMPs by M1 macrophages during the later stages of fibrosis may shift the 
equilibrium towards ECM degradation and play an important anti-fibrotic role (see below). 
In M1 macrophages NF-κB is activated early after renal damage and controls the expression 
of multiple proinflammatory factors, such as chemokines (to recruit additional immune 
cells), adhesion molecules (to help the leukocyte adhesion and extravasation into the tissue), 
proinflammatory cytokines (to activate tissue or accumulated immune cells), lipid mediators 
and reactive oxygen species that support neutrophils in direct pathogen killing (Blackwell & 
Christman 1997). Furthermore, in M1 macrophages the synthesis of inducible nitric oxide 
synthase is also triggered by NF-κB proinflammatory pathway (Musial & Eissa, 2001). Nitric 
oxide (NO) produced by inducible nitric oxide synthase has a well known protective 
function against renal fibrosis (Hochberg et al., 2000; Morrissey et al., 1996). M1 
macrophages express Major Histocompatibility Complex (MHC) class II molecules on their 
cell surface, so have antigen-presenting capacity to activate naive T cells by antigen-specific 
manner. In this process macrophage IL-12 and IL-18 as a cofactor play an important role, 
because they promote the generation of T helper (Th)1 cell phenotype and potentially 
maintenance of proinflammatory Th1 responses (Kitching et al., 2005). M1 macrophages 
produce one of the most important proinflammatory cytokine IL-6, which have a significant 
role in releasing acute phase proteins from the liver, which is an early sign of inflammation. 
Elevated levels of the acute phase C-reactive protein may promote early renal inflammation 
and fibrosis by the activation of both proinflammatory NF-κB and profibrotic transforming 
growth factor (TGF)-β/Smad signaling pathways (Li et al., 2011). Following renal damage, 
renal epithelial cells, denditic cells and M1 macrophages release large amount of TNF-α, 
which has a paracrine/autocrine effect on macrophage activation. TNF-α mediates 
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proapoptotic effects to limit the survival of activated immune cells (Wajant et al., 2003), but 
also induces activation and apoptosis of renal mesangial cells (Misseri et al., 2005; Duffield 
et al., 2000). NF-κB regulates the expression of TNF-α, which in turn may activate NF-κB 
(Ozes et al., 1999). Like TNF-α, after renal injury IL-1 cytokine levels are also upregulated. 
IL-1 may contribute to the development of renal interstitial injury and fibrosis, because IL-1 
receptor blockade decreases the number of infiltrated macrophages and alpha smooth 
muscle actin (α-SMA)+ myofibroblasts (Yamagishi et al., 2001).  
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Apoptotic cells of the injured kidney are rapidly recognized and phagocytosed by 
macrophages. This process effectively promotes their differentiation into alternatively 
activated M2 macrophages (Ricardo et al., 2008; Fadok et al., 1998). M2 macrophages express 
typically high-level of scavenger and mannose receptors, which may promote macrophage 
activation and phagocytosis by a TLR-independent manner. Besides the phagocytosis of 
apoptotic cells, the induction of M2 macrophages requires other anti-inflammatory signals 
favor macrophage polarization, like Th2 or regulatory T (Treg) cytokines and other anti-
inflammatory agents such as corticosteroids (Goerdt & Orfanos, 1999). Like M1 
macrophages, M2 macrophages are also characterized by expression of MHC class II 
molecules, and have antigen-presenting capacity to activate naive T cells towards Th2 or 
Treg phenotype (Gordon, 2003). The phagocytosis of the apoptotic cells that generated 
during the early immune response especially promotes the differentiation of anti-
inflammatory M2c/supressor phenotype (Swaminathan & Griffin, 2008). Regulatory T cells 
via release of IL-10 and TGF-β are also required to the polarization of macrophages towards 
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predominantly the Th1 response (Herbert et al., 2004). They secrete anti-inflammatory 
mediators, such as IL-10, TGF-β and other immune suppressive factors (Mosser & Edwards, 
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reepithelization) and vascular (angiogenesis) repair and tissue remodeling. Insufficient 
tissue repair lead to increased secretion of different profibrotic cytokines and growth factors 
such as TGF-β (Kaneto et al., 1993) or platelet derived growth factor receptor (PDGF) 
(Fellström et al., 1989), which promote the differentiation of macrophages into M2a/wound 
healing macrophages that accelerate fibrogenesis (Gurtner et al., 2008). This process is 
supported by Th2 cells that release IL-4 and IL-13 cytokines, which further promote the 
polarization of M2a macrophage phenotype (Mantovani et al., 2004). M2a macrophages 
preferentially express the macrophage scavenger receptor (CD204), the mannose receptor 
(CD206) and fibronectin-1 which provide signals for tissue repair and proliferation. M2a 
macrophages are characterized  by the generation of arginase-1, which may enhance 
collagen biosynthesis by supressing proinflammatory NO production (Bronte & Zanovello, 
2005). Interestingly organ fibrosis may be reversible. Recently the role of fibrolytic M2b 
macrophages was demonstrated in this process. Actually M2b macrophages have the 
potential to limit or reverse fibrogenesis by the secretion of different matrix 
metalloproteinases (Ronco & Chatziantoniou, 2008). MMPs have a digestive capacity against 
ECM proteins (especially against collagen IV and denatured collagen I) without concomitant 
secretion of proinflammatory cytokines. Indeed MMPs have dual role in renal inflammation 
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metalloproteinases-1 (TIMP-1) and -2 (TIMP-2), which are the main regulators of MMP 
synthesis can vary. Increased TIMP activity during the early phase of renal fibrosis lead to 
the decreased expression of MMP-2 and MMP-9 in the obstructed kidneys, which inhibits 
the degradation of ECM components. However, TIMP expression is attenuated in the 
chronic stage of UUO, which allows MMP synthesis by fibrolytic macrophages and ECM 
degradation, so collagen levels may return to control values (Sharma et al., 1995; Kim et al., 
2001). Recent studies demonstrated that the early inhibition of MMP-2 activity ameliorates 
renal fibrosis, but MMP-2 inhibition during the late phase of fibrosis may results in more 
severe disease progression (Nishida et al., 2007; Lutz et al., 2005).  
2.3 Dendritic cells 
Dendritic cells (DCs) are antigen-presenting innate immune cells, which belong to the 
mononuclear phagocyte system and fulfill a sentinel function. In the obstructed kidney, flow 
cytometric analysis showed– beside other leukocytes - increased number of F4/80+ 
macrophages and dendritic cells (Machida et al., 2010). Kitamoto et al. demonstrated in the 
early stage of UUO, that either F4/80+ monocytes/macrophages, F4/80+ dendritic cells, or 
both cell types contribute to the development of renal fibrosis and tubular apoptosis 
(Kitamoto et al., 2009). Other studies found that DC accumulation in the interstitium is 
associated with the loss of renal function and the progression of tubulointerstitial fibrosis 
(Wu et al., 2006; Zhou et al., 2009). According to their typical antigen and chemokine 
expression and the tendency to migrate toward inflamed tissue DCs are differentiated either 
myeloid (mDC) or plasmacytoid phenotype (pDC). Myeloid DCs are characterized by the 
expression of CD11c/blood dendritic cell antigen 1, while the specific marker of 
plasmacytoid DCs is the CD11c/ blood dendritic cell antigen 2. Verkade et al. showed an 
impaired terminal differentiation of mDCs in patients with severe chronic kidney disease 
(Verkade et al., 2007). Tucci et al found that the number of peripheral pDCs is correlated 
with the degree of lupus nephritis, whereas mDCs were almost absent in the glomeruli. In 
this disease only IL-18R+ pDCs were susceptible to increased expression of IL-18 and 
relocate within the glomeruli, where they triggers the resident T cells, thus promoting renal 
damage (Tucci et al., 2008, 2009). Infiltrated DCs become activated through pattern 
recognition receptors by DAMP/PAMP signals or by immune complexes via Fc receptors or 
complement receptors. These dendritic cells are the early source of the proinflammatory 
mediators after acute kidney injury and play a specific role in recruitment and activation of 
effector/memory T cells. The capacity of macrophages and dendritic cells to present 
antigens on MHC molecules and additionally produce IL-12/IL-23 or IL-10 strongly 
influences the outcome of the Th1/Th17 or Th2 T cell response (Langenkamp et al., 2000; 
Dong et al., 2008; Liu et al, 1998). Dendritic cell-specific intercellular adhesion molecule 3-
grabbing nonintegrin (DC-SIGN) is a marker of dendritic cells, which is important for DC in 
migrating, recognizing, antigen presenting and in initiating T cell responses. In a nephritis 
model, the expression of DC-SIGN, which was mainly expressed on tubular epithelial cells 
and DCs correlated with the degree of fibrosis, and was elevated by TNF-α treatment. These 
results suggest that DC-SIGN plays an important role in renal fibrosis by DC-mediated 
immuno-inflammatory responses (Zhou et al., 2009). Angiotensin II (Ang II) mediates 
proinflammatory effect also in the relationship of DCs, because AngII blockade with the 
Ang II receptor antagonist valsartan inhibited the local accumulation of dendritic cells and 
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attenuated renal tubulointerstitial damage in rat fibrotic renal tissue (Wu et al, 2006). Muller 
et al demonstrated by using human renin and angiotensinogen double-transgenic rats, that 
Ang II induces DC migration directly, whereas in vivo TNF-α is involved in DC infiltration 
and maturation (Muller et al., 2002). 
2.4 Mast cells 
Mast cells (MCs) are known to participate in the pathogenesis of tubulointerstitial fibrosis in 
the different kidney diseases (Colvin et al., 1974; Pavone-Macaluso, 1960). MCs are present 
in every vascularized tissue, including the kidney (Kitamura, 1989). The localization of MCs 
is mainly interstitial, or in smaller extent periglomerular, but they have were never found in 
the glomeruli (Ehara & Shigematsu, 1998;  Hiromura et al., 1998). MCs can be identified by 
their specific granular proteoglycans content by staining with metachromatic dyes or by 
using immunohistochemical staining with anti-tryptase and anti-chymase antibodies. In 
general, three MC subtypes are present in the kidney: the tryptase-positive mucosal type, 
the double-positive tryptase–chymase connective tissue type, and the third chymase-
positive type MCs. The ratio of the different subtypes of MCs (in the renal interstitium can 
differ in the various renal diseases (Beil et al., 1998). There are certain factors, which can 
promote the recruitment of MCs into the damaged kidney. Perhaps the most well known is 
the stem cell factor, which is known as the prototypic growth factor for MCs. Stem cell factor 
is produced mainly by tubular epithelial cells and by infiltrating interstitial leukocytes (El-
Koraie et al., 2001). TGF-β also has been described as a powerful chemoattractant for MCs 
(Gruber et al., 1994). In addition to these factors, IL-9, a Th2 cytokine, may enhance survival 
and proliferation of MCs (Godfraind et al., 1998). The activation of mast cells takes place by 
different ways: while the classical pathway of mast cell activation is through 
Immunglobulin (Ig)E-Fcε receptor crosslinking (Beaven & Metzger, 1993), the alternative 
way includes the activation of pattern recognition (such as TLRs) (McCurdy et al., 2001; 
Supajatura et al., 2002) or complement receptors (Prodeus et al., 1997). Activated MCs have 
a capacity to secrete a large variety of inflammatory mediators such as a range of bioactive 
amines and proteoglycans; histamine, which is a potent vasodilator and enhance vascular 
permeability; lipid mediators such as prostaglandins and leukotrienes, which are potent 
chemoattractants for CD8+ T cells and a large set of chemokines and cytokines, which are 
able to recruiting and activating leukocytes (Galli et al., 2005). Furthermore, they promote 
the vascular endothelial expression of selectins and adhesion molecules, which indirectly 
support leukocyte recruitment (Meng et al., 1995). MCs also have a direct 
immunoregulatory role by interacting with T cells, B cells, and dendritic cells (Galli et al., 
2005). They are able to present antigens to naive T cells in an MHC-restricted manner 
(Dimitriadou et al., 1998) and influence T cell differentiation towards Th2 (by IL-4, IL-10 and 
histamin) (Jutel et al., 2002) or Th17 phenotype (Nakae et al., 2007). Furthermore, MCs seem 
to be essential to induce the development of Tregs that limit the infiltration of autoreactive T 
cells, and mediate peripheral tolerance (Lu et al., 2006). Experimental studies suggest that 
degranulation of MCs leads to the release of TGF-β, TNF-α, MCP-1, fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), IL-4 and MMP-9 and a variety of unique 
proteases, principally tryptase and chymase (Holdsworth & Summers, 2008), which 
contribute to progressive fibrogenesis (Cairns & Walls, 1997). Tryptase is prestored in 
cytoplasmic granules of MCs and has potent proteolytic activity against ECM proteins 
(Payne & Kam, 2004) and it supports the proliferation of fibroblasts and the synthesis of 
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metalloproteinases-1 (TIMP-1) and -2 (TIMP-2), which are the main regulators of MMP 
synthesis can vary. Increased TIMP activity during the early phase of renal fibrosis lead to 
the decreased expression of MMP-2 and MMP-9 in the obstructed kidneys, which inhibits 
the degradation of ECM components. However, TIMP expression is attenuated in the 
chronic stage of UUO, which allows MMP synthesis by fibrolytic macrophages and ECM 
degradation, so collagen levels may return to control values (Sharma et al., 1995; Kim et al., 
2001). Recent studies demonstrated that the early inhibition of MMP-2 activity ameliorates 
renal fibrosis, but MMP-2 inhibition during the late phase of fibrosis may results in more 
severe disease progression (Nishida et al., 2007; Lutz et al., 2005).  
2.3 Dendritic cells 
Dendritic cells (DCs) are antigen-presenting innate immune cells, which belong to the 
mononuclear phagocyte system and fulfill a sentinel function. In the obstructed kidney, flow 
cytometric analysis showed– beside other leukocytes - increased number of F4/80+ 
macrophages and dendritic cells (Machida et al., 2010). Kitamoto et al. demonstrated in the 
early stage of UUO, that either F4/80+ monocytes/macrophages, F4/80+ dendritic cells, or 
both cell types contribute to the development of renal fibrosis and tubular apoptosis 
(Kitamoto et al., 2009). Other studies found that DC accumulation in the interstitium is 
associated with the loss of renal function and the progression of tubulointerstitial fibrosis 
(Wu et al., 2006; Zhou et al., 2009). According to their typical antigen and chemokine 
expression and the tendency to migrate toward inflamed tissue DCs are differentiated either 
myeloid (mDC) or plasmacytoid phenotype (pDC). Myeloid DCs are characterized by the 
expression of CD11c/blood dendritic cell antigen 1, while the specific marker of 
plasmacytoid DCs is the CD11c/ blood dendritic cell antigen 2. Verkade et al. showed an 
impaired terminal differentiation of mDCs in patients with severe chronic kidney disease 
(Verkade et al., 2007). Tucci et al found that the number of peripheral pDCs is correlated 
with the degree of lupus nephritis, whereas mDCs were almost absent in the glomeruli. In 
this disease only IL-18R+ pDCs were susceptible to increased expression of IL-18 and 
relocate within the glomeruli, where they triggers the resident T cells, thus promoting renal 
damage (Tucci et al., 2008, 2009). Infiltrated DCs become activated through pattern 
recognition receptors by DAMP/PAMP signals or by immune complexes via Fc receptors or 
complement receptors. These dendritic cells are the early source of the proinflammatory 
mediators after acute kidney injury and play a specific role in recruitment and activation of 
effector/memory T cells. The capacity of macrophages and dendritic cells to present 
antigens on MHC molecules and additionally produce IL-12/IL-23 or IL-10 strongly 
influences the outcome of the Th1/Th17 or Th2 T cell response (Langenkamp et al., 2000; 
Dong et al., 2008; Liu et al, 1998). Dendritic cell-specific intercellular adhesion molecule 3-
grabbing nonintegrin (DC-SIGN) is a marker of dendritic cells, which is important for DC in 
migrating, recognizing, antigen presenting and in initiating T cell responses. In a nephritis 
model, the expression of DC-SIGN, which was mainly expressed on tubular epithelial cells 
and DCs correlated with the degree of fibrosis, and was elevated by TNF-α treatment. These 
results suggest that DC-SIGN plays an important role in renal fibrosis by DC-mediated 
immuno-inflammatory responses (Zhou et al., 2009). Angiotensin II (Ang II) mediates 
proinflammatory effect also in the relationship of DCs, because AngII blockade with the 
Ang II receptor antagonist valsartan inhibited the local accumulation of dendritic cells and 
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attenuated renal tubulointerstitial damage in rat fibrotic renal tissue (Wu et al, 2006). Muller 
et al demonstrated by using human renin and angiotensinogen double-transgenic rats, that 
Ang II induces DC migration directly, whereas in vivo TNF-α is involved in DC infiltration 
and maturation (Muller et al., 2002). 
2.4 Mast cells 
Mast cells (MCs) are known to participate in the pathogenesis of tubulointerstitial fibrosis in 
the different kidney diseases (Colvin et al., 1974; Pavone-Macaluso, 1960). MCs are present 
in every vascularized tissue, including the kidney (Kitamura, 1989). The localization of MCs 
is mainly interstitial, or in smaller extent periglomerular, but they have were never found in 
the glomeruli (Ehara & Shigematsu, 1998;  Hiromura et al., 1998). MCs can be identified by 
their specific granular proteoglycans content by staining with metachromatic dyes or by 
using immunohistochemical staining with anti-tryptase and anti-chymase antibodies. In 
general, three MC subtypes are present in the kidney: the tryptase-positive mucosal type, 
the double-positive tryptase–chymase connective tissue type, and the third chymase-
positive type MCs. The ratio of the different subtypes of MCs (in the renal interstitium can 
differ in the various renal diseases (Beil et al., 1998). There are certain factors, which can 
promote the recruitment of MCs into the damaged kidney. Perhaps the most well known is 
the stem cell factor, which is known as the prototypic growth factor for MCs. Stem cell factor 
is produced mainly by tubular epithelial cells and by infiltrating interstitial leukocytes (El-
Koraie et al., 2001). TGF-β also has been described as a powerful chemoattractant for MCs 
(Gruber et al., 1994). In addition to these factors, IL-9, a Th2 cytokine, may enhance survival 
and proliferation of MCs (Godfraind et al., 1998). The activation of mast cells takes place by 
different ways: while the classical pathway of mast cell activation is through 
Immunglobulin (Ig)E-Fcε receptor crosslinking (Beaven & Metzger, 1993), the alternative 
way includes the activation of pattern recognition (such as TLRs) (McCurdy et al., 2001; 
Supajatura et al., 2002) or complement receptors (Prodeus et al., 1997). Activated MCs have 
a capacity to secrete a large variety of inflammatory mediators such as a range of bioactive 
amines and proteoglycans; histamine, which is a potent vasodilator and enhance vascular 
permeability; lipid mediators such as prostaglandins and leukotrienes, which are potent 
chemoattractants for CD8+ T cells and a large set of chemokines and cytokines, which are 
able to recruiting and activating leukocytes (Galli et al., 2005). Furthermore, they promote 
the vascular endothelial expression of selectins and adhesion molecules, which indirectly 
support leukocyte recruitment (Meng et al., 1995). MCs also have a direct 
immunoregulatory role by interacting with T cells, B cells, and dendritic cells (Galli et al., 
2005). They are able to present antigens to naive T cells in an MHC-restricted manner 
(Dimitriadou et al., 1998) and influence T cell differentiation towards Th2 (by IL-4, IL-10 and 
histamin) (Jutel et al., 2002) or Th17 phenotype (Nakae et al., 2007). Furthermore, MCs seem 
to be essential to induce the development of Tregs that limit the infiltration of autoreactive T 
cells, and mediate peripheral tolerance (Lu et al., 2006). Experimental studies suggest that 
degranulation of MCs leads to the release of TGF-β, TNF-α, MCP-1, fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), IL-4 and MMP-9 and a variety of unique 
proteases, principally tryptase and chymase (Holdsworth & Summers, 2008), which 
contribute to progressive fibrogenesis (Cairns & Walls, 1997). Tryptase is prestored in 
cytoplasmic granules of MCs and has potent proteolytic activity against ECM proteins 
(Payne & Kam, 2004) and it supports the proliferation of fibroblasts and the synthesis of 
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type I collagen (Cairns & Walls, 1997). Chymase can activate MMP-2 and MMP-9, disrupt of 
tight junction proteins (Scudamore et al., 1998) and involved in the activation of renin–
angiotensin system (Huang et al., 2003). On the other hand MCs can also participate in 
tissue remodeling and restoration of the normal kidney homeostasis (Bradding et al., 2006; 
Bankl & Valent, 2002). For example heparin produced by MCs is a potent anti-thrombotic, 
anti-inflammatory, anti-coagulant and anti-fibrotic agent, which is able to modulate renal 
fibroblast proliferation by arachidonic acid-derived lipid mediators such as leukotriene and 
prostaglandin (Clarkson et al., 1998) or by inhibition of TGF-β (Miyazawa et al., 2004). 
2.5 T lymphocytes 
T lymphocytes are main effector cells of adaptive immune system and activated by specific 
antigen stimuli. Although macrophages constitute the predominant infiltrating cell 
population of the injured kidneys, increased number of T lymphocytes were also observed 
in chronic renal diseases. It is also well known that the degree of tubulointerstitial fibrosis is 
related to the number of infiltrating T cell, implying their role in the fibrotic process 
(Tapmeier et al., 2010). In accordance with this observation Niedermayer et al. have shown 
that lymphocyte deficiency cause a substantial reduction in collagen I deposition in the 
obstructed kidney (Niedermayer et al., 2009). In the early phase of renal injury 
chemoattractants released by damaged and infiltrating immune cells directing the migration 
of activated T lymphocytes into the injured tissue. In this process CC (RANTES/CCL5), 
CXC (IP-10/CXCL10) chemokines, MIPs, lipid mediators (leukotriene) and anaphylatoxic 
complement fragments play a pivotal role (Kuroiwa et al., 2000). The activation of T cells 
occurs by antigenspecific manner. Antigens are presented by MHC molecules expressed on 
the cell surface of antigen-presenting cells (dendritic cells, macrophages, B cells) and 
recognized by T cell receptor/CD3 complex, which are the specific antigen-recognizing 
receptors of T lymphocytes. There are two different populations of the effector T 
lymphocytes: while CD8+ cytotoxic T cells have a direct cell-killing activity, Th cells are 
characterized by the expression of CD4 costimulator molecule and release a wide range of 
cytokines to mediate immune functions. Endogen antigens are presented on MHC type I 
molecules to CD8+ T cells, while exogen antigens are presented on MHC type II molecules 
to CD4+ T cells. After antigen recognition T cells become activated effector T cells or long-
lived memory T cells. Cytokines released by the antigen presenting cells, such as 
macrophages and dendritic cells play a pivotal role in polarization of CD4+ T cells to 
different Th subtypes: IL-12 and IL-18 as a cofactor promote the generation of Th1 
phenotype and the proinflammatory Th1-type cellular immune response. In Goldblatt 
hypertensive rats antihypertensive therapy induces a significant proinflammatory Th1 
immune response with increased Th1-type chemokine (IP-10) and cytokine (IFN-γ) 
expression (Steinmetz et al., 2007). Similarly, the absence of Ang II type 1 receptor (AT1) in 
AT1R KO mice is associated with Th1-type immune response (Ouyang et al., 2005). IFN-γ, 
which is secreted by Th1 cells (and also other immune cells) is required to the classical 
activation of M1-type macrophages, which have proinflammatory but not fibrotic 
properties. These data suggest that Th1 cells mediate proinflammatory, rather than fibrotic 
effects. Th2 lymphocytes may mediate the activation of alternatively activated M2 type 
macrophages by producing IL-4, IL-5, IL-10, IL-13 and TGF-β. The activated M2 
macrophages may promote fibrotic diseases and mediate collagen synthesis, suggesting the 
role of Th2-mediated immune response in fibrotic process (Wynn, 2004). Beside Th1-Th2 
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polarization, the Treg-Th17 axis is the other important player of immune response observed 
in chronic kidney diseases. Foxp3+ Treg have immunoregulatory and anti-inflammatory 
role via release of TGF-β and IL-10 (Mu et al., 2005). IL-10-secreting Treg cells suppress the 
activation of Th1, Th2 and Th17 cells, thus ameliorate the severity of inflammatory process, 
for example in mice with lupus nephritis (Zhang et al., 2010). Treg cells may promote the 
polarization of monocytes towards M2 macrophages, which may mediate profibrotic effects. 
Th17 cells produce IL-17 (IL-17A), IL-17F, IL-21, IL-22 which may promote inflammation by 
directly causing tissue injury and enhancing secretion of proinflammatory cytokines and 
chemokines by resident cells. This results in augmented infiltration of leukocytes, mainly 
neutrophils to the injured tissue where they induce inflammation (Turner et al., 2010). 
Dudas et al. described that IL-17A also mediate proinflammatory/profibrotic activity on 
proximal tubule epithelial cells that may contribute to allograft rejection (Dudas et al., 2011). 
In general both CD8 and CD4 positive cells may directly stimulate the migration, 
proliferation and differentiation of renal cells resulting in the accumulation of α-SMA 
positive myofibroblasts. T cells may also act indirectly on the infiltrating macrophage 
population by inducing a profibrotic phenotype, which, in turn, secrete pro-proliferative 
and profibrotic cytokines and growth factors (for example PDGF, TGF-β). Moreover, T cells 
may directly interact with epithelial cells to induce secretion of cytokines and growth factors 
that, in turn, act on fibroblasts (Strutz & Neilson, 1994).  
2.6 B lymphocytes  
B lymphocytes are effector cells of the adaptive immune system. B cells are activated 
through their specific antigen-recognizing B cell receptor complex on T cell dependent or 
independent manner. Activated B cells mature to plasma cells and mediate humoral 
immune response by producing specific antibodies or differentiate into long-lived memory 
B cells. B cells themselves may also act as antigen presenting cells and influence T cell 
response in the lymphoid folliculi.  B cells may contribute to renal fibrosis in different ways, 
but their exact role in the process is less known. On the one hand autoantibodies produced 
by B cells are largely present in immune complexes, which may accumulate in the glomeruli 
in severe autoimmune and kidney diseases and activate innate immune cells by their 
immunoglobulin Fc receptors. Autoantibody synthesis could also occur after bacterial or 
viral infection, oxidant synthesis, or T cell mediated immunity.  
On the other hand infiltrated B cells have an important role in renal interstitial 
inflammation: indeed, Heller et al. found that mature B cells formed a prominent part of the 
renal interstitial infiltrating cells in renal biopsies from patients with acute or chronic 
interstitial nephritis and IgA nephropathy. The expression of CXCL13, which is a 
chemoattractant for B cells, was elevated in these inflamed kidneys. CXCL13 level was 
correlated with the infiltrated B cell number and contributed to the formation of intrarenal 
lymphoid follicle-like structures, which might represent an intrarenal immune system 
(Heller et al., 2007). B cell activating factor – which belongs to TNF superfamily - has an 
important role in the development and survival of B lymphocytes. Xu et al. demonstrated in 
kidney allograft biopsies, that B cell activating factor expression may be associated with the 
development of antibody-mediated allograft rejection and renal interstitial fibrosis in kidney 
transplants (Xu et al., 2009). Moreover, IgG4-associated tubulointerstitial nephritis is 
characterized by high levels of serum IgG4 and IgE and a significant number of IgG4-
producing plasma cells in the renal fibrotic lesions (Saeki et al., 2007; Raissian et al., 2011). 
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type I collagen (Cairns & Walls, 1997). Chymase can activate MMP-2 and MMP-9, disrupt of 
tight junction proteins (Scudamore et al., 1998) and involved in the activation of renin–
angiotensin system (Huang et al., 2003). On the other hand MCs can also participate in 
tissue remodeling and restoration of the normal kidney homeostasis (Bradding et al., 2006; 
Bankl & Valent, 2002). For example heparin produced by MCs is a potent anti-thrombotic, 
anti-inflammatory, anti-coagulant and anti-fibrotic agent, which is able to modulate renal 
fibroblast proliferation by arachidonic acid-derived lipid mediators such as leukotriene and 
prostaglandin (Clarkson et al., 1998) or by inhibition of TGF-β (Miyazawa et al., 2004). 
2.5 T lymphocytes 
T lymphocytes are main effector cells of adaptive immune system and activated by specific 
antigen stimuli. Although macrophages constitute the predominant infiltrating cell 
population of the injured kidneys, increased number of T lymphocytes were also observed 
in chronic renal diseases. It is also well known that the degree of tubulointerstitial fibrosis is 
related to the number of infiltrating T cell, implying their role in the fibrotic process 
(Tapmeier et al., 2010). In accordance with this observation Niedermayer et al. have shown 
that lymphocyte deficiency cause a substantial reduction in collagen I deposition in the 
obstructed kidney (Niedermayer et al., 2009). In the early phase of renal injury 
chemoattractants released by damaged and infiltrating immune cells directing the migration 
of activated T lymphocytes into the injured tissue. In this process CC (RANTES/CCL5), 
CXC (IP-10/CXCL10) chemokines, MIPs, lipid mediators (leukotriene) and anaphylatoxic 
complement fragments play a pivotal role (Kuroiwa et al., 2000). The activation of T cells 
occurs by antigenspecific manner. Antigens are presented by MHC molecules expressed on 
the cell surface of antigen-presenting cells (dendritic cells, macrophages, B cells) and 
recognized by T cell receptor/CD3 complex, which are the specific antigen-recognizing 
receptors of T lymphocytes. There are two different populations of the effector T 
lymphocytes: while CD8+ cytotoxic T cells have a direct cell-killing activity, Th cells are 
characterized by the expression of CD4 costimulator molecule and release a wide range of 
cytokines to mediate immune functions. Endogen antigens are presented on MHC type I 
molecules to CD8+ T cells, while exogen antigens are presented on MHC type II molecules 
to CD4+ T cells. After antigen recognition T cells become activated effector T cells or long-
lived memory T cells. Cytokines released by the antigen presenting cells, such as 
macrophages and dendritic cells play a pivotal role in polarization of CD4+ T cells to 
different Th subtypes: IL-12 and IL-18 as a cofactor promote the generation of Th1 
phenotype and the proinflammatory Th1-type cellular immune response. In Goldblatt 
hypertensive rats antihypertensive therapy induces a significant proinflammatory Th1 
immune response with increased Th1-type chemokine (IP-10) and cytokine (IFN-γ) 
expression (Steinmetz et al., 2007). Similarly, the absence of Ang II type 1 receptor (AT1) in 
AT1R KO mice is associated with Th1-type immune response (Ouyang et al., 2005). IFN-γ, 
which is secreted by Th1 cells (and also other immune cells) is required to the classical 
activation of M1-type macrophages, which have proinflammatory but not fibrotic 
properties. These data suggest that Th1 cells mediate proinflammatory, rather than fibrotic 
effects. Th2 lymphocytes may mediate the activation of alternatively activated M2 type 
macrophages by producing IL-4, IL-5, IL-10, IL-13 and TGF-β. The activated M2 
macrophages may promote fibrotic diseases and mediate collagen synthesis, suggesting the 
role of Th2-mediated immune response in fibrotic process (Wynn, 2004). Beside Th1-Th2 
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polarization, the Treg-Th17 axis is the other important player of immune response observed 
in chronic kidney diseases. Foxp3+ Treg have immunoregulatory and anti-inflammatory 
role via release of TGF-β and IL-10 (Mu et al., 2005). IL-10-secreting Treg cells suppress the 
activation of Th1, Th2 and Th17 cells, thus ameliorate the severity of inflammatory process, 
for example in mice with lupus nephritis (Zhang et al., 2010). Treg cells may promote the 
polarization of monocytes towards M2 macrophages, which may mediate profibrotic effects. 
Th17 cells produce IL-17 (IL-17A), IL-17F, IL-21, IL-22 which may promote inflammation by 
directly causing tissue injury and enhancing secretion of proinflammatory cytokines and 
chemokines by resident cells. This results in augmented infiltration of leukocytes, mainly 
neutrophils to the injured tissue where they induce inflammation (Turner et al., 2010). 
Dudas et al. described that IL-17A also mediate proinflammatory/profibrotic activity on 
proximal tubule epithelial cells that may contribute to allograft rejection (Dudas et al., 2011). 
In general both CD8 and CD4 positive cells may directly stimulate the migration, 
proliferation and differentiation of renal cells resulting in the accumulation of α-SMA 
positive myofibroblasts. T cells may also act indirectly on the infiltrating macrophage 
population by inducing a profibrotic phenotype, which, in turn, secrete pro-proliferative 
and profibrotic cytokines and growth factors (for example PDGF, TGF-β). Moreover, T cells 
may directly interact with epithelial cells to induce secretion of cytokines and growth factors 
that, in turn, act on fibroblasts (Strutz & Neilson, 1994).  
2.6 B lymphocytes  
B lymphocytes are effector cells of the adaptive immune system. B cells are activated 
through their specific antigen-recognizing B cell receptor complex on T cell dependent or 
independent manner. Activated B cells mature to plasma cells and mediate humoral 
immune response by producing specific antibodies or differentiate into long-lived memory 
B cells. B cells themselves may also act as antigen presenting cells and influence T cell 
response in the lymphoid folliculi.  B cells may contribute to renal fibrosis in different ways, 
but their exact role in the process is less known. On the one hand autoantibodies produced 
by B cells are largely present in immune complexes, which may accumulate in the glomeruli 
in severe autoimmune and kidney diseases and activate innate immune cells by their 
immunoglobulin Fc receptors. Autoantibody synthesis could also occur after bacterial or 
viral infection, oxidant synthesis, or T cell mediated immunity.  
On the other hand infiltrated B cells have an important role in renal interstitial 
inflammation: indeed, Heller et al. found that mature B cells formed a prominent part of the 
renal interstitial infiltrating cells in renal biopsies from patients with acute or chronic 
interstitial nephritis and IgA nephropathy. The expression of CXCL13, which is a 
chemoattractant for B cells, was elevated in these inflamed kidneys. CXCL13 level was 
correlated with the infiltrated B cell number and contributed to the formation of intrarenal 
lymphoid follicle-like structures, which might represent an intrarenal immune system 
(Heller et al., 2007). B cell activating factor – which belongs to TNF superfamily - has an 
important role in the development and survival of B lymphocytes. Xu et al. demonstrated in 
kidney allograft biopsies, that B cell activating factor expression may be associated with the 
development of antibody-mediated allograft rejection and renal interstitial fibrosis in kidney 
transplants (Xu et al., 2009). Moreover, IgG4-associated tubulointerstitial nephritis is 
characterized by high levels of serum IgG4 and IgE and a significant number of IgG4-
producing plasma cells in the renal fibrotic lesions (Saeki et al., 2007; Raissian et al., 2011). 
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2.7 Complement activation  
Complement system is an essential, and conserved part of the immune system, defends the 
host against invading pathogens, prevents immune complex disease and aids the acquired 
immune response. It consists of a number of small proteins, which are generally synthesized 
by the liver and normally circulating in the blood as inactive precursors. In response to 
several triggers, proteases (convertases) cleave the specific proteins of the complement 
system and initiate a cascade of further cleavages. Finally the activated complement proteins 
as multimeric membrane attack complexes bind to the surface of target cells and and lyse 
them (Lesher & Song, 2010). Immune complexes contain a large amount of complement 
fragments, which may accumulate in the glomeruli in different autoimmune diseases and 
activate the innate immune cells by their complement receptors. Detection of complement 
deposition in the glomerulus using immunochemistry has become an important element of 
the histological analysis of renal biopsies, and is key to the diagnosis of many types of 
glomerulonephritis. In recent years it has become evident that complement activation is 
involved in the pathogenesis of other types of renal disease including progressive 
tubulointerstitial fibrosis (Brown et al., 2007). For example, deficiency in the expression of 
C5 (Boor et al., 2007), C4d (Xu et al., 2009) or C6 (He et al., 2005) complement fragments 
caused reduced renal damage and interstitial fibrosis in different kidney diseases. Blocking 
the receptors of the potent anaphylatoxins C5a and C3a lead to significantly reduced renal 
leukocyte infiltration, tubulointerstitial inflammation and fibrosis (Boor et al., 2007; Bao et 
al., 2011).  
3. Important molecular pathways 
In addition to the above mentioned activation of the immune cells the increased amount of 
different cytokines and growth factors are also participate in the accumulation of the ECM 
in renal the interstitium along the tubules. To date more than a dozen different cytokines 
(IFNγ, IL-1), growth factors (TGF, connective tissue growth factor, bone morphogenic 
protein, Insulin-like growth factor-1, TNFα) and other molecules (Ang II, NO) have been 
demonstrated to induce interstitial inflammation, maturation of myofibroblasts and 
degradation or production of ECM. Here we are going to summarize our knowledge about 
TGFβ, Ang II and PDGF and their downstream signaling pathways. 
3.1 Transforming Growth Factor β (TGF β) 
TGFβ is a member of the TGFβ superfamily that include activins, inhibins and bone 
morfogenic proteins (Peng, 2003). In the healthy kidney TGFβ participate in the maintaining 
of the homeostasis. However, when the kidney is exposed to an injury then TGFβ is 
excessively produced by the resident renal cells and also by the infiltrating leukocytes 
(Border & Noble, 1993; Coimbra et al., 1996; Eddy, 2000). Fukuda et al. (Fukuda et al., 2001) 
using in situ hybridization and immunohistochemistry demonstrated that TGFβ1 is mainly 
expressed by mesangial and epithelial cells of the glomeruli and the distal tubules in the 
healthy kidneys. Following UUO they observed increased TGFβ1 expression in the renal 
tubular epithelial cells of the renal cortex and outer medulla and also in the infiltrating 
macrophages. Indeed similar upregulation of TGFβ is present in every animal model of 
chronic renal disease and also in humans (Ketteler et al., 1994). 
Immunological and Molecular Mechanisms  
Leading to Fibrosis: Origin of Renal Myofibroblasts 
 
57 
TGFβ1 and its isoforms (TGFβ2 and 3) are secreted as precursos in a complex with latent 
TGFβ binding proteins. TGFβ become active when it is cleaved by plasmin, 
thrombospondin-1 or reactive oxygen species and thus dissociated from latent TGFβ 
binding proteins. The activated TGFβ then form dimers and bind to their type I and II cell-
surface serin/threonine kinase receptors (TBR I and TBR II, respectively). So far two TBR I 
(activin like receptor kinase 1 and 5) and one TBR II (TGFBR2) have been have been shown 
to bind TGFβ. TGFβ first binds to the constitutively active TBR II followed by the 
phosphorylation of the glycine/serin rich domain of the TBR I to create activated receptor 
heterodimer. Subsequently the activated receptor complex phosphorilates the downstream 
signaling mediators such as SMAD2/3, ERK1/2, Jun N-terminal Kinase 1/2 (Matsuzaki & 
Okazaki, 2006). In the injured tissue TGFβ through its activated signaling pathways can 
trigger the increased production and decreased degradation of ECM (Pohlers et al., 2009) 
and thus the renal fibrosis. Koesters et al. showed marked peritubular fibrosis in the double 
transgenic mice overexpressing TGFβ1 in their tubular epithelial cells (Koesters et al., 2010). 
They observed the proliferation of the peritubular cells and the deposition of collagen type I 
rich ECM. Moreover, they observed the TGFβ1 dependent autophagy of the tubular cells 
which may represent a novel mechanism of tubular decomposition. On the other hand Isaka 
et al. demonstrated that introduction of antisense oligodeoxynucleotides against TGFβ1 into 
interstitial fibroblasts block the interstitial fibrosis in rats with unilateral ureteral obstruction 
(Isaka et al., 2000). Similarly, Miyajima et al. observed that administration of neutralizing 
anti-TGFβ1 antibody attenuate the tubular apoptosis in a rat model of UUO (Miyajima et al., 
2000). Also Decorin, which is an ECM protein that bind TGFβ, or soluble TGFβ receptor 
have been also shown to inhibit renal fibrosis (Peters et al., 1997; De Heer et al., 2000). 
3.2 Renin-Angiotensin System  
The RAS is the most important regulator of blood pressure, fluid and electrolyte 
homeostasis. The different components of the Renin-Angiotensin System, such as 
angiotensinogen, renin, AngI, angiotensin converting enzyme (ACE) Ang II, aldosterone 
and Ang II type I and II (AT1, AT2, respectively) receptors are all present in the kidney. 
Renin acts on angiotensinogen to form AngI, which is then converted by ACE to Ang II. The 
effects of Ang II are mediated by two high affinity receptors, AT1 and AT2. Since the overall 
abundance of AT1 receptors significantly exceeds that of AT2 type receptors in the adult 
kidney the most effects of Ang II are mediated through the AT1 receptor (Siragy, 2004). AT1 
receptors are distributed on the luminal surface of the renal tubules, including proximal 
tubule, thick ascending limb of loop of Henle, distal tubule, macula densa and collecting 
duct (Allen et al., 2000). Recently the urinary angiotensinogen (Kim et al., 2011) and the 
intrarenal Ang II level (Del Prete et al., 2003) have been demonstrated to correlate with the 
severity of the chronic renal disease. As Ang II plays a key role in regulation of vascular 
tone (Cockcroft et al., 1995) and may induce proteinuria (Ren et al., 2011), oxidative stress, 
inflammation and renal fibrosis (Benigni et al., 2010) it is not surprising that ACE inhibitors 
or AT1 receptor antagonists have a renoprotective effect, which is independent from their 
antihypertensive effect (Mallamaci et al., 2011). Actually, the captopril trial on patients with 
type I diabetic nephropathy patients has shown a 50 % reduction in the end point of death 
by captopril administration (Lewis et al, 2003). Although the clinical relevance of Ang II in 
chronic renal disease is obvious, its precise role is still unclear. It is well known that Ang II 
may induce EMT on the epithelial cells in vitro. However, since the significance of in vivo 
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2.7 Complement activation  
Complement system is an essential, and conserved part of the immune system, defends the 
host against invading pathogens, prevents immune complex disease and aids the acquired 
immune response. It consists of a number of small proteins, which are generally synthesized 
by the liver and normally circulating in the blood as inactive precursors. In response to 
several triggers, proteases (convertases) cleave the specific proteins of the complement 
system and initiate a cascade of further cleavages. Finally the activated complement proteins 
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them (Lesher & Song, 2010). Immune complexes contain a large amount of complement 
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activate the innate immune cells by their complement receptors. Detection of complement 
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TGFβ1 and its isoforms (TGFβ2 and 3) are secreted as precursos in a complex with latent 
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phosphorylation of the glycine/serin rich domain of the TBR I to create activated receptor 
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Renin acts on angiotensinogen to form AngI, which is then converted by ACE to Ang II. The 
effects of Ang II are mediated by two high affinity receptors, AT1 and AT2. Since the overall 
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kidney the most effects of Ang II are mediated through the AT1 receptor (Siragy, 2004). AT1 
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tone (Cockcroft et al., 1995) and may induce proteinuria (Ren et al., 2011), oxidative stress, 
inflammation and renal fibrosis (Benigni et al., 2010) it is not surprising that ACE inhibitors 
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EMT is strongly questioned the in vivo relevance of Ang II on EMT is also questionable. 
Recently Kang et al. revealed that Ang II may decrease the NF-E2-related factor 2 (Nrf2) 
mediated signaling in murine renal epithelial TCMK-1 cells (Kang et al., 2011). Nrf2 is a 
transcriptional factor which by binding to the antioxidant response element on the promoter 
of different antioxidant genes can induce their expression. Kang et al. suggested that Ang II 
by inducing activating transcription factor 3 expression could inhibit the Nrf2 mediated 
upregulation of the antioxidant genes. Ang II increases vascular permeability via the release 
of prostaglandins and VEGF; contribute to the recruitment of inflammatory cells into the 
tissue through the regulation of adhesion molecules, chemokines (MCP-1, RANTES) and 
other molecules (osteopontin, see above) by resident cells; could directly activate infiltrating 
immunocompetent cells by cytokines (such as IL-6). AT1R or AT2R blockade (Esteban et al., 
2003; Kellner et al., 2006) or treatment with ACE inhibitors (Ishidoya et al., 1995) greatly 
reduced monocyte/macrophage infiltration in short-term UUO, and AT1R-deficient 
macrophages have impaired phagocytic function (Nishida et al., 2002). Finally Ang II also 
may increase the expression of other molecules that play a pivotal role in organ fibrosis 
inducing TGFβ, TNFα or PDGF or bFGF (Rüster & Wolf, 2011). Moreover Ang II can 
potentiate the effect of TGFβ on the expression of SMA in TCMK-1 cells. Furthermore, AngII 
participates in tissue repair and remodeling, through the regulation of cell growth and 
matrix synthesis (Suzuki et al., 2003). 
3.3 Platelet Derived Growth Factor (PDGF) 
PDGF is a growth factor that regulates multiple cell function, such as cell growth (Bonner, 
2004) or division and in particular in formation of blood vessels (Hellberg et al., 2010). 
Recently, its role in organ fibrosis has been also suggested (Trojanowska, 2008). PDGF 
family consist of five homo- or heterodimeric growth factors (PDGF-AA, -AB, -BB, -CC and -
DD).   PDGF-A has two splice variant, a longer (≈16 kD) which is retained to the cell surface 
and a shorter, which is released into the extracellular space. PDGF-AA and -BB can bind to 
different ECM proteins. PDGF-CC and -DD were identified just recently. PDGF-CC and -DD 
are secreted in a latent form and cleavage of the N terminal CUB (complement 
subcomponent C1r/C1s, Uegf and Bmp1) domain is required for their activation. While 
PDGF-CC is activated by tissue type plasminogen activator and plasmin PDGF-DD is 
activated by urokinase type plasminogen activator. Many inherent renal cell express one or 
more PDGF isoforms, such as pericytes (Winkler et al., 2010), podocytes (Changsirikulchai et 
al., 2002), endothelial (Eitner  et al., 2003), tubular epithelial (Eitner et al., 2002) and smooth 
muscle cells (Seifert et al., 1998). The different isoforms of PDGF bind to the homo- or 
heterodimeric tyrosine kinase receptors (PDGFR-αα, -ββ and -αβ). The specifity and affinity 
of the different PDGF monomers to the α or β chain of the receptor PDGFRs are different. 
While PDGF-A can bind to the α, PDGF-B to the α and β chains. The receptor affinity of 
PDGF-C and –D is less characterized, but it is likely that similarly to PDGF-B they can bind 
to the α and β chain as well. Upon receptor binding the α and β chains dimerize and 
possesses tyrosine kinase activity. After autophosphorylation the PDGFRs provide docking 
site for downstream signaling molecules containing SH2 (Floege J, 2008), SH3, PTB, PH 
(Andrae et al., 2008) and other domains thus activating several signaling pathways such as 
MAPK, PLCγ or PI3K (Ostendorf et al., 2011). Increased expression of the different PDGF 
isoforms was observed in most if not all animal models of kidney injury. PDGFR-α chain, 
which is the receptor for PDGF-A and -C is widely expressed in the different renal cell 
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types, such as myofibroblasts, mesangial and smooth muscle cells (Alpers et al., 1993). 
Interestingly, while infusion of high doses of PDGF-A (5mg/kg) did not induced renal 
lesion (Tang et al., 1996) inhibition of PDGF-C with a neutralizing antibody exhibited a 
significant reduction of renal fibrosis, myofibroblast accumulation and decreased leukocyte 
infiltration in a mice model of UUO (Eitner et al., 2008).  PDGF-BB has a central proliferative 
effect on the mesangial cells. Actually infusion of PDGF-BB into of healthy rats led to 
increased mesangial cell proliferation and accumulation of the mesangial matrix (Tang et al., 
1996). More recently, the role of PDGF has been suggested in the transformation of 
pericytes, the main source of myofibroblasts, into myofibroblasts following kidney injury 
(Chen et al., 2011). Inhibition of PDGFR-α or PDGFR-β signaling with a neutralizing 
antibody or with Imatinib, a PDGF tyrosine kinase inhibitor, treatment the UUO induced 
differentiation and proliferation of the pericytes decreased. The treatment of the animals 
with a neutralizing antibody against PDGFR-α or PDGFR-β reduced the UUO induced 
macrophage infiltration, renal TGFβ, PDGF and CCL2 expression and renal fibrosis. Hence 
PDGFR-α and PDGFR-β are potential candidates for antifibrotic therapy in the future.  
4. Origin of myofibroblasts 
Understanding the origin of myofibroblasts in the kidney is great interest because these cells 
are responsible for scar formation in fibrotic kidney diseases. Myofibroblasts have migratory 
capacity, are resistant to apoptosis, and can produce different components of the 
extracellular matrix, growth factors, cytokines and therefore contribute to organ fibrosis and 
to the maintenance of inflammation (Zeisberg et al., 2008). Actually, in the healthy kidney 
there are no known endogenous myofibroblasts. In the fibrotic kidney (as in other organs) 
the origin of the renal myofibroblast is still controversial, however there are some 
hypotheses. Recently the derivation of myofibroblasts from epithelial or endothelial cells, 
fibrocytes and pericytes has been suggested (Fig. 1.).  
 
Fig. 1. Different possible origins of the myofibroblasts. There are different hypothesis about 
the possible origin of the myofibroblasts, which are effector cells of the organ fibrosis. The 
derivation of the myofibroblasts from endothelial and epithelial cells, from fibrocytes and 
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4.1 Epithelial-mesenchymal transition (EMT) 
A hypothesis that recently has become popular is the mesenchymal transition of the renal 
tubular epithelial cells. The process when the epithelial cells lose their polarity and epithelial 
adhesion properties and starts the de novo synthesis of mesenchymal markers, such as 
αSMA is the so called EMT. This process is already well known in different physiological 
and pathological processes, notably in embryogenesis, carcinogenesis (Kalluri & Weinberg, 
2009). The first remarkable evidence of EMT in the fibrotic kidney was demonstrated by Ng 
et al (Ng et al., 1998). They investigated the localization of αSMA after 1-21 weeks of 5/6 
nephrectomy of Sprague-Dawley rats. In normal kidneys in situ hybridization and 
immunohistochemical staining revealed the mRNA or protein expression of αSMA only in 
the vascular smooth muscle cells. Later on the 3rd week after the 5/6 nephrectomy, mRNA 
and protein expression of αSMA was present in the proximal tubular epithelial cells (TEC) 
as well. Indeed they observed a gradually increasing number of αSMA+ TEC peaking at 
week 9. Moreover, about 70% of the αSMA+ TEC were proliferating based on their 
proliferating cell nuclear antigen positivity. Finally these cells became elongated separated 
from their neighboring cells and appeared to migrate into the renal interstitium through the 
damaged basement membrane. These original observations were confirmed at the 
ultrasructural level of the renal tubules by electron microscopy. They found that in the early 
transformed TECs contain large round or oval shaped nucleus, several mitochondria 
indicating the activation of these cells. Characteristic microfilaments and dense bodies 
(stress fibers) were present in the transformed TECs, lying next to the damaged TBM. Later 
in advanced state of EMT TECs exhibit elongated morphology and abundant microfilaments 
and dense bodies. At this stage microfilaments are diffusely fill the entire cytoplasm of 
TECs. Later Iwano et al. strengthened the hypothesis of in vivo EMT using genetic fate 
mapping method (Iwano et al., 2002). Briefly, they developed transgen mice that express Cre 
recombinase under the promoter of γGT. As γGT is a brush border protein, its promoter is 
active only in the proximal TECs (PTEC). These γGT-Cre mice were then bred with a R26R 
reporter mice (Fig. 2). In the PTECs of the bigenic mice the expressed Cre recombinase 
mediates the excision of the loxP stop cassette and activate the expression of β galactosidase 
from the gene of LacZ. Thus irreversibly marking the PTECs with β galactosidase, despite 
the subsequent phenotypic changes. 
 
Fig. 2. Model of transgen mice that express Cre recombinase under the promoter of γGT. 
These γGT-Cre mice were then bred with a R26R reporter mice. 
Later, ten days after UUO the PTECs of the double transgenic, γGT-Cre; R26R mice started 
to express (beside β galactosidase) fibroblast specific protein-1 (FSP-1), suggesting the EMT 
of TECs (Fig. 3/b; LacZ-red and FSP1-green, merge-yellow). Some of these FSP-1 and β 
LoxP                LoxP
γGT promoter Cre
Rosa 26 promoter LacZSTOP
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galactosidase double positive PTECs also began to take an elongated shape of 
myofibroblasts (Fig. 3/b; arrows). Moreover, these double positive cells appeared in the 
fibrotic tissues surrounding the tubules (Fig. 3/c and d). Finally by counting the FSP1 and 
LacZ immunopositive cells in the renal interstitium, they suggested that after 10 days of 
UUO about 36% of the myofibroblasts originate from the renal tubular epithelial cells.  
 
Fig. 3. Confocal microscopy images of contralateral (a) and injured (b, c and d) kidneys 10 
days after the UUO (Iwano et al., 2002).  Proximal tubular epithelial cells are stained with an 
anti-β galactosidase antibody (red) and the fibroblasts with an anti-FSP1 antibody (green). 
(b, c, d) Ten days after the onset of UUO the β galactosidase positive PTECs also expressed 
FSP-1 (β galactosidase+/FSP-1+ PTECs cells staining yellow), suggesting the mesenchymal 
transition of cells. (b, c, d) Some of these FSP-1+ PTECs (arrow) had the elongated shape of 
myofibroblasts, and appeared in the fibrotic tissues surrounding the tubules. (After Iwano et 
al., 2002) 
Subsequently numerous in vitro studies confirmed the original observation of Ng (Ng et al., 
1998) and Iwano et al. (Iwano  et al., 2002). These studies on different cell lines (HK-2, 
HEK298, NRK) and on primer renal tubular epithelial cells have clearly shown that 
epithelial cells when exposed to hypoxia, reactive oxygen species, advanced glycation end 
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products, pro-fibrotic cytokines, TGF-β1, angiotensin II (ANGII), platelet-derived growth 
factor, epidermal growth factor and fibroblast growth factor-2 (Liu, 2010) growth factors or 
metalloproteinases (Yang & Liu, 2001) may undergo EMT. During EMT these molecules 
activate different signaling pathways on a coordinated manner. As a result the Ras/Rho 
GTPase, Rho-activated kinase, c-Src tyrozin kinase, Integrin-linked kinase, Wnt-1, Smad 2 
and 3, p38 mitogen-activated protein kinase, extracellular signal-regulated kinase (ERK) and 
phosphatidil-inositol-3 kinase (PI3K) signaling pathways can be activated (Thiery & 
Sleeman, 2006). Activation of these signaling pathways leads to the phenotypical conversion 
of the TECs. During EMT TECs lose their cellular polarity, downregulate epithelial markers 
and acquire mesenchymal features, such as the de novo synthesis of α-SMA. Finally the 
epithelial cells are transformed to myofibroblasts as a determinative step in renal fibrosis 
(Iwano et al., 2002). In the 2008 EMT congress in Cold Spring Harbor according to the in 
vivo and in vitro findings this process that led to tissue scaring was defined as type II EMT. 
Based on these studies EMT has been widely accepted as one of the main mechanism by 
which myofibroblast formed during renal fibrosis. However the presence of this 
phenomenon, even on primer epithelial cells is evident in vitro, recently it has been 
questioned in vivo. Unfortunately, the results of Iwano et al. have not been confirmed by 
other groups. In contrast others using genetic fate mapping techniques were not able to 
demonstrate any evidence of EMT in vivo. Humphreys et al. developed two transgenic Cre 
driver mice that express bacterial Cre recombinase under the regulation of Six2 or HoxB7 
promoters (Humphreys et al., 2010) (Fig. 4/A). Both Six2 and HoxB7 are transcriptional 
factors that transiently expressed during development. Six2 is expressed only in those cells 
of metanephric mesenchyme that are fated to be epithelial cell of the proximal or distal 
tubules. HoxB7 is expressed in the cells of ureteric bund that are fated to be the cells of the 
collecting duct. These transgenic mice were bred with R26R reporter mice expressing β 
galactosidase. In the kidney samples of the healthy Six2-Cre; R262 bigenic mice strong 
epithelial β galactosidase activity was present in the podocytes and in the whole tubulus 
until the collecting duct. In case of HoxB7-Cre; R262 double transgenic mice this positivity 
was restricted to the epithelia of the collecting duct (Figure 4/B). Fourteen days after the 
UUO there was no change in the localization of β galactosidase activity. β galactosidase 
activity was present in the epithelial cell of the bigenic mice (Six2-Cre; R262 or HoxB7-Cre; 
R262), but none of the αSMA positive interstitial cells were positive for β galactosidase 
activity. These results strongly suggest that epithelial cells do not leave their original place, 
behind the basement membrane and they do not migrate into the interstitium of the ureteral 
obstructed kidney. 
Based on these conflicting data it is not evident whether in vivo EMT is an existing process 
in the fibrotic kidney or not. While in vitro data strongly suggest the existence of EMT in 
vivo studies of Humphreys et al. and others suggest that TECs do not invade the basement 
membrane and do not become real interstitial myofibroblasts (Humphreys et al., 2010). But 
are the in vitro and in vivo data really contradictory? Actually in vitro studies investigate 
the molecular mechanism of EMT but do not investigate the basement membrane invading 
capacity of the transformed cells. On the other hand in vivo experiments investigate the 
basement membrane invading capacity of the TECs but do not investigate the molecular 
changes of the TECs during the fibrotic process. So some scientists believe that the aim of 
the in vitro and in vivo studies is different and thus the results of these studies are not 
necessarily contradictory. 
Immunological and Molecular Mechanisms  





Fig. 4. Control and kidneys 14 days after the UUO from Six2-GC; R26R and HoxB7-Cre; R26R 
mice show no evidence for β galactosidase activity in the renal interstitium. A: Double 
transgen Six2-GC; R26R mice activated Cre expression in the cells of the metanephric 
mesenchyme that are fated to become the cells of the renal tubules. Expression of Cre results 
in removal of the LoxP-STOP-LoxP sequence in epithelial cells, leading to permanent, 
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activation of Cre expression in the ureteric bud led to the expression of β galactosidase in 
the epithelial cells of the collecting duct. B: Representative light microscopy images of X-gal 
stain indicating of β galactosidase activity in the control (left) and in the obstructed (right) 
kidneys. (After Humphreys et al., 2002) 
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4.2 Endothelial-mesenchymal transition (EndMT)  
EndMT was first described during embryonic heart development, where mesenchymal cells 
of the endocardial cushion (a tissue that later gives rise to the cardiac septa and valves) arise 
from endothelial cells of the endocardium. Endothelium is a specialized type of a squamous 
type epithelium. Thus EndMT is a specific form of EMT. Simirarly to EMT during EndMT 
endothelial cells (EC) lose their endothelial markers and acquire markers of myofibroblasts. 
Studies on different organs have demonstrated the relevance of EndMT in the 
pathomechanism of organ fibrosis. Zeisberg et al. used Tie1 Cre; R26R bigenic mice to fate 
the EC during cardiac fibrosis (Zeisberg et al., 2007a). They have demonstrated that EC 
undergo phenotypic conversion and contribute to organ fibrosis. Similarly, Hashimoto et al. 
using Tie2 Cre; CAG-CAT-LacZ transgenic mice have shown that EC give a significant 
percent of myofibroblasts in bleomycin induced pulmonary fibrosis (Hashimoto et al., 2010). 
Recently, the importance of EndMT was suggested in different models of renal fibrosis as 
well. Zeisberg et al. investigated the contribution of endothelial cells to fibrosis in different 
animal models of CKD: 1) a mouse model of unilateral obstructive nephropathy; 2) a model 
of streptozotocin (STZ) induced DN; 3) a mouse model of Alport disease (COL4A3 KO, lack 
the collagen IV α3 chain). First they investigated the effect of UUO on the population of FSP-
1 or αSMA positive myofibroblast. Previously, it has been demonstrated that FSP-1 or 
αSMA identify distinct population of myofibroblast with a minimal overlap between the 
different populations (Zeisberg et al., 2007a, 2007b). One week after the ligation of the ureter 
the number of the FSP-1 or αSMA positive myofibroblast population increased. To 
investigate the possible endothelial origin of the myofibroblast double immunostaining 
were performed. The number of the CD31 (marker of the EC) and FSP-1 or CD31 and αSMA 
positive myofibroblasts were 36% or 25%, respectively (Fig. 5).  
 
Fig. 5. Immune fluorescent staining to investigate the possible endothelial origin of the 
myofibroblast. CD31 (red) is a marker of ECs, FSP-1 (green) is that of myofibroblasts. (After 
work of Zeisberg et al., 2007). 
To strengthen the endothelial origin of these double CD31 and FSP-1 or CD31 and αSMA 
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cells of endothelial origin express yellow fluorescent protein (YFP). After UUO a substantial 
portion of FSP-1 or αSMA positive myofibroblast coexpressed YFP, suggesting their 
endothelial origin. These data strongly suggest that EndMT may account for a considerable 
percent of myofibroblasts in the mouse model of UUO. Zeisberg et al. also investigated the 
origin of myofibroblasts in a mouse STZ induced DN. They have demonstrated that 6 moths 
after the induction diabetes about 50% of the αSMA and 40% of the FSP-1 positive cells were 
also CD31 positive in the kidney, suggesting the relevance of EndMT in the fibrotic changes 
in DN. Finally, Zeisberg et al. investigated the origin of myofibroblast in COL4A3 KO mice, 
in a model of Alport syndrome. In these mice proteinuria, glomerulonephritis and 
tubulointersitial fibrosis starts at the 8th week of age. In the investigated 22 weeks old mice 
strong interstitial fibrosis was present as revealed by the Masson Trichrome staining (MTS). 
In accordance with MTS the number of myofibroblast was elevated in COL4A3 KO 
compared to wild type mice. To investigate the origin these myofibroblast the coexpression 
of FSP-1 or αSMA and CD31 was investigated by double immunostaining. They found that 
about 45% of the αSMA and 60% of the FSP-1 positive myofibroblast were CD31 positive, 
suggesting the endothelial origin of these cells. In accordance with Zeisberg et al. Li and 
coworkers revealed the contribution of EndMT in the development of STZ induced renal 
fibrosis. They developed a Tie2Cre; EGFP mice to trace the localization of the cells with 
endothelial origin in a mice model of STZ induced DN. Tie2 is a pan endothelial marker 
which is expressed in EC during embryogenesis and thereafter during adulthood. In the 
bigenic mice Cre recombinase is expressed under the promoter of Tie2 and mediates the 
excision of a loxP stop cassette thus activating the expression of EGFP. In accordance with 
other studies (Schlaeger et al., 1997; Koni et al., 2001; Limbourg et al., 2005) the Cre mediated 
recombination occurred mainly in the ECs, with only a little activity in other cells. In the 
normal kidneys of Tie2Cre; EGFP mice CD31 staining colocalized with the EGFP positive 
cells. However, 1 or 6 months after the induction of STZ induced DN 10.4% or 23.5% of renal 
αSMA positive interstitial myofibroblasts were EGFP positive, suggesting there endothelial 
origin. Apparently these studies clearly demonstrate the significant role of EndMT in the 
pathomechanism of renal fibrosis. However, ECs are specialized squamous epithelium and 
the similarities between EMT and EndMT is evident suggesting that EndMT is a specific 
form of EMT. So the question emerges why ECs can invade the basement membrane and 
become real interstitial myofibroblasts if epithelial cells can not.  
4.3 Pericytes, perivascular cells or resident fibroblasts 
The definition of pericytes (also known as Rouget cells), perivascular cells or resident 
fibroblasts in the kidney is still a matter of debate.  Pericytes occurs around peritubular 
capillaries and postcapillary venules in the kidney. Pericytes characteristically line at the 
outer surface of EC and are covered fully or in part with capillary basement membrane thus 
fulfilling the major criterias of pericytes. These gaps of capillary basement membrane are 
frequently colocalise with the projections of pericytes, which are believed to be sites of 
intercellular communication (Grgic et al., 2011). Some projections of the pericytes also can 
reach the basement membrane of the TECs, make them similar or identical to the cells called 
resident fibroblast (Kaissling et al., 1996). Recently it has been suggested that activation of 
pericytes - which are relatively undifferentiated cells - may led to phenotype transformation 
of them into myofibroblasts. To investigate the potential role of pericytes as myofibroblast 
precursors Lin et al. generated a transgenic mice expressing GFP under the promoter of 
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cells of endothelial origin express yellow fluorescent protein (YFP). After UUO a substantial 
portion of FSP-1 or αSMA positive myofibroblast coexpressed YFP, suggesting their 
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percent of myofibroblasts in the mouse model of UUO. Zeisberg et al. also investigated the 
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after the induction diabetes about 50% of the αSMA and 40% of the FSP-1 positive cells were 
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collagen type I, α1 (Lin et al., 2008). In these animals the presence of GFP labels, with high 
sensitivity, the collagen I, α1 producing cell. In healthy kidney of this, coll1a1-GFP mice 
peritubular capillaries were lined intermittently with collagen type I, α1 producing cells, 
which were subendothelial in a direct apposition with CD31 positive ECs and exhibited 
pedicle like attachment plaques suggesting the direct interaction of collagen type I, α1 
producing cells with the ECs. These characteristics define these collagen type I, α1 
producing cells as pericytes. In developed, but young, 12 days old animals the majority 
(98,4%) of these cells also expressed chondroitin sulfate proteoglycan 4 (CSPG4), αSMA and 
PDGFRβ which are all known markers of pericytes. Later in healthy adult mice renal 
pericytes lost their CSPG4 and αSMA positivity with time. To investigate the contribution of 
the pericytes to renal fibrosis Lin et al. induced UUO in these coll1a1-GFP mice. In the 
kidney of diseased mice pericytes do not lose their CSPG4, αSMA and PDGFRβ positivity, 
rather their population expands. In this model of renal fibrosis 7 days after ureteral 
obstruction there was a close but imperfect correlation between the collagen 1, α1producing 
(GFP+) and αSMA positive interstitial cells. Actually 1% of the GFP producing cell did not 
express αSMA and 25% of the αSMA producing cells did not express GFP in the renal 
interstitium. These study of Lin et al. strongly suggest that the main source of the 
myofibroblasts are the collagen I, α1 producing cells, most likely pericytes in the obstructed 
kidneys. However, these data also suggest that a remarkable percent of the αSMA 
producing myofibroblasts may originate from other cells then pericytes. Later this group to 
strengthen their observations made a genetic fate mapping study to test that pericytes are 
the primary source of myofibroblasts in the UUO model of fibrosis. Humphreys et al. 
developed a transgenic Cre driver mice that express bacterial Cre recombinase under the 
regulation of forkhead box D1 (FoxD1) promoter (Fig.6.) (Humphreys et al., 2010). FoxD1 is 
a transcriptional factor that is transiently expressed during development in metanephric 
mesenchyme cells that are fated to become mesangial, vascular smooth muscle cells and 
pericytes. These transgenic mice were then bred with R26R reporter mice. In the kidney of 
the FoxD1-Cre; R262 bigenic mice mesangial and vascular smooth muscle cells and many 
PDGFRβ positive interstitial pericytes were detectable after X-gal staining. Fourteen days 
after UUO they found a marked expansion of LacZ positive cells in the interstitium of the 
injured kidneys. These β galactosidase positive cells were αSMA positive and all SMA 
positive cells exhibited β galactosidase activity as well. Suggesting that there was no 
significant population of cells becoming myofibroblast, except the previously FoxD1 
positive cells. However, following UUO FoxD1 transcripts were detected in the kidney 
samples of FoxD1-Cre; R262 bigenic mice. This means that not only the cells with the 
heritable marker of R26R mice, but also the de novo FoxD1 expressing cells are labeled with 
β galactosidase. To circumvent this problem Humphreys B.D. et al developed FoxD1-GCE 
transgen mice, in which Cre recombinase is expressed under FoxD1 promoter in a 
tamoxifen-inducible manner. These mice were then bred with R26R reporter mice. FoxD1-
GCE; R26R mice that received tamoxifen during the nephrogenesis had β galactosidase 
positive cells in the renal interstitium which also expressed PDGFRβ and were negative for 
αSMA (myofibroblast), CD31 (endothelial cell) or F4/80 (macrophages) defining them as 
pericytes. However, it should be noted that in FoxD1-GCE; R26R mice approximately 20% of 
pericytes were labeled with β galactosidase activity. Ten days after UUO all β galactosidase 
positive interstitial cells remained PDGFRβ positive and acquired expression of αSMA 
demonstrating that pericytes differentiated into myofibroblast. Nowadays the most 
accepted theory is the transformation of perycites into myofibroblasts. However, since these 
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experiments are rather new it is still not known how the traditional fibrosis inducing factors 
like TGFβ-1 or Angiotensin can alter the ECM producing capacity of myofibroblasts derived 
from perycites.   
 
 
Fig. 6. Fourteen days after UUO a marked expansion of β galactosidase positive cells (blue) 
was observed in the interstitium of the injured FoxD1-GC; R26R mouse kidneys. Merged 
light and fluorescence image show the co-expression of β galactosidase (blue) with SMA 
(red) after UUO day 14. (After Humphreys et al., 2010). 
4.4 Bone marrow derived fibrocytes 
Fibrocytes are bone marrow (BM) derived mesenchymal cells (Mori et al., 2005; Kisseleva et 
al., 2006) that express the markers of hematopoietic stem cells, monocytes and fibroblasts 
(Yang  et al., 2002; Mori et al., 2005; Abe et al., 2001). Previously these CD14+ and CD16- 
fibrocyte precursors were termed as inflammatory monocytes (Gordon & Taylor, 2005). In 
response to tissue damage these cells are released in high number from the BM and then 
migrate into the site of the injury. In the tissue most of these inflammatory monocytes then 
believed to differentiate into macrophages, dendritic cells (Tacke & Randolph, 2006). 
However, a subpopulation of these CD14+ and CD16- cells can differentiate into other cells 
types, such as myoblasts, osteoblasts, epithelial, endothelial, neuronal cells (Zhao et al., 2003; 
Kuwana et al., 2003) or fibrocytes as an intermediate stage of differentiation into mature 
myofibroblasts. In vitro the co-culture of the CD14+ fibrocyte progenitors with T cells or 
stimulation of them with TGFβ1, PDGF, IL-4 or IL-13 promotes their maturation into 
fibrocytes. By contrast aggregated IgG, serum amyloid P, INFγ or IL-12 inhibits the 
differentiation of CD14+ mononuclear cells into fibrocytes. Fibrocytes express CD34 and 
CD105 hematopoietic stem cell markers and MHC I and MHC II and the costimulatory 
molecules CD80 and CD86. Today the presence of CD45, CD34, or other myeloid antigen 
like CD11b and CD13 is considered to discriminate fibrocytes from leukocytes. Fibrocytes 
still do not express large amount of ECM (Chesney et al., 1998), however they produce ECM 
degrading enzymes, such as MMP9 (García-de-Alba et al., 2010). Fibrocytes can differentiate 
into myofibroblast in vivo (Mori et al., 2005; Schmidt et al., 2003). The further differentiation 
of the fibrocytes into myofibroblasts is stimulated by TGFβ1 and endothelin-1. The matured 
myofibroblasts then produce significantly more collagen then fibrocytes and express αSMA. 
Myofibroblasts also lose the CD34 and CD45 markers of fibrocytes. Despite our huge 
knowledge about the differentiation of CD14+ mononuclear cells into myofibroblast, the 
contribution of these BM derived cells to the population of myofibroblast is generally 
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accepted theory is the transformation of perycites into myofibroblasts. However, since these 
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experiments are rather new it is still not known how the traditional fibrosis inducing factors 
like TGFβ-1 or Angiotensin can alter the ECM producing capacity of myofibroblasts derived 
from perycites.   
 
 
Fig. 6. Fourteen days after UUO a marked expansion of β galactosidase positive cells (blue) 
was observed in the interstitium of the injured FoxD1-GC; R26R mouse kidneys. Merged 
light and fluorescence image show the co-expression of β galactosidase (blue) with SMA 
(red) after UUO day 14. (After Humphreys et al., 2010). 
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(Yang  et al., 2002; Mori et al., 2005; Abe et al., 2001). Previously these CD14+ and CD16- 
fibrocyte precursors were termed as inflammatory monocytes (Gordon & Taylor, 2005). In 
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migrate into the site of the injury. In the tissue most of these inflammatory monocytes then 
believed to differentiate into macrophages, dendritic cells (Tacke & Randolph, 2006). 
However, a subpopulation of these CD14+ and CD16- cells can differentiate into other cells 
types, such as myoblasts, osteoblasts, epithelial, endothelial, neuronal cells (Zhao et al., 2003; 
Kuwana et al., 2003) or fibrocytes as an intermediate stage of differentiation into mature 
myofibroblasts. In vitro the co-culture of the CD14+ fibrocyte progenitors with T cells or 
stimulation of them with TGFβ1, PDGF, IL-4 or IL-13 promotes their maturation into 
fibrocytes. By contrast aggregated IgG, serum amyloid P, INFγ or IL-12 inhibits the 
differentiation of CD14+ mononuclear cells into fibrocytes. Fibrocytes express CD34 and 
CD105 hematopoietic stem cell markers and MHC I and MHC II and the costimulatory 
molecules CD80 and CD86. Today the presence of CD45, CD34, or other myeloid antigen 
like CD11b and CD13 is considered to discriminate fibrocytes from leukocytes. Fibrocytes 
still do not express large amount of ECM (Chesney et al., 1998), however they produce ECM 
degrading enzymes, such as MMP9 (García-de-Alba et al., 2010). Fibrocytes can differentiate 
into myofibroblast in vivo (Mori et al., 2005; Schmidt et al., 2003). The further differentiation 
of the fibrocytes into myofibroblasts is stimulated by TGFβ1 and endothelin-1. The matured 
myofibroblasts then produce significantly more collagen then fibrocytes and express αSMA. 
Myofibroblasts also lose the CD34 and CD45 markers of fibrocytes. Despite our huge 
knowledge about the differentiation of CD14+ mononuclear cells into myofibroblast, the 
contribution of these BM derived cells to the population of myofibroblast is generally 
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believed to be small. To investigate the contribution of fibrocytes to the population of 
myofibroblast Iwano M. et al. generated transgenic mice, in which EGFP is expressed under 
the promoter of FSP-1. In this experiment they used FSP-1 as marker of myofibroblast 
(Iwano M et al., 2002). The T cell depleted BM of these transgenic mice was intravenously 
injected into lethally irradiated Balb/c, wild type recipients. Thirty days after the BM 
transfer the chimeric mice underwent UUO. Finally, 10 days after the UUO the number of 
FSP-1 and EGFP double positive BM derived cells were counted in the injured and in the 
collateral, normal kidney samples. By counting several random cortical fields they found 
that about the 12% of the renal FSP-1 positive cells have BM origin in the normal and about 
15% in the injured kidneys. These data suggest that 10 days after UUO only 3% of the FSP-1 
positive myofibroblasts are originated from the BM. Others investigating the contribution of 
fibrocytes to the population of myofibroblast have found similar results. Lin et al. 
transplanted the BM cells of coll1a1-GFP mice into a lethally irradiated wild type recipient 
mice. In these chimeric mice all collagen type I, α1 producing cell with BM origin express 
GFP. To induce renal fibrosis UUO was performed on these chimeric mice. Interestingly, 
they found that 7 days after UUO only the 0.1% of the myofibroblast expressed the CD34 
and CD45 markers of fibrocytes (Abe et al., 2001) in the chimeric mice. Taken together these 
data suggest that the contribution of CD14+ CD16- BM cells to the population of 
myofibroblasts is not significant. One week after the UUO only a few percent (0.1-3%) of the 
myofibroblasts are originated from these CD14+ CD16- BM cells. 
5. Summary and concluding remarks 
Today there are different theories about the possible origin of the myofibroblasts that are 
responsible for scar formation in the injured kidney. A hypothesis that recently became 
popular is the mesenchymal transition of the renal tubular epithelial cells. During EMT 
epithelial cells undergo phenotypic conversion, which means that they lose their polarity, 
epithelial adhesion properties and starts the de novo synthesis of αSMA and other 
mesenchymal factors. This process is already well known in different physiological and 
pathological processes, notably in embryogenesis and carcinogenesis. In vitro experiments 
on different epithelial cell lines and on primer epithelial cells strongly suggest the existence 
of EMT based on their increased expression of αSMA, vimentin and decreased expression of 
E-cadherin. However, the role of EMT is controversial in renal fibrosis. Recently, 
Humphreys et al. using double transgenic animals, clearly demonstrated that tubular 
epithelial cells can not invade the basement membrane, suggesting that EMT does not lead 
to formation of myofibroblasts, actually not in vivo in the mice model of UUO. Interestingly, 
the concept of EndMT is widely accepted, despite that the endothelial cells are specialized 
squamous type epithelial cells suggesting that EndMT is only a specific form of EMT. 
Actually, the similarities between EMT and EndMT is evident. During the phenotype 
conversion endothelial or epithelial cells lose their original markers and start to express 
mesenchymal ones, such as αSMA. However, the question why endothelial cells can invade 
the basement membrane and epithelial cells can not is still unanswered. Today, perhaps the 
most accepted theory about the possible origin of myofibroblasts is the transformation of 
perycites into myofibroblasts. This observation is rather new and it is still not known how 
the traditional fibrosis inducing factors like TGFβ or angiotensin can alter the ECM 
producing capacity of myofibroblasts derived from perycites. Finally the contribution of 
CD14+ CD16- BM cells to the population of myofibroblasts is not significant. These cells are 
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responsible for only 1-2% of the myofibroblast. There estimated number of patients with 
chronic kidney disease is over 2.5 millions in Europe and the number of patients on chronic 
renal replacement therapy number is continuously increasing. Thus research in that field 
has not only scientific impact, but has also important implications on general health and 
health care systems considering the quality of life in uremia and the socio-economic costs of 
renal replacement therapies. Actually regardless of the initiating cause (infection, 
autoimmune response, chemical insult, radiation or tissue injury etc.) fibrosis is the final 
common pathway for all progressive renal diseases. That is why it is so important to 
understand the complex interplay among immune cells, myofibroblasts precursors and renal 
cells. The development of new antifibrotic therapies is getting more and more important, and 
it requires the understanding of the cellular origin and precise role of myofibroblasts.  
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1. Introduction 
Maternal conditions affect the growth of the fetal kidney, which begins to secrete urine 
during late gestation (Bakala et al., 1985; Schaeverbeke & Cheignon, 1980). For example, 
during pregnancy, the maternal kidney undergoes various changes such as an increase in 
glomerular filtration rate (Baylis, 1994; Atherton & Pirie, 1981) and an alteration in tubular 
function (Dafnis & Sabatini, 1992). Furthermore, maternal undernutrition by the restriction 
of protein intake induces low fetal birth and leads to renal morphological and physiological 
changes (Mesquita et al., 2010). Maternal bilateral ligation of the uterine artery, protein 
restriction, smoking, nephrotoxic medication as well as salt loading cause intrauterine 
growth retardation (IUGR) to fetuses (Bentz & Amann, 2010), inducing fetal programing of 
renal function. Previously, we investigated the development of the fetal kidney during 
maternal renal dysfunction induced by bilateral ureteral ligation (Okada et al., 1997) and 
uninephrectomy (Okada et al., 2000, 2006), and we found that the development of the fetal 
kidney is accelerated by the operations. Furthermore, we found that maternal bilateral 
ureteral ligation (Okada & Morikawa, 1988) and uninephrectomy (Okada et al., 1998) 
decrease fetal body weight. In this chapter, we present a summary of the changes that occur 
in the fetal kidney after maternal bilateral ureteral ligation, uninephrectomy, and subtotal 
(5/6) nephrectomy, in addition to a summary of the changes that occur in the remaining 
kidney after uninephrectomy and 5/6 nephrectomy. Although 5/6 nephrectomy produces a 
bigger functional demand to maternal and fetal kidneys than the other two operations, little 
information is available on fetal development of the kidney when the maternal kidney is 
5/6th removed. Therefore, we focused on studying the remaining kidney of unilateral and 
5/6 nephrectomy and the fetal kidney under maternal renal dysfunction. 
2. Effects of nehrectomy on remaining kidney 
Nephrectomy can be used for research on renal growth and renal failure. Specifically 
uninephrectomy can be performed for research on the biology of compensatory renal 
growth (Fine, 1986) and subtotal nephrectomy for renal failure. In studies of subtotal 
nephrectomy, 3/4 nephrectomy (Friedman & Pityer, 1986) and 5/6 nephrectomy 
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1. Introduction 
Maternal conditions affect the growth of the fetal kidney, which begins to secrete urine 
during late gestation (Bakala et al., 1985; Schaeverbeke & Cheignon, 1980). For example, 
during pregnancy, the maternal kidney undergoes various changes such as an increase in 
glomerular filtration rate (Baylis, 1994; Atherton & Pirie, 1981) and an alteration in tubular 
function (Dafnis & Sabatini, 1992). Furthermore, maternal undernutrition by the restriction 
of protein intake induces low fetal birth and leads to renal morphological and physiological 
changes (Mesquita et al., 2010). Maternal bilateral ligation of the uterine artery, protein 
restriction, smoking, nephrotoxic medication as well as salt loading cause intrauterine 
growth retardation (IUGR) to fetuses (Bentz & Amann, 2010), inducing fetal programing of 
renal function. Previously, we investigated the development of the fetal kidney during 
maternal renal dysfunction induced by bilateral ureteral ligation (Okada et al., 1997) and 
uninephrectomy (Okada et al., 2000, 2006), and we found that the development of the fetal 
kidney is accelerated by the operations. Furthermore, we found that maternal bilateral 
ureteral ligation (Okada & Morikawa, 1988) and uninephrectomy (Okada et al., 1998) 
decrease fetal body weight. In this chapter, we present a summary of the changes that occur 
in the fetal kidney after maternal bilateral ureteral ligation, uninephrectomy, and subtotal 
(5/6) nephrectomy, in addition to a summary of the changes that occur in the remaining 
kidney after uninephrectomy and 5/6 nephrectomy. Although 5/6 nephrectomy produces a 
bigger functional demand to maternal and fetal kidneys than the other two operations, little 
information is available on fetal development of the kidney when the maternal kidney is 
5/6th removed. Therefore, we focused on studying the remaining kidney of unilateral and 
5/6 nephrectomy and the fetal kidney under maternal renal dysfunction. 
2. Effects of nehrectomy on remaining kidney 
Nephrectomy can be used for research on renal growth and renal failure. Specifically 
uninephrectomy can be performed for research on the biology of compensatory renal 
growth (Fine, 1986) and subtotal nephrectomy for renal failure. In studies of subtotal 
nephrectomy, 3/4 nephrectomy (Friedman & Pityer, 1986) and 5/6 nephrectomy 
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(Manotham et al., 2004) have been performed. In this section, effects of uninephrectomy and 
5/6 nephrectomy on the remaining kidney are discussed. 
2.1 Effects of uninephrectomy on the cell proliferation and EGF in the remaining 
kidney 
Compensatory renal growth after unilateral nephrectomy has been intensely investigated 
(Dicker & Shirley, 1971; Johnson & Vera Roman, 1966; Mok et al., 2003) and includes cellular 
hypertrophy, hyperplasia, and apoptosis (Wang et al., 1997). In the adult kidney, 
differentiated nephrons are relatively quiescent, with few cells undergoing mitosis (Girardi 
et al., 2002). Compensatory response after renal mass ablation shows increase in both cell 
size and cellular protein content without any increase in cell number (Girardi et al., 2002). 
The compensatory renal growth largely occurs by hypertrophy rather than hyperplasia of 
the remaining nephrons (Chen et al., 2005). Kanda et al. (1993) have observed that 24 h after 
uninephrectomy of an adult mouse kidney, there was an initiation of the proliferation of 
cortical tubular cells in the remaining kidney stained with anti-BrdU antibody. On the other 
hand, it has been seen that the compensatory response to uninephrectomy is stronger in 
immature animals than in adult ones (Fine, 1986) and the removal of the contralateral 
kidney induces an evident increase in cell proliferation, especially in proximal tubules, in 
young uninephrectomized rats (Girardi et al., 2002). Furthermore, we have recently reported 
that in the remaining kidney of uninephrectomized immature (3-week-old) rats few 
proliferatiomg cell nuclear antigen (PCNA)-positive cells in distal tubules were little 
observed and that a significant increase in the PCNA-positive cell ratios was observed in the 
proximal convoluted and straight tubules (Okada et al., 2010). Moreover, we have reported 
that in the immature rats 1 and 3 days after uninephrectomy there were significant increases 
in renal weight and the PCNA-positive cell ratios of the glomerulus and proximal 
convoluted and straight tubules (Okada et al., 2010). Kanda et al. (1993) have also reported 
that in immature rats, the increase in kidney mass immediately after nephrectomy is mainly 
due to hyperplasia, whereas 2 weeks after nephrectomy both hyperplasia and hypertrophy 
processes equally participate. Therefore, we concluded that there is an increase in 
proliferative activity in the proximal tubules during the early stage of compensatory renal 
growth in immature rats. Thus, the compensatory reaction of immature animals is different 
from that of adult animals, in terms of proliferative activity but is similar with regard to an 
increase in proliferating cells during the 24 h after uninephrectomy. 
Considering the relationship of epidermal growth factor (EGF) to the elevated proliferating 
activity of nephrectomized immature animals, we examined the immunolocalization of EGF 
(Okada et al., 2010). Although Toubeau et al. (1994) and Jung et al. (2005) have observed the 
immunolocalizations of EGF in distal convoluted tubules and the thick ascending limb of 
Henle’s loop of adult rat kidneys, our results revealed that EGF-positive cells localized to 
the proximal and the distal tubules in the kidney of immature rats indicating the difference 
of immunolocalization of EGF in the kidney between adult and immature animals (Okada et 
al., 2010). There are controversial reports on the involvement of EGF on the proliferative 
activity of the adult kidney. For example, Pugh et al. (1995) have found that the addition of 
EGF to renal organ culture medium increases uptake of BrdU while Toubeau et al. (1994) 
have found that cell proliferation occurs immediately after the decrease of renal EGF and its 
receptor (EGFR) in the rat experimentally subjected to acute renal failure. Further, in the 
unilaterally ureter obstructed rat model, the administration of EGF causes a decrease in 
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proliferative activity in the contralateral kidney (Chevalier, 1999). Moreover, EGF expression 
and the role of EGF in the developing kidney is also controversial as follows: in the 
developing kidney, EGF expression appears as nephrons mature (Nouwen et al., 1994); 
exogenous EGF delays the development of the loop of Henle by reducing both apoptosis 
and cell proliferation (Lee et al., 2004); robust EGF synthesis is clearly a characteristic of the 
mature kidney rather than that of a rapidly-growing fetal organ (Goodyer et al., 1991a); 
renal EGF is undetectable in the human fetus (Goodyer, et al., 1991b) and renal EGF content 
is increased from days 6 to 21 after birth in mice  (Gattone et al., 1992). 
We have recently observed that on the first post-operative day, the proximal tubular cells 
showed a weaker reaction to EGF antibody in uninephrectomized rats than in sham-
operated rats and that the degree of reactivity to EGF was the same in both groups on the 
third post-operative day and that the level of expression of preproEGF mRNA was 
significantly lower in uninephrectomized rats than in sham-operated rats at the first post-
operative day (Okada et al., 2010). These findings reveal that unilateral nephrectomy in 
immature rats causes an increased proliferative activity and a decreased expression of EGF 
in the remaining kidney during the early period of compensatory renal growth. 
2.2 Effects of subtotal (5/6) nephrectomy on the remaining kidney: Growth factor and 
protein restriction 
Subtotal (5/6) nephrectomy has been performed on laboratory animals to achieve a model 
for chronic renal failure (Manotham et al., 2004; Zhang et al., 1999). After the reduction of 
renal mass, remnant renal tissue was less able to maintain stability of blood flow and 
filtration rate during variations in renal perfusion pressure (Brown et al., 1995), and various 
pathological changes are observed. In the remaining kidney, glomerular sclerosis is 
observed following increased proliferative activity in glomeruli (Floege et al., 1992), and 
renal fibrosis is accompanied with apoptotic cells (Li et al., 2004). The remaining kidney of 
5/6 nephrectomized animals was utilized as a model for renal fibrosis (Johnson et al., 1997; 
Nangaku et al., 2002; Yang et al., 2001) and a model for glomerular sclerosis (Floege et al., 
1992; Griffin et al., 1994). Since in immature rats as well as adult animals, 5/6 nephrectomy 
induces significant increases in BUN, glomerular sclerosis index (GSI), and interstitial 
fibrosis score (IFS), compared with sham-oprated ones (Mino et al., 2007), 5/6 
nephrectomized immature animals are useful as animal model for renal failure.  
In adult animals, it has been reported that a low protein diet reduces uremic toxicity in 
experimentally-induced uremia (Sterner et al, 1994) and that in the 5/6 nephrectomized 
renal failure model, the restriction of protein intake improves renal failure (Heller et al., 
1994). It has been reported that a low protein intake improves survival over normal protein 
intake in 3/4 nephrectomized immature rats (Friedman & Pityer, 1986). Further, Mino et al. 
(2007) have reported that a low protein diet induces a significant decrease in BUN, GSI, and 
IFS in 5/6 nephrectomized immature rats. These findings suggest that protein intake 
restriction is effective in preventing renal failure in immature animals, which is in accord 
with the results in adult rats.   
Increased glomerular hydraulic pressure and the ultrafiltration plasma proteins contribute 
to the onset and progression of chronic renal damage (Remuzzi et al., 2005). Inhibitor of 
angiotensin converting enzyme (ACE) and angiotensin type II receptor antagonists can be 
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Henle’s loop of adult rat kidneys, our results revealed that EGF-positive cells localized to 
the proximal and the distal tubules in the kidney of immature rats indicating the difference 
of immunolocalization of EGF in the kidney between adult and immature animals (Okada et 
al., 2010). There are controversial reports on the involvement of EGF on the proliferative 
activity of the adult kidney. For example, Pugh et al. (1995) have found that the addition of 
EGF to renal organ culture medium increases uptake of BrdU while Toubeau et al. (1994) 
have found that cell proliferation occurs immediately after the decrease of renal EGF and its 
receptor (EGFR) in the rat experimentally subjected to acute renal failure. Further, in the 
unilaterally ureter obstructed rat model, the administration of EGF causes a decrease in 
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proliferative activity in the contralateral kidney (Chevalier, 1999). Moreover, EGF expression 
and the role of EGF in the developing kidney is also controversial as follows: in the 
developing kidney, EGF expression appears as nephrons mature (Nouwen et al., 1994); 
exogenous EGF delays the development of the loop of Henle by reducing both apoptosis 
and cell proliferation (Lee et al., 2004); robust EGF synthesis is clearly a characteristic of the 
mature kidney rather than that of a rapidly-growing fetal organ (Goodyer et al., 1991a); 
renal EGF is undetectable in the human fetus (Goodyer, et al., 1991b) and renal EGF content 
is increased from days 6 to 21 after birth in mice  (Gattone et al., 1992). 
We have recently observed that on the first post-operative day, the proximal tubular cells 
showed a weaker reaction to EGF antibody in uninephrectomized rats than in sham-
operated rats and that the degree of reactivity to EGF was the same in both groups on the 
third post-operative day and that the level of expression of preproEGF mRNA was 
significantly lower in uninephrectomized rats than in sham-operated rats at the first post-
operative day (Okada et al., 2010). These findings reveal that unilateral nephrectomy in 
immature rats causes an increased proliferative activity and a decreased expression of EGF 
in the remaining kidney during the early period of compensatory renal growth. 
2.2 Effects of subtotal (5/6) nephrectomy on the remaining kidney: Growth factor and 
protein restriction 
Subtotal (5/6) nephrectomy has been performed on laboratory animals to achieve a model 
for chronic renal failure (Manotham et al., 2004; Zhang et al., 1999). After the reduction of 
renal mass, remnant renal tissue was less able to maintain stability of blood flow and 
filtration rate during variations in renal perfusion pressure (Brown et al., 1995), and various 
pathological changes are observed. In the remaining kidney, glomerular sclerosis is 
observed following increased proliferative activity in glomeruli (Floege et al., 1992), and 
renal fibrosis is accompanied with apoptotic cells (Li et al., 2004). The remaining kidney of 
5/6 nephrectomized animals was utilized as a model for renal fibrosis (Johnson et al., 1997; 
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1992; Griffin et al., 1994). Since in immature rats as well as adult animals, 5/6 nephrectomy 
induces significant increases in BUN, glomerular sclerosis index (GSI), and interstitial 
fibrosis score (IFS), compared with sham-oprated ones (Mino et al., 2007), 5/6 
nephrectomized immature animals are useful as animal model for renal failure.  
In adult animals, it has been reported that a low protein diet reduces uremic toxicity in 
experimentally-induced uremia (Sterner et al, 1994) and that in the 5/6 nephrectomized 
renal failure model, the restriction of protein intake improves renal failure (Heller et al., 
1994). It has been reported that a low protein intake improves survival over normal protein 
intake in 3/4 nephrectomized immature rats (Friedman & Pityer, 1986). Further, Mino et al. 
(2007) have reported that a low protein diet induces a significant decrease in BUN, GSI, and 
IFS in 5/6 nephrectomized immature rats. These findings suggest that protein intake 
restriction is effective in preventing renal failure in immature animals, which is in accord 
with the results in adult rats.   
Increased glomerular hydraulic pressure and the ultrafiltration plasma proteins contribute 
to the onset and progression of chronic renal damage (Remuzzi et al., 2005). Inhibitor of 
angiotensin converting enzyme (ACE) and angiotensin type II receptor antagonists can be 
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used in combination to maximize renin-angiotensin-aldosterone system (RAAS) inhibition 
and more effectively reduce proteinuria and GFR decline in diabetic and non-diabetic renal 
disease (Remuzzi et al., 2005; Klein et al., 2003). Since activation of RAAS induces decreased 
level of endothelial nitric oxide synthase (eNOS) expression (Zhao et al., 2005), it is thought 
that NO also plays an important role in the progression of renal failure. Therefore, in 5/6 
nephrectomized animals, factors, including RAAS and NO, relating to the progression of 
renal failure and effects of protein restriction are discussed. 
We have previously reported that in the normal developing kidney in perinatal rats, EGF 
plays an important role in proliferative activity (Okada et al., 2001) and apoptosis (Okada et 
al., 2003). Further, chronic renal failure caused by 5/6 nephrectomy is improved by extrinsic 
EGF (Moskowitz et al., 1992), and EGF accelerates the regeneration of tubular cells and 
ameliorates renal failure (Humes et al., 1989). Furthermore, in 5/6 nephrectomized 
immature rats, the incidence of TUNEL positive cells in distal tubules was lowered and 
more EGF-positive cells in the segments were observed after protein restriction (Mino et al., 
2007). These findings reveal that protein restriction is effective in preventing renal tubular 
scarring in immature rats and that EGF is involved in the process of this prevention.  
Transforming growth factor-β (TGF-β) suppresses proliferative activity of the cells (Cheng & 
Grande, 2002) and converts renal tubular epithelial cells to fibroblasts (Stahl & Felsen, 2001). 
The fibroblast cells induce fibrosis of the renal tubular interstitium (Blobe et al., 2002; Iwano 
et al., 2002). TGF-β is also related to the infiltration of macrophages (Wahl et al., 1987). 
Feeding of a low protein (6% protein) diet to 5/6 nephrectomized immature rats induces 
decreased immunoreactivity of TGF-β (Fig. 1) and ED1 (Fig. 2). The increased expression of 
TGF-β in the distal tubules of the kidney is involved in the damage of the remaining kidney 
of 5/6 nephrectomized animals and protein restriction suppresses the elevation of TGF-β 
expression and the progression of renal failure. 
The expression of NO is increased in the kidney of animals with renal failure, and increased 
expression of NO is involved in the process of renal failure (Matubara et al., 2000). In the 
developing kidney, NO plays an important role in maintaining normal physiological 
function (Solhaug et al., 1996) and in regulating renal homodynamics (Han et al., 2005). 
Maintenance of adequate NO is an additional mechanism for the preservation of vasculature 
in progressive renal diseases (Kang et al., 2002). Inhibition of inducible NO synthase (iNOS) 
provides a mechanism against the developing ischemic renal injury and inflammation in the 
adult rat kidney (Mark et al., 2005). Nuclear factor-kappa B (NF-κB) is known to be involved 
in the induction of the human iNOS gene (Taylor et al., 1998). Furthermore, elevation in 
renin-angiotensin system (RAS) activity and DNA-binding activity of NF-κB are involved in 
the progression of renal failure in the remnant kidney of 5/6 nephrectomized rats (Ots et al., 
1998; Fujihara et al., 2007). On the other hand, decreased expression levels of eNOS in the 
glomerulus are often seen in rats with renal disease (Bremer et al., 1997). In the remnant 
kidney model, inhibition of NO synthesis with L-NAME resulted in a decline of renal 
function and severe glomerulosclerosis (Kang, et al., 2002). In the current model for 
endotoxin-induced thrombotic microangiopathy, which accompanies glomerular injury, 
endothelial injury is associated with decreased eNOS expression levels (Shao et al., 2001).  
NO produced by eNOS confers antioxidant properties on vascular cells (Walford & 
Loscalzo, 2003), and the endogenous low steady state levels of NO produced by eNOS 
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dynamically regulates mitochondrial respiration. This regulation thus provides protection 
against H2O2 mediated injury and death (Paxinou et al., 2001). 
  
  
Fig. 1. Kidneys of 5/6 nephrectomized immature rats stained with an anti-TGF-β antibody.  
bar = 50 μm.  A, low protein group 4 weeks after the operation. TGF-β positive cells are seen 
in the distal tubules. B, normal protein group 4 weeks after the operation. TGF-β positive 
cells are seen in the distal tubules and the reaction activity to TGF-β antibody is stronger 
compared to that in the age-matched low protein group in figure 1A. C, low protein group 8 
weeks after the operation. The reaction activity to TGF-β antibody is stronger when 
compared with those in the low protein group 4 weeks after the operation in figure 1A. D, 
normal protein group 8 weeks after the operation. The reaction activity to TGF-β is stronger 
compared to those in the age-matched low protein group in figure 1C and is stronger 
compared to that in the normal protein group 4 weeks after the operation in figure 1B. 
Thus, eNOS has a protective role in glomerulonephritis (Shao et al., 2001; Heering et al., 
2002), and RAS is involved in changes in eNOS expression (Zhao et al., 2005; Varziri et al., 
2002). As shown in figure 3, the eNOS positive cells were observed in the glomerulus in the 
rats of every group at 4 and 8 weeks after the operation in 5/6 nephrectomized immature 
rats (Fig. 3B and D). The positive reaction to the anti-eNOS antibody was stronger in the 4-
week postoperative rats than in the 8-week postoperative rats, and the reaction was stronger 
in the protein-restricted rats than in the control rats 4 weeks after the operation (Fig. 3). 
Mino et al. (2010) have observed that the remaining kidney of 5/6 nephrectomized and 
protein-restricted immature rats exhibits an elevated levels of the endothelial eNOS protein 
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Fig. 1. Kidneys of 5/6 nephrectomized immature rats stained with an anti-TGF-β antibody.  
bar = 50 μm.  A, low protein group 4 weeks after the operation. TGF-β positive cells are seen 
in the distal tubules. B, normal protein group 4 weeks after the operation. TGF-β positive 
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Thus, eNOS has a protective role in glomerulonephritis (Shao et al., 2001; Heering et al., 
2002), and RAS is involved in changes in eNOS expression (Zhao et al., 2005; Varziri et al., 
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week postoperative rats than in the 8-week postoperative rats, and the reaction was stronger 
in the protein-restricted rats than in the control rats 4 weeks after the operation (Fig. 3). 
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expression and a decrement in iNOS positive cells in the distal tubules and in the expression 
of renin mRNA. They also concluded that protein-restriction is effective in preventing renal 
failure of immature rats and that the changes in the expression levels of renin, eNOS, and 
iNOS are involved in the process of this prevention. 
 
Fig. 2. A, Kidney stained with anti-ED1 antibody. ED1 positive cells (arrows) are observed in 
the interstitium. B, Changes in number of ED1 positive cells per area (300 x 400 μm) 
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gestation, fetal waste products are primarily excreted by maternal kidneys through placental 
circulation (Liggins, 1972) and fetal kidneys start secreting urine during the final days of 
gestation (Bakala et al., 1985). This implies that an increase of fetal waste products in 
circulation, indicative of the latter gestational period, stimulates fetal kidneys to start urine 
production. Therefore, development of the fetal kidney is thought to be stimulated by 
functional demands associated with maternal renal dysfunction. 
3.1 Effects of ligation of maternal ureters on the development of the fetal kidney 
When pregnant rats are subjected to bilateral ureteral ligation for one day, the BUN level is 
elevated 5 to 8 times of control values, and BUN passes through the placenta into the fetal 
circulation to stimulate fetal kidney urine production (Matsuo et al., 1986). Fetal urine 
production is thereby stimulated by maternal ureteral ligation (Wells, 1946). We observed 
that in the kidney of fetuses of fetal days 20 and 22 from bilaterally ureter ligated mothers 
apical vacuoles in the proximal tubular cells are increased by the ligation (Okada & 
Morikawa, 1990). Furthermore, the surface area of the glomerular basement membrane and 
the length of the glomerular capillary per unit volume of glomerulus are increased (Okada 
& Morikawa, 1993) and shortening of the time for filtration of HRP through the glomerular 
basement membrane is observed in the fetuses from the ligated mothers (Okada et al., 1997). 
Therefore, the maternal bilateral ligation causes an elevation of BUN concentration, 
acceleration of the growth and differentiation of the proximal tubules, accelerated formation 
of fetal glomerular basement membrane, and stimulated glomerular function in the filtration 
in the fetal rat kidney when the fetal kidney is functional in urine production. 
3.2 Effects of maternal uninephrectomy on the development of fetal kidney  
In uninephrectomized pregnant rats on day 5 of gestation, BUN concentration is 
significantly increased 1 day after the operation and remained high at term (Okada et al., 
1998). Previously, we have reported that glomerular volume (Okada et al., 1994) and 
proximal tubular length (Okada et al., 1995) are larger in pups from uninephrectomized 
mothers than in those from sham-operated ones, suggesting the accelerated renal 
development was influenced by maternal uninephrectomy. By the electron microscopic 
observation on distribution of cationized ferritin (CF) in fetal glomerulus after CF injection, 
we found that the formation of anionic sites in the glomerular basement membrane of 
fetuses is accelerated by uninephrectomy (Okada et al., 1998). Furthermore, we previously 
reported that maternal uninephrectomy induces lowered proliferative activity in mature 
glomerulus and enhanced positive reactions to both EGF and EGFR antibodies in proximal 
tubular cells in the fetal kidney (Okada et al., 2000). Recently, we have revealed that an 
increase in apoptosis in the collecting ducts of fetal kidney is induced by maternal 
uninephrectomy and that the increase is related to the decreased expression of bcl-2, an 
apoptotic suppressor gene (Okada et al., 2006). 
3.3 Effects of maternal subtotal nephrectomy on the development of fetal kidney 
3.3.1 Aim of study 
Fetal waste products are primarily excreted by maternal kidneys through placental 
circulation (Liggins, 1972). During the final days of gestation, fetal kidneys start secreting 
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urine (Bakala et al., 1985). This implies that an increase of fetal waste products in circulation, 
indicative of the latter gestational period, stimulates fetal kidneys to start urine production.  
Therefore, development of the fetal kidney is thought to be stimulated by functional 
demands associated with maternal renal dysfunction. Bilateral ureteral ligation for 1 day 
(Matsuo et al., 1986) and uninephrectomy (Okada et al., 1998) induce an elevation in BUN, 5 
to 8 times of control values and 1.5 times of control values, respectively. In a preliminary 
study, rats died in the third day after bilateral ureteral ligation; we therefore concluded that 
bilateral ureteral ligation cannot be used as a model for chronic renal failure. Similarly, 
uninephrectomy cannot be used as a model of renal failure because it does not cause 
pathological changes in the remaining kidney. Therefore, 5/6 nephrectomy, which induces 
renal fibrosis (Nangaku et al., 2002; Yang et al., 2001) and glomerular sclerosis (Griffin et al., 
1994), is used for to model chronic renal failure (Manotham et al., 2004). There have been 
several reports on the development of the fetus from 5/6 nephrectomized mothers. Gibson 
et al. (2007) have examined changes in growth and urine volume of fetal sheep with 
maternal 5/6 nephrectomy. Salas et al. (2003) have examined fetal body weight and 
placental weight with maternal 5/6 nephrectomy. However, neither groups studied the 
kidney from the 5/6 nephrectomized mothers. Brandon et al. (2009) have determined the 
plasma renin level of offspring from 5/6 nephrectomized mothers and reported that in the 
neonates there is an impaired ability to regulate glomerular filtration independent of 
arterial pressure. In this section, experiments were designed to investigate the 
development of the fetal kidney under maternal renal dysfunction by 5/6 nephrectomy.  
3.3.2 Materials & methods 
 Animals and tissue processing: Wistar strain rats were reared under ordinary conditions (24 ± 
1C, 14 hrs light and 10 hrs dark) and were given both a commercial diet (CE-2, Clea, Osaka, 
Japan) and water ad libitum. The day following an overnight mating was determined as day 
1 of gestation. To make maternal renal dysfunction conditions, 5/6 nephrectomy was 
performed. Under isoflurane anesthesia, on day 5 of gestation 2/3 of the left kidney were 
excised and on day 12 of gestation the right kidney was removed. The body weights of 5/6 
nephrectomized or sham-operated mothers were measured on days 3, 5, 7, 10, 12, 14, 18, 20, 
and 22 of gestation. BUN levels of 5/6 nephrectomized or sham-operated mothers were 
measured. Under isoflurane anesthesia, blood was drawn from the plexus ophthalamicus 
with a capillary glass tube at days 3, 7, 10, 14, 18, 20, and 22 of gestation. BUN concentration 
was determined with an automatic dry chemistry analyzer system (Spotchem SP-4410, 
Kyoto Daiichi-Kagaku Kyoto, Japan). On day 22 of gestation, fetuses were removed from the 
uterus under isoflurane anesthesia. Under the anesthesia, fetal kidneys were removed and 
fixed in methanol-Carnoy’s solution [a mixture of methanol, chloroform, acetic acid (6:3:1)] 
or 10 % neutral buffered formalin. The kidneys were dehydrated in a graded series of 
alcohol, embedded in Tissue Prep (Fisher Scientific, Fair Lawn, NJ, USA), and sectioned at 6 
μm. The sections from methanol-Carnoy fixed material were treated with PCNA, TGF-β, 
and TGF-β receptors (TGF-βRI and TGF-βRII) antibodies. The sections from formalin fixed 
material were treated with TUNEL method.  
Detection of apoptotic cells and immunohistochemical procedures: After deparaffinization with 
xylene, the sections were transferred to distilled water through a degraded series of ethanol 
and were rinsed in phosphate buffered saline.  The apoptotic cells were detected by TUNEL 
 
Renal Failure – The Facts 
 
88
gestation, fetal waste products are primarily excreted by maternal kidneys through placental 
circulation (Liggins, 1972) and fetal kidneys start secreting urine during the final days of 
gestation (Bakala et al., 1985). This implies that an increase of fetal waste products in 
circulation, indicative of the latter gestational period, stimulates fetal kidneys to start urine 
production. Therefore, development of the fetal kidney is thought to be stimulated by 
functional demands associated with maternal renal dysfunction. 
3.1 Effects of ligation of maternal ureters on the development of the fetal kidney 
When pregnant rats are subjected to bilateral ureteral ligation for one day, the BUN level is 
elevated 5 to 8 times of control values, and BUN passes through the placenta into the fetal 
circulation to stimulate fetal kidney urine production (Matsuo et al., 1986). Fetal urine 
production is thereby stimulated by maternal ureteral ligation (Wells, 1946). We observed 
that in the kidney of fetuses of fetal days 20 and 22 from bilaterally ureter ligated mothers 
apical vacuoles in the proximal tubular cells are increased by the ligation (Okada & 
Morikawa, 1990). Furthermore, the surface area of the glomerular basement membrane and 
the length of the glomerular capillary per unit volume of glomerulus are increased (Okada 
& Morikawa, 1993) and shortening of the time for filtration of HRP through the glomerular 
basement membrane is observed in the fetuses from the ligated mothers (Okada et al., 1997). 
Therefore, the maternal bilateral ligation causes an elevation of BUN concentration, 
acceleration of the growth and differentiation of the proximal tubules, accelerated formation 
of fetal glomerular basement membrane, and stimulated glomerular function in the filtration 
in the fetal rat kidney when the fetal kidney is functional in urine production. 
3.2 Effects of maternal uninephrectomy on the development of fetal kidney  
In uninephrectomized pregnant rats on day 5 of gestation, BUN concentration is 
significantly increased 1 day after the operation and remained high at term (Okada et al., 
1998). Previously, we have reported that glomerular volume (Okada et al., 1994) and 
proximal tubular length (Okada et al., 1995) are larger in pups from uninephrectomized 
mothers than in those from sham-operated ones, suggesting the accelerated renal 
development was influenced by maternal uninephrectomy. By the electron microscopic 
observation on distribution of cationized ferritin (CF) in fetal glomerulus after CF injection, 
we found that the formation of anionic sites in the glomerular basement membrane of 
fetuses is accelerated by uninephrectomy (Okada et al., 1998). Furthermore, we previously 
reported that maternal uninephrectomy induces lowered proliferative activity in mature 
glomerulus and enhanced positive reactions to both EGF and EGFR antibodies in proximal 
tubular cells in the fetal kidney (Okada et al., 2000). Recently, we have revealed that an 
increase in apoptosis in the collecting ducts of fetal kidney is induced by maternal 
uninephrectomy and that the increase is related to the decreased expression of bcl-2, an 
apoptotic suppressor gene (Okada et al., 2006). 
3.3 Effects of maternal subtotal nephrectomy on the development of fetal kidney 
3.3.1 Aim of study 
Fetal waste products are primarily excreted by maternal kidneys through placental 
circulation (Liggins, 1972). During the final days of gestation, fetal kidneys start secreting 
 
Effects of Maternal Renal Dysfunction on Fetal Development 
 
89 
urine (Bakala et al., 1985). This implies that an increase of fetal waste products in circulation, 
indicative of the latter gestational period, stimulates fetal kidneys to start urine production.  
Therefore, development of the fetal kidney is thought to be stimulated by functional 
demands associated with maternal renal dysfunction. Bilateral ureteral ligation for 1 day 
(Matsuo et al., 1986) and uninephrectomy (Okada et al., 1998) induce an elevation in BUN, 5 
to 8 times of control values and 1.5 times of control values, respectively. In a preliminary 
study, rats died in the third day after bilateral ureteral ligation; we therefore concluded that 
bilateral ureteral ligation cannot be used as a model for chronic renal failure. Similarly, 
uninephrectomy cannot be used as a model of renal failure because it does not cause 
pathological changes in the remaining kidney. Therefore, 5/6 nephrectomy, which induces 
renal fibrosis (Nangaku et al., 2002; Yang et al., 2001) and glomerular sclerosis (Griffin et al., 
1994), is used for to model chronic renal failure (Manotham et al., 2004). There have been 
several reports on the development of the fetus from 5/6 nephrectomized mothers. Gibson 
et al. (2007) have examined changes in growth and urine volume of fetal sheep with 
maternal 5/6 nephrectomy. Salas et al. (2003) have examined fetal body weight and 
placental weight with maternal 5/6 nephrectomy. However, neither groups studied the 
kidney from the 5/6 nephrectomized mothers. Brandon et al. (2009) have determined the 
plasma renin level of offspring from 5/6 nephrectomized mothers and reported that in the 
neonates there is an impaired ability to regulate glomerular filtration independent of 
arterial pressure. In this section, experiments were designed to investigate the 
development of the fetal kidney under maternal renal dysfunction by 5/6 nephrectomy.  
3.3.2 Materials & methods 
 Animals and tissue processing: Wistar strain rats were reared under ordinary conditions (24 ± 
1C, 14 hrs light and 10 hrs dark) and were given both a commercial diet (CE-2, Clea, Osaka, 
Japan) and water ad libitum. The day following an overnight mating was determined as day 
1 of gestation. To make maternal renal dysfunction conditions, 5/6 nephrectomy was 
performed. Under isoflurane anesthesia, on day 5 of gestation 2/3 of the left kidney were 
excised and on day 12 of gestation the right kidney was removed. The body weights of 5/6 
nephrectomized or sham-operated mothers were measured on days 3, 5, 7, 10, 12, 14, 18, 20, 
and 22 of gestation. BUN levels of 5/6 nephrectomized or sham-operated mothers were 
measured. Under isoflurane anesthesia, blood was drawn from the plexus ophthalamicus 
with a capillary glass tube at days 3, 7, 10, 14, 18, 20, and 22 of gestation. BUN concentration 
was determined with an automatic dry chemistry analyzer system (Spotchem SP-4410, 
Kyoto Daiichi-Kagaku Kyoto, Japan). On day 22 of gestation, fetuses were removed from the 
uterus under isoflurane anesthesia. Under the anesthesia, fetal kidneys were removed and 
fixed in methanol-Carnoy’s solution [a mixture of methanol, chloroform, acetic acid (6:3:1)] 
or 10 % neutral buffered formalin. The kidneys were dehydrated in a graded series of 
alcohol, embedded in Tissue Prep (Fisher Scientific, Fair Lawn, NJ, USA), and sectioned at 6 
μm. The sections from methanol-Carnoy fixed material were treated with PCNA, TGF-β, 
and TGF-β receptors (TGF-βRI and TGF-βRII) antibodies. The sections from formalin fixed 
material were treated with TUNEL method.  
Detection of apoptotic cells and immunohistochemical procedures: After deparaffinization with 
xylene, the sections were transferred to distilled water through a degraded series of ethanol 
and were rinsed in phosphate buffered saline.  The apoptotic cells were detected by TUNEL 
 
Renal Failure – The Facts 
 
90
methods, using an in situ apoptosis detection kit (Takara, Kyoto, Japan).  Briefly, the 
sections were incubated with the TdT enzyme and FITC-labeled dUTP at 37 °C for 90 min, 
further incubated with an anti-FITC HRP conjugate at 37 °C for 30 min, and finally 
incubated with DAB for 5 min.  Negative controls were produced by omitting the TdT 
enzyme. Immunostaining for PCNA was performed by incubating with mouse anti-human 
PCNA antibody (19A2, Coulter Immunology, Hialeah, FL, USA, 1:160) at 4 °C overnight, 
after which the sections were incubated with biotinylated rabbit anti-mouse 
immunoglobulins antibody (BioGenex Laboratories, San Roman, CA, USA, 1:50) and 
streptavidin conjugated peroxidase (Zymed Laboratories, South San Francisco, CA, USA, 
1:50) for 30 min, respectively. The TGF-β and the TGF-βRI immunostainings were 
performed as follows: The sections were incubated with rabbit anti-human TGF-βRI 
antibody (Santa Cruz Biotech, Santa Cruz, CA, USA, 1:100) at 4 °C overnight or rabbit anti-
porcine TGF-β antibody (R&D Systems, Minneapolis, MN, USA, 1:100) at 4 °C for 3 nights. 
Then, the sections were incubated with biotinylated goat anti-rabbit IgG antibody (1:200) 
and avidin-biotin peroxidase complex (1:200) for 30 minutes, respectively.  Last, the sections 
were incubated with DAB for 5 min. Negative controls were produced by omitting the 
primary antibody in immunohistochemical procedure. No positive immunoreactivity was 
recognized when antibody was preincubated with an excess of antigen (25μg/ml human 
TGF-βRI peptide, Santa Cruz Biotech, Santa Cruz, CA, USA; TGFβ antibody, 1mg/ml 
human TGFβ King Brewing, Kakogawa, Japan). 
Determination of PCNA positive cell ratio: To determine the PCNA positive ratio in the 
glomerulus, 10 glomeruli were used.  To determine the ratio in the proximal tubules, more 
than 500 nuclei were used in the proximal convoluted and straight tubules respectively. The 
nuclei positive and negative to PCNA were counted and the ratio of positive nuclei to total 
nuclei was expressed as a percentage. 
3.3.3 Results & discussion 
The result that a 5/6 nephrectomy operation on pregnant rats induced a significant decrease 
in body weight on day 14 of gestation and thereafter (Fig. 4) indicates that the operation has 
applied a burden to the mother. A slightly but significant increment in BUN concentration 
was induced after removing 2/3 of the left kidney, an intense increase in BUN was induced 
after removing the right kidney, and gradual decrease in BUN was observed on day 14 and 
thereafter (Fig. 5). The elevation in BUN concentration of nephrectomized mothers implies 
the elevation in functional demand to remaining kidney. Since the fetal kidney becomes 
functional during the late gestation period (Bakala et al., 1985), the decrease in BUN from 
day 14 to 22 of gestation reflects the instigation of fetal urine production. On day 22 of 
gestation, the concentration of urea nitrogen (UN) in maternal blood, fetal blood, and 
amniotic fluid were significantly higher in 5/6 nephrectomized pregnant rats than in sham-
operated ones (Fig. 6). This finding suggests that increased UN in 5/6 nephrectomized 
mother passes through placenta to fetal blood circulation and that fetal kidney secretes the 
UN to the amniotic fluid. This notion is well in-line with the reports by Matsuo et al. (1986) 
which suggest that increased maternal BUN induces the elevation in fetal BUN and by 
Garcia et al. (1988) that found that an increase in fetal renal function induces the elevation in 
urea nitrogen levels of the amniotic fluid. 
 




Fig. 4. Changes in body weights (Means±SEM) of 5/6 nephrectomized ( ) and sham-
operated ( ) mothers 
     #, Significantly different from age-matched sham-operated mothers (p<0.05) 
 
Fig. 5. Changes in BUN concentration (Means±SEM) of 5/6 nephrectomized ( ) and 
sham-operated ( ) mothers 
#, Significantly different from age-matched sham-operated mothers (p<0.05) 
A, Significantly different from preceding age group (p<0.05) 
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Fig. 6. The concentration of urea nitrogen in maternal blood, fetal blood, and amniotic fluid 
(Means±SEM) of 5/6 nephrectomized (E) and sham-operated (C) pregnant rats on day 22 of 
gestation. 
#, Significantly different from sham-operated group (p<0.05) 
A, Significantly different from maternal blood, in the same group (p<0.05) 
 
Fig. 7. PCNA positive cell ratio (Means±SEM) in the kidneys of fetuses from 5/6 
nephrectomized (E) and sham-operated (C) mothers. 
 An insiginficant difference is observed between the 2 groups. 
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The PCNA positive cell ratio in the kidney of fetuses from 5/6 nephrectomized mothers was 
slightly lower than that of fetuses from sham-operated mothers but not significant (Fig. 7). 
We previously reported that the more the glomerulus develops, the lower the PCNA 
positive cell ratio in the kidney of perinatal rats (Okada et al., 2001); therefore, the slight 
decrease in the ratio of fetal glomerulus with maternal 5/6 nephrectomy reflects 
nonsuppressive effect on renal development by the operation.   
  
Fig. 8. Fetal kidneys stained with an anti-TGF-β antibody. bar = 100μm. A, fetus from sham-
operated mothers. B, fetus from 5/6 nephrectomized mothers. In both fetuses, positive 
reactions are observed in the proximal tubules and the loop of Henle and no remarkable 
difference is observed between the fetuses. Ps, proximal straight tubules; Pc, proximal 
convoluted tubules; H. loop of Henle. 
TGF-β was mainly localized in the distal tubule and insignificant differences in 
immunoreactivity of TGF-β between fetuses from 5/6 nephrectomized and sham-operated 
mothers were observed (Fig. 8). The stronger immunoreactivity of the TGF-βRI in collecting 
tubules was noted in fetuses from 5/6 nephrectomized mothers (Fig. 9). Addition of TGF-β 
to the culture medium induces an inhibition of the differentiation from the metanephric  
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Fig. 9. Fetal kidneys stained with an anti-TGF-βRI antibody. A and B, fetus from sham-
operated mothers. C and D, fetus of from 5/6 nephrectomized mothers. More TGF-βRI 
positive cells of the collecting ducts in the medullary zone are seen in the fetus from 5/6 
nephrectomized mothers than in sham-operated ones. P, proximal tubules, C, collecting ducts. 
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Fig. 10. Fetal kidneys stained with TUNEL methods from sham-operated mothers (A and B), 
and 5/6 nephrectomized mothers (C and D). More TUNEL positive cells (arrows) are seen 
in the fetus from 5/6 nephrectomized mothers than in that from sham-operated mothers, 
especially in the collecting ducts in the medulla.  
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blastema to the nephron and addition of neutral antibody to TGF-β causes the acceleration 
in nephron formation (Rogers et al., 1993). The changes in TGF-βRI of the fetal kidney by 
maternal 5/6 nephrectomy may be related to the differentiation of collecting tubules, 
especially apoptosis in the tubules, because more TUNEL positive cells were observed in the 
kidney of fetuses from 5/6 nephrectomized mothers than in the kidney of fetuses from 
sham-operated ones (Fig. 10). Kim et al. (1996) has reported on the developing kidney of the 
rat and found that intercalated cells show an apoptotic feature and are removed by 
neighboring principal cells or inner medullary collecting duct (IMCD) cells, resulting in the 
differentiation of the collecting ducts. Lee et al. (2004) have observed a delayed elimination 
of type A intercalated cells in the medullary collecting duct with a decreased apoptotic 
index in the collecting duct of the renal medulla and concluded that apoptosis plays an 
important role in the morphogenesis of the renal papilla during kidney development. 
Therefore, the result that the number of TUNEL positive cells in the collecting ducts per unit 
area (1mm2) of the kidney was significantly larger in fetuses from 5/6 nephrectomized 
mothers than in fetuses from sham-operated ones (Fig. 11) indicates that 5/6 nephrectomy 
of pregnant rats causes the acceleration of the differentiation of the collecting ducts in the 
fetal kidney. These results suggest that maternal renal dysfunction induces apoptosis in the 
fetal kidney and that the development of collecting ducts is largely involved in the elevated 
expression of TGF-β receptor. 
 
Fig. 11. The number of TUNEL positive cells per unit area (1mm2) (Means±SEM) of the 
kidney of fetuses from 5/6 nephrectomeized (E) and sham-operated (C) mothers. 
#, Significantly different from fetuses from sham-operated mothers. 
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4. Effects of the maternal renal dysfunction on the fetus 
Infants who are born small have been reported to have higher blood pressure in adulthood 
(Woods & Weeks, 2004). Furthermore, a clear relation between low birth weight and adverse 
renal outcome is evident as early as during childhood (Dötsch et al., 2011). The Intrauterine 
Growth Retardation (IUGR) is very important health problem with a prevalence estimated 
at ~10% in the general population (Gardosi, 2011). The IUGR model can be produced by 
bilateral ligation of uterine artery, protein restriction, smoking, nephrotoxic medication as 
well as salt loading (Bentz & Amann, 2010). Exposure to maternal low protein diet in utero 
induces IUGR and increases expression of glomerular AT1 receptors and reduces AT2 
receptor expression in young rat (Battista et al., 2002; Sahajpal & Ashton, 2005). A low 
protein diet of the mother is associated with lower birth weight and higher blood pressure 
in offspring, due to the suppression of renin mRNA and the decrease in the angiotensin II 
levels in the newborn rat kidney (Woods et al., 2001; Zimmerman & Dunham, 1997). 
As described in the above sections, the development of the fetal kidney is accelerated by 
maternal bilateral ureteral ligation and maternal uninephrectomy. However, the operations 
induce the suppression of fetal growth in terms of the body and renal weights in Table 1. 
Maternal 5/6 nephrectomy also induces low body and renal weight in fetuses. Therefore, 
maternal 5/6 nephrectomy may be one of the means for producing an IUGR model. Thus, to 
clarify whether maternal 5/6 nephrectomy is a good model for IUGR, further studies 
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Table 1. Body weight and renal weight (Means±SEM) of fetuses on fetal day 22 from 
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accelerated renal development is influenced by maternal uninephrectomy. Acceleration of 
development of the fetal kidney is also seen 24 hours after maternal bilateral ureteral 
ligation, which is a model of acute renal failure. 5/6 nephrectomy to immature and adult 
animals induces renal fibrosis and glomerular sclerosis and leads to renal failure, and the 
progression of renal failure is suppressed by protein intake restriction. The 5/6 
nephrectomy to pregnant rats (as a model of pregnant renal failure) induced a significant 
decrease in body weight and a significant increase in BUN concentration. By maternal 5/6 
nephrectomy, however, the immunoreactivity of TGF-βRI is strengthened and TUNEL 
positive cells are increased in the collecting ducts of the kidney of fetuses, suggesting the 
acceleration of fetal development of the kidney. Based upon these findings, maternal renal 
dysfunction induces various desirable effects on fetuses, while a phenomenon similar to 
IUGR is also seen. 
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Acute kidney injury (AKI), previously termed acute renal failure, is a frequent clinical 
condition in critically ill patients, especially in intensive care units (ICU). It is characterized 
by a rapid decline or loss of renal function. Its incidence varies from 1-7 % of all hospitalized 
patients to 30-50 % of patients in ICU [29,69]. Clinical manifestations include a rapid 
decrease (oliguria) or cessation (anuria) of urine output and of glomerular filtration rate 
(GFR) below 10 mL/min within hours to days. AKI is further indicated by accumulation of 
nitrogenous-waste substances in blood resulting in elevated serum levels of creatinine and 
blood urea nitrogen (BUN). It is important to differentiate AKI from chronic kidney disease 
(CKD), as AKI has the potential to be reversible. AKI and CKD can be differentiated by the 
dynamics nitrogenous-waste substances increase in the serum and urinary output decreases.  
Irrespective of the progress being made in the understanding of the pathophysiology of AKI 
and its underlying processes and the advances in critical care medicine, mortality rate 
associated with AKI remains high especially in ICU patients at more than 50 % [97]. In 
addition, a significant proportion of surviving patients (20 %) develops CKD and end-stage 
renal disease, requiring chronic renal replacement therapy [8,32]. Long-term outcome is 
worse for patients after recovery from AKI [45,14], further impacting health care cost and 
quality of life [10].  
Advances in our understanding, prevention and treatment of AKI have been hampered 
especially by two factors. Firstly, until recently there was a lack of uniform criteria for 
definition and classification of AKI. Secondly, there is still an incomplete understanding of 
the pathogenesis of AKI [72]. The risk to develop AKI is determined by patient’s 
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susceptibility and exposure or causative factors. Patient susceptibility in developing 
countries varies from that of the developed countries. In developing countries, AKI is more 
common in young and pediatric patients, while in developed countries elderly patients are 
predominant [95,34]. However, it is difficult to differentiate demographic variables which 
directly contribute to the risk of developing AKI from those that are more attributed to the 
underlying disease [72]. Conditions known to cause AKI in susceptible populations include 
sepsis, ischemia, heart failure, liver disease, major surgery (especially vascular and cardiac), 
rhabdomyolysis, urinary tract obstruction and various nephrotoxic drugs and radiocontrast 
agents [80].  In critically ill patients the most common cause of AKI is sepsis, accounting for 
50 % of all cases [2,4,5]. 
2. Diagnostic problem 
In order to standardize and detect AKI, two different sets of definition criteria have been 
recently established. The Acute Dialysis Quality Initiative developed the RIFLE criteria for 
the diagnosis of acute renal failure in critically ill patients [6] and the Acute Kidney Injury 
Network developed the AKIN criteria for the diagnosis of AKI [51]. Both criteria (Figure 1) 
for diagnosis are mainly based on measurements of urine output and serum creatinine. In 
clinical practice, however, AKI is predominantly detected by changes in serum creatinine [51].  
 
Fig. 1. AKI staging according to the RIFLE and AKIN criteria. 
Creatinine is a 113 Dalton molecule derived from creatine metabolism after creatinine’s 
release from the muscle. As creatinine is freely filtered by the glomerulus and excreted 
without significant metabolic changes or reabsorption by the kidney, this molecule has been 
< 0.3 mL/kg/h for > 24 h or anuria for > 12 h> 300 % or dialysis3
< 0.5 mL/kg/h for > 12 h201 – 300 %2
< 0.5 mL/kg/h within 6 – 12 h≥ 0.3 mg/dL or 150 – 200 %1
Urine output ↓Serum creatinine ↑Stage
AKIN criteria (Mehta et al., Crit Care 2007, [51])
< 0.3 mL/kg/h for 24 h or anuria for 12 h300 % or ≥ 4 mg/dL or > 75 % Failure
Persistent AKI = Complete loss of renal funktion > 4 wkLoss
End-stage renal disease = Complete loss of renal function > 3 moESRD
< 0.5 mL/kg/h for 12 h200 % or > 50 – 75 %Injury
< 0.5 mL/kg/h for 6 h150 % or > 25 – 50 %Risk
Urine output ↓Serum creatinine ↑ or GFR ↓Stage
RIFLE criteria (Bellomo et al., Crit Care 2004, [6])
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a useful indicator of kidney function. However, serum creatinine has important limitations 
as a tool for assessing GFR. Firstly, creatinine levels are affected by a variety of non-renal 
factors such as age, gender, muscle mass, diet and nutritional status [76]. Although 
equations have been developed to correct for some of these factors, these are only applicable 
for CKD but not for AKI as they require stable creatinine metabolism [41]. Secondly, serum 
creatinine concentration and its value is influenced by its volume of distribution that can be 
substantially affected by volume overload, a common situation in AKI [75]. Finally, and 
probably most importantly, serum creatinine increases only after substantial loss of GFR 
resulting in a lag phase in the temporal relationship between serum creatinine increase and 
loss of GFR. As a result, current clinical diagnosis of AKI based on creatinine limits its early 
detection in clinical routine as well as the early implementation of preventive measures. 
Therefore, the development of new AKI biomarkers have had high priority in the 
nephrological community during the last years with the aim to identify markers that are 
superior to serum creatinine in the early detection of AKI. In the following part we will 
shortly summarise the most promising single biomarkers for AKI.  
3. Single biomarkers for AKI 
New biomarkers for AKI can be categorized as inflammatory mediators, excreted tubular 
proteins and surrogate markers indicative for tubular damage (albumin, α 1-microglobulin, 
β 2-glycoprotein, plasma retinol binding protein, N-acetyl-β-D-glucosaminidase (NAG)) and 
liver-type fatty acid binding protein (L-FABP) [90,18]. The most promising of the AKI 
biomarker candidates, namely neutrophil gelatinase-associated lipocalin (NGAL), kidney 
injury molecule-1 (KIM-1), interleukin-18 (IL-18) and cystatin C (CysC) will be presented in 
more detail:  
3.1 Neutrophil gelatinase-associated lipocalin (NGAL) 
Function: NGAL, also known as lipocalin-2, is a 25-kDa protein strongly up-regulated by 
interleukin-1 during inflammation. NGAL has the ability of sequestering siderophores, 
microbial iron-chelating agents required for bacterial growth, and prevents urinary tract 
infection. 
Diagnostic evidence: NGAL has been presented as biomarker for early detection of AKI and 
for AKI prognosis [68]. The first study that pointed out the association of NGAL with AKI 
development was performed by Mishra and colleagues in 2005 [55]. In this prospective 
study urine and plasma NGAL rose significantly in children developing AKI after cardiac 
surgery within 2 h postoperatively. However, the classification performance of NGAL 
decreased in similar studies performed in adults also having cardiac surgery [21] possibly 
due to confounding variables and comorbid conditions that accumulate with age. Other 
positive results have been obtained when NGAL has been tested as a biomarker of AKI in 
kidney transplantation and the subsequent development of delayed graft function [56]. 
Among other, NGAL was tested in hemolytic uremic syndrome [78], urinary tract infections 
[96], critically ill children and adults [91,70] and also CKD [20]. Taken together, NGAL is the 
most promising novel renal biomarker in urine and also in plasma. However, as pointed out 
by Chawla and Kellum [9], NGAL is expressed in multiple organs affording further studies 
to understand how non-kidney sources of NGAL have an impact on urinary NGAL. As a 
consequence, prospective multicenter studies are urgently required to determine the 
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performance of plasma and urinary NGAL in unselected ICU patient populations including 
patients with preexisting CKD [53,50]. Since the reported cut-off values for NGAL differ 
across a wide range it seems reasonable to speculate, that each clinical setting may require 
different cut-off values [57].  
3.2 Interleukin-18 (IL-18) 
Function: IL-18 is an 18-kDa proinflammatory cytokine secreted by macrophages and other 
antigen presenting cells. It has the ability to induce interferon γ production in type-1 T 
helper cells and is a sensitive mediator of ischemic injury in different organs such as heart, 
brain and kidney [73]. 
Diagnostic evidence: A first evidence for IL-18’s role in ischemic AKI was given by animal 
studies [52,26]. Later studies in humans suggested that urinary IL-18 may serve as marker of 
AKI development after cardiac surgery, of graft function after kidney allograft 
transplantation, and of mortality in acute respiratory distress syndrome [61,62,89]. Siew et 
al. [71] reported that urinary IL-18, when measured within 48 h of AKI development, could 
not reliably predict AKI in a broadly selected, critically ill adult patients cohort. Despite this 
negative result, urinary IL-18 remained predictive in this study for worse clinical outcome 
such as death and acute dialysis within 28 days of ascertainment independently of other 
factors [71]. A matter of concern is that IL-18 increases in a variety of pathophysiological 
conditions, such as sepsis, inflammatory arthritis, inflammatory bowel disease, systemic 
lupus erythematosus, psoriasis, hepatitis and multiple sclerosis. This property significantly 
limits its application, due to reduced sensitivity and specificity [81]. 
3.3 Kidney injury molecule-1 (KIM-1) 
Function: KIM-1 is a type 1 transmembrane glycoprotein that is undetectable in normal 
kidneys but highly expressed by proximal tubules epithelial cells after ischemic or toxic 
injury [31,25] with the ectodomain being shedded into the tubular lumen [100]. It functions 
as a phosphatidyl-serine receptor and confers a phagocytic phenotype on epithelial cells, 
most likely to clear cellular debris during enhanced apoptosis [30].  
Diagnostic evidence: In previous studies in adults, KIM-1 was able to discriminate patients 
with acute tubular necrosis from those without, and predicted AKI in adults undergoing 
cardiac surgery [24,82,87]. In another prospective study on 201 hospital patients with AKI, 
an increase of urinary KIM-1 was associated with increased mortality or dialysis 
requirement [44]. Its potential use as an early marker is based so far on limited data: a rise in 
its urinary levels was detectable before the increase of BUN and creatinine in plasma during 
cadmium-induced renal damage [64] as well as its expression in biopsy sections of kidney 
allograft recipients before histological signs of acute tubular necrosis became evident [99]. 
3.4 Cystatin C (CysC) 
Function: CysC is a cysteine protease inhibitor that is synthesized and continuously released 
into the blood by nucleated cells. Its levels are not significantly affected by age, gender, 
infection, liver disease or muscle mass in contrast to serum creatinine. This molecule is 
freely filtered by the glomerulus but, unlike creatinine, reabsorbed and metabolized by the 
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proximal tubule. Therefore, elevated levels of CysC in serum correlate inversely with GFR 
while increased urinary CysC indicates renal tubular damage [40] and in fact the diagnostic 
accuracy of serum CysC to reflect GFR has been shown to be superior compared to serum 
creatinine since its levels are less influenced by inflammation, infection, body mass, diet and 
drugs [65].  
Diagnostic evidence: Serum CysC is not a biomarker of AKI since its levels are not a direct 
marker of renal injury, and rather serves as GFR marker [73]. Several studies have focused 
on the diagnostic accuracy of CysC in predicting AKI. Unfortunately, results have been 
conflicting. In high-risk patients serum CysC detected AKI 1-2 days earlier than serum 
creatinine [27]. However, in a mixed heterogeneous, multicenter ICU population serum and 
urinary CysC were poor predictors of AKI and the need for renal replacement therapy [66]. 
In a meta-analysis performed by Zhang et al. [101] using the data of 19 studies from 11 
countries and 3,336 patients, it was found that serum CysC could be used as reliable marker 
with an odds ratio of 23.5 in the prediction of AKI whereas urinary CysC showed only 
moderate diagnostic accuracy with an odds ratio of only 2.6.  
Endre et al. [17] in a recent prospective observational study of 529 ICU patients and Lameire 
et al. [38] in a commentary on this work came to a sobering conclusion on the diagnostic and 
prognostic performance of these single AKI markers. In the study of Endre et al. [17] none of 
these markers reached an AUC value above 0.7 for the prediction of AKI on ICU entry and 
of death in 7 days, while urinary NGAL, CysC and IL-18 predicted dialysis in 7 days with 
AUC’s of 0.79, 0.71 and 0.73, respectively. This is in contrast to some previous studies with 
AUC values above 0.9 [47,55] which was attributed by their selection of homogeneous study 
populations [38]. In conclusion, the single AKI markers performed well in selected, 
predominantly homogenous patient cohorts, whereas they failed for the most part in 
multicenter, heterogenous cohorts which rather represent clinical routine (see Table 1 for a 
listing of clinical studies). Due to this, multimarker patterns were suggested by experts in 
this field for which proteomic technologies are predestined. 
4. Proteomic approaches and biomarkers profiles for AKI 
The main rationale for the application of proteome analysis in the context of AKI is that AKI 
is a multifactorial and heterogeneous process. Due to the diversity of pathological processes 
leading to AKI, it is highly unlikely that one single diagnostic marker may serve as reliable 
predictor for all AKI forms. A broadly applicable, multimarker diagnostic model will avoid 
this. The advantage of such a multimarker strategy is that it allows compensation for 
potential biological, pre-analytical and analytical variances of single biomarkers. 
Mass spectrometry combined with chromatographic separation techniques has advanced 
exceptionally in recent years and has become a valuable tool for profiling of human 
proteomes and a systematic search of protein and peptide markers indicative for various 
renal and non-renal diseases without the need for a hypothesis-driven propagation process 
[54,19,1,93].  
While proteome analysis aiming at biomarkers for renal disease can be focused on urine, 
plasma, or serum, urine seems to be the most attractive body fluid for several reasons. 
Firstly, urine can be obtained in large quantities in a non-invasive manner. Secondly, the 
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Abbreviations: AKI, acute kidney injury; AUC, area under the curve; CPB, cardiopulmonary bypass; Cr, 
creatinine; CysC, Cystatin C; ED, emergency department; eGFR, estimated glomerular filtration rate; IL-
18, Interleukin-18; KIM-1, Kidney injury molecule-1; L-FABP, Liver-type fatty acid-binding protein; 
NAG, N-acetyl-β-D-glucosaminidase; NGAL, Neutrophil gelatinase-associated lipocalin; p, plasma; s, 
serum; u, urinary. 
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urinary proteome is relative stable since it is retained in the bladder for several hours, 
providing sufficient time for complete proteolytic processing by endogenous proteases. The 
low molecular weight proteome of the urine does not undergo any significant change if 
urine is stored for up to 3 days at 4°C or 6 h at room temperature [67,77].  
For these reasons, several groups have embraced the search for urinary proteomic 
biomarkers for the early detection of AKI using different analytical platforms. In an early 
study conducted in 2005, Nguyen et al. [59] identified 4 proteins with a mass-to-charge ratio 
(m/z) of 6.4, 28.5, 43 and 66 kDa, being increased at baseline and at 2 and 6 h post-operation 
in the urine of children that developed ischemic kidney injury 2-3 days after 
cardiopulmonary bypass (CPB). These proteins in combination allowed detection of AKI in 
this small patient cohort with 100 % sensitivity and specificity. One of these proteins (m/z 
6.4) was later identified as aprotinin [60], a very basic polypeptide with serine protease 
inhibitory activity, negatively affecting both coagulation and fibrinolysis [48]. The other 3 
peaks were identified as acute-phase proteins α 1-microglobulin (28.5 kDa), α 1-acid 
glycoprotein (43 kDa) and albumin (66 kDa) [15]. 
Using the same analytical platform Ho and colleagues identified, besides known up-
regulated tubular injury markers, two novel peptide peaks at 2.43 and 2.78 kDa that were 
significantly increased in patients after CPB surgery not developing AKI [28]. The authors 
were able to resolve one of these peptides as hepcidin-25, the active form of hepcidin, which is 
secreted by the liver to maintain iron homeostasis and which is up-regulated during acute phase 
response [83].  
Metzger et al. [53] used capillary electrophoresis mass spectrometry to identify urinary 
peptide markers predictive for AKI in urine samples obtained from ICU patients who later 
developed AKI defined by a serum creatinine increase ≥ 50 % in ≤ 48 hours (maximum 5 
days prior AKI) or remained normal in kidney function. The 20 statistically most significant 
peptide markers in a comparative group analysis (Figure 2) were combined to a support 
vector machine-based classifier, which allowed classification of a blinded test set of ICU 
patient samples (n=20, 9 case and 11 controls) with 89 % sensitivity and 82 % specificity. In 
order to evaluate general applicability, this classifier was further applied to the classification 
of urine samples from hematopoietic stem cell transplanted patients of whom 13 developed 
AKI after transplantation and 16 did not. AUC in this validation set was 0.90 with sensitivity 
and specificity values of 94 and 82 %, respectively. The 20 polypeptides were identified by 
amino acid sequencing as degradation products of 6 proteins. Fragments of albumin, α 1-
antitrypsin and β 2-microglobulin were up-regulated, fibrinogen α chain, collagen 1 α(I) and 
collagen 1 α(III) were down-regulated in AKI. The alterations of these polypeptides 
identified in the urine may be attributed to differences in production rates, increased 
assembly into filaments, increased proteolysis in the plasma or urine, abnormal renal 
function, or a combination of the above, and may be relevant at different points of the 
disease process as outlined in figure 3. 
A recent study of Maddens et al. [46] using LTQ-OrbiTRAP for mass spectrometry analysis 
identified urinary NGAL, thioredoxin, gelsolin, chitinase 3-like protein 1 and 3 and acidic 
mammalian chitinase as being the most discriminating markers for experimental sepsis-
induced AKI in mice. Differential expression was verified by immunoblot analysis in urine, 
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plasma and renal tissue homogenates. In a small set of human septic patients the authors 
detected possible differences in excretion levels of the human homologue of chitinase 3-like 
protein 1 and acidic mammalian chitinase protein between patients with compared to those 
without AKI. However, the study was too small to draw any conclusions. The potential use 
of chitinase proteins as sensitive markers for diagnosis of septic-induced AKI is limited, as 
the authors stated, mostly by the fact that increased levels are also detectable during 
inflammatory responses, such as asthma or inflammatory bowel disease, liver fibrosis and 
also for non-AKI patients of the AKI study group without recognizable comorbidities. 
 
Fig. 2. Distribution of urinary peptides included in the AKI-specific biomarker panel of 
Metzger et al., 2010 [53]. AUC’s for ROC comparison of AKI and non-AKI within the ICU 
and HSCT patient groups are shown in the insets. Abbreviations: AKI, acute kidney injury; 
AUC, area under the curve; HSCT, hematopoietic stem cell transplantation; ICU, intensive 
care unit; ROC, receiver operating characteristics. Modified from data shown in Metzger et 
al., 2010 [53]. 
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Gel-based proteomics has also been tested as a platform in the search for biomarkers of AKI. 
Using this methodological approach, Aregger et al [3] identified 3 proteins in a cohort of 36 
patients undergoing CPB to be differentially regulated between patients who developed 
AKI and those who not. The identified proteins were albumin, being upregulated, and zinc 
α 2-glycoprotein and adrenomedullin-binding protein, both down-regulated. Limiting the 
results of the study, only zinc α 2-glycoprotein was applied to a validation set of 22 patients 
with AKI and 46 patients without to test its diagnostic performance in immunoblot and 
ELISA. An AUC value of 0.68 revealed that zinc α 2-glycoprotein is only a weak predictor of 
AKI.    
 
Fig. 3. Pathophysiological relevance of parent proteins from the peptides included in the 
AKI-specific proteomic biomarker model of Metzger et al., 2010 [53]. 
Abbreviations: A1AT, α 1-antitrypsin; ALBU, albumin; B2MG, β 2-microglobulin;  
CO1A1, collagen 1 α(I) chain; CO1A3, collagen 1 α(III) chain; ECM, extracellular matrix;  
FIBA, fibrinogen α chain; MMP, matrix metallopeptidases. 
5. Conclusion 
It is evident that an effective prevention or intervention strategy for patients particularly 
in the ICU (with the possible therapeutic options depicted in figure 4) relies on accurate 
and early detection of AKI. Considering the heterogeneity and complexity of AKI, a 
multiple marker approach seems to be more favourable over single markers. A 
multimarker approach will not rely on particular, single aspects of AKI, i.e. tubular 
damage, fibrosis, inflammation, necrosis or apoptosis, but combine the significant 
findings indicative of specific etiologies, ideally enabling detection of AKI independent of 
the underlying cause.  
Irrespective of the approach, large, prospective, multicentre clinical trials on unselected 
patient populations are required to validate the different proposed biomarkers or classifiers. 
In analogy to a recent editorial by Vlahou [84], such a large study would best be performed 
in a way that allows testing all the biomarkers currently proposed. Unfortunately, neither 
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Once suitable biomarkers and classifiers for accurate, early detection of AKI have been 
identified, it is essential to design an easy-to-apply analytical test based on these markers 
that is suitable for routine laboratory use ideally as a point of care device in intensive care 
units. One promising approach is the application of MALDI-MS as a robust and fast 
platform for efficient analysis of urinary biomarkers, which has been demonstrated feasible 
in CKD [39]. 
 
Fig. 4. Intervention aiming at AKI prevention. 
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1. Introduction 
Dialysis disequilibrium syndrome (DDS) is a central nervous system disorder, usually 
occurs in patients during hemodialysis (HD) or within 24 hours of HD. DDS was first 
described by Kennedy et al. in 1962. 11 If a critically ill patient on HD develops severe sepsis 
and septic shock with multiple organ failure (MOF), the adverse effect of HD on the brain is 
likely to be amplified, which may predispose to the DDS. 
Severe sepsis and septic shock are the common indications for intensive care therapy 
admission. Sepsis/ severe sepsis are usually manifested by inadequate organ 
perfusion/function. Multiple organ dysfunction syndrome (MODS) is the presence of 
altered organ function, in an acutely ill septic patient whose homeostasis is maintained with 
the intervention.4 
Mechanism (Fig1) for the occurrence of MODS is result of imbalance between the pro and 
anti-inflammatory response and the dominance of pro-inflammatory reaction. This leads to 
the systemic microvascular thrombosis, hypoxic hypoxia, immunosuppressant and 
apoptosis.9 Which ultimately leads to organ dysfunction/failure in severe sepsis/ septic 
shock patients  
Acute renal failure is one of the common complications of severe sepsis and septic shock. It 
occurs in 23% of severe sepsis and 51% of septic shock patients and requires hemodialysis. 
In case of renal failure due to sepsis, the renal vasoconstriction occurs due to the increased 
sympathetic tone; in contrast to the systemic vasodilatation. 16  
Twenty three percent of septic shock patients develop septic encephalopathy.8 various 
anatomical abnormalities are found in these patients of severe sepsis and septic shock with 
brain involvement, these are collectively termed as the septic encephalopathy. These 
abnormalities includes proliferation of astrocytes, cerebral infarcts, multiple white matter 
hemorrhages, central pontine myelinolysis, multiple microabceses, reduction in cerebral 
blood flow , cerebral capillary leakage, and malfunctioning of the blood brain barrier.10 
These septic encephalopathy changes can be amplified if patient is having traumatic brain 
injury, subarachnoid hemorrhage or on hemodialysis.  
Critically ill patients frequently require renal replacement therapy and intermittent HD. 
DDS is an acute neurological manifestation due to cerebral edema that occurs during or 
after dialysis, these manifestations can be mild, such as nausea and vomiting, or severe, as 
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seizures, coma, and death. 3 Walter et al. demonstrated by CT scan of the brain that about 2% 
of patients who underwent HD developed brain edema. 22 In all reported cases of DDS, the 
patients were conscious and undergoing HD for the first time. Hence DDS was easy to 
detect and treated promptly. Di-Fresco et al. successfully treated a case of DDS. 5  
 
Fig. 1. Mechanism for MODS8. 
The risk factors for the development of DDS are rapid elevation of pCO 2, 14 head injury, 7 
young age, metabolic acidosis, 1 and severe sepsis. 17 Patients requiring intensive care 
therapy are different from patients with end-stage renal failure or chronic renal failure, they 
usually have severe sepsis or septic shock, MOF; and are sedated. Bagshaw et al. reported a 
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He underwent his first episode of aggressive HD resulting in severe and fatal DDS. 2 If 
patients are on slow HD for several consecutive days, develops septic shock; and they are 
supposed to have sepsis-induced changes in the brain.  
Severe sepsis and septic shock with polymicrobial bacteremia causes a widespread of 
immune activation. This may alter the blood-brain permeability and may lead to DDS.2 
Overall, there are 2 main theories for the development of DDS. The first theory, also called 
the reverse osmotic shift, relates to the acute removal of urea, which occurs comparatively 
slower across the blood-brain barrier than in plasma, thus generating a reverse osmotic 
gradient. This might promote the movement of water to the brain and cause brain edema. 20 
This reverse osmotic shift in DDS has been demonstrated in experimental animals. Silver et 
al. demonstrated that rats undergoing rapid HD, urea nitrogen levels were lowered from 72 
to 34 mmol in 90 min. This change was associated with a 6% increase in brain water. 
Surprisingly, neither undialysed nor dialysed rats with urea bath developed cerebral edema. 
18 The second theory suggests that increased osmolarity of the extracellular fluid leads to 
adoptive accumulation of intracellular osmolytes in the brain. This decreases the cerebral 
cell dehydration and causes paradoxical reduction in the cerebral pH, resulting in brain 
edema during or after HD. 6 Recently, experimental studies helped in demonstrating the 
molecular basis for the development of DDS; the water and urea movement across the 
plasma membrane is facilitated by specific channels, called, aquaporins and urea 
transporters (UT), respectively. In the absence of these channels, water and urea diffusion 
through the cell membrane is slow. Also, because of the less number of UT, the urea exit 
from the astrocytes may be delayed, while rapid removal of extracellular urea during fast 
HD can lead to water entry into the cells, subsequently causing brain edema. 21 The aim of 
treatment of DDS is to reduce brain edema and to avoid its complication. Only one case of 
DDS has been reported in the literature, which was successfully treated using mannitol 
and hyperventilation. 5 Ideal management of DDS is prevention. The following methods 
have been tried to prevent DDS: Doorenbos et al. used urea to keep blood urea levels 
constant during HD and succeeded in avoiding DDS. 6 Another way is a gentle initiation 
of HD and gradual correction of biochemical abnormalities with slow and less efficient 
HD. 12 When aggressive HD is indicated, phenytoin may be used to prevent the 
development of DDS. 15 
If the patient has fluid overload, he can be shifted to hemofiltration and a short period of 
HD, or he can be started on peritoneal dialysis. So far, DDS is not reported with peritoneal 
dialysis. 1 To our knowledge, there are 2 reported cases of DDS occurring after more than 1 
week of daily HD. Both these patients had septic shock, but were stable with inotropic and 
ventilatory support.13 Their follow-up CT of brain and radiography of chest was without 
any major pathology. Both patients suffered neurologic deterioration during or 1 hour after 
the HD session and an emergency CT of brain showed severe brain edema with brain 
herniation (Fig2). Authors made the DDS diagnosis because the neurologic deterioration 
and herniation occurred during or within a few hours of the HD session, and after excluding 
other risk factors for hypotension and fatality as per advanced cardiac life support 
guidelines. 13 Severe sepsis and septic shock affects brain by reducing the blood flow to the 
brain and also causing capillary leakage and dysfunction of the blood-brain barrier. These 
effects are due to either toxic mediators or the indirect effect of hypoperfusion, 
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hyperthermia, and increased intracranial pressure. 19 These effects will also be amplified if 
the patient is having a brain injury. 19 Patients on regular daily HD are likely to have brain 
edema, if they also develop septic shock, the effects on the brain may be amplified and 
leading to DDS.  
 
Fig. 2. Diffuse and severe brain edema in DDS 
2. Conclusion 
If a patient on HD develops severe sepsis or septic shock, DDS can occur even after repeated 
sessions of HD. DDS may  contribute to the sudden deterioration and death in these septic 
patients. The acute care physicians, intensivists, and nephrologists should be aware of the 
risks of DDS and act accordingly. 
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Acute kidney injury (AKI) following cardiac surgery is associated with increased morbidity 
and mortality, longer hospital stays, and significantly increased health care costs. The 
physiological functions performed by the kidney, which include acid-base control, blood 
pressure regulation, water balance, and waste excretion, are crucial to the maintenance of 
homeostasis and can only partially be accomplished using renal replacement therapy (RRT). 
A number of risk factors have been identified that should be recognized in order to counsel 
patients appropriately and attempt to prevent AKI. Several pharmacologic and therapeutic 
modalities have been suggested, with varying levels of evidence, to aid in prevention of AKI 
and limit the extent of injury and morbidity once renal dysfunction has been recognized. 
The purpose of this chapter is to review the epidemiology, prevention, diagnosis, and 
treatment of acute kidney injury following cardiac surgery. These topics will be reviewed in 
detail in the discussion that follows. 
2. Epidemiology 
The incidence of AKI following cardiac surgery has historically been difficult to determine. Mild 
renal injury (creatinine rise <25%) may occur in as many as 50% of patients undergoing cardiac 
surgery. Moderate kidney injury has been reported in 8-15% of patients, while up to 5% of 
patients develop renal failure requiring dialysis following cardiac surgery. (Shaw, Swaminathan 
et al. 2008) Individual reports differ significantly as a result of inconsistent definitions, varied 
surgeries, and a heterogeneous patient population.(Bellomo, Ronco et al. 2004)  
In many series, renal failure is defined as a 50% rise in serum creatinine, while others define 
it arbitrarily as a doubling of the creatinine, and yet others include only dialysis dependent 
patients in their analyses.(Bellomo, Kellum et al. 2004) The RIFLE and AKIN criteria were 
developed by panels of experts to provide a uniform definition of acute kidney injury and 
facilitate recommendations for patients suffering from renal failure.(Kellum, Mehta et al. 
2002; Mehta, Kellum et al. 2007) (Figure 1) These definitions rely upon serum creatinine 
levels and urine output to define and categorize the severity of kidney injury. Regardless of 
the definition, once renal failure progresses and a patient becomes dialysis dependant, 
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levels and urine output to define and categorize the severity of kidney injury. Regardless of 
the definition, once renal failure progresses and a patient becomes dialysis dependant, 
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mortality rates rise considerably and are often reported to be above 50%.(Andersson, Ekroth 
et al. 1993; Chertow, Levy et al. 1998)  Even with the progress of modern medicine and 
implementation of newer dialysis technology, the mortality associated with postoperative 
renal failure has not noticeably improved. (Ympa, Sakr et al. 2005) One may suggest that this 
is because renal failure in itself is often not the primary problem, but only a sign of 
significant low cardiac output and multi-organ failure, however, this is likely not the case. 
Other authors have proposed that the high mortality associated with renal failure is not 
related to RRT itself, rather it predisposes patients to other morbidities. A large study 
reviewing 16,000 patients with contrast induced nephropathy suggested that patient’s 
whose hospitalisations were complicated by sepsis, coagulopathies, respiratory, or 
neurologic failure, were more likely to die during their hospitalisation, while it was rare for 
patients with uncomplicated renal failure not to survive. (Levy, Viscoli et al. 1996) Chertow et 
al, reporting on over 43,000 patients with AKI following cardiac surgery, found that these 
patients were more likely to suffer myocardial infarction, require reoperation for bleeding, and 
develop endocarditis or mediastinitis.(Chertow, Lazarus et al. 1997) Patients with renal failure 
also had an overall greater risk of death in the index hospitalization.  
 
Fig. 1. RIFLE and AKIN criteria. Reproduced from Reproduced with permission from 
Biomed Central (Cruz, Ricci et al. 2009) 
While patients with AKI requiring RRT demonstrate substantially elevated mortality rates, 
even patients with milder renal dysfunction not requiring RRT show decreased survival and 
worse outcomes compared to those without postoperative AKI.(1994; Conlon, Stafford-Smith 
et al. 1999) Although it may be intuitive that morbidity will increase with severe renal 
dysfunction, it is less obvious that a modest rise in creatinine can negatively affect quality of 
life and life expectancy.(Lassnigg, Schmidlin et al. 2004; Lassnigg, Schmid et al. 2008) In 
addition to increasing mortality, acute kidney injury prolongs ICU stay and increases the 
proportion of patients discharged to a nursing care facility. This data suggests that the ill-
effects of acute kidney injury are not simply a sign of sicker patients with other comorbid 
conditions, rather AKI is an independent predictor of morbidity and mortality following cardiac 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
131 
surgery. As a result, all efforts must be made to identify patients at risk for AKI, focusing on 
prevention of renal dysfunction rather than simply treating it once the injury has occurred. 
3. Pathophysiology of AKI following cardiac surgery 
The pathophysiology and etiology of postoperative AKI in cardiac surgery is multifactorial, 
resulting from a combination vascular and tubular injury.(Mahon and Shorten 2006) A 
variety of events occur in the perioperative period that could individually and cumulatively 
result in renal dysfunction. During cardiopulmonary bypass (CPB), the kidneys are exposed 
to interruptions and alterations in blood flow due to changes in pump flow and the lack of 
pulsatility, which can lead to ischemia-reperfusion injury. Concurrently, the kidneys risk 
being affected by embolic materials originating from air entry into the circulation, platelet 
aggregates, lipids, and atheromatous plaques.(Sear 2005) Exposure to the CPB circuit 
initiates several cascades that can cause kidney injury, such as complement activation, free 
radical formation, and inflammatory cytokine production.(Mahon and Shorten 2006) 
Bellomo et al developed the following comprehensive list of pathophysiologic mechanisms 
behind AKI: (1) exogenous and endogenous toxins, (2) metabolic factors, (3) ischemia-
reperfusion, (4) neurohormonal activation, (5) inflammation, and (6) oxidative 
stress.(Bellomo, Auriemma et al. 2008) The sum of these factors culminates in a significant 
and constant risk of renal tubular injury in patients undergoing cardiac surgery. While it is 
important to appreciate the pathophysiology of renal dysfunction, understanding and 
considering the differential diagnosis is clearly necessary to provide appropriate therapy. 
Figure 2 summarizes the differential diagnosis of acute renal failure. 
 
Fig. 2. Classification and major causes of acute renal failure. NSAIDs = non-steroidal anti-
inflammatory agents; ACE = angiotensin-converting enzyme. Reproduced with permission 
from Elsevier (Lameire, Van Biesen et al. 2005) 
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4. Diagnosis of postoperative AKI 
Although new concepts such as RIFLE and AKIN have helped standardize the definition of 
AKI, the criteria involved in making the diagnosis can take hours to days, leading to 
delayed recognition of renal dysfunction. This delay may be partly responsible for the 
limited progress that has been made in preventing and treating postoperative renal failure, 
and highlights the need for more immediate markers of AKI. The present and future tools 
available to diagnose AKI in cardiac surgery will be discussed below.  
4.1 Creatinine 
When comparing the progress in the diagnosic tools available for AKI to that of 
myocardial infarction, the state-of-the-art is lagging significantly. Fifty years ago 
creatinine kinase (CK) was the only available marker for cardiac injury, as was serum 
creatinine for renal injury. In current practice, cardiac injury is identified through several 
laboratory tests, such as levels CK-MB, Troponin-I, Troponin-T, Myoglobin, and BNP. 
However, creatinine is still the only biomarker routinely used to identify kidney injury. 
Creatinine and urine output together are relied upon to assess global kidney function. 
While creatinine is a relatively specific marker of renal injury, its sensitivity can be called 
into question and it bears some inherent limitations. Circulating levels vary with age, 
gender, muscle mass, vigorous exercise, and medications. In addition, levels rise only 
when GFR is reduced by more than 50% and it can take up to 24 hours before there is a 
sufficient increase to allow for the diagnosis of AKI.(Bagshaw and Gibney 2008) In light of 
these shortcomings, there is a clear need for newer, more sensitive, methods of diagnosing 
renal dysfunction.  
4.2 Urine output 
The most readily available surrogate marker of renal function is urine output. Compared 
to creatinine, it is more sensitive to changes in renal hemodynamics. Unfortunately, 
variations in urine output are considerably less specific, except when severely diminished 
or absent. Oliguria is defined as urine output of less than 0.5mg/kg/hour. The presence 
of an oliguric state gives physicians a sign that their patient’s kidney function is at risk or 
already perturbed, however, the presence of normal urine output cannot provide 
assurance that renal function is unperturbed. In non-oliguric renal failure, the kidney’s 
ability to produce urine is preserved but its ability to excrete water-soluble waste 
products is lost or markedly reduced. The reality is that even the combination of urine 
output and serum creatinine cannot reliably diagnose renal injury in a timely manner. 
This once again highlights the importance of uncovering and validating other methods to 
identify AKI. 
4.3 Urinalysis 
In patients with decreased urine output or suspected acute kidney injury, urinalysis is an 
important tool that can differentiate prerenal from renal failure. Consequently, it can be very 
useful in guiding treatment. Table 1 describes select variables and their association with the 
etiology of acute kidney injury. 
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 Prerenal Renal 
Urinalysis Normal Abnormal 
Specific gravity 1.020 1.010 
Osmolality (mmol/kg) >500 >300 
Sodium (mmol/L) <20 >40 
Fractional excretion of sodium (%) <1 >2 
Fractional excretion of urea (%) <35 >35 
Fractional excretion of uric acid (%) <7 >35 
Fractional excretion of lithium <7 >15 
Low-molecular weight proteins Low High 
Brush border enzymes Low High 
Table 1. Important variables in differentiating prerenal from renal acute renal failure. 
Adapted from Lameire et al (Lameire, Van Biesen et al. 2005) 
4.4 Neutrophil gelatinase-associated lipocalin (NGAL)  
NGAL is a protein, known to bind small iron-carrying molecules, that is significantly 
upregulated in response to acute renal injury. Its concentration rises within three hours in 
response to renal tubular injury and can precede the rise in creatinine by more than 24 
hours.(Schmidt-Ott, Mori et al. 2006) The use of this protein to diagnose AKI has been most 
extensively studied in cardiac surgery. When evaluated in both adult and pediatric cardiac 
surgery patients, NGAL has shown good sensitivity and specificity for diagnosis of AKI, 
with a significantly earlier rise following injury when compared to creatinine. NGAL began 
to rise within two hours after renal insult, while creatinine rise occurred over a period of one 
to three days.(Mishra, Dent et al. 2005; Wagener, Jan et al. 2006; Dent, Ma et al. 2007; 
Bennett, Dent et al. 2008) NGAL levels have been shown predictive when measured both in 
the serum and the urine. The performance of NGAL in these and other clinical studies 
appears sufficient to recommend its inclusion in an early diagnostic panel for AKI, 
suggesting that we will likely see rapid expansion of its use in the coming years.  
4.5 Cystatin C 
Cystatin C is a cysteine protease inhibitor. Serum level of cystatin C is a reflection of GFR, 
making changes in serum and urine levels a reflection on changes in GFR. This is in 
contrast to NGAL, which is a reactive protein and a measure of tubular stress. Cystatin C 
levels are not significantly affected by age, race, gender, muscle mass, or infection, 
making it a better measure of GFR than serum creatinine.(Dharnidharka, Kwon et al. 
2002) Due to these promising characteristics, cystatin C has been investigated in a variety 
of clinical settings, including cardiac surgery. With the exception of one inconclusive 
study, cystatin C has consistently been shown superior to serum creatinine in predicting 
AKI following cardiac surgery.(Koyner, Bennett et al. 2008; Haase-Fielitz, Bellomo et al. 
2009; Heise, Waeschle et al. 2009) Cystatin C, like NGAL, also appears to offer prognostic 
value in this setting. When considering all available data, cystatin C appears to be a 
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reliable marker of chronic renal dysfunction and both cystatin C and NGAL are 
dependable early predictors of AKI. However, NGAL may slightly outperform in cystatin 
C as an early predictor of injury. 
4.6 Liver-type fatty acid binding protein (L-FABP) 
L-FABP is a protein expressed in various organs, including the kidney, and plays a role in 
the cellular uptake of fatty acids. The molecule is filtered and reabsorbed by the kidney, 
resulting in elevated urine L-FABP levels in the presence of decreased GFR.(Negishi, Noiri 
et al. 2008; Portilla, Dent et al. 2008; Negishi, Noiri et al. 2009) Some clinical studies have 
demonstrated usefulness for L-FABP in identifying patients at risk for AKI.(Nakamura, 
Sugaya et al. 2006) It has also shown promise as a marker for postoperative AKI, although it 
appears to rise later than NGAL.(Portilla, Dent et al. 2008) The literature to date suggests 
that L-FABP may be a useful addition to preoperative risk assessment and postoperative 
diagnosis of AKI, with further investigation being warranted. 
4.7 Interleukin-18 (IL-18) 
IL-18 is a proinflammatory cytokine and a reliable signal for ischemia-induced AKI in 
animal models.(Melnikov, Ecder et al. 2001) Data from pediatric cardiac surgery, kidney 
transplantation, and acute respiratory distress syndrome have shown that urine IL-18 
performs well as an early predictor of AKI.(Parikh, Abraham et al. 2005; Parikh, Jani et al. 
2006; Parikh, Mishra et al. 2006) A recent prospective observational trial questioned the 
specificity of IL-18 as a marker of renal injury in cardiac surgery, suggesting that it may be 
a non-specific sign of post cardiopulmonary bypass inflammation.(Haase, Bellomo et al. 
2008) As a consequence of these inconsistent results, IL-18 will require further 
investigation and validation before it can be considered for routine inclusion on urinary 
panels.  
4.8 Kidney injury molecule-1 (KIM-1) 
KIM-1 is a transmembrane glycoprotein that can be detected in the urine following 
AKI.(Zhang, Humphreys et al. 2007) Although it is not expressed in normal kidneys, KIM-1 
is upregulated following nephrotoxic or ischemic injury.(Han, Bailly et al. 2002) Clinical 
studies have suggested that KIM-1 may be useful in improving early detection of AKI 
following cardiac surgery, particularly when measured in conjunction with other novel 
biomarkers.(Han, Wagener et al. 2009) 
4.9 Summary of novel biomarkers of AKI in cardiac surgery 
The cause of AKI in cardiac surgery is multifactorial, making it is unlikely that a single 
biomarker will prove sufficiently accurate and reliable to be trusted for risk stratification 
and diagnosis of AKI. Outlined above are the most promising biomarkers, which recognize 
damage in different pathways of renal injury. Table 2 is a summary of novel biomarkers and 
their key properties. In the future, combinations of these markers, used in parallel with 
clinical parameters, will likely emerge as practical tools to help predict and verify the onset 
of AKI in a variety of settings, including cardiac surgery. 
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Biomarker Variable assessed Time to detection (h) 
Serum Cystatin GFR 12-14 
Serum NGAL Proximal tubular injury 2-4 
Urine NGAL Proximal tubular injury 2-4 
Urine L-FABP Proximal tubular injury 4-6 
Urine IL-18 Proximal tubular injury 4-6 
Urine KIM-1 Proximal tubular injury 12-24 
Table 2. Novel biomarkers for detection of acute kidney injury. GFR = glomerular filtration 
rate, NGAL = neutrophil gelatinase-associated lipocalin, L-FABP = Liver-type fatty acid 
binding protein IL = interleukin, KIM = kidney injury molecule. 
5. Risk factors for acute kidney injury 
5.1 Preoperative 
Prevention postoperative renal failure begins by identifying patients at risk. Several risk 
factors have been for postoperative AKI have been identified, some more consistently than 
others. One of the largest studies addressing the topic was published by Chertow et al in 
1997.(Chertow, Lazarus et al. 1997) This group developed a model for preoperative renal 
risk stratification by prospectively following 43,000 patients in 43 different centres over a 
seven-year period. The overall incidence of acute renal failure requiring dialysis was 1.1 %. 
Thirty-day mortality in patients requiring dialysis was 64%, compared to 4.3% for patients 
without renal failure. The authors identified ten clinical variables as independent predictors 
of dialysis dependant renal failure following cardiac surgery. (Table 3) These included 
preoperative renal dysfunction (OR 1.3-5.8, depending on creatinine clearance), valvular 
surgery (OR 1.98), intra-aortic balloon pump (OR 3.19), redo surgery (OR 1.93), NYHA class 
IV (OR 1.55), decreased left ventricular ejection fraction (OR 1.45), peripheral vascular 
disease (OR 1.51), chronic obstructive pulmonary disease (OR 1.26), pulmonary rales (OR 
1.37), and the extremes of systolic blood pressure. Based on these factors, the authors 
developed a clinical algorithm to quantify risk and identify patients most in danger of 
requiring postoperative dialysis. Mangano et al studied a smaller population and identified 
other preoperative characteristics associated with postoperative dialysis.(Mangano, 
Diamondstone et al. 1998) Similar to Chertow, they identified congestive heart failure (RR 
1.8), previous surgery (RR 1.8), and elevated creatinine (RR 2.3) as predisposing factors, and 
they also showed that age 70-79 years (RR 1.6) and 80-95 years (RR 3.5), type-1 diabetes (RR 
1.8), and elevated preoperative serum glucose (exceeding 16.6 mmol/L, RR 3.7) significantly 
increased the risk of postoperative dialysis. These findings have been echoed by several 
other studies.(Abrahamov, Tamariz et al. 2001; Diaz, Moitra et al. 2008) Preoperative renal 
dysfunction has consistently been the most predictive of postoperative renal complications. 
A preoperative creatinine between 175 and 350mmol/L is associated with a 10-20% risk of 
postoperative dialysis, while patients with a creatinine greater than 350mmol/L may have a 
25-28% risk of dialysis.(Frost, Pedersen et al. 1991; Chertow, Lazarus et al. 1997; Fortescue, 
Bates et al. 2000; Thakar, Liangos et al. 2003; Thakar, Liangos et al. 2003) Other authors have 
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also found female gender, left main coronary disease, concomitant liver disease, and pre-
existing sepsis to contribute to postoperative renal dysfunction.(Conlon, Stafford-Smith et 
al. 1999; Rosner and Okusa 2006; Rosner, Portilla et al. 2008) (Table 3) 
 
Preoperative renal dysfunction 
Valvular surgery 
Intra-aortic balloon pump 
Redo surgery 
NYHA class IV 
Decreased LVEF 
Peripheral vascular disease 
COPD  
Pulmonary rales 




Table 3. Risk factors for dialysis dependant renal failure following cardiac surgery. LVEF = 
Left ventricular ejection fraction, COPD = chronic obstructive pulmonary disease 
A significant modifiable risk factor that may play a role in postoperative AKI is the timing of 
surgery following contrast angiography. Medalion et al reviewed data on 365 patients who 
underwent CABG surgery.(Medalion, Cohen et al. 2010) Multivariate analysis identified 
several risk factors for postoperative AKI, including surgery within 24 hours of contrast 
administration and preoperative renal dysfunction (clearance < 60mL/min). Contrast dose 
greater than >1.4ml/kg was predictive of AKI if surgery was performed within five days of 
angiography. The authors suggest avoiding surgery within 24 hours of angiography 
whenever possible and delaying surgery for five days in patients having received a large 
contrast dose, particularly if the presence of chronic renal dysfunction.  
It is unclear whether medications such as nonsteroidal anti-inflammatory drugs and 
angiotensin receptor blocker should be discontinued prior to surgery. Several authors have 
suggested that these medications increase the risk of postoperative AKI.(Rosner, Portilla et 
al. 2008). Finally, genetic predispositions to AKI have been reported more recently. A study 
from Duke University found that patient with the inherited apolipoprotein epsilon-4 allele 
were less likely to develop AKI compared to patients with other forms of the allele.(Chew, 
Newman et al. 2000)  
It is essential to remember that preoperative renal dysfunction may not be obvious when 
looking at the creatinine alone. It is paramount to calculate the creatinine clearance for all 
patients, but particularly for those in extremes of age and body habitus, as this will permit a 
better identification of patients with increased risk of perioperative renal dysfunction. 
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5.2 Intraoperative risk factors 
Many preoperative risk factors have become accepted by the community, as a large amount 
of data suggested their role in the development of postoperative renal dysfunction. 
Intraoperative risk factors, however, are notoriously difficult to control for and are 
sometimes challenged. 
The maintenance of cardiovascular stability during CPB is dependant on many factors, 
including a proper functioning CPB circuit and patient factors, such as venous compliance, 
systemic vascular resistance, and autoregulatory systems. The goal of CPB is to maintain 
adequate end-organ perfusion at a level that allows optimal cellular functioning. Any 
deviation in perfusion pressure and flow rates can significantly affect the oxygen delivery to 
all organs and may result in periods of decreased flow or perfusion pressure, leading to 
renal injury.(Urzua, Troncoso et al. 1992; Fischer, Weissenberger et al. 2002)  
Prolonged cardiopulmonary bypass and aortic cross-clamp times are relatively well-
accepted as being linked to increased postoperative AKI, although this finding has not been 
present in all studies.(Fischer, Weissenberger et al. 2002; Tuttle, Worrall et al. 2003) 
Unfortunately, because of the heterogenous patient populations, no specific time frame has 
been established after which the risk of AKI increases. Additionally, although prolonged 
bypass times may play a role in postoperative AKI, it is likely a combination of all of the 
previously mentioned factors that will decide each individual patient’s propensity for 
postoperative renal dysfunction. Other modifiable characteristics of CPB that may influence 
the incidence of AKI include pulsatile versus non-pulsatile flow during CPB, and 
normothermic versus hypothermic CPB. However, neither of these factors has been shown 
clinically to affect the incidence of postoperative AKI.(Urzua, Troncoso et al. 1992; Abramov, 
Tamariz et al. 2003; Provenchère, Plantefève et al. 2003)  
Dilutional anemia during CPB has been associated with increased overall morbidity 
following cardiac surgery. Specifically, lowest on-pump hematocrit below 22-24% may put 
patients at risk for postoperative AKI.(Habib, Zacharias et al. 2003; Habib, Zacharias et al. 
2005) Aprotinin is a serine protease inhibitor that, until recently, was commonly given 
perioperatively to decrease blood loss related to open-heart surgery.(van Oeveren, Jansen et 
al. 1987; Royston 1995) It has been suggested that aprotinin may cause vasoconstriction of 
the afferent arteriole, thus reducing glomerular perfusion pressure and occasioning renal 
dysfunction. A propensity based analysis of over 4000 patients receiving aprotinin and other 
fibrinolytic agents perioperatively concluded that the administration of aprotinin was 
associated with a doubling of the risk acute renal failure requiring RRT.(Mangano, Tudor et 
al. 2006) This finding has since been supported and opposed by similar large observational 
studies.(Furnary, Wu et al. 2007; Dietrich, Busley et al. 2008; Shaw, Stafford-Smith et al. 
2008) More recently, an increased 30-day mortality in the aprotinin arm of the BART study 
(Blood Conservation Using Antifibrinolytics in a Randomized Trial) prompted the Food and 
Drug Administration to suspend marketing of the drug.(Fergusson, Hébert et al. 2008) 
5.2.1 On vs Off pump CABG 
One of the most debated topics on the subject of AKI prevention is the proposed renal 
protection offered by off-pump coronary artery bypass surgery (OPCAB) compared to 
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dysfunction. A propensity based analysis of over 4000 patients receiving aprotinin and other 
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CABG with CPB. Advocates of off-pump surgery generally cite a reduced risk of AKI as a 
benefit of the OPCAB approach, however, there is little data to support this claim. Critics of 
OPCAB surgery suggest that instances of perioperative low cardiac output due to contortion 
of the heart may offset the detrimental effects of the CPB circuit. Niwekar et al. recently 
published a meta-analysis evaluating the results of on-pump vs off-pump surgery in 
twenty-two studies, including six randomized controlled trials (RCT) comprising over 
27,000 patients.(Nigwekar, Kandula et al. 2009) In the pooled analysis there was a reduction 
in the overall incidence of AKI and in AKI requiring RRT. In a separate analysis of the RCTs 
only, overall incidence of AKI was reduced but there was no significant difference in the 
proportion of patients requiring renal replacement therapy. It is worth noting that one of the 
major limitations of this report is the lack of a uniform definition of AKI across the studies. 
The authors also report that the RCTs tended to enroll healthier patients with a lower risk of 
postoperative AKI. This bias, combined with smaller sample sizes, made the RCTs 
underpowered to study AKI.  
In the absence of a randomized trial focusing on AKI after cardiac surgery, the best available 
evidence consists mostly of observational studies from which our conclusions must be 
drawn. Based on this data, it is reasonable to conclude that in patients at higher risk for AKI, 
an OPCAB approach, when appropriate, may reduce the likelihood of developing 
postoperative renal dysfunction. When interpreting this data, one must remember that renal 
protection is just one of the many important factors to consider when choosing an 
appropriate revascularisation method. The pros and cons of OPCAB versus CABG surgery 
with CPB must be analysed while considering each individual patient and each surgeon’s 
preference and experience.  
6. Prevention of postoperative AKI    
A vast number of therapies have been proposed for limiting the incidence of perioperative 
renal dysfunction. These range from simple manoeuvres, such as maintaining hydration, to 
more advanced pharmacological interventions. The most well studied methods will be 
reviewed here. 
6.1 Hydration 
There is little argument that adequate hydration is a prerequisite to maintaining healthy 
kidney function.  A randomized study evaluating contrast-induced nephropathy compared 
patients receiving an intravenous infusion of sodium chloride for twelve hours preceding 
their intervention to a control group of patients with unrestricted fluid ingestion. The 
authors found that intravenous fluid administration protected patients from AKI.(Trivedi, 
Moore et al. 2003) Other studies have echoed these results, particularly in patients with 
underlying renal dysfunction.(Solomon, Werner et al. 1994; Dussol, Morange et al. 2006) 
Another randomized trial compared a regimen of half-isotonic saline infusion to standard 
preoperative fluid restriction in patients with known renal dysfunction, defined as 
glomerular filtration rate <45mL/min.(Marathias, Vassili et al. 2006) Patients in the 
hydration group were significantly less likely to develop postoperative renal failure and no 
patients required RRT, compared to 27% of patients in the control group. While these may 
be arguments for preoperative fluid loading and avoiding perioperative hypovolemia, the 
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ideal method of perioperative volume resuscitation remains a highly debated topic. Much 
effort has been put into identifying the ideal fluid, or ideal combination of fluids, to 
maintain perioperative circulating volume. This question has been investigated most 
thoroughly in the critical care literature, with several observational studies, randomized 
trials, and meta-analyses addressing the issue. Unfortunately, many studies have had 
conflicting results and little has been concluded on the subject.(Choi, Yip et al. 1999; Finfer, 
Bellomo et al. 2004; Roberts, Alderson et al. 2004; Rioux, Lessard et al. 2009; Bunn, Trivedi 
et al. 2011) Regarding renal failure specifically, a recent Cochrane review found that 
evidence was lacking to conclude that colloid use is associated with renal failure in a non-
septic population.(Dart, Mutter et al. 2010) Data specific to cardiac surgery is also 
available but offers little help. A recent randomized pilot study by Magder et al compared 
the use of colloids to crystalloids in a postoperative cardiac surgery population.(Magder, 
Potter et al. 2010) The colloid based resuscitation protocol was associated with less 
catecholamine use, a lower incidence of pneumonia and mediastinal infection, and less 
need for cardiac pacing. A conflicting study found that there was indeed a dose-
dependant relationship between pentastarch administration and AKI, with an optimal 
cutoff volume at 14mL/kg.(Rioux, Lessard et al. 2009) It is likely that either colloids or 
crystalloids are suitable solutions for fluid resuscitation and that a balanced resuscitation 
avoiding high doses of colloids or crystalloids alone would lead to optimal patient 
outcome. 
6.2 Glycemic control 
In 2001, van den Berghe published a seminal randomized trial establishing the benefit of 
intensive insulin therapy to maintain tight glycemic control in postoperative critically ill 
patients.(van den Berghe, Wouters et al. 2001) More than 60% of patients studied had 
undergone cardiac surgery. In addition to a significant mortality benefit, intensive insulin 
therapy was associated with a 41% reduction in patients requiring dialysis or hemofiltration. 
A subsequent large observational study found an even more prominent effect on prevention 
of AKI after instituting a similar protocol. (Krinsley 2004) Studies addressing diabetic 
patients specifically have also found increased postoperative AKI associated with poor 
perioperative glycemic control, however, it is unclear whether interventions to treat and 
prevent hyperglycemia can improve outcomes in this population.(Furnary, Gao et al. 2003; 
Ouattara, Lecomte et al. 2005) In fact, some groups have found that although tight glycemic 
control can prevent AKI, there may be a tradeoff for other complications, such as an 
increased incidence of death and stroke.(Gandhi, Nuttall et al. 2007; Investigators, Finfer et 
al. 2009) 
6.3 Dopamine 
Dopamine is an endogenous catecholamine with dose-dependent effects on dopaminergic, 
alpha- and beta1-adrenergic receptors. Experimentally, dopamine stimulates the renal 
dopaminergic receptors to result in increased renal blood flow and GFR, and acts as a 
diuretic and natriuretic. Based on promising studies in animals and healthy volunteers, the 
clinical use of low-dose dopamine (3 mg/kg/min) became popular and has been used 
routinely in some institutions.(MacGregor, Smith et al. 2000) Unfortunately, these results 
have not been reproduced in clinical reports, including several well-designed studies and 
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meta-analyses.(Kellum 1997; Marik and Iglesias 1999; Bellomo, Chapman et al. 2000; Marik 
2002) After reviewing the available data from 1966-2000, comprised of 2149 patients, Kellum 
at el concluded that “the use of low-dose dopamine for the treatment or prevention of acute 
renal failure cannot be justified on the basis of available evidence and should be eliminated 
from routine clinical use.”(Kellum and M  Decker 2001)  
6.4 Other dopaminergic drugs 
Fenoldopam is a synthetic derivative of dopamine with DA1 receptor selectivity that 
increases blood flow to the kidneys.(Mathur, Swan et al. 1999; Meco and Cirri 2010) Several 
small studies have reported favorable effects of fenoldopam on GFR and serum creatinine in 
cardiac surgery patients.(Halpenny, Lakshmi et al. 2001; Caimmi, Pagani et al. 2003; 
Garwood, Swamidoss et al. 2003) However, a number of well-designed trials have found no 
benefit with fenoldopam when compared to placebo, dopamine, or other treatments.(Bove, 
Landoni et al. 2005; Morelli, Ricci et al. 2005; Brienza, Malcangi et al. 2006) A 2007 meta-
analysis published pooled results from 16 RCTs and concluded that fenoldopam reduces the 
need for renal replacement therapy and mortality in patients with AKI.(Landoni, Biondi-
Zoccai et al. 2007) The results of this analysis may be questioned, however, due to the 
heterogeneity of the trials, including an inconsistant definition of AKI and no clear criteria 
for the commencement of renal replacement therapy. Dopexamine is a predominantly B2-
agonist. This molecule has been less-thoroughly studied than the other dopamingeic drugs, 
but existing data is also inconsistent.(Hakim, Foulds et al. 1988; Stephan, Sonntag et al. 1990; 
MacGregor, Butterworth et al. 1994; Sherry, Tooley et al. 1997) As a result, dopexamine 
cannot be recommended as an effective way to reduce postoperative AKI. 
Although none of the dopaminergic medications appear to be associated with prohibitive 
side effects, the evidence to date does not support their use in the context of preventing AKI 
following cardiac surgery. Further study may be warranted in the case of fenoldopam. 
6.5 Loop diuretics 
Furosemide is a loop diuretic that inhibits sodium absorption in the medullary portion of 
the loop of Henle. It has been suggested that by decreasing tubular cell workload, it may 
limit hypoxia within the nephron. Although this theoretical mechanism exists, there is little 
evidence supporting its use in preventing and treating AKI. Ho et al performed a meta-
analysis of nine randomized controlled trials studying 849 patients with an increased risk of 
renal failure.(Ho and Sheridan 2006) A pooled analysis of the data failed to show 
improvements in mortality, requirement of RRT, or number of dialysis sessions. The review 
also found that high doses of furosemide put patients at risk for deafness and tinnitus. An 
earlier systematic review reported similar results. Not only has administration of loop 
diuretics failed to show a benefit when given in the perioperative setting, there is evidence 
that if may worsen renal dysfunction. Lassnigg et al randomized 126 low-risk patients to 
receive furosemide infusion, low-dose dopamine, or saline infusion during and after 
cardiac surgery.(Lassnigg, Donner et al. 2000) The maximum postoperative creatinine was 
doubled in the furosemide group compared to the other two groups. The mechanism of 
increased renal injury was not clearly elucidated but intravascular hypovolemia likely 
played a role. 
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In summary, there is no clear evidence to support the use of loop diuretics in decreasing the 
incidence or extent of renal injury following cardiac surgery. These medications should be 
prescribed when indicated for volume overload and other clinically appropriate scenarios.  
6.6 Mannitol 
Mannitol is an osmotic diuretic with several suggested benefits in the perioperative period. 
Theoretically, it increases intravascular volume, improving preload and cardiac output, 
increases blood to the kidneys through the release of atrial natriuretic peptide, and facilitates 
the flushing of debris from renal tubules by increasing urinary output.(Better, Rubinstein et 
al. 1997) Mannitol is known to have additional properties as a free radical scavenger, which 
may help attenuate the effects of reperfusion injury. Routine mannitol use became popular 
in cardiac surgery as a result of limited data published several decades ago.(BARRY and 
BERMAN 1961) More recent publications have consistently failed to show a benefit with 
mannitol therapy when given in the perioperative period.(Ip-Yam, Murphy et al. 1994; 
Better, Rubinstein et al. 1997; Poullis 1999; Carcoana, Mathew et al. 2003) 
In light of these results, although it has become routine practice in many institutions to add 
mannitol to the pump prime solution, there is little evidence to support this therapy. It is 
also important to consider the possible detrimental effect of induced osmotic diuresis, which 
may include hypovolemia and hypernatremia. Unfortunately, until more robust data is 
available, individual cardiac surgery teams must base their decision to use mannitol on their 
own interpretation of the limited information available in the literature. 
6.7 N-acetylcysteine 
There is conflicting evidence supporting the use of the antioxidant n-acetylcysteine in the 
prevention of contrast-induced nephropathy.(Marenzi, Assanelli et al. 2006; Krämer and 
Hoffmann 2007) When studied in high-risk patients undergoing on-pump cardiac surgery, 
n-acetylcysteine failed to show a benefit compared to placebo in the prevention of 
postoperative renal failure.(Burns, Chu et al. 2005; El-Hamamsy, Stevens et al. 2007; Haase, 
Haase-Fielitz et al. 2007; Sisillo, Ceriani et al. 2008) Several meta-analyses reviewing this 
subject support the results of these individual trials.(Baker, Anglade et al. 2009; Nigwekar 
and Kandula 2009) The lack of benefit in cardiac surgery populations compared to contrast-
induced nephropathy is likely related to the different mechanism of AKI, which is more 
clearly related to ischemia-reperfusion injury than nephrotoxicity.  
6.8 Calcium channel blockers 
Calcium channel blockers have been shown experimentally to promote renal vasodilatation, 
increase renal blood flow, and increase GFR. Studies in patients undergoing cardiac surgery 
have been contradictory.(Young, Diab et al. 1998; Piper, Kumle et al. 2003)  
6.9 Natriuretic peptides 
Natriuretic peptides are known to oppose the renin-angiotensin-aldosterone and arginine 
vasopressin systems through multiple mechanisms.(Nakao, Itoh et al. 1989) As a result they 
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2002) After reviewing the available data from 1966-2000, comprised of 2149 patients, Kellum 
at el concluded that “the use of low-dose dopamine for the treatment or prevention of acute 
renal failure cannot be justified on the basis of available evidence and should be eliminated 
from routine clinical use.”(Kellum and M  Decker 2001)  
6.4 Other dopaminergic drugs 
Fenoldopam is a synthetic derivative of dopamine with DA1 receptor selectivity that 
increases blood flow to the kidneys.(Mathur, Swan et al. 1999; Meco and Cirri 2010) Several 
small studies have reported favorable effects of fenoldopam on GFR and serum creatinine in 
cardiac surgery patients.(Halpenny, Lakshmi et al. 2001; Caimmi, Pagani et al. 2003; 
Garwood, Swamidoss et al. 2003) However, a number of well-designed trials have found no 
benefit with fenoldopam when compared to placebo, dopamine, or other treatments.(Bove, 
Landoni et al. 2005; Morelli, Ricci et al. 2005; Brienza, Malcangi et al. 2006) A 2007 meta-
analysis published pooled results from 16 RCTs and concluded that fenoldopam reduces the 
need for renal replacement therapy and mortality in patients with AKI.(Landoni, Biondi-
Zoccai et al. 2007) The results of this analysis may be questioned, however, due to the 
heterogeneity of the trials, including an inconsistant definition of AKI and no clear criteria 
for the commencement of renal replacement therapy. Dopexamine is a predominantly B2-
agonist. This molecule has been less-thoroughly studied than the other dopamingeic drugs, 
but existing data is also inconsistent.(Hakim, Foulds et al. 1988; Stephan, Sonntag et al. 1990; 
MacGregor, Butterworth et al. 1994; Sherry, Tooley et al. 1997) As a result, dopexamine 
cannot be recommended as an effective way to reduce postoperative AKI. 
Although none of the dopaminergic medications appear to be associated with prohibitive 
side effects, the evidence to date does not support their use in the context of preventing AKI 
following cardiac surgery. Further study may be warranted in the case of fenoldopam. 
6.5 Loop diuretics 
Furosemide is a loop diuretic that inhibits sodium absorption in the medullary portion of 
the loop of Henle. It has been suggested that by decreasing tubular cell workload, it may 
limit hypoxia within the nephron. Although this theoretical mechanism exists, there is little 
evidence supporting its use in preventing and treating AKI. Ho et al performed a meta-
analysis of nine randomized controlled trials studying 849 patients with an increased risk of 
renal failure.(Ho and Sheridan 2006) A pooled analysis of the data failed to show 
improvements in mortality, requirement of RRT, or number of dialysis sessions. The review 
also found that high doses of furosemide put patients at risk for deafness and tinnitus. An 
earlier systematic review reported similar results. Not only has administration of loop 
diuretics failed to show a benefit when given in the perioperative setting, there is evidence 
that if may worsen renal dysfunction. Lassnigg et al randomized 126 low-risk patients to 
receive furosemide infusion, low-dose dopamine, or saline infusion during and after 
cardiac surgery.(Lassnigg, Donner et al. 2000) The maximum postoperative creatinine was 
doubled in the furosemide group compared to the other two groups. The mechanism of 
increased renal injury was not clearly elucidated but intravascular hypovolemia likely 
played a role. 
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In summary, there is no clear evidence to support the use of loop diuretics in decreasing the 
incidence or extent of renal injury following cardiac surgery. These medications should be 
prescribed when indicated for volume overload and other clinically appropriate scenarios.  
6.6 Mannitol 
Mannitol is an osmotic diuretic with several suggested benefits in the perioperative period. 
Theoretically, it increases intravascular volume, improving preload and cardiac output, 
increases blood to the kidneys through the release of atrial natriuretic peptide, and facilitates 
the flushing of debris from renal tubules by increasing urinary output.(Better, Rubinstein et 
al. 1997) Mannitol is known to have additional properties as a free radical scavenger, which 
may help attenuate the effects of reperfusion injury. Routine mannitol use became popular 
in cardiac surgery as a result of limited data published several decades ago.(BARRY and 
BERMAN 1961) More recent publications have consistently failed to show a benefit with 
mannitol therapy when given in the perioperative period.(Ip-Yam, Murphy et al. 1994; 
Better, Rubinstein et al. 1997; Poullis 1999; Carcoana, Mathew et al. 2003) 
In light of these results, although it has become routine practice in many institutions to add 
mannitol to the pump prime solution, there is little evidence to support this therapy. It is 
also important to consider the possible detrimental effect of induced osmotic diuresis, which 
may include hypovolemia and hypernatremia. Unfortunately, until more robust data is 
available, individual cardiac surgery teams must base their decision to use mannitol on their 
own interpretation of the limited information available in the literature. 
6.7 N-acetylcysteine 
There is conflicting evidence supporting the use of the antioxidant n-acetylcysteine in the 
prevention of contrast-induced nephropathy.(Marenzi, Assanelli et al. 2006; Krämer and 
Hoffmann 2007) When studied in high-risk patients undergoing on-pump cardiac surgery, 
n-acetylcysteine failed to show a benefit compared to placebo in the prevention of 
postoperative renal failure.(Burns, Chu et al. 2005; El-Hamamsy, Stevens et al. 2007; Haase, 
Haase-Fielitz et al. 2007; Sisillo, Ceriani et al. 2008) Several meta-analyses reviewing this 
subject support the results of these individual trials.(Baker, Anglade et al. 2009; Nigwekar 
and Kandula 2009) The lack of benefit in cardiac surgery populations compared to contrast-
induced nephropathy is likely related to the different mechanism of AKI, which is more 
clearly related to ischemia-reperfusion injury than nephrotoxicity.  
6.8 Calcium channel blockers 
Calcium channel blockers have been shown experimentally to promote renal vasodilatation, 
increase renal blood flow, and increase GFR. Studies in patients undergoing cardiac surgery 
have been contradictory.(Young, Diab et al. 1998; Piper, Kumle et al. 2003)  
6.9 Natriuretic peptides 
Natriuretic peptides are known to oppose the renin-angiotensin-aldosterone and arginine 
vasopressin systems through multiple mechanisms.(Nakao, Itoh et al. 1989) As a result they 
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can induce natriuresis and vasodilatation to prevent hypervolemia and oppose the 
vasoconstrictive response induced by hypovolemia. Synthetic analogues of these proteins 
have been suggested as therapies to prevent renal failure following cardiac surgery.  
Anaritide, the human recombinant form of atrial natriuretic peptide (ANP), is 
administered intravenously to induce arterial and venous dilatation, thus decreasing 
blood pressure. This drug failed to show a benefit in two randomized controlled trials of 
critically ill patients with acute tubular necrosis.(Allgren, Marbury et al. 1997; Lewis, 
Salem et al. 2000) 
Nesiritide, a human recombinant form of Brain-type natriuretic peptide (BNP) is used in 
the treatment of decompensated heart failure. In a randomized controlled trial of heart 
failure patients, nesiritide improved diuresis and decreased pulmonary congestion and 
edema.(Mills, LeJemtel et al. 1999) Despite these benefits, a recent meta-analysis raised 
concerns about a possible detrimental effect on renal function.(Sackner-Bernstein, 
Skopicki et al. 2005) More recently, the NAPA investigators randomized 303 patients with 
left ventricular dysfunction undergoing cardiac surgery to receive nesiritide or 
placebo.(Mentzer, Oz et al. 2007) The primary outcomes were postoperative renal 
function, hemodynamics, and drug use.  The authors found that nesiritide attenuated 
peak increase in creatinine, decreased hospital stay, and improved survival at 180 days. 
Two other randomized trials published in recent years showed favorable laboratory 
results in the nesiritide groups, however, they failed to show a significant clinical 
benefit.(Chen, Sundt et al. 2007; Ejaz, Martin et al. 2009) Although data regarding this 
drug has been conflicting, interesting results would suggest that further investigation is 
justified.  
6.10 Sodium bicarbonate 
Sodium bicarbonate is known to alkalinize urine and, when given intravenously, has been 
shown to attenuate renal dysfunction in the context of contrast infusion.(Merten, Burgess et 
al. 2004; Briguori, Airoldi et al. 2007; Recio-Mayoral, Chaparro et al. 2007) A recent 
randomized pilot study evaluated the effect of perioperative sodium bicarbonate infusion in 
a group of patients at increased risk of renal failure undergoing cardiac surgery.(Haase, 
Haase-Fielitz et al. 2009) Patients were randomized to receive a 24-hour infusion of sodium 
bicarbonate or sodium chloride, beginning just after the induction of anesthesia. A lower 
rate of renal dysfunction was found in the treatment group, evidenced by a lower incidence 
of increased creatinine and neutrophil gelatinase-associated lipocalin. Base on these results, 
the authors suggest that further trials are merited  
6.11 Summary of results for preventive strategies 
It is not surprising that no single molecule has been shown unequivocally to prevent or 
effectively treat renal failure following cardiac surgery. The mechanisms of renal injury are 
multifactorial and the incidence of significant renal failure requiring is RRT is relatively low. 
Additionally, most RCTs enroll low risk patients, making most studies underpowered to 
demonstrate any benefits that may exist. The two drugs that have shown the most promise 
and would benefit from further study are fenoldopam and nesiritide. 
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7. Principles of treatment and renal replacement therapy 
7.1 General principles and supportive care 
Once the diagnosis of AKI has been established, it is important to understand the clinical 
situation and initiate supportive care without delay. As with any patient in an acute care 
setting, vital signs and basic hemodynamics must be evaluated. Assessment of cardiac 
output and filling pressures will give clues as to whether cardiac tamponade should be 
suspected. Subsequently, any drugs with potentially adverse effects on the kidney should be 
identified and, if possible, withdrawn. Finally, it is important to complete the clinical 
picture, with the help of additional laboratory tests if necessary, and determine whether 
there is a renal or pre-renal cause of injury. 
Serum values of BUN, creatinine, electrolytes and osmolality, as well as examination of 
urinary sediment, electrolytes and osmolality, will help determine whether there is a pre-
renal cause correctable with fluid administration, or if an acute tubular injury is more likely. 
For example, a slight increase in creatinine with a large jump in BUN often suggests a pre-
renal process, while a proportional rise in BUN and creatinine often signals AKI. Urine 
sodium >20 mEq/L and urine osmolality >500mOsm/kg are often seen in pre-renal 
disease. Calculation of the fractional excretion of sodium (FENa) can be useful in oliguric 
patients, with FENa <1% reflecting preserved renal function, consistent with a pre-renal 
disease state. FENa will usually be >2% in the context of AKI with impaired kidney 
function.  (See Table 1) 
Once the nature of kidney injury is understood, the practical management of patients with 
acute renal failure remains primarily supportive. If pre-renal oliguria is likely, it should be 
treated early and aggressively to prevent further tubular injury and loss of renal function. If 
AKI is established, only supportive care can be offered and efforts must be directed toward 
prevention of further kidney damage, hypervolemia, and treatment of metabolic and 
electrolyte issues as they arise. Frequent assessment of electrolytes, blood glucose, and acid-
base balance is imperative to permit corrections if necessary.  
When AKI is suspected or proven, optimization of hemodynamics should be prioritized to 
prevent further injury. Practically speaking, this includes optimizing preload and cardiac 
output. If oliguria persists despite these measures, symptomatic treatment can be instituted. 
This included managing the consequences of renal failure, which include hypervolemia, 
hyperkalemia, acidosis, and hyperphosphatemia.  
As a result of earlier diagnosis and greater access to dialysis, mortality from hyperkalemia 
has decreased significantly. In patients with AKI, it is important to restrict daily potassium 
intake by withholding food and medications containing potassium. When potassium levels 
become high or ECG changes develop, emergency treatment may include intravenous 
infusion of calcium, sodium bicarbonate, or glucose and insulin, or an inhaled beta-
agonist(Kim and Han 2002). These medications cause an intracellular potassium shift, thus 
decreasing serum levels. Since these medications do not actually remove potassium from the 
body, their effect is only temporary, and other interventions are necessary to eliminate it 
from the body. Administration of loop diuretics can be useful to eliminate potassium, 
however, varied responses to this medication render the effect unreliable. A sodium-
potassium exchange resin, such as sodium polystyrene sulfonate (Kayexalate), can be 
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can induce natriuresis and vasodilatation to prevent hypervolemia and oppose the 
vasoconstrictive response induced by hypovolemia. Synthetic analogues of these proteins 
have been suggested as therapies to prevent renal failure following cardiac surgery.  
Anaritide, the human recombinant form of atrial natriuretic peptide (ANP), is 
administered intravenously to induce arterial and venous dilatation, thus decreasing 
blood pressure. This drug failed to show a benefit in two randomized controlled trials of 
critically ill patients with acute tubular necrosis.(Allgren, Marbury et al. 1997; Lewis, 
Salem et al. 2000) 
Nesiritide, a human recombinant form of Brain-type natriuretic peptide (BNP) is used in 
the treatment of decompensated heart failure. In a randomized controlled trial of heart 
failure patients, nesiritide improved diuresis and decreased pulmonary congestion and 
edema.(Mills, LeJemtel et al. 1999) Despite these benefits, a recent meta-analysis raised 
concerns about a possible detrimental effect on renal function.(Sackner-Bernstein, 
Skopicki et al. 2005) More recently, the NAPA investigators randomized 303 patients with 
left ventricular dysfunction undergoing cardiac surgery to receive nesiritide or 
placebo.(Mentzer, Oz et al. 2007) The primary outcomes were postoperative renal 
function, hemodynamics, and drug use.  The authors found that nesiritide attenuated 
peak increase in creatinine, decreased hospital stay, and improved survival at 180 days. 
Two other randomized trials published in recent years showed favorable laboratory 
results in the nesiritide groups, however, they failed to show a significant clinical 
benefit.(Chen, Sundt et al. 2007; Ejaz, Martin et al. 2009) Although data regarding this 
drug has been conflicting, interesting results would suggest that further investigation is 
justified.  
6.10 Sodium bicarbonate 
Sodium bicarbonate is known to alkalinize urine and, when given intravenously, has been 
shown to attenuate renal dysfunction in the context of contrast infusion.(Merten, Burgess et 
al. 2004; Briguori, Airoldi et al. 2007; Recio-Mayoral, Chaparro et al. 2007) A recent 
randomized pilot study evaluated the effect of perioperative sodium bicarbonate infusion in 
a group of patients at increased risk of renal failure undergoing cardiac surgery.(Haase, 
Haase-Fielitz et al. 2009) Patients were randomized to receive a 24-hour infusion of sodium 
bicarbonate or sodium chloride, beginning just after the induction of anesthesia. A lower 
rate of renal dysfunction was found in the treatment group, evidenced by a lower incidence 
of increased creatinine and neutrophil gelatinase-associated lipocalin. Base on these results, 
the authors suggest that further trials are merited  
6.11 Summary of results for preventive strategies 
It is not surprising that no single molecule has been shown unequivocally to prevent or 
effectively treat renal failure following cardiac surgery. The mechanisms of renal injury are 
multifactorial and the incidence of significant renal failure requiring is RRT is relatively low. 
Additionally, most RCTs enroll low risk patients, making most studies underpowered to 
demonstrate any benefits that may exist. The two drugs that have shown the most promise 
and would benefit from further study are fenoldopam and nesiritide. 
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7. Principles of treatment and renal replacement therapy 
7.1 General principles and supportive care 
Once the diagnosis of AKI has been established, it is important to understand the clinical 
situation and initiate supportive care without delay. As with any patient in an acute care 
setting, vital signs and basic hemodynamics must be evaluated. Assessment of cardiac 
output and filling pressures will give clues as to whether cardiac tamponade should be 
suspected. Subsequently, any drugs with potentially adverse effects on the kidney should be 
identified and, if possible, withdrawn. Finally, it is important to complete the clinical 
picture, with the help of additional laboratory tests if necessary, and determine whether 
there is a renal or pre-renal cause of injury. 
Serum values of BUN, creatinine, electrolytes and osmolality, as well as examination of 
urinary sediment, electrolytes and osmolality, will help determine whether there is a pre-
renal cause correctable with fluid administration, or if an acute tubular injury is more likely. 
For example, a slight increase in creatinine with a large jump in BUN often suggests a pre-
renal process, while a proportional rise in BUN and creatinine often signals AKI. Urine 
sodium >20 mEq/L and urine osmolality >500mOsm/kg are often seen in pre-renal 
disease. Calculation of the fractional excretion of sodium (FENa) can be useful in oliguric 
patients, with FENa <1% reflecting preserved renal function, consistent with a pre-renal 
disease state. FENa will usually be >2% in the context of AKI with impaired kidney 
function.  (See Table 1) 
Once the nature of kidney injury is understood, the practical management of patients with 
acute renal failure remains primarily supportive. If pre-renal oliguria is likely, it should be 
treated early and aggressively to prevent further tubular injury and loss of renal function. If 
AKI is established, only supportive care can be offered and efforts must be directed toward 
prevention of further kidney damage, hypervolemia, and treatment of metabolic and 
electrolyte issues as they arise. Frequent assessment of electrolytes, blood glucose, and acid-
base balance is imperative to permit corrections if necessary.  
When AKI is suspected or proven, optimization of hemodynamics should be prioritized to 
prevent further injury. Practically speaking, this includes optimizing preload and cardiac 
output. If oliguria persists despite these measures, symptomatic treatment can be instituted. 
This included managing the consequences of renal failure, which include hypervolemia, 
hyperkalemia, acidosis, and hyperphosphatemia.  
As a result of earlier diagnosis and greater access to dialysis, mortality from hyperkalemia 
has decreased significantly. In patients with AKI, it is important to restrict daily potassium 
intake by withholding food and medications containing potassium. When potassium levels 
become high or ECG changes develop, emergency treatment may include intravenous 
infusion of calcium, sodium bicarbonate, or glucose and insulin, or an inhaled beta-
agonist(Kim and Han 2002). These medications cause an intracellular potassium shift, thus 
decreasing serum levels. Since these medications do not actually remove potassium from the 
body, their effect is only temporary, and other interventions are necessary to eliminate it 
from the body. Administration of loop diuretics can be useful to eliminate potassium, 
however, varied responses to this medication render the effect unreliable. A sodium-
potassium exchange resin, such as sodium polystyrene sulfonate (Kayexalate), can be 
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effective in removing potassium, although the maximal effect occurs only after 4-6 hours. 
Kayexalate can be administered orally or intrarectally in doses of 15-60 grams, one to four 
times daily. The most significant complication of Kayexalate administration is 
gastrointestinal necrosis, which occurs very rarely but can be extremely morbid. 
Constipation is a more common side effect. While loop diuretics and Kayexalate are options 
in select patients, the most effective and rapid method of potassium elimination is 
hemodialysis.  
Acidosis occurs frequently in acute renal failure, often complicating treatment in the 
critically ill patient due to altered homeostasis, decreased cardiac contractility, and 
attenuated responses to catecholamines. Management of metabolic acidosis should focus on 
correction of the cause and concomitant morbidity. If acidosis remains once treatment is 
optimized, hemodialysis is the most effective and proven method of correction. There is 
significant controversy regarding the use of bicarbonate in management of acidosis in the 
critically ill patient. Observational and randomized studies have failed to show a mortality 
or morbidity benefit when sodium bicarbonate is administered to correct acidosis.(Forsythe 
and Schmidt 2000; Kraut and Kurtz 2001; Kurtz, Kraut et al. 2008) The proposed rationale 
for the lack of benefit is that, while bicarbonate may increase extracellular pH, it exacerbates 
intracellular acidosis by the generation of carbon dioxide in the buffering process. 
Consequently, the practice of many critical care physicians is to administer sodium 
bicarbonate only in the presence of profound acidosis (pH <7.1) and associated 
hemodynamic instability. The goal of treatment should be a pH of approximately 7.2. 
Continuous infusion is favored over bolus injection in order to limit carbon dioxide 
production.(Kraut and Madias 2010) 
As discussed above, loop diuretics have not been shown to prevent or attenuate renal 
failure. Despite a seemingly positive effect on urine output, the available literature suggests 
that routine furosemide administration may even have deleterious effects, particularly if 
given at high doses or if it results in an unwarranted delay in commencement of 
RRT.(Kellum, Leblanc et al. 2008) Furosemide may be useful when acute kidney injury is 
accompanied by hyperkalemia or hypervolemia. If none are present, furosemide is not 
indicated.  
7.2 Renal replacement therapy 
7.2.1 Indications 
The primary roles of the kidney are to excrete toxins, maintain volemia, control electrolytes, 
and preserve acid-base homeostasis. Failure of the kidneys to perform any of these functions 
may precipitate an urgent indication for RRT. While there are no absolute guidelines 
mandating the initiation of RRT in the context of acute kidney injury, generally accepted 
indications for RRT in critically ill patients include electrolyte imbalances, hypervolemia 
with pulmonary edema, uremia, and metabolic acidosis. Specific suggested criteria are 
described in Table 4.  
There is an ongoing debate regarding the ideal timing of initiation of RRT in the critically-ill 
patient, particularly following cardiac surgery. Several factors are responsible for the lack of 
a definitive answer, including the heterogeneous definition of AKI in the literature and a 
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paucity of well-designed studies. Bouman et al analysed two RCTs and four retrospective 
studies addressing the question.(Bouman and Oudemans-Van Straaten 2007) Five of these 
studies, two of which focused uniquely on cardiac surgical patients, found a survival 
advantage with earlier initiation of RRT.(Gettings, Reynolds et al. 1999; Bouman, 
Oudemans-Van Straaten et al. 2002; Demirkiliç, Kuralay et al. 2004; Elahi, Lim et al. 2004; 
Jiang, Xue et al. 2005; Piccinni, Dan et al. 2006) Unfortunately the criteria for early and late 
initiation were different for each study and, due to the retrospective nature of several 
studies, they were fraught with confounding variables. In general, criteria for early initiation 
was dependent on oliguria, while late RRT was instituted based on serum biomarkers or 
clinical indications. The single randomized study in a surgical population found no 
difference in mortality between the early and late initiation groups.(Bouman, Oudemans-
Van Straaten et al. 2002) However, it has been suggested that the severity of disease in this 
study was too low to demonstrate a significant difference between the two approaches, 
resulting in an underpowered trial.(John and Eckardt 2007) Conversely, there may have 
been a significant selection bias in the retrospective studies showing a benefit with early 
RRT. The question of early versus late initiation of RRT will remain until larger RCTs are 
available. In the interim, it may be reasonable to consider early hemodialysis in patients 
with other organ failure, persistent shock, or to avoid the contribution of acidosis and 
electrolyte abnormalities to an underlying shock state.  
 
Indication Description 
Metabolic acidosis • pH < 7.0 
Electrolyte 
abnormalities 
• Hyperkalemia (>6.5mmol/L) 
• Hyper/hyponatremia (Na >155 or <120 mmol/L)  
Fluid overload • Pulmonary edema 
• Oliguria (urine output <200mL/12 hours) 
• Anuria (urine output <50mL/12 hours) 
Uremia • Azotemia (Urea >30mmol/L) 
• Neuropathy, myopathy 
• Encephalopathy 
• Pericarditis 
Table 4. Proposed indications for RRT in acute renal failure. Adapted from John et al, 2007 
(John and Eckardt 2007) 
7.2.2 Dosing and mode of RRT 
A detailed discussion of the many dosing regimens and modes of RRT is beyond the scope 
of this chapter. Numerous retrospective and randomized trials have studied each of these 
topics, with a brief summary of the literature presented here.  
The quantification of urea removal is usually referred to as the dose of dialysis. It is an 
important parameter when measuring the efficiency of RRT, with increased removal of urea 
being equivalent to a higher dialysis dose. While there is some evidence suggesting that a 
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effective in removing potassium, although the maximal effect occurs only after 4-6 hours. 
Kayexalate can be administered orally or intrarectally in doses of 15-60 grams, one to four 
times daily. The most significant complication of Kayexalate administration is 
gastrointestinal necrosis, which occurs very rarely but can be extremely morbid. 
Constipation is a more common side effect. While loop diuretics and Kayexalate are options 
in select patients, the most effective and rapid method of potassium elimination is 
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Acidosis occurs frequently in acute renal failure, often complicating treatment in the 
critically ill patient due to altered homeostasis, decreased cardiac contractility, and 
attenuated responses to catecholamines. Management of metabolic acidosis should focus on 
correction of the cause and concomitant morbidity. If acidosis remains once treatment is 
optimized, hemodialysis is the most effective and proven method of correction. There is 
significant controversy regarding the use of bicarbonate in management of acidosis in the 
critically ill patient. Observational and randomized studies have failed to show a mortality 
or morbidity benefit when sodium bicarbonate is administered to correct acidosis.(Forsythe 
and Schmidt 2000; Kraut and Kurtz 2001; Kurtz, Kraut et al. 2008) The proposed rationale 
for the lack of benefit is that, while bicarbonate may increase extracellular pH, it exacerbates 
intracellular acidosis by the generation of carbon dioxide in the buffering process. 
Consequently, the practice of many critical care physicians is to administer sodium 
bicarbonate only in the presence of profound acidosis (pH <7.1) and associated 
hemodynamic instability. The goal of treatment should be a pH of approximately 7.2. 
Continuous infusion is favored over bolus injection in order to limit carbon dioxide 
production.(Kraut and Madias 2010) 
As discussed above, loop diuretics have not been shown to prevent or attenuate renal 
failure. Despite a seemingly positive effect on urine output, the available literature suggests 
that routine furosemide administration may even have deleterious effects, particularly if 
given at high doses or if it results in an unwarranted delay in commencement of 
RRT.(Kellum, Leblanc et al. 2008) Furosemide may be useful when acute kidney injury is 
accompanied by hyperkalemia or hypervolemia. If none are present, furosemide is not 
indicated.  
7.2 Renal replacement therapy 
7.2.1 Indications 
The primary roles of the kidney are to excrete toxins, maintain volemia, control electrolytes, 
and preserve acid-base homeostasis. Failure of the kidneys to perform any of these functions 
may precipitate an urgent indication for RRT. While there are no absolute guidelines 
mandating the initiation of RRT in the context of acute kidney injury, generally accepted 
indications for RRT in critically ill patients include electrolyte imbalances, hypervolemia 
with pulmonary edema, uremia, and metabolic acidosis. Specific suggested criteria are 
described in Table 4.  
There is an ongoing debate regarding the ideal timing of initiation of RRT in the critically-ill 
patient, particularly following cardiac surgery. Several factors are responsible for the lack of 
a definitive answer, including the heterogeneous definition of AKI in the literature and a 
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paucity of well-designed studies. Bouman et al analysed two RCTs and four retrospective 
studies addressing the question.(Bouman and Oudemans-Van Straaten 2007) Five of these 
studies, two of which focused uniquely on cardiac surgical patients, found a survival 
advantage with earlier initiation of RRT.(Gettings, Reynolds et al. 1999; Bouman, 
Oudemans-Van Straaten et al. 2002; Demirkiliç, Kuralay et al. 2004; Elahi, Lim et al. 2004; 
Jiang, Xue et al. 2005; Piccinni, Dan et al. 2006) Unfortunately the criteria for early and late 
initiation were different for each study and, due to the retrospective nature of several 
studies, they were fraught with confounding variables. In general, criteria for early initiation 
was dependent on oliguria, while late RRT was instituted based on serum biomarkers or 
clinical indications. The single randomized study in a surgical population found no 
difference in mortality between the early and late initiation groups.(Bouman, Oudemans-
Van Straaten et al. 2002) However, it has been suggested that the severity of disease in this 
study was too low to demonstrate a significant difference between the two approaches, 
resulting in an underpowered trial.(John and Eckardt 2007) Conversely, there may have 
been a significant selection bias in the retrospective studies showing a benefit with early 
RRT. The question of early versus late initiation of RRT will remain until larger RCTs are 
available. In the interim, it may be reasonable to consider early hemodialysis in patients 
with other organ failure, persistent shock, or to avoid the contribution of acidosis and 
electrolyte abnormalities to an underlying shock state.  
 
Indication Description 
Metabolic acidosis • pH < 7.0 
Electrolyte 
abnormalities 
• Hyperkalemia (>6.5mmol/L) 
• Hyper/hyponatremia (Na >155 or <120 mmol/L)  
Fluid overload • Pulmonary edema 
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Table 4. Proposed indications for RRT in acute renal failure. Adapted from John et al, 2007 
(John and Eckardt 2007) 
7.2.2 Dosing and mode of RRT 
A detailed discussion of the many dosing regimens and modes of RRT is beyond the scope 
of this chapter. Numerous retrospective and randomized trials have studied each of these 
topics, with a brief summary of the literature presented here.  
The quantification of urea removal is usually referred to as the dose of dialysis. It is an 
important parameter when measuring the efficiency of RRT, with increased removal of urea 
being equivalent to a higher dialysis dose. While there is some evidence suggesting that a 
 
Renal Failure – The Facts 
 
146 
very low dialysis dose (0.5-0.6L/hr) is associated with worse outcomes, the results of several 
studies with regard to moderate  (20mL/kg/hr) or high dosing (35mL/kg/hr) have been 
either neutral or in favour of high doses.(Storck, Hartl et al. 1991; Ronco, Bellomo et al. 2000; 
Bouman, Oudemans-Van Straaten et al. 2002) The VA/NIH Acute Renal Failure Trial 
Network study randomized 1124 patients undergoing either intermittent hemodialysis 
(hemodynamically stable) or continuous venovenous hemodiafiltration (hemodynamically 
unstable) to low intensity or high intensity regimens.(Network, Palevsky et al. 2008) At 60 
days, there was no difference between the two groups in the rate of mortality, recovery of 
kidney function, or the rate of nonrenal organ failure. The authors suggest that other 
strategies will be necessary to decrease mortality in critically ill patients with acute kidney 
injury.  
 
 Intermittent hemodialysis Continuous renal replacement 
therapy 
Advantages • Lower risk of systemic bleeding 
• More time available for 
diagnostic and therapeutic 
interventions 
• More suitable for severe 
hyperkalemia 
•  Lower cost 
• Better hemodynamic stability 
• Fewer cardiac arrhythmias  
• Improved nutritional support  
• Better pulmonary gas exchange  
• Better fluid control 
• Better biochemical control Shorter 
stay in intensive-care unit 
Disadvantages • Availability of dialysis staff 
• More difficult hemodynamic 
control  
• Inadequate dialysis dose 
• Inadequate fluid control  
• Inadequate nutritional support 
• Not suitable for patients with 
intracranial hypertension 
• No removal of cytokines  
• Potential complement activation 
by non-biocompatible 
membranes 
• Greater vascular access problems  
• Higher risk of systemic bleeding  
• Long-term immobilization of 
patient  
• More filter problems (ruptures, 
clotting)  
• Greater cost 
Table 5. Advantages and disadvantages of intermittent versus continuous renal replacement 
therapy. Adapted from Lemaire et at, 2009(Lemaire, Jones et al. 2009) 
The mode of RRT is a complex subject, primarily because such a wide variety of modes 
exist. The two principle categories of RRT are intermittent hemodialysis (IHD) and 
continuous renal replacement therapy (CRRT). Intermittent hemodialysis is performed over 
several hours at variable intervals, ranging from once daily to three times per week. 
Sustained, low-efficiency dialysis (SLED) and extended daily dialysis are subgroups of IHD 
and are useful in less stable patients that may not tolerate large fluid shifts.(Kihara, Ikeda et 
al. 1994) CRRT, which is performed continuously, uses much slower flow rates compared to 
IHD, thus affording better hemodynamic stability. The most common modes of CRRT are 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
147 
continuous venovenous hemofiltration, continuous venovenous hemodialysis, and 
continuous venovenous hemodiafiltration(Pannu, Klarenbach et al. 2008) One of the 
significant disadvantages  of CRRT is the requirement for anticoagulation due to the slower 
flow through the system. In the postoperative setting with a patient at increased risk of 
bleeding, alternative strategies can be applied, such as regular saline flushes or citrate 
infusion.(Kutsogiannis, Gibney et al. 2005)  
Pannu et al reviewed data from 9 RCTs and found no difference in survival between IHD 
and CRRT.(Pannu, Klarenbach et al. 2008) Despite these equivocal results, there may be 
distinct clinical advantages for individual patients that must be considered. For example, 
while IHD might be an obvious choice for patients who have passed the critical stage of 
their illness, a patient in severe shock on high doses of catecholamines would be more likely 
to tolerate CRRT. Cost is another important consideration, with IHD being considerably less 
costly. Table 5 summarizes the advantages and disadvantages of IHD and CRRT in the ICU 
setting. 
8. Summary 
Acute kidney injury is one of the most common complications following cardiac surgery, 
particularly in high-risk patients. Although our understanding of the pathophysiology of 
AKI has improved over time, we have been unable to significantly improve the prognosis of 
patients with this serious complication. Strategies for prevention, diagnosis and treatment 
are still in development, with significant effort being put into advancing our knowledge and 
progressing beyond our current limitations. While it is clear that further study is necessary 
to address the shortcomings in the variety of topics reviewed here, there is no substitute for 
astute clinical evaluation and adherence to basic principles of care in critically ill patients. 
Clinicians must be conscious of individual patient’s risks and recognize early signs of AKI in 
order to optimize treatment and limit sequelae.  
9. References 
(1994). "Randomised trial of normothermic versus hypothermic coronary bypass surgery. 
The Warm Heart Investigators." Lancet 343(8897): 559-563. 
Abrahamov, D., M. Tamariz, et al. (2001). "Renal dysfunction after cardiac surgery." Can J 
Cardiol 17(5): 565-570. 
Abramov, D., M. Tamariz, et al. (2003). "The influence of cardiopulmonary bypass flow 
characteristics on the clinical outcome of 1820 coronary bypass patients." Can J 
Cardiol 19(3): 237-243. 
Allgren, R. L., T. C. Marbury, et al. (1997). "Anaritide in acute tubular necrosis. Auriculin 
Anaritide Acute Renal Failure Study Group." N Engl J Med 336(12): 828-834. 
Andersson, L. G., R. Ekroth, et al. (1993). "Acute renal failure after coronary surgery--a study 
of incidence and risk factors in 2009 consecutive patients." Thorac Cardiovasc Surg 
41(4): 237-241. 
Bagshaw, S. M. and R. T. N. Gibney (2008). "Conventional markers of kidney function." 
Critical Care Medicine 36(4 Suppl): S152-158. 
Baker, W. L., M. W. Anglade, et al. (2009). "Use of N-acetylcysteine to reduce post-
cardiothoracic surgery complications: a meta-analysis." European journal of cardio-
 
Renal Failure – The Facts 
 
146 
very low dialysis dose (0.5-0.6L/hr) is associated with worse outcomes, the results of several 
studies with regard to moderate  (20mL/kg/hr) or high dosing (35mL/kg/hr) have been 
either neutral or in favour of high doses.(Storck, Hartl et al. 1991; Ronco, Bellomo et al. 2000; 
Bouman, Oudemans-Van Straaten et al. 2002) The VA/NIH Acute Renal Failure Trial 
Network study randomized 1124 patients undergoing either intermittent hemodialysis 
(hemodynamically stable) or continuous venovenous hemodiafiltration (hemodynamically 
unstable) to low intensity or high intensity regimens.(Network, Palevsky et al. 2008) At 60 
days, there was no difference between the two groups in the rate of mortality, recovery of 
kidney function, or the rate of nonrenal organ failure. The authors suggest that other 
strategies will be necessary to decrease mortality in critically ill patients with acute kidney 
injury.  
 
 Intermittent hemodialysis Continuous renal replacement 
therapy 
Advantages • Lower risk of systemic bleeding 
• More time available for 
diagnostic and therapeutic 
interventions 
• More suitable for severe 
hyperkalemia 
•  Lower cost 
• Better hemodynamic stability 
• Fewer cardiac arrhythmias  
• Improved nutritional support  
• Better pulmonary gas exchange  
• Better fluid control 
• Better biochemical control Shorter 
stay in intensive-care unit 
Disadvantages • Availability of dialysis staff 
• More difficult hemodynamic 
control  
• Inadequate dialysis dose 
• Inadequate fluid control  
• Inadequate nutritional support 
• Not suitable for patients with 
intracranial hypertension 
• No removal of cytokines  
• Potential complement activation 
by non-biocompatible 
membranes 
• Greater vascular access problems  
• Higher risk of systemic bleeding  
• Long-term immobilization of 
patient  
• More filter problems (ruptures, 
clotting)  
• Greater cost 
Table 5. Advantages and disadvantages of intermittent versus continuous renal replacement 
therapy. Adapted from Lemaire et at, 2009(Lemaire, Jones et al. 2009) 
The mode of RRT is a complex subject, primarily because such a wide variety of modes 
exist. The two principle categories of RRT are intermittent hemodialysis (IHD) and 
continuous renal replacement therapy (CRRT). Intermittent hemodialysis is performed over 
several hours at variable intervals, ranging from once daily to three times per week. 
Sustained, low-efficiency dialysis (SLED) and extended daily dialysis are subgroups of IHD 
and are useful in less stable patients that may not tolerate large fluid shifts.(Kihara, Ikeda et 
al. 1994) CRRT, which is performed continuously, uses much slower flow rates compared to 
IHD, thus affording better hemodynamic stability. The most common modes of CRRT are 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
147 
continuous venovenous hemofiltration, continuous venovenous hemodialysis, and 
continuous venovenous hemodiafiltration(Pannu, Klarenbach et al. 2008) One of the 
significant disadvantages  of CRRT is the requirement for anticoagulation due to the slower 
flow through the system. In the postoperative setting with a patient at increased risk of 
bleeding, alternative strategies can be applied, such as regular saline flushes or citrate 
infusion.(Kutsogiannis, Gibney et al. 2005)  
Pannu et al reviewed data from 9 RCTs and found no difference in survival between IHD 
and CRRT.(Pannu, Klarenbach et al. 2008) Despite these equivocal results, there may be 
distinct clinical advantages for individual patients that must be considered. For example, 
while IHD might be an obvious choice for patients who have passed the critical stage of 
their illness, a patient in severe shock on high doses of catecholamines would be more likely 
to tolerate CRRT. Cost is another important consideration, with IHD being considerably less 
costly. Table 5 summarizes the advantages and disadvantages of IHD and CRRT in the ICU 
setting. 
8. Summary 
Acute kidney injury is one of the most common complications following cardiac surgery, 
particularly in high-risk patients. Although our understanding of the pathophysiology of 
AKI has improved over time, we have been unable to significantly improve the prognosis of 
patients with this serious complication. Strategies for prevention, diagnosis and treatment 
are still in development, with significant effort being put into advancing our knowledge and 
progressing beyond our current limitations. While it is clear that further study is necessary 
to address the shortcomings in the variety of topics reviewed here, there is no substitute for 
astute clinical evaluation and adherence to basic principles of care in critically ill patients. 
Clinicians must be conscious of individual patient’s risks and recognize early signs of AKI in 
order to optimize treatment and limit sequelae.  
9. References 
(1994). "Randomised trial of normothermic versus hypothermic coronary bypass surgery. 
The Warm Heart Investigators." Lancet 343(8897): 559-563. 
Abrahamov, D., M. Tamariz, et al. (2001). "Renal dysfunction after cardiac surgery." Can J 
Cardiol 17(5): 565-570. 
Abramov, D., M. Tamariz, et al. (2003). "The influence of cardiopulmonary bypass flow 
characteristics on the clinical outcome of 1820 coronary bypass patients." Can J 
Cardiol 19(3): 237-243. 
Allgren, R. L., T. C. Marbury, et al. (1997). "Anaritide in acute tubular necrosis. Auriculin 
Anaritide Acute Renal Failure Study Group." N Engl J Med 336(12): 828-834. 
Andersson, L. G., R. Ekroth, et al. (1993). "Acute renal failure after coronary surgery--a study 
of incidence and risk factors in 2009 consecutive patients." Thorac Cardiovasc Surg 
41(4): 237-241. 
Bagshaw, S. M. and R. T. N. Gibney (2008). "Conventional markers of kidney function." 
Critical Care Medicine 36(4 Suppl): S152-158. 
Baker, W. L., M. W. Anglade, et al. (2009). "Use of N-acetylcysteine to reduce post-
cardiothoracic surgery complications: a meta-analysis." European journal of cardio-
 
Renal Failure – The Facts 
 
148 
thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 
35(3): 521-527. 
Barry, K. G. and A. R. Berman (1961). "Mannitol infusion. III. The acute effect of the 
intravenous infusion of mannitol on blood and plasma volumes." N Engl J Med 264: 
1085-1088. 
Bellomo, R., S. Auriemma, et al. (2008). "The pathophysiology of cardiac surgery-associated 
acute kidney injury (CSA-AKI)." Int J Artif Organs 31(2): 166-178. 
Bellomo, R., M. Chapman, et al. (2000). "Low-dose dopamine in patients with early renal 
dysfunction: a placebo-controlled randomised trial. Australian and New Zealand 
Intensive Care Society (ANZICS) Clinical Trials Group." Lancet 356(9248): 2139-
2143. 
Bellomo, R., J. A. Kellum, et al. (2004). "Defining acute renal failure: physiological 
principles." Intensive Care Medicine 30(1): 33-37. 
Bellomo, R., C. Ronco, et al. (2004). "Acute renal failure - definition, outcome measures, 
animal models, fluid therapy and information technology needs: the Second 
International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) 
Group." Crit Care 8(4): R204-212. 
Bennett, M., C. L. Dent, et al. (2008). "Urine NGAL predicts severity of acute kidney injury 
after cardiac surgery: a prospective study." Clin J Am Soc Nephrol 3(3): 665-673. 
Better, O. S., I. Rubinstein, et al. (1997). "Mannitol therapy revisited (1940-1997)." Kidney Int 
52(4): 886-894. 
Bouman, C. S. C. and H. M. Oudemans-Van Straaten (2007). "Timing of renal replacement 
therapy in critically ill patients with acute kidney injury." Curr Opin Crit Care 13(6): 
656-661. 
Bouman, C. S. C., H. M. Oudemans-Van Straaten, et al. (2002). "Effects of early high-volume 
continuous venovenous hemofiltration on survival and recovery of renal function 
in intensive care patients with acute renal failure: a prospective, randomized trial." 
Critical Care Medicine 30(10): 2205-2211. 
Bove, T., G. Landoni, et al. (2005). "Renoprotective action of fenoldopam in high-risk 
patients undergoing cardiac surgery: a prospective, double-blind, randomized 
clinical trial." Circulation 111(24): 3230-3235. 
Brienza, N., V. Malcangi, et al. (2006). "A comparison between fenoldopam and low-dose 
dopamine in early renal dysfunction of critically ill patients." Critical Care Medicine 
34(3): 707-714. 
Briguori, C., F. Airoldi, et al. (2007). "Renal Insufficiency Following Contrast Media 
Administration Trial (REMEDIAL): a randomized comparison of 3 preventive 
strategies." Circulation 115(10): 1211-1217. 
Bunn, F., D. Trivedi, et al. (2011). "Colloid solutions for fluid resuscitation." Cochrane 
Database Syst Rev(3): CD001319. 
Burns, K. E. A., M. W. A. Chu, et al. (2005). "Perioperative N-acetylcysteine to prevent renal 
dysfunction in high-risk patients undergoing cabg surgery: a randomized 
controlled trial." JAMA 294(3): 342-350. 
Caimmi, P.-P., L. Pagani, et al. (2003). "Fenoldopam for renal protection in patients 
undergoing cardiopulmonary bypass." Journal of Cardiothoracic and Vascular 
Anesthesia 17(4): 491-494. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
149 
Carcoana, O. V., J. P. Mathew, et al. (2003). "Mannitol and dopamine in patients undergoing 
cardiopulmonary bypass: a randomized clinical trial." Anesth Analg 97(5): 1222-
1229. 
Chen, H. H., T. M. Sundt, et al. (2007). "Low dose nesiritide and the preservation of renal 
function in patients with renal dysfunction undergoing cardiopulmonary-bypass 
surgery: a double-blind placebo-controlled pilot study." Circulation 116(11 Suppl): 
I134-138. 
Chertow, G. M., J. M. Lazarus, et al. (1997). "Preoperative renal risk stratification." Circulation 
95(4): 878-884. 
Chertow, G. M., E. M. Levy, et al. (1998). "Independent association between acute renal 
failure and mortality following cardiac surgery." Am J Med 104(4): 343-348. 
Chew, S. T., M. F. Newman, et al. (2000). "Preliminary report on the association of 
apolipoprotein E polymorphisms, with postoperative peak serum creatinine 
concentrations in cardiac surgical patients." Anesthesiology 93(2): 325-331. 
Choi, P. T., G. Yip, et al. (1999). "Crystalloids vs. colloids in fluid resuscitation: a systematic 
review." Critical Care Medicine 27(1): 200-210. 
Conlon, P. J., M. Stafford-Smith, et al. (1999). "Acute renal failure following cardiac surgery." 
Nephrol Dial Transplant 14(5): 1158-1162. 
Cruz, D. N., Z. Ricci, et al. (2009). "Clinical review: RIFLE and AKIN--time for reappraisal." 
Critical Care 13(3): 211. 
Dart, A. B., T. C. Mutter, et al. (2010). "Hydroxyethyl starch (HES) versus other fluid 
therapies: effects on kidney function." Cochrane Database Syst Rev(1): CD007594. 
Demirkiliç, U., E. Kuralay, et al. (2004). "Timing of replacement therapy for acute renal 
failure after cardiac surgery." J Card Surg 19(1): 17-20. 
Dent, C. L., Q. Ma, et al. (2007). "Plasma neutrophil gelatinase-associated lipocalin predicts 
acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a 
prospective uncontrolled cohort study." Crit Care 11(6): R127. 
Dharnidharka, V. R., C. Kwon, et al. (2002). "Serum cystatin C is superior to serum 
creatinine as a marker of kidney function: a meta-analysis." Am J Kidney Dis 40(2): 
221-226. 
Diaz, G. C., V. Moitra, et al. (2008). "Hepatic and renal protection during cardiac surgery." 
Anesthesiol Clin 26(3): 565-590. 
Dietrich, W., R. Busley, et al. (2008). "Effects of aprotinin dosage on renal function: an 
analysis of 8,548 cardiac surgical patients treated with different dosages of 
aprotinin." Anesthesiology 108(2): 189-198. 
Dussol, B., S. Morange, et al. (2006). "A randomized trial of saline hydration to prevent 
contrast nephropathy in chronic renal failure patients." Nephrol Dial Transplant 
21(8): 2120-2126. 
Ejaz, A. A., T. D. Martin, et al. (2009). "Prophylactic nesiritide does not prevent dialysis or 
all-cause mortality in patients undergoing high-risk cardiac surgery." The Journal of 
Thoracic and Cardiovascular Surgery 138(4): 959-964. 
El-Hamamsy, I., L.-M. Stevens, et al. (2007). "Effect of intravenous N-acetylcysteine on 
outcomes after coronary artery bypass surgery: a randomized, double-blind, 
placebo-controlled clinical trial." The Journal of Thoracic and Cardiovascular Surgery 
133(1): 7-12. 
 
Renal Failure – The Facts 
 
148 
thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 
35(3): 521-527. 
Barry, K. G. and A. R. Berman (1961). "Mannitol infusion. III. The acute effect of the 
intravenous infusion of mannitol on blood and plasma volumes." N Engl J Med 264: 
1085-1088. 
Bellomo, R., S. Auriemma, et al. (2008). "The pathophysiology of cardiac surgery-associated 
acute kidney injury (CSA-AKI)." Int J Artif Organs 31(2): 166-178. 
Bellomo, R., M. Chapman, et al. (2000). "Low-dose dopamine in patients with early renal 
dysfunction: a placebo-controlled randomised trial. Australian and New Zealand 
Intensive Care Society (ANZICS) Clinical Trials Group." Lancet 356(9248): 2139-
2143. 
Bellomo, R., J. A. Kellum, et al. (2004). "Defining acute renal failure: physiological 
principles." Intensive Care Medicine 30(1): 33-37. 
Bellomo, R., C. Ronco, et al. (2004). "Acute renal failure - definition, outcome measures, 
animal models, fluid therapy and information technology needs: the Second 
International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) 
Group." Crit Care 8(4): R204-212. 
Bennett, M., C. L. Dent, et al. (2008). "Urine NGAL predicts severity of acute kidney injury 
after cardiac surgery: a prospective study." Clin J Am Soc Nephrol 3(3): 665-673. 
Better, O. S., I. Rubinstein, et al. (1997). "Mannitol therapy revisited (1940-1997)." Kidney Int 
52(4): 886-894. 
Bouman, C. S. C. and H. M. Oudemans-Van Straaten (2007). "Timing of renal replacement 
therapy in critically ill patients with acute kidney injury." Curr Opin Crit Care 13(6): 
656-661. 
Bouman, C. S. C., H. M. Oudemans-Van Straaten, et al. (2002). "Effects of early high-volume 
continuous venovenous hemofiltration on survival and recovery of renal function 
in intensive care patients with acute renal failure: a prospective, randomized trial." 
Critical Care Medicine 30(10): 2205-2211. 
Bove, T., G. Landoni, et al. (2005). "Renoprotective action of fenoldopam in high-risk 
patients undergoing cardiac surgery: a prospective, double-blind, randomized 
clinical trial." Circulation 111(24): 3230-3235. 
Brienza, N., V. Malcangi, et al. (2006). "A comparison between fenoldopam and low-dose 
dopamine in early renal dysfunction of critically ill patients." Critical Care Medicine 
34(3): 707-714. 
Briguori, C., F. Airoldi, et al. (2007). "Renal Insufficiency Following Contrast Media 
Administration Trial (REMEDIAL): a randomized comparison of 3 preventive 
strategies." Circulation 115(10): 1211-1217. 
Bunn, F., D. Trivedi, et al. (2011). "Colloid solutions for fluid resuscitation." Cochrane 
Database Syst Rev(3): CD001319. 
Burns, K. E. A., M. W. A. Chu, et al. (2005). "Perioperative N-acetylcysteine to prevent renal 
dysfunction in high-risk patients undergoing cabg surgery: a randomized 
controlled trial." JAMA 294(3): 342-350. 
Caimmi, P.-P., L. Pagani, et al. (2003). "Fenoldopam for renal protection in patients 
undergoing cardiopulmonary bypass." Journal of Cardiothoracic and Vascular 
Anesthesia 17(4): 491-494. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
149 
Carcoana, O. V., J. P. Mathew, et al. (2003). "Mannitol and dopamine in patients undergoing 
cardiopulmonary bypass: a randomized clinical trial." Anesth Analg 97(5): 1222-
1229. 
Chen, H. H., T. M. Sundt, et al. (2007). "Low dose nesiritide and the preservation of renal 
function in patients with renal dysfunction undergoing cardiopulmonary-bypass 
surgery: a double-blind placebo-controlled pilot study." Circulation 116(11 Suppl): 
I134-138. 
Chertow, G. M., J. M. Lazarus, et al. (1997). "Preoperative renal risk stratification." Circulation 
95(4): 878-884. 
Chertow, G. M., E. M. Levy, et al. (1998). "Independent association between acute renal 
failure and mortality following cardiac surgery." Am J Med 104(4): 343-348. 
Chew, S. T., M. F. Newman, et al. (2000). "Preliminary report on the association of 
apolipoprotein E polymorphisms, with postoperative peak serum creatinine 
concentrations in cardiac surgical patients." Anesthesiology 93(2): 325-331. 
Choi, P. T., G. Yip, et al. (1999). "Crystalloids vs. colloids in fluid resuscitation: a systematic 
review." Critical Care Medicine 27(1): 200-210. 
Conlon, P. J., M. Stafford-Smith, et al. (1999). "Acute renal failure following cardiac surgery." 
Nephrol Dial Transplant 14(5): 1158-1162. 
Cruz, D. N., Z. Ricci, et al. (2009). "Clinical review: RIFLE and AKIN--time for reappraisal." 
Critical Care 13(3): 211. 
Dart, A. B., T. C. Mutter, et al. (2010). "Hydroxyethyl starch (HES) versus other fluid 
therapies: effects on kidney function." Cochrane Database Syst Rev(1): CD007594. 
Demirkiliç, U., E. Kuralay, et al. (2004). "Timing of replacement therapy for acute renal 
failure after cardiac surgery." J Card Surg 19(1): 17-20. 
Dent, C. L., Q. Ma, et al. (2007). "Plasma neutrophil gelatinase-associated lipocalin predicts 
acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a 
prospective uncontrolled cohort study." Crit Care 11(6): R127. 
Dharnidharka, V. R., C. Kwon, et al. (2002). "Serum cystatin C is superior to serum 
creatinine as a marker of kidney function: a meta-analysis." Am J Kidney Dis 40(2): 
221-226. 
Diaz, G. C., V. Moitra, et al. (2008). "Hepatic and renal protection during cardiac surgery." 
Anesthesiol Clin 26(3): 565-590. 
Dietrich, W., R. Busley, et al. (2008). "Effects of aprotinin dosage on renal function: an 
analysis of 8,548 cardiac surgical patients treated with different dosages of 
aprotinin." Anesthesiology 108(2): 189-198. 
Dussol, B., S. Morange, et al. (2006). "A randomized trial of saline hydration to prevent 
contrast nephropathy in chronic renal failure patients." Nephrol Dial Transplant 
21(8): 2120-2126. 
Ejaz, A. A., T. D. Martin, et al. (2009). "Prophylactic nesiritide does not prevent dialysis or 
all-cause mortality in patients undergoing high-risk cardiac surgery." The Journal of 
Thoracic and Cardiovascular Surgery 138(4): 959-964. 
El-Hamamsy, I., L.-M. Stevens, et al. (2007). "Effect of intravenous N-acetylcysteine on 
outcomes after coronary artery bypass surgery: a randomized, double-blind, 
placebo-controlled clinical trial." The Journal of Thoracic and Cardiovascular Surgery 
133(1): 7-12. 
 
Renal Failure – The Facts 
 
150 
Elahi, M. M., M. Y. Lim, et al. (2004). "Early hemofiltration improves survival in post-
cardiotomy patients with acute renal failure." European journal of cardio-thoracic 
surgery : official journal of the European Association for Cardio-thoracic Surgery 26(5): 
1027-1031. 
Fergusson, D. A., P. C. Hébert, et al. (2008). "A comparison of aprotinin and lysine analogues 
in high-risk cardiac surgery." N Engl J Med 358(22): 2319-2331. 
Finfer, S., R. Bellomo, et al. (2004). "A comparison of albumin and saline for fluid 
resuscitation in the intensive care unit." N Engl J Med 350(22): 2247-2256. 
Fischer, U. M., W. K. Weissenberger, et al. (2002). "Impact of cardiopulmonary bypass 
management on postcardiac surgery renal function." Perfusion 17(6): 401-406. 
Forsythe, S. M. and G. A. Schmidt (2000). "Sodium bicarbonate for the treatment of lactic 
acidosis." Chest 117(1): 260-267. 
Fortescue, E. B., D. W. Bates, et al. (2000). "Predicting acute renal failure after coronary 
bypass surgery: cross-validation of two risk-stratification algorithms." Kidney Int 
57(6): 2594-2602. 
Frost, L., R. S. Pedersen, et al. (1991). "Prognosis and risk factors in acute, dialysis-requiring 
renal failure after open-heart surgery." Scand J Thorac Cardiovasc Surg 25(3): 161-166. 
Furnary, A. P., G. Gao, et al. (2003). "Continuous insulin infusion reduces mortality in 
patients with diabetes undergoing coronary artery bypass grafting." The Journal of 
Thoracic and Cardiovascular Surgery 125(5): 1007-1021. 
Furnary, A. P., Y. Wu, et al. (2007). "Aprotinin does not increase the risk of renal failure in 
cardiac surgery patients." Circulation 116(11 Suppl): I127-133. 
Gandhi, G. Y., G. A. Nuttall, et al. (2007). "Intensive intraoperative insulin therapy versus 
conventional glucose management during cardiac surgery: a randomized trial." 
Ann Intern Med 146(4): 233-243. 
Garwood, S., C. P. Swamidoss, et al. (2003). "A case series of low-dose fenoldopam in 
seventy cardiac surgical patients at increased risk of renal dysfunction." Journal of 
Cardiothoracic and Vascular Anesthesia 17(1): 17-21. 
Gettings, L. G., H. N. Reynolds, et al. (1999). "Outcome in post-traumatic acute renal failure 
when continuous renal replacement therapy is applied early vs. late." Intensive Care 
Med 25(8): 805-813. 
Haase, M., R. Bellomo, et al. (2008). "Urinary interleukin-18 does not predict acute kidney 
injury after adult cardiac surgery: a prospective observational cohort study." Crit 
Care 12(4): R96. 
Haase, M., A. Haase-Fielitz, et al. (2007). "Phase II, randomized, controlled trial of high-dose 
N-acetylcysteine in high-risk cardiac surgery patients." Critical Care Medicine 35(5): 
1324-1331. 
Haase, M., A. Haase-Fielitz, et al. (2009). "Sodium bicarbonate to prevent increases in serum 
creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial." 
Critical Care Medicine 37(1): 39-47. 
Haase-Fielitz, A., R. Bellomo, et al. (2009). "Novel and conventional serum biomarkers 
predicting acute kidney injury in adult cardiac surgery--a prospective cohort 
study." Critical Care Medicine 37(2): 553-560. 
Habib, R. H., A. Zacharias, et al. (2003). "Adverse effects of low hematocrit during 
cardiopulmonary bypass in the adult: should current practice be changed?" J Thorac 
Cardiovasc Surg 125(6): 1438-1450. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
151 
Habib, R. H., A. Zacharias, et al. (2005). "Role of hemodilutional anemia and transfusion 
during cardiopulmonary bypass in renal injury after coronary revascularization: 
implications on operative outcome." Crit Care Med 33(8): 1749-1756. 
Hakim, M., R. Foulds, et al. (1988). "Dopexamine hydrochloride, a beta 2 adrenergic and 
dopaminergic agonist; haemodynamic effects following cardiac surgery." Eur Heart 
J 9(8): 853-858. 
Halpenny, M., S. Lakshmi, et al. (2001). "Fenoldopam: renal and splanchnic effects in 
patients undergoing coronary artery bypass grafting." Anaesthesia 56(10): 953-960. 
Han, W. K., V. Bailly, et al. (2002). "Kidney Injury Molecule-1 (KIM-1): a novel biomarker for 
human renal proximal tubule injury." Kidney Int 62(1): 237-244. 
Han, W. K., G. Wagener, et al. (2009). "Urinary biomarkers in the early detection of acute 
kidney injury after cardiac surgery." Clin J Am Soc Nephrol 4(5): 873-882. 
Heise, D., R. M. Waeschle, et al. (2009). "Utility of cystatin C for assessment of renal function 
after cardiac surgery." Nephron Clin Pract 112(2): c107-114. 
Ho, K. M. and D. J. Sheridan (2006). "Meta-analysis of frusemide to prevent or treat acute 
renal failure." BMJ 333(7565): 420. 
Investigators, N.-S. S., S. Finfer, et al. (2009). "Intensive versus conventional glucose control 
in critically ill patients." N Engl J Med 360(13): 1283-1297. 
Ip-Yam, P. C., S. Murphy, et al. (1994). "Renal function and proteinuria after 
cardiopulmonary bypass: the effects of temperature and mannitol." Anesth Analg 
78(5): 842-847. 
Jiang, H.-L., W.-J. Xue, et al. (2005). "Influence of continuous veno-venous hemofiltration on 
the course of acute pancreatitis." World J Gastroenterol 11(31): 4815-4821. 
John, S. and K.-U. Eckardt (2007). "Renal replacement strategies in the ICU." Chest 132(4): 
1379-1388. 
Kellum, J. (1997). "The use of diuretics and dopamine in acute renal failure: a systematic 
review of the evidence." Crit Care 1(2): 53-59. 
Kellum, J. A., M. Leblanc, et al. (2008). "Acute renal failure." Clin Evid (Online) 2008. 
Kellum, J. A. and J. M  Decker (2001). "Use of dopamine in acute renal failure: a meta-
analysis." Critical Care Medicine 29(8): 1526-1531. 
Kellum, J. A., R. L. Mehta, et al. (2002). "The first international consensus conference on 
continuous renal replacement therapy." Kidney Int 62(5): 1855-1863. 
Kihara, M., Y. Ikeda, et al. (1994). "Slow hemodialysis performed during the day in 
managing renal failure in critically ill patients." Nephron 67(1): 36-41. 
Kim, H.-J. and S.-W. Han (2002). "Therapeutic approach to hyperkalemia." Nephron 92 Suppl 
1: 33-40. 
Koyner, J. L., M. R. Bennett, et al. (2008). "Urinary cystatin C as an early biomarker of acute 
kidney injury following adult cardiothoracic surgery." Kidney Int 74(8): 1059-1069. 
Krämer, B. K. and U. Hoffmann (2007). "Benefit of acetylcysteine for prevention of contrast-
induced nephropathy after primary angioplasty." Nat Clin Pract Nephrol 3(1): 10-11. 
Kraut, J. A. and I. Kurtz (2001). "Use of base in the treatment of severe acidemic states." Am J 
Kidney Dis 38(4): 703-727. 
Kraut, J. A. and N. E. Madias (2010). "Metabolic acidosis: pathophysiology, diagnosis and 
management." Nat Rev Nephrol 6(5): 274-285. 
Krinsley, J. S. (2004). "Effect of an intensive glucose management protocol on the mortality 
of critically ill adult patients." Mayo Clin Proc 79(8): 992-1000. 
 
Renal Failure – The Facts 
 
150 
Elahi, M. M., M. Y. Lim, et al. (2004). "Early hemofiltration improves survival in post-
cardiotomy patients with acute renal failure." European journal of cardio-thoracic 
surgery : official journal of the European Association for Cardio-thoracic Surgery 26(5): 
1027-1031. 
Fergusson, D. A., P. C. Hébert, et al. (2008). "A comparison of aprotinin and lysine analogues 
in high-risk cardiac surgery." N Engl J Med 358(22): 2319-2331. 
Finfer, S., R. Bellomo, et al. (2004). "A comparison of albumin and saline for fluid 
resuscitation in the intensive care unit." N Engl J Med 350(22): 2247-2256. 
Fischer, U. M., W. K. Weissenberger, et al. (2002). "Impact of cardiopulmonary bypass 
management on postcardiac surgery renal function." Perfusion 17(6): 401-406. 
Forsythe, S. M. and G. A. Schmidt (2000). "Sodium bicarbonate for the treatment of lactic 
acidosis." Chest 117(1): 260-267. 
Fortescue, E. B., D. W. Bates, et al. (2000). "Predicting acute renal failure after coronary 
bypass surgery: cross-validation of two risk-stratification algorithms." Kidney Int 
57(6): 2594-2602. 
Frost, L., R. S. Pedersen, et al. (1991). "Prognosis and risk factors in acute, dialysis-requiring 
renal failure after open-heart surgery." Scand J Thorac Cardiovasc Surg 25(3): 161-166. 
Furnary, A. P., G. Gao, et al. (2003). "Continuous insulin infusion reduces mortality in 
patients with diabetes undergoing coronary artery bypass grafting." The Journal of 
Thoracic and Cardiovascular Surgery 125(5): 1007-1021. 
Furnary, A. P., Y. Wu, et al. (2007). "Aprotinin does not increase the risk of renal failure in 
cardiac surgery patients." Circulation 116(11 Suppl): I127-133. 
Gandhi, G. Y., G. A. Nuttall, et al. (2007). "Intensive intraoperative insulin therapy versus 
conventional glucose management during cardiac surgery: a randomized trial." 
Ann Intern Med 146(4): 233-243. 
Garwood, S., C. P. Swamidoss, et al. (2003). "A case series of low-dose fenoldopam in 
seventy cardiac surgical patients at increased risk of renal dysfunction." Journal of 
Cardiothoracic and Vascular Anesthesia 17(1): 17-21. 
Gettings, L. G., H. N. Reynolds, et al. (1999). "Outcome in post-traumatic acute renal failure 
when continuous renal replacement therapy is applied early vs. late." Intensive Care 
Med 25(8): 805-813. 
Haase, M., R. Bellomo, et al. (2008). "Urinary interleukin-18 does not predict acute kidney 
injury after adult cardiac surgery: a prospective observational cohort study." Crit 
Care 12(4): R96. 
Haase, M., A. Haase-Fielitz, et al. (2007). "Phase II, randomized, controlled trial of high-dose 
N-acetylcysteine in high-risk cardiac surgery patients." Critical Care Medicine 35(5): 
1324-1331. 
Haase, M., A. Haase-Fielitz, et al. (2009). "Sodium bicarbonate to prevent increases in serum 
creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial." 
Critical Care Medicine 37(1): 39-47. 
Haase-Fielitz, A., R. Bellomo, et al. (2009). "Novel and conventional serum biomarkers 
predicting acute kidney injury in adult cardiac surgery--a prospective cohort 
study." Critical Care Medicine 37(2): 553-560. 
Habib, R. H., A. Zacharias, et al. (2003). "Adverse effects of low hematocrit during 
cardiopulmonary bypass in the adult: should current practice be changed?" J Thorac 
Cardiovasc Surg 125(6): 1438-1450. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
151 
Habib, R. H., A. Zacharias, et al. (2005). "Role of hemodilutional anemia and transfusion 
during cardiopulmonary bypass in renal injury after coronary revascularization: 
implications on operative outcome." Crit Care Med 33(8): 1749-1756. 
Hakim, M., R. Foulds, et al. (1988). "Dopexamine hydrochloride, a beta 2 adrenergic and 
dopaminergic agonist; haemodynamic effects following cardiac surgery." Eur Heart 
J 9(8): 853-858. 
Halpenny, M., S. Lakshmi, et al. (2001). "Fenoldopam: renal and splanchnic effects in 
patients undergoing coronary artery bypass grafting." Anaesthesia 56(10): 953-960. 
Han, W. K., V. Bailly, et al. (2002). "Kidney Injury Molecule-1 (KIM-1): a novel biomarker for 
human renal proximal tubule injury." Kidney Int 62(1): 237-244. 
Han, W. K., G. Wagener, et al. (2009). "Urinary biomarkers in the early detection of acute 
kidney injury after cardiac surgery." Clin J Am Soc Nephrol 4(5): 873-882. 
Heise, D., R. M. Waeschle, et al. (2009). "Utility of cystatin C for assessment of renal function 
after cardiac surgery." Nephron Clin Pract 112(2): c107-114. 
Ho, K. M. and D. J. Sheridan (2006). "Meta-analysis of frusemide to prevent or treat acute 
renal failure." BMJ 333(7565): 420. 
Investigators, N.-S. S., S. Finfer, et al. (2009). "Intensive versus conventional glucose control 
in critically ill patients." N Engl J Med 360(13): 1283-1297. 
Ip-Yam, P. C., S. Murphy, et al. (1994). "Renal function and proteinuria after 
cardiopulmonary bypass: the effects of temperature and mannitol." Anesth Analg 
78(5): 842-847. 
Jiang, H.-L., W.-J. Xue, et al. (2005). "Influence of continuous veno-venous hemofiltration on 
the course of acute pancreatitis." World J Gastroenterol 11(31): 4815-4821. 
John, S. and K.-U. Eckardt (2007). "Renal replacement strategies in the ICU." Chest 132(4): 
1379-1388. 
Kellum, J. (1997). "The use of diuretics and dopamine in acute renal failure: a systematic 
review of the evidence." Crit Care 1(2): 53-59. 
Kellum, J. A., M. Leblanc, et al. (2008). "Acute renal failure." Clin Evid (Online) 2008. 
Kellum, J. A. and J. M  Decker (2001). "Use of dopamine in acute renal failure: a meta-
analysis." Critical Care Medicine 29(8): 1526-1531. 
Kellum, J. A., R. L. Mehta, et al. (2002). "The first international consensus conference on 
continuous renal replacement therapy." Kidney Int 62(5): 1855-1863. 
Kihara, M., Y. Ikeda, et al. (1994). "Slow hemodialysis performed during the day in 
managing renal failure in critically ill patients." Nephron 67(1): 36-41. 
Kim, H.-J. and S.-W. Han (2002). "Therapeutic approach to hyperkalemia." Nephron 92 Suppl 
1: 33-40. 
Koyner, J. L., M. R. Bennett, et al. (2008). "Urinary cystatin C as an early biomarker of acute 
kidney injury following adult cardiothoracic surgery." Kidney Int 74(8): 1059-1069. 
Krämer, B. K. and U. Hoffmann (2007). "Benefit of acetylcysteine for prevention of contrast-
induced nephropathy after primary angioplasty." Nat Clin Pract Nephrol 3(1): 10-11. 
Kraut, J. A. and I. Kurtz (2001). "Use of base in the treatment of severe acidemic states." Am J 
Kidney Dis 38(4): 703-727. 
Kraut, J. A. and N. E. Madias (2010). "Metabolic acidosis: pathophysiology, diagnosis and 
management." Nat Rev Nephrol 6(5): 274-285. 
Krinsley, J. S. (2004). "Effect of an intensive glucose management protocol on the mortality 
of critically ill adult patients." Mayo Clin Proc 79(8): 992-1000. 
 
Renal Failure – The Facts 
 
152 
Kurtz, I., J. Kraut, et al. (2008). "Acid-base analysis: a critique of the Stewart and bicarbonate-
centered approaches." Am J Physiol Renal Physiol 294(5): F1009-1031. 
Kutsogiannis, D. J., R. T. N. Gibney, et al. (2005). "Regional citrate versus systemic heparin 
anticoagulation for continuous renal replacement in critically ill patients." Kidney 
Int 67(6): 2361-2367. 
Lameire, N., W. Van Biesen, et al. (2005). "Acute renal failure." Lancet 365(9457): 417-430. 
Landoni, G., G. G. L. Biondi-Zoccai, et al. (2007). "Beneficial impact of fenoldopam in 
critically ill patients with or at risk for acute renal failure: a meta-analysis of 
randomized clinical trials." Am J Kidney Dis 49(1): 56-68. 
Lassnigg, A., E. Donner, et al. (2000). "Lack of renoprotective effects of dopamine and 
furosemide during cardiac surgery." J Am Soc Nephrol 11(1): 97-104. 
Lassnigg, A., E. R. Schmid, et al. (2008). "Impact of minimal increases in serum creatinine on 
outcome in patients after cardiothoracic surgery: do we have to revise current 
definitions of acute renal failure?" Critical Care Medicine 36(4): 1129-1137. 
Lassnigg, A., D. Schmidlin, et al. (2004). "Minimal changes of serum creatinine predict 
prognosis in patients after cardiothoracic surgery: a prospective cohort study." J Am 
Soc Nephrol 15(6): 1597-1605. 
Lemaire, S. A., M. M. Jones, et al. (2009). "Randomized comparison of cold blood and cold 
crystalloid renal perfusion for renal protection during thoracoabdominal aortic 
aneurysm repair." Journal of Vascular Surgery 49(1): 11-19. 
Levy, E. M., C. M. Viscoli, et al. (1996). "The effect of acute renal failure on mortality. A 
cohort analysis." JAMA 275(19): 1489-1494. 
Lewis, J., M. M. Salem, et al. (2000). "Atrial natriuretic factor in oliguric acute renal failure. 
Anaritide Acute Renal Failure Study Group." Am J Kidney Dis 36(4): 767-774. 
MacGregor, D. A., J. F. Butterworth, et al. (1994). "Hemodynamic and renal effects of 
dopexamine and dobutamine in patients with reduced cardiac output following 
coronary artery bypass grafting." Chest 106(3): 835-841. 
MacGregor, D. A., T. E. Smith, et al. (2000). "Pharmacokinetics of dopamine in healthy male 
subjects." Anesthesiology 92(2): 338-346. 
Magder, S., B. J. Potter, et al. (2010). "Fluids after cardiac surgery: a pilot study of the use of 
colloids versus crystalloids." Critical Care Medicine 38(11): 2117-2124. 
Mahon, P. and G. Shorten (2006). "Perioperative acute renal failure." Current Opinion in 
Anaesthesiology 19(3): 332-338. 
Mangano, C. M., L. S. Diamondstone, et al. (1998). "Renal dysfunction after myocardial 
revascularization: risk factors, adverse outcomes, and hospital resource utilization. 
The Multicenter Study of Perioperative Ischemia Research Group." Ann Intern Med 
128(3): 194-203. 
Mangano, D. T., I. C. Tudor, et al. (2006). "The risk associated with aprotinin in cardiac 
surgery." N Engl J Med 354(4): 353-365. 
Marathias, K. P., M. Vassili, et al. (2006). "Preoperative intravenous hydration confers 
renoprotection in patients with chronic kidney disease undergoing cardiac 
surgery." Artif Organs 30(8): 615-621. 
Marenzi, G., E. Assanelli, et al. (2006). "N-acetylcysteine and contrast-induced nephropathy 
in primary angioplasty." N Engl J Med 354(26): 2773-2782. 
Marik, P. E. (2002). "Low-dose dopamine: a systematic review." Intensive Care Medicine 28(7): 
877-883. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
153 
Marik, P. E. and J. Iglesias (1999). "Low-dose dopamine does not prevent acute renal failure 
in patients with septic shock and oliguria. NORASEPT II Study Investigators." Am J 
Med 107(4): 387-390. 
Mathur, V. S., S. K. Swan, et al. (1999). "The effects of fenoldopam, a selective dopamine 
receptor agonist, on systemic and renal hemodynamics in normotensive subjects." 
Critical Care Medicine 27(9): 1832-1837. 
Meco, M. and S. Cirri (2010). "The effect of various fenoldopam doses on renal perfusion in 
patients undergoing cardiac surgery." The Annals of Thoracic Surgery 89(2): 497-503. 
Medalion, B., H. Cohen, et al. (2010). "The effect of cardiac angiography timing, contrast 
media dose, and preoperative renal function on acute renal failure after coronary 
artery bypass grafting." J Thorac Cardiovasc Surg 139(6): 1539-1544. 
Mehta, R. L., J. A. Kellum, et al. (2007). "Acute Kidney Injury Network: report of an initiative 
to improve outcomes in acute kidney injury." Crit Care 11(2): R31. 
Melnikov, V. Y., T. Ecder, et al. (2001). "Impaired IL-18 processing protects caspase-1-
deficient mice from ischemic acute renal failure." J Clin Invest 107(9): 1145-1152. 
Mentzer, R. M., M. C. Oz, et al. (2007). "Effects of perioperative nesiritide in patients with 
left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial." Journal of 
the American College of Cardiology 49(6): 716-726. 
Merten, G. J., W. P. Burgess, et al. (2004). "Prevention of contrast-induced nephropathy with 
sodium bicarbonate: a randomized controlled trial." JAMA 291(19): 2328-2334. 
Mills, R. M., T. H. LeJemtel, et al. (1999). "Sustained hemodynamic effects of an infusion of 
nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, 
double-blind, placebo-controlled clinical trial. Natrecor Study Group." Journal of the 
American College of Cardiology 34(1): 155-162. 
Mishra, J., C. Dent, et al. (2005). "Neutrophil gelatinase-associated lipocalin (NGAL) as a 
biomarker for acute renal injury after cardiac surgery." Lancet 365(9466): 1231-1238. 
Morelli, A., Z. Ricci, et al. (2005). "Prophylactic fenoldopam for renal protection in sepsis: a 
randomized, double-blind, placebo-controlled pilot trial." Critical Care Medicine 
33(11): 2451-2456. 
Nakamura, T., T. Sugaya, et al. (2006). "Urinary excretion of liver-type fatty acid-binding 
protein in contrast medium-induced nephropathy." Am J Kidney Dis 47(3): 439-444. 
Nakao, K., H. Itoh, et al. (1989). "[A family of natriuretic peptides (ANP.BNP)]." Nippon 
Rinsho 47(9): 1987-1995. 
Negishi, K., E. Noiri, et al. (2009). "Monitoring of urinary L-type fatty acid-binding protein 
predicts histological severity of acute kidney injury." Am J Pathol 174(4): 1154-1159. 
Negishi, K., E. Noiri, et al. (2008). "Renal L-type fatty acid-binding protein mediates the 
bezafibrate reduction of cisplatin-induced acute kidney injury." Kidney Int 73(12): 
1374-1384. 
Network, V. N. A. R. F. T., P. M. Palevsky, et al. (2008). "Intensity of renal support in 
critically ill patients with acute kidney injury." N Engl J Med 359(1): 7-20. 
Nigwekar, S. U. and P. Kandula (2009). "N-acetylcysteine in cardiovascular-surgery-
associated renal failure: a meta-analysis." The Annals of Thoracic Surgery 87(1): 139-
147. 
Nigwekar, S. U., P. Kandula, et al. (2009). "Off-pump coronary artery bypass surgery and 
acute kidney injury: a meta-analysis of randomized and observational studies." Am 
J Kidney Dis 54(3): 413-423. 
 
Renal Failure – The Facts 
 
152 
Kurtz, I., J. Kraut, et al. (2008). "Acid-base analysis: a critique of the Stewart and bicarbonate-
centered approaches." Am J Physiol Renal Physiol 294(5): F1009-1031. 
Kutsogiannis, D. J., R. T. N. Gibney, et al. (2005). "Regional citrate versus systemic heparin 
anticoagulation for continuous renal replacement in critically ill patients." Kidney 
Int 67(6): 2361-2367. 
Lameire, N., W. Van Biesen, et al. (2005). "Acute renal failure." Lancet 365(9457): 417-430. 
Landoni, G., G. G. L. Biondi-Zoccai, et al. (2007). "Beneficial impact of fenoldopam in 
critically ill patients with or at risk for acute renal failure: a meta-analysis of 
randomized clinical trials." Am J Kidney Dis 49(1): 56-68. 
Lassnigg, A., E. Donner, et al. (2000). "Lack of renoprotective effects of dopamine and 
furosemide during cardiac surgery." J Am Soc Nephrol 11(1): 97-104. 
Lassnigg, A., E. R. Schmid, et al. (2008). "Impact of minimal increases in serum creatinine on 
outcome in patients after cardiothoracic surgery: do we have to revise current 
definitions of acute renal failure?" Critical Care Medicine 36(4): 1129-1137. 
Lassnigg, A., D. Schmidlin, et al. (2004). "Minimal changes of serum creatinine predict 
prognosis in patients after cardiothoracic surgery: a prospective cohort study." J Am 
Soc Nephrol 15(6): 1597-1605. 
Lemaire, S. A., M. M. Jones, et al. (2009). "Randomized comparison of cold blood and cold 
crystalloid renal perfusion for renal protection during thoracoabdominal aortic 
aneurysm repair." Journal of Vascular Surgery 49(1): 11-19. 
Levy, E. M., C. M. Viscoli, et al. (1996). "The effect of acute renal failure on mortality. A 
cohort analysis." JAMA 275(19): 1489-1494. 
Lewis, J., M. M. Salem, et al. (2000). "Atrial natriuretic factor in oliguric acute renal failure. 
Anaritide Acute Renal Failure Study Group." Am J Kidney Dis 36(4): 767-774. 
MacGregor, D. A., J. F. Butterworth, et al. (1994). "Hemodynamic and renal effects of 
dopexamine and dobutamine in patients with reduced cardiac output following 
coronary artery bypass grafting." Chest 106(3): 835-841. 
MacGregor, D. A., T. E. Smith, et al. (2000). "Pharmacokinetics of dopamine in healthy male 
subjects." Anesthesiology 92(2): 338-346. 
Magder, S., B. J. Potter, et al. (2010). "Fluids after cardiac surgery: a pilot study of the use of 
colloids versus crystalloids." Critical Care Medicine 38(11): 2117-2124. 
Mahon, P. and G. Shorten (2006). "Perioperative acute renal failure." Current Opinion in 
Anaesthesiology 19(3): 332-338. 
Mangano, C. M., L. S. Diamondstone, et al. (1998). "Renal dysfunction after myocardial 
revascularization: risk factors, adverse outcomes, and hospital resource utilization. 
The Multicenter Study of Perioperative Ischemia Research Group." Ann Intern Med 
128(3): 194-203. 
Mangano, D. T., I. C. Tudor, et al. (2006). "The risk associated with aprotinin in cardiac 
surgery." N Engl J Med 354(4): 353-365. 
Marathias, K. P., M. Vassili, et al. (2006). "Preoperative intravenous hydration confers 
renoprotection in patients with chronic kidney disease undergoing cardiac 
surgery." Artif Organs 30(8): 615-621. 
Marenzi, G., E. Assanelli, et al. (2006). "N-acetylcysteine and contrast-induced nephropathy 
in primary angioplasty." N Engl J Med 354(26): 2773-2782. 
Marik, P. E. (2002). "Low-dose dopamine: a systematic review." Intensive Care Medicine 28(7): 
877-883. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
153 
Marik, P. E. and J. Iglesias (1999). "Low-dose dopamine does not prevent acute renal failure 
in patients with septic shock and oliguria. NORASEPT II Study Investigators." Am J 
Med 107(4): 387-390. 
Mathur, V. S., S. K. Swan, et al. (1999). "The effects of fenoldopam, a selective dopamine 
receptor agonist, on systemic and renal hemodynamics in normotensive subjects." 
Critical Care Medicine 27(9): 1832-1837. 
Meco, M. and S. Cirri (2010). "The effect of various fenoldopam doses on renal perfusion in 
patients undergoing cardiac surgery." The Annals of Thoracic Surgery 89(2): 497-503. 
Medalion, B., H. Cohen, et al. (2010). "The effect of cardiac angiography timing, contrast 
media dose, and preoperative renal function on acute renal failure after coronary 
artery bypass grafting." J Thorac Cardiovasc Surg 139(6): 1539-1544. 
Mehta, R. L., J. A. Kellum, et al. (2007). "Acute Kidney Injury Network: report of an initiative 
to improve outcomes in acute kidney injury." Crit Care 11(2): R31. 
Melnikov, V. Y., T. Ecder, et al. (2001). "Impaired IL-18 processing protects caspase-1-
deficient mice from ischemic acute renal failure." J Clin Invest 107(9): 1145-1152. 
Mentzer, R. M., M. C. Oz, et al. (2007). "Effects of perioperative nesiritide in patients with 
left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial." Journal of 
the American College of Cardiology 49(6): 716-726. 
Merten, G. J., W. P. Burgess, et al. (2004). "Prevention of contrast-induced nephropathy with 
sodium bicarbonate: a randomized controlled trial." JAMA 291(19): 2328-2334. 
Mills, R. M., T. H. LeJemtel, et al. (1999). "Sustained hemodynamic effects of an infusion of 
nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, 
double-blind, placebo-controlled clinical trial. Natrecor Study Group." Journal of the 
American College of Cardiology 34(1): 155-162. 
Mishra, J., C. Dent, et al. (2005). "Neutrophil gelatinase-associated lipocalin (NGAL) as a 
biomarker for acute renal injury after cardiac surgery." Lancet 365(9466): 1231-1238. 
Morelli, A., Z. Ricci, et al. (2005). "Prophylactic fenoldopam for renal protection in sepsis: a 
randomized, double-blind, placebo-controlled pilot trial." Critical Care Medicine 
33(11): 2451-2456. 
Nakamura, T., T. Sugaya, et al. (2006). "Urinary excretion of liver-type fatty acid-binding 
protein in contrast medium-induced nephropathy." Am J Kidney Dis 47(3): 439-444. 
Nakao, K., H. Itoh, et al. (1989). "[A family of natriuretic peptides (ANP.BNP)]." Nippon 
Rinsho 47(9): 1987-1995. 
Negishi, K., E. Noiri, et al. (2009). "Monitoring of urinary L-type fatty acid-binding protein 
predicts histological severity of acute kidney injury." Am J Pathol 174(4): 1154-1159. 
Negishi, K., E. Noiri, et al. (2008). "Renal L-type fatty acid-binding protein mediates the 
bezafibrate reduction of cisplatin-induced acute kidney injury." Kidney Int 73(12): 
1374-1384. 
Network, V. N. A. R. F. T., P. M. Palevsky, et al. (2008). "Intensity of renal support in 
critically ill patients with acute kidney injury." N Engl J Med 359(1): 7-20. 
Nigwekar, S. U. and P. Kandula (2009). "N-acetylcysteine in cardiovascular-surgery-
associated renal failure: a meta-analysis." The Annals of Thoracic Surgery 87(1): 139-
147. 
Nigwekar, S. U., P. Kandula, et al. (2009). "Off-pump coronary artery bypass surgery and 
acute kidney injury: a meta-analysis of randomized and observational studies." Am 
J Kidney Dis 54(3): 413-423. 
 
Renal Failure – The Facts 
 
154 
Ouattara, A., P. Lecomte, et al. (2005). "Poor intraoperative blood glucose control is 
associated with a worsened hospital outcome after cardiac surgery in diabetic 
patients." Anesthesiology 103(4): 687-694. 
Pannu, N., S. Klarenbach, et al. (2008). "Renal Replacement Therapy in Patients With Acute 
Renal Failure: A Systematic Review." JAMA: The Journal of the American Medical 
Association 299(7): 793-805. 
Parikh, C. R., E. Abraham, et al. (2005). "Urine IL-18 is an early diagnostic marker for acute 
kidney injury and predicts mortality in the intensive care unit." J Am Soc Nephrol 
16(10): 3046-3052. 
Parikh, C. R., A. Jani, et al. (2006). "Urine NGAL and IL-18 are predictive biomarkers for 
delayed graft function following kidney transplantation." Am J Transplant 6(7): 
1639-1645. 
Parikh, C. R., J. Mishra, et al. (2006). "Urinary IL-18 is an early predictive biomarker of acute 
kidney injury after cardiac surgery." Kidney Int 70(1): 199-203. 
Piccinni, P., M. Dan, et al. (2006). "Early isovolaemic haemofiltration in oliguric patients with 
septic shock." Intensive Care Med 32(1): 80-86. 
Piper, S. N., B. Kumle, et al. (2003). "Diltiazem may preserve renal tubular integrity after 
cardiac surgery." Can J Anaesth 50(3): 285-292. 
Portilla, D., C. Dent, et al. (2008). "Liver fatty acid-binding protein as a biomarker of acute 
kidney injury after cardiac surgery." Kidney Int 73(4): 465-472. 
Poullis, M. (1999). "Mannitol and cardiac surgery." Thorac Cardiovasc Surg 47(1): 58-62. 
Provenchère, S., G. Plantefève, et al. (2003). "Renal dysfunction after cardiac surgery with 
normothermic cardiopulmonary bypass: incidence, risk factors, and effect on 
clinical outcome." Anesth Analg 96(5): 1258-1264, table of contents. 
Recio-Mayoral, A., M. Chaparro, et al. (2007). "The reno-protective effect of hydration with 
sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency 
percutaneous coronary intervention: the RENO Study." Journal of the American 
College of Cardiology 49(12): 1283-1288. 
Rioux, J.-P., M. Lessard, et al. (2009). "Pentastarch 10% (250 kDa/0.45) is an independent risk 
factor of acute kidney injury following cardiac surgery." Critical Care Medicine 37(4): 
1293-1298. 
Roberts, I., P. Alderson, et al. (2004). "Colloids versus crystalloids for fluid resuscitation in 
critically ill patients." Cochrane Database Syst Rev(4): CD000567. 
Ronco, C., R. Bellomo, et al. (2000). "Effects of different doses in continuous veno-venous 
haemofiltration on outcomes of acute renal failure: a prospective randomised trial." 
Lancet 356(9223): 26-30. 
Rosner, M. H. and M. D. Okusa (2006). "Acute kidney injury associated with cardiac 
surgery." Clin J Am Soc Nephrol 1(1): 19-32. 
Rosner, M. H., D. Portilla, et al. (2008). "Cardiac surgery as a cause of acute kidney injury: 
pathogenesis and potential therapies." J Intensive Care Med 23(1): 3-18. 
Royston, D. (1995). "Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-
aminocaproic acid." Int Anesthesiol Clin 33(1): 155-179. 
Sackner-Bernstein, J. D., H. A. Skopicki, et al. (2005). "Risk of worsening renal function with 
nesiritide in patients with acutely decompensated heart failure." Circulation 111(12): 
1487-1491. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
155 
Schmidt-Ott, K. M., K. Mori, et al. (2006). "Neutrophil gelatinase-associated lipocalin-
mediated iron traffic in kidney epithelia." Curr Opin Nephrol Hypertens 15(4): 442-
449. 
Sear, J. W. (2005). "Kidney dysfunction in the postoperative period." Br J Anaesth 95(1): 20-
32. 
Shaw, A., M. Swaminathan, et al. (2008). "Cardiac surgery-associated acute kidney injury: 
putting together the pieces of the puzzle." Nephron Physiol 109(4): p55-60. 
Shaw, A. D., M. Stafford-Smith, et al. (2008). "The effect of aprotinin on outcome after 
coronary-artery bypass grafting." N Engl J Med 358(8): 784-793. 
Sherry, E., M. A. Tooley, et al. (1997). "Effect of dopexamine hydrochloride on renal vascular 
resistance index and haemodynamic responses following coronary artery bypass 
graft surgery." Eur J Anaesthesiol 14(2): 184-189. 
Sisillo, E., R. Ceriani, et al. (2008). "N-acetylcysteine for prevention of acute renal failure in 
patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, 
randomized, clinical trial." Critical Care Medicine 36(1): 81-86. 
Solomon, R., C. Werner, et al. (1994). "Effects of saline, mannitol, and furosemide to prevent 
acute decreases in renal function induced by radiocontrast agents." N Engl J Med 
331(21): 1416-1420. 
Stephan, H., H. Sonntag, et al. (1990). "Cardiovascular and renal haemodynamic effects of 
dopexamine: comparison with dopamine." Br J Anaesth 65(3): 380-387. 
Storck, M., W. H. Hartl, et al. (1991). "Comparison of pump-driven and spontaneous 
continuous haemofiltration in postoperative acute renal failure." Lancet 337(8739): 
452-455. 
Thakar, C. V., O. Liangos, et al. (2003). "ARF after open-heart surgery: Influence of gender 
and race." Am J Kidney Dis 41(4): 742-751. 
Thakar, C. V., O. Liangos, et al. (2003). "Predicting acute renal failure after cardiac surgery: 
validation and re-definition of a risk-stratification algorithm." Hemodial Int 7(2): 
143-147. 
Trivedi, H. S., H. Moore, et al. (2003). "A randomized prospective trial to assess the role of 
saline hydration on the development of contrast nephrotoxicity." Nephron Clin Pract 
93(1): C29-34. 
Tuttle, K. R., N. K. Worrall, et al. (2003). "Predictors of ARF after cardiac surgical 
procedures." Am J Kidney Dis 41(1): 76-83. 
Urzua, J., S. Troncoso, et al. (1992). "Renal function and cardiopulmonary bypass: effect of 
perfusion pressure." Journal of Cardiothoracic and Vascular Anesthesia 6(3): 299-303. 
van den Berghe, G., P. Wouters, et al. (2001). "Intensive insulin therapy in the critically ill 
patients." N Engl J Med 345(19): 1359-1367. 
van Oeveren, W., N. J. Jansen, et al. (1987). "Effects of aprotinin on hemostatic mechanisms 
during cardiopulmonary bypass." The Annals of Thoracic Surgery 44(6): 640-645. 
Wagener, G., M. Jan, et al. (2006). "Association between increases in urinary neutrophil 
gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac 
surgery." Anesthesiology 105(3): 485-491. 
Ympa, Y. P., Y. Sakr, et al. (2005). "Has mortality from acute renal failure decreased? A 
systematic review of the literature." Am J Med 118(8): 827-832. 
Young, E. W., A. Diab, et al. (1998). "Intravenous diltiazem and acute renal failure after 
cardiac operations." The Annals of Thoracic Surgery 65(5): 1316-1319. 
 
Renal Failure – The Facts 
 
154 
Ouattara, A., P. Lecomte, et al. (2005). "Poor intraoperative blood glucose control is 
associated with a worsened hospital outcome after cardiac surgery in diabetic 
patients." Anesthesiology 103(4): 687-694. 
Pannu, N., S. Klarenbach, et al. (2008). "Renal Replacement Therapy in Patients With Acute 
Renal Failure: A Systematic Review." JAMA: The Journal of the American Medical 
Association 299(7): 793-805. 
Parikh, C. R., E. Abraham, et al. (2005). "Urine IL-18 is an early diagnostic marker for acute 
kidney injury and predicts mortality in the intensive care unit." J Am Soc Nephrol 
16(10): 3046-3052. 
Parikh, C. R., A. Jani, et al. (2006). "Urine NGAL and IL-18 are predictive biomarkers for 
delayed graft function following kidney transplantation." Am J Transplant 6(7): 
1639-1645. 
Parikh, C. R., J. Mishra, et al. (2006). "Urinary IL-18 is an early predictive biomarker of acute 
kidney injury after cardiac surgery." Kidney Int 70(1): 199-203. 
Piccinni, P., M. Dan, et al. (2006). "Early isovolaemic haemofiltration in oliguric patients with 
septic shock." Intensive Care Med 32(1): 80-86. 
Piper, S. N., B. Kumle, et al. (2003). "Diltiazem may preserve renal tubular integrity after 
cardiac surgery." Can J Anaesth 50(3): 285-292. 
Portilla, D., C. Dent, et al. (2008). "Liver fatty acid-binding protein as a biomarker of acute 
kidney injury after cardiac surgery." Kidney Int 73(4): 465-472. 
Poullis, M. (1999). "Mannitol and cardiac surgery." Thorac Cardiovasc Surg 47(1): 58-62. 
Provenchère, S., G. Plantefève, et al. (2003). "Renal dysfunction after cardiac surgery with 
normothermic cardiopulmonary bypass: incidence, risk factors, and effect on 
clinical outcome." Anesth Analg 96(5): 1258-1264, table of contents. 
Recio-Mayoral, A., M. Chaparro, et al. (2007). "The reno-protective effect of hydration with 
sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency 
percutaneous coronary intervention: the RENO Study." Journal of the American 
College of Cardiology 49(12): 1283-1288. 
Rioux, J.-P., M. Lessard, et al. (2009). "Pentastarch 10% (250 kDa/0.45) is an independent risk 
factor of acute kidney injury following cardiac surgery." Critical Care Medicine 37(4): 
1293-1298. 
Roberts, I., P. Alderson, et al. (2004). "Colloids versus crystalloids for fluid resuscitation in 
critically ill patients." Cochrane Database Syst Rev(4): CD000567. 
Ronco, C., R. Bellomo, et al. (2000). "Effects of different doses in continuous veno-venous 
haemofiltration on outcomes of acute renal failure: a prospective randomised trial." 
Lancet 356(9223): 26-30. 
Rosner, M. H. and M. D. Okusa (2006). "Acute kidney injury associated with cardiac 
surgery." Clin J Am Soc Nephrol 1(1): 19-32. 
Rosner, M. H., D. Portilla, et al. (2008). "Cardiac surgery as a cause of acute kidney injury: 
pathogenesis and potential therapies." J Intensive Care Med 23(1): 3-18. 
Royston, D. (1995). "Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-
aminocaproic acid." Int Anesthesiol Clin 33(1): 155-179. 
Sackner-Bernstein, J. D., H. A. Skopicki, et al. (2005). "Risk of worsening renal function with 
nesiritide in patients with acutely decompensated heart failure." Circulation 111(12): 
1487-1491. 
 
Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management 
 
155 
Schmidt-Ott, K. M., K. Mori, et al. (2006). "Neutrophil gelatinase-associated lipocalin-
mediated iron traffic in kidney epithelia." Curr Opin Nephrol Hypertens 15(4): 442-
449. 
Sear, J. W. (2005). "Kidney dysfunction in the postoperative period." Br J Anaesth 95(1): 20-
32. 
Shaw, A., M. Swaminathan, et al. (2008). "Cardiac surgery-associated acute kidney injury: 
putting together the pieces of the puzzle." Nephron Physiol 109(4): p55-60. 
Shaw, A. D., M. Stafford-Smith, et al. (2008). "The effect of aprotinin on outcome after 
coronary-artery bypass grafting." N Engl J Med 358(8): 784-793. 
Sherry, E., M. A. Tooley, et al. (1997). "Effect of dopexamine hydrochloride on renal vascular 
resistance index and haemodynamic responses following coronary artery bypass 
graft surgery." Eur J Anaesthesiol 14(2): 184-189. 
Sisillo, E., R. Ceriani, et al. (2008). "N-acetylcysteine for prevention of acute renal failure in 
patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, 
randomized, clinical trial." Critical Care Medicine 36(1): 81-86. 
Solomon, R., C. Werner, et al. (1994). "Effects of saline, mannitol, and furosemide to prevent 
acute decreases in renal function induced by radiocontrast agents." N Engl J Med 
331(21): 1416-1420. 
Stephan, H., H. Sonntag, et al. (1990). "Cardiovascular and renal haemodynamic effects of 
dopexamine: comparison with dopamine." Br J Anaesth 65(3): 380-387. 
Storck, M., W. H. Hartl, et al. (1991). "Comparison of pump-driven and spontaneous 
continuous haemofiltration in postoperative acute renal failure." Lancet 337(8739): 
452-455. 
Thakar, C. V., O. Liangos, et al. (2003). "ARF after open-heart surgery: Influence of gender 
and race." Am J Kidney Dis 41(4): 742-751. 
Thakar, C. V., O. Liangos, et al. (2003). "Predicting acute renal failure after cardiac surgery: 
validation and re-definition of a risk-stratification algorithm." Hemodial Int 7(2): 
143-147. 
Trivedi, H. S., H. Moore, et al. (2003). "A randomized prospective trial to assess the role of 
saline hydration on the development of contrast nephrotoxicity." Nephron Clin Pract 
93(1): C29-34. 
Tuttle, K. R., N. K. Worrall, et al. (2003). "Predictors of ARF after cardiac surgical 
procedures." Am J Kidney Dis 41(1): 76-83. 
Urzua, J., S. Troncoso, et al. (1992). "Renal function and cardiopulmonary bypass: effect of 
perfusion pressure." Journal of Cardiothoracic and Vascular Anesthesia 6(3): 299-303. 
van den Berghe, G., P. Wouters, et al. (2001). "Intensive insulin therapy in the critically ill 
patients." N Engl J Med 345(19): 1359-1367. 
van Oeveren, W., N. J. Jansen, et al. (1987). "Effects of aprotinin on hemostatic mechanisms 
during cardiopulmonary bypass." The Annals of Thoracic Surgery 44(6): 640-645. 
Wagener, G., M. Jan, et al. (2006). "Association between increases in urinary neutrophil 
gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac 
surgery." Anesthesiology 105(3): 485-491. 
Ympa, Y. P., Y. Sakr, et al. (2005). "Has mortality from acute renal failure decreased? A 
systematic review of the literature." Am J Med 118(8): 827-832. 
Young, E. W., A. Diab, et al. (1998). "Intravenous diltiazem and acute renal failure after 
cardiac operations." The Annals of Thoracic Surgery 65(5): 1316-1319. 
 
Renal Failure – The Facts 
 
156 
Zhang, Z., B. D. Humphreys, et al. (2007). "Shedding of the urinary biomarker kidney injury 
molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region." J Am 
Soc Nephrol 18(10): 2704-2714. 
9 
Acute Kidney Injury  
Induced by Snake and Arthropod Venoms  
Markus Berger1, Maria Aparecida Ribeiro Vieira2  
and Jorge Almeida Guimarães1 
1Center of Biotechnology, Departament of Molecular Biology and Biotechnology, 
 Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, 
2Institute of Biological Sciences, Department of Fisiology and Biology,  
Federal University of Minas Gerais (UFMG)   
Brazil 
1. Introduction  
Snakebites and accidents caused by venomous arthropods (mainly spiders, scorpions, 
bees, wasps and caterpillars) are important public health problem. Despite of this, public 
health authorities, nationally and internationally, have given little attention to this 
problem worldwide (Warrell, 2010; Williams et al., 2010). As a consequence, the morbidity 
and mortality associated with snake and arthropod envenoming produce a great impact 
on the population and on the health-care systems. One of the most important and lethal 
effect of these animal venoms is nephrotoxicity (Sitprija, 2006). Specifically in South 
America and Brazil, the main snakes responsible for cases of acute kidney injury (AKI) are 
those from Bothrops and Crotalus genus. Among venomous arthropods, AKI has been 
reported after accidents with bees, spiders of the genus Loxosceles and caterpillars of the 
genus Lonomia.  
Taking in account the importance of accidents with these venomous animals, in this chapter 
we reviewed the main mechanisms that play a role in AKI induced by the most common 
snakes and arthropods found in South America. The following key aspects are addressed: 
Epidemiology, clinical renal manifestations, renal pathophysiology, diagnosis, clinical 
management of AKI and the currently experimental models used to study the venom- 
induced AKI.  
2. Epidemiology and prevalence of venomous snakes and arthropods in 
South America 
Given the wide distribution of venomous animals, particularly in tropical and subtropical 
regions, the extensive number of accidents and the complexity of the clinical conditions it 
causes, the distint types of envenomation can be considered a global problem because they 
assume great public health importance, especially in the poorest areas of the world  (World 
Health Organization [WHO], 2007). This environmental and occupational disease affects 
mainly agricultural workers and their children in some of the most impoverished rural 
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communities of developing countries in Africa, Asia, Latin America and Oceania. 
Populations in these regions experience high morbidity and mortality because of the poor 
access to health services, which are often suboptimal, and, in some instances, a scarcity of 
antivenom, which is the only specific treatment so far tecnically possible to be available. A 
large number of victims survive with permanent physical and psychological sequelae 
(Gutiérrez et al., 2010; Kasturiratne et al., 2008; Warrell, 2010).  
A group of venomous animals is responsible for medically important accidents: snakes, 
scorpions, spiders, caterpillars, bees and wasps. Global epidemiological data on accidents 
with these different types of animals are scarce and often depend on the existence of 
country-specific estimates based on hospital admissions data and community-based 
population surveys. Unfortunately, in the low-income countries, where most accidents 
occur, there is not such a well organized health systems in order to correctly report the 
envenomation cases (Kasturiratne et al., 2008; Williams et al., 2010). Nevertheless, after the 
incorporation of snakebite envenomations on the World Health Organization list of 
neglected tropical diseases in 2009 (www.who.int/neglected_diseases/diseases/ 
snakebites/en/), more attention has been given to the lack of information on the true 
epidemiological impact of accidents, especially in the cases of snakebites. Current data 
indicate that 5.4 to 5.5 million people are bitten by snakes each year, resulting in near 
400,000 amputations, and between 20,000 to 125,000 deaths (Chippaux, 1998, Kasturiratne et 
al., 2008; Williams et al., 2010). The highest burden of snakebite was identified in South and 
Southeast Asia, sub-Saharan Africa and Central and South America. Annually, Asia and 
Africa have incidence rates of 1.2 million and 1 million bites with 60,000 and 20,000 deaths, 
respectively. In Central and South America, epidemiological data indicate the occurrence of 
300,000 snakebites per year which result in 4,000 deaths and approximately 12,000 cases of 
physical sequelae (Chippaux, 2011; Gutiérrez et al., 2010).  
Specifically in Brazil, data from the System of Health Surveillance of the Ministry of Health 
indicate the ocorrence of 107,364 accidents with venomous animals in the year of 2009 
(including cases of snake, scorpion, spider, caterpillar and bee envenomations) which 
resulted in 290 deaths. When compared to the 2008 year  there were an increase of 12 % and 
16 % in the total number of accidents and deaths, respectively (Boletim eletrônico 
epidemiológico, 2010). The majority of reported cases was caused by snakes and scorpions, 
which were also responsible for the highest rates of lethality (Table 1). Most snakebite (53 %) 
occurred from January to May, which reflect the influence of seasonal factors, such as an 
increase in temperature and humidity associated with the rainy season in some regions of 
Brazil. Human agricultural activities were also associated with envenomations, since 78 % of 
accidents occurred in rural areas. Snakes of Bothrops genus (Lance-headed pit vipers) were 
responsible for 90.5 % of the accidents while snakes of Crotalus genus (South American 
rattlesnakes) accounted for 7.7 % of total cases, showing however, a much higher lethality 
index (1.25 %) than that for Bothrops snakes (0.35 %) (Ministério da Saúde, 2001). Analysing 
the different regions of Brazil, the highest proportion of snakebites in relation to the 
population is localized in the North Region (Amazon Forest) with 53.9 accidents/100,000 
inhabitants, probably due to the difficulty of patients to access health services and/or to the 
delay in the administration of antivenom (Table 1). Among all venomous animals, the 
scorpion stands out for its high and growing number of accidents in Brazil. Compared to the 
2008 year, there was an increase of 7,050 cases in 2009 (45,721 versus 38,671 cases in 2008). 
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According to Chippaux and Goyffon (2008), scorpions are responsible annually for 1.2 
million accidents and for about 3,250 deaths in the world. In Brazil, the increased number of 
scorpion accidents has been attributed to its adaptation to urban and domiciliar areas 
(Ministério da Saúde, 2001). In this case, the highest incidence was registred in the Northeast 
Region (Table 1). In contrast, accidents with spiders, caterpillars and bees are a growing 
problem in states of Southern Brazil. Specifically in the state of Paraná the brown spider 
(Loxosceles genus) is the most important venomous animal responsible for the high incidence 
of spider envenomation in the whole South Region (da Silva et al., 2004). In contrast, in the 
states of Rio Grande do Sul and Santa Catarina the caterpillar Lonomia obliqua, also called 
taturana (from the American-Indian Tupi-Guarani tatá, which means fire, and raná, similar 
to), has been associated with severe cases of hemorrhagic syndrome (Veiga et al., 2009). In 
this  case, although accidents may occur throughout the year, 80 % of cases were reported 
during summer, when the animal is in the larval stage of its life cycle. Between 1997 and 
2005 there were 984 accidents only in the state of Rio Grande do Sul, resulting in a mortality 
rate of 0.5 % (Abella et al., 2006). Currently, the therapeutic use of specific antivenom 
(antilonomic serum) has decreased the number of deaths (Table 1). Among bee accidents, 
the most dangerous are caused by Apis mellifera (Africanized bees). In these cases the high 
number of deaths (30 in 2009) has been associated mainly with the absence of a specific 
antivenom and the occurence of allergic reactions (Boletim eletrônico epidemiológico, 
2010).   
 
ACCIDENTS WITH VENOMOUS ANIMALS IN BRAZIL. REPORTED DATA: 
YEAR  2009 *.
 Snakes Spiders Scorpions Caterpillars Bees 
Total number of accidents 27,655 23,515 45,721 4,028 6,445 
Incidence per 100,000 
inhabitants 14.4 12.3 24 2.1 3.4 
Number of deaths 125 26 104 5 30 
Lethality (%) 0.45 0.11 0.23 0.13 0.05 
Brazilian Regions Incidence per 100,000 inhabitants 
North 53.9 3.6 16.2 1.7 1.9 
Northeast 14.6 1.3 39.6 0.4 2.5 
Midwest 20 2.6 13.3 0.7 2.2 
Southeast 7.4 7.1 23.7 1.7 3.2 
South 10.1 58.5 3.5 7.3 7 
* Data from Brazilian Ministry of Health, 2010 (Boletim Eletrônico Epidemiológico, April 2010). 
Table 1. Epidemiological data of accidents with venomous animals in Brazil. 
3. Clinical renal manifestations due to snake and arthropod envenomation 
A broad clinical spectrum of renal function impairment has been reported in snake and 
arthropod envenomations (Sitprija, 2006). As the kidneys are highly vascularized organs 
and have the ability to concentrate substances into the urine they are particularly susceptible 
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occurred from January to May, which reflect the influence of seasonal factors, such as an 
increase in temperature and humidity associated with the rainy season in some regions of 
Brazil. Human agricultural activities were also associated with envenomations, since 78 % of 
accidents occurred in rural areas. Snakes of Bothrops genus (Lance-headed pit vipers) were 
responsible for 90.5 % of the accidents while snakes of Crotalus genus (South American 
rattlesnakes) accounted for 7.7 % of total cases, showing however, a much higher lethality 
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inhabitants, probably due to the difficulty of patients to access health services and/or to the 
delay in the administration of antivenom (Table 1). Among all venomous animals, the 
scorpion stands out for its high and growing number of accidents in Brazil. Compared to the 
2008 year, there was an increase of 7,050 cases in 2009 (45,721 versus 38,671 cases in 2008). 
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According to Chippaux and Goyffon (2008), scorpions are responsible annually for 1.2 
million accidents and for about 3,250 deaths in the world. In Brazil, the increased number of 
scorpion accidents has been attributed to its adaptation to urban and domiciliar areas 
(Ministério da Saúde, 2001). In this case, the highest incidence was registred in the Northeast 
Region (Table 1). In contrast, accidents with spiders, caterpillars and bees are a growing 
problem in states of Southern Brazil. Specifically in the state of Paraná the brown spider 
(Loxosceles genus) is the most important venomous animal responsible for the high incidence 
of spider envenomation in the whole South Region (da Silva et al., 2004). In contrast, in the 
states of Rio Grande do Sul and Santa Catarina the caterpillar Lonomia obliqua, also called 
taturana (from the American-Indian Tupi-Guarani tatá, which means fire, and raná, similar 
to), has been associated with severe cases of hemorrhagic syndrome (Veiga et al., 2009). In 
this  case, although accidents may occur throughout the year, 80 % of cases were reported 
during summer, when the animal is in the larval stage of its life cycle. Between 1997 and 
2005 there were 984 accidents only in the state of Rio Grande do Sul, resulting in a mortality 
rate of 0.5 % (Abella et al., 2006). Currently, the therapeutic use of specific antivenom 
(antilonomic serum) has decreased the number of deaths (Table 1). Among bee accidents, 
the most dangerous are caused by Apis mellifera (Africanized bees). In these cases the high 
number of deaths (30 in 2009) has been associated mainly with the absence of a specific 
antivenom and the occurence of allergic reactions (Boletim eletrônico epidemiológico, 
2010).   
 
ACCIDENTS WITH VENOMOUS ANIMALS IN BRAZIL. REPORTED DATA: 
YEAR  2009 *.
 Snakes Spiders Scorpions Caterpillars Bees 
Total number of accidents 27,655 23,515 45,721 4,028 6,445 
Incidence per 100,000 
inhabitants 14.4 12.3 24 2.1 3.4 
Number of deaths 125 26 104 5 30 
Lethality (%) 0.45 0.11 0.23 0.13 0.05 
Brazilian Regions Incidence per 100,000 inhabitants 
North 53.9 3.6 16.2 1.7 1.9 
Northeast 14.6 1.3 39.6 0.4 2.5 
Midwest 20 2.6 13.3 0.7 2.2 
Southeast 7.4 7.1 23.7 1.7 3.2 
South 10.1 58.5 3.5 7.3 7 
* Data from Brazilian Ministry of Health, 2010 (Boletim Eletrônico Epidemiológico, April 2010). 
Table 1. Epidemiological data of accidents with venomous animals in Brazil. 
3. Clinical renal manifestations due to snake and arthropod envenomation 
A broad clinical spectrum of renal function impairment has been reported in snake and 
arthropod envenomations (Sitprija, 2006). As the kidneys are highly vascularized organs 
and have the ability to concentrate substances into the urine they are particularly susceptible 
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to venom toxins. The most common clinical renal manifestations seen in human patients is 
acute tubular necrosis, but all renal structures may be involved. Thus, the occurrence of 
acute tubulointerstitial nephritis, renal cortical necrosis, mesangiolysis, vasculitis, 
glomerulonephritis, proteinuria, haematuria and myoglobinuria have also been described 
(Sitprija, 2006). 
In this subsection, we reviewed the clinical characteristics of human accidents with snakes 
and arthropods that cause AKI which are highly prevalent in Brazil and other regions of 
Latin America. Envenomations by the following animals were analysed: Bothrops and 
Crotalus snakes, the brown spider Loxosceles, africanized bees, wasps and the caterpillars of 
genus Lonomia. Despite the significant number of accidents with scorpions (Table 1), cases of 
AKI have not been associated to them. In fact, it is known that the main target of scorpion 
venom is the nervous and cardiac systems (Cologna et al., 2009). 
3.1 Snakebite envenomation 
Envenomation by snakebite, indenpendently of the species responsible for the bite, enforces 
medical emergencies since different organs and tissues can be affected at the same time. In 
Brazil, most severe cases result from bites by snakes of the family Viperidae (pit vipers and 
true vipers). Within this family are the Bothrops and Crotalus snakes. Specifically in the 
Bothrops genus there are more than 30 species distributed from southern Mexico to 
Argentina, including Brazil. The most important species are Bothrops asper, B. jararaca, B. 
atrox, B. moojeni, B. jararacussu and B. alternatus. Bothrops snakes preferentially inhabit rural 
areas and moist forest environments. But these snakes also invade cultivated areas and 
ambients with rodents’ proliferation. Bothrops snakes have nocturnal habits and an 
aggressive defensive behavior and its venom present proteolytic, coagulant and 
hemorrhagic active principles that are directly or indirectly implicated in the local and 
systemic effects observed upon envenoming  acidents (Warrel, 2010). Local effects due to the 
envenoming by these snakes are characterized by bleeding, swelling, pain and sometimes 
blisters, and can be frenquently complicated by the development of local abscesses and 
necrosis. Occasionally, compartmental syndrome may develop, which results in functional 
or anatomic loss of the bitten limb (Gutiérrez et al., 2006). Signs of systemic envenoming 
include gingival hemorrhage, microscopic hematuria, ecchymosis and consumption 
coagulopathy and, more rarely, epistaxis, hemoptosis, menorrhagia and hematemesis 
(Gutiérrez et al., 2006; Otero et al., 2002). Disturbances of hemostasis also include severe 
afibrinogenemia, thrombocytopenia and platelet aggregation dysfunction (Santoro and 
Sano-Martins, 2004). Deaths are usually attributed to renal injury, shock, severe bleeding, 
and complicating sepsis. 
Renal dysfunction can occur early in the human bothropic envenomation which often 
induces oliguria and is accompanied by an increase in the plasma creatinine concentration. 
The need for dialysis ranges from 33 % to 75 % of cases (Pinho et al., 2008). AKI is mainly 
due to acute tubular necrosis and acute cortical necrosis and occasionally 
glomerulonephritis (Table 2) (Rodrigues-Sgrignolli et al., 2011). These renal pathological 
alterations have been attributed mainly to hemodynamic changes in response to 
envenomation, hemoglobinuria, intravascular clot formation and direct venom 
nephrotoxicity. 
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By analyzing a series of retrospective studies, Pinho et al. (2008) reported that the prevalence 
of AKI after Bothrops envenomation ranges from 1.6 % to 38.5 %. In most of these reports 
AKI diagnosis was based on the increase in the plasma creatinine and/or blood nitrogen 
urea being, the creatinine clearance barely estimated. The main reported factors influencing 
AKI prevalence upon such envenomation are: the patient’s age (children under 10 year of 
age have been shown to be more susceptible to develop AKI); the snake’s age (venom 
composition can vary even within the same species, according to the snake’s age); bite site 
and amount of inoculated venom; and the time elapsed until antivenom treatment. 
Moreover, pre-existing diseases such as hypertension, diabetes or previous nephropathies 
may become patients more vulnerable to the effects of venom (Rodrigues-Sgrignolli et al., 
2011; Zelanis et al., 2010). Taking in consideration all the above factors, the mortality rate of 
Bothrops venom-induced AKI range from 13 % to 19 %. 
Other snakes well known for their nephrotoxicity are the South American rattlesnakes 
(Crotalus snakes). In Brazil, the Crotalus genus is represented by a single specie, Crotalus 
durissus, that is composed of six subspecies: Crotalus durissus terrificus, C. d.collilineatus, C.d. 
cascavella, C.d. ruruima, C.d. marajoensis and C.d. trigonicus. Besides sharing some common 
characteristics with other venomous snakes, the Crotalus genus presents a rattle at the end of 
its tail, which is a particular characteristic of these snakes making easier their identification. 
In general the Crotalus snakes are found in rocky and drier regions. They are rarely found in 
humid forests and feed mainly of small rodents. They are robust (may reach 1 meter in 
length) and are less agressive than Bothrops snakes (Ministério da Saúde, 2001). 
Among the six different subspecies, C.d. terrificus is the most frequently implicated in 
envenomation cases registered in Brazil. The venom has neurotoxic, myotoxic, and 
nephrotoxic activities (Table 2). In neuromuscular junctions, the venom leads to a powerful 
presynaptic inhibition of acetylcholine release, which is responsible for the neuromuscular 
blockade and progressive flaccid paralysis of variable degrees. Eyelid ptosis, blurred and/or 
double vision, ophthalmoplegia and facial muscle paralysis are common manifestations of 
venom neurotoxicity. The myotoxic activity of the venom also produces severe skeletal 
muscle injury leading to myalgia and rhabdomyolysis with the subsequent release of 
myoglobin from damaged skeletal muscle into serum and urine (Azevedo-Marques et al., 
1987). Indeed, the serum creatine kinase (CK) levels are significantly higher (260-folds that 
of normal values) in patients who develop AKI after a Crotalus bite. Other markers of 
rhabdomyolysis, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) 
and lactate dehydrogenase (LDH) are also increased in patients with AKI (Pinho et al., 
2005). High serum and urine levels of myoglobin are potentially nephrotoxic, leading to 
acute tubular necrosis, which is the primary and most serious complication of human 
crotalid envenomation. Tissue damage at the site of the bite has been reported to be minimal 
or absent, a feature that differentiates the South American rattlesnake from other species of 
Crotalus and from Bothrops envenomations. Spontaneous bleeding has only been rarely 
observed in human patients, despite the presence of blood incoagulability in some cases 
(Jorge & Ribeiro, 1992). AKI is the main cause of death among patients surviving to the early 
effects of Crotalus snakebites. 
In a study of 100 cases of Crotalus bites, Pinho et al. (2005) showed that AKI develops within 
the first 24 to 48 hours after envenomation. Envenomed patients presented a significant 
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to venom toxins. The most common clinical renal manifestations seen in human patients is 
acute tubular necrosis, but all renal structures may be involved. Thus, the occurrence of 
acute tubulointerstitial nephritis, renal cortical necrosis, mesangiolysis, vasculitis, 
glomerulonephritis, proteinuria, haematuria and myoglobinuria have also been described 
(Sitprija, 2006). 
In this subsection, we reviewed the clinical characteristics of human accidents with snakes 
and arthropods that cause AKI which are highly prevalent in Brazil and other regions of 
Latin America. Envenomations by the following animals were analysed: Bothrops and 
Crotalus snakes, the brown spider Loxosceles, africanized bees, wasps and the caterpillars of 
genus Lonomia. Despite the significant number of accidents with scorpions (Table 1), cases of 
AKI have not been associated to them. In fact, it is known that the main target of scorpion 
venom is the nervous and cardiac systems (Cologna et al., 2009). 
3.1 Snakebite envenomation 
Envenomation by snakebite, indenpendently of the species responsible for the bite, enforces 
medical emergencies since different organs and tissues can be affected at the same time. In 
Brazil, most severe cases result from bites by snakes of the family Viperidae (pit vipers and 
true vipers). Within this family are the Bothrops and Crotalus snakes. Specifically in the 
Bothrops genus there are more than 30 species distributed from southern Mexico to 
Argentina, including Brazil. The most important species are Bothrops asper, B. jararaca, B. 
atrox, B. moojeni, B. jararacussu and B. alternatus. Bothrops snakes preferentially inhabit rural 
areas and moist forest environments. But these snakes also invade cultivated areas and 
ambients with rodents’ proliferation. Bothrops snakes have nocturnal habits and an 
aggressive defensive behavior and its venom present proteolytic, coagulant and 
hemorrhagic active principles that are directly or indirectly implicated in the local and 
systemic effects observed upon envenoming  acidents (Warrel, 2010). Local effects due to the 
envenoming by these snakes are characterized by bleeding, swelling, pain and sometimes 
blisters, and can be frenquently complicated by the development of local abscesses and 
necrosis. Occasionally, compartmental syndrome may develop, which results in functional 
or anatomic loss of the bitten limb (Gutiérrez et al., 2006). Signs of systemic envenoming 
include gingival hemorrhage, microscopic hematuria, ecchymosis and consumption 
coagulopathy and, more rarely, epistaxis, hemoptosis, menorrhagia and hematemesis 
(Gutiérrez et al., 2006; Otero et al., 2002). Disturbances of hemostasis also include severe 
afibrinogenemia, thrombocytopenia and platelet aggregation dysfunction (Santoro and 
Sano-Martins, 2004). Deaths are usually attributed to renal injury, shock, severe bleeding, 
and complicating sepsis. 
Renal dysfunction can occur early in the human bothropic envenomation which often 
induces oliguria and is accompanied by an increase in the plasma creatinine concentration. 
The need for dialysis ranges from 33 % to 75 % of cases (Pinho et al., 2008). AKI is mainly 
due to acute tubular necrosis and acute cortical necrosis and occasionally 
glomerulonephritis (Table 2) (Rodrigues-Sgrignolli et al., 2011). These renal pathological 
alterations have been attributed mainly to hemodynamic changes in response to 
envenomation, hemoglobinuria, intravascular clot formation and direct venom 
nephrotoxicity. 
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By analyzing a series of retrospective studies, Pinho et al. (2008) reported that the prevalence 
of AKI after Bothrops envenomation ranges from 1.6 % to 38.5 %. In most of these reports 
AKI diagnosis was based on the increase in the plasma creatinine and/or blood nitrogen 
urea being, the creatinine clearance barely estimated. The main reported factors influencing 
AKI prevalence upon such envenomation are: the patient’s age (children under 10 year of 
age have been shown to be more susceptible to develop AKI); the snake’s age (venom 
composition can vary even within the same species, according to the snake’s age); bite site 
and amount of inoculated venom; and the time elapsed until antivenom treatment. 
Moreover, pre-existing diseases such as hypertension, diabetes or previous nephropathies 
may become patients more vulnerable to the effects of venom (Rodrigues-Sgrignolli et al., 
2011; Zelanis et al., 2010). Taking in consideration all the above factors, the mortality rate of 
Bothrops venom-induced AKI range from 13 % to 19 %. 
Other snakes well known for their nephrotoxicity are the South American rattlesnakes 
(Crotalus snakes). In Brazil, the Crotalus genus is represented by a single specie, Crotalus 
durissus, that is composed of six subspecies: Crotalus durissus terrificus, C. d.collilineatus, C.d. 
cascavella, C.d. ruruima, C.d. marajoensis and C.d. trigonicus. Besides sharing some common 
characteristics with other venomous snakes, the Crotalus genus presents a rattle at the end of 
its tail, which is a particular characteristic of these snakes making easier their identification. 
In general the Crotalus snakes are found in rocky and drier regions. They are rarely found in 
humid forests and feed mainly of small rodents. They are robust (may reach 1 meter in 
length) and are less agressive than Bothrops snakes (Ministério da Saúde, 2001). 
Among the six different subspecies, C.d. terrificus is the most frequently implicated in 
envenomation cases registered in Brazil. The venom has neurotoxic, myotoxic, and 
nephrotoxic activities (Table 2). In neuromuscular junctions, the venom leads to a powerful 
presynaptic inhibition of acetylcholine release, which is responsible for the neuromuscular 
blockade and progressive flaccid paralysis of variable degrees. Eyelid ptosis, blurred and/or 
double vision, ophthalmoplegia and facial muscle paralysis are common manifestations of 
venom neurotoxicity. The myotoxic activity of the venom also produces severe skeletal 
muscle injury leading to myalgia and rhabdomyolysis with the subsequent release of 
myoglobin from damaged skeletal muscle into serum and urine (Azevedo-Marques et al., 
1987). Indeed, the serum creatine kinase (CK) levels are significantly higher (260-folds that 
of normal values) in patients who develop AKI after a Crotalus bite. Other markers of 
rhabdomyolysis, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) 
and lactate dehydrogenase (LDH) are also increased in patients with AKI (Pinho et al., 
2005). High serum and urine levels of myoglobin are potentially nephrotoxic, leading to 
acute tubular necrosis, which is the primary and most serious complication of human 
crotalid envenomation. Tissue damage at the site of the bite has been reported to be minimal 
or absent, a feature that differentiates the South American rattlesnake from other species of 
Crotalus and from Bothrops envenomations. Spontaneous bleeding has only been rarely 
observed in human patients, despite the presence of blood incoagulability in some cases 
(Jorge & Ribeiro, 1992). AKI is the main cause of death among patients surviving to the early 
effects of Crotalus snakebites. 
In a study of 100 cases of Crotalus bites, Pinho et al. (2005) showed that AKI develops within 
the first 24 to 48 hours after envenomation. Envenomed patients presented a significant 
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reduction in glomerular filtration rate (estimated by the creatinine clearance). AKI patients 
also presented dark-brown urine and a fractional excretion of sodium significantly higher 
than the normal (Pinho et al., 2005). The major kidney pathological alteration is acute 
tubular necrosis, although interstitial nephritis has also been observed (Amaral et al., 1986; 
Azevedo-Marques et al., 1985) (Table 2). In this type of envenomation the occurrence of 
severe rhabdomyolysis is one of the more accepted explanations for the acute tubular 
necrosis. Other factors potentially associated with venom-induced AKI such as shock, 
hypotension and hemolysis are present in some cases, but have not been confirmed in 
Crotalus envenomation (Azevedo-Marques et al., 1987; Pinho et al., 2008). Despite of in vitro 
hemolytic activity of Crotalus venom, it was confirmed that in vivo C.d. terrificus 
envenomation causes myolysis rather than intravascular hemolysis (Azevedo-Marques et 
al., 1987). 
The prevalence of AKI associated with Crotalid envenomation ranges from 10 to 29 % and 
68 to 77 % of AKI patients require dialysis treatment. The mortality rate of Crotalus venom-
induced AKI ranges from 8 to 17 % (Amaral et al., 1986; Pinho et al., 2008; Silveira & 
Nishioka, 1992). Although most risk factors for AKI are very similar to those described for 
bothropic envenomation it was reported that early after Crotalus snakebite the plasma levels 
of CK (higher than 2,000 U/L) were associated with a 12-fold increase in the risk of 
developing AKI (Pinho et al., 2005). 
3.2 Brown spider envenomation 
Among arthropods, spider and scorpion bites are the most frequent and of medical care 
importance. Although the number of accidents with scorpions often overcome those with 
spiders, reports of AKI after human envenomation with scorpion are scarce (Abdulkader et 
al., 2008). One species of spider that can cause severe renal injury is the brown spider 
(Loxosceles genus). Spiders of the genus Loxosceles have a worldwide distribution, since they 
can live under variable conditions such as temperature ranging from 8 to 43°C and that 
they can stay long time intervals living without food or water (Hogan et al., 2004; 
Swanson and Vetter, 2006). In Brazil, seven species have been described, but some of them 
are the most frequently implicated in bites in humans, namely Loxosceles intermedia, L. 
gaucho and L. laeta. These spiders are commonly found inside the residences both in rural 
and urban areas. They are small, measuring between 8 and 15 mm of body length while 
their legs measure 8-30 mm. Their colour varies from a pale brown (L. laeta) to a dark 
brown (L. gaucho). Loxosceles spiders are not aggressive and the bites usually occur when 
they are pressed against the body, mainly while the victim is sleeping or dressing (da 
Silva et al., 2004).  
The venom has proteolytic, dermonecrotic, hemolytic and nephrotoxic activities (Isbister & 
Fan, 2011) (Table 2). The accident may have local and systemic manifestations that are 
exhibited in two different clinical forms: cutaneous and viscerocutaneous loxoscelism (da 
Silva et al., 2004). Most patients have only the local manifestation or cutaneous 
loxoscelism. In these cases, the accident may cause mild cutaneous inflammatory reaction 
or a local injury characterized by pain, edema and erithrema, later developing to 
dermonecrosis with gravitational spreading. In the minority of cases loxoscelism can 
cause a systemic injury or the viscerocutaneous loxoscelism. This form occurs 
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predominantly in children, and patients can develop AKI, which is considered the main 
cause of death after brown spider envenomation. Viscerocutaneous loxoscelism is 
characterized by fever, malaise, weakness, nausea and vomiting, hemolysis, hematuria, 
jaundice, thrombocytopenia and disseminated intravascular coagulation. This severe 
multisystemic clinical picture can occur as early as 24 hours after the bite (Abdulkader et 
al., 2008; da Silva et al., 2004; Isbister & Fan, 2011).  
Analysis of 267 loxoscelism cases reported in Brazil showed that the viscerocutaneous form 
was diagnosed in 13.1 % of the cases, where L laeta was the main specie implicated in the 
accidents. The investigators reported jaundice in 68.6 %, oliguria in 45.7 %, anuria in 8.6 %, 
dark urine in 28.6 %, hemorrhage in 25.7 %, and shock in 2.9 % of the patients. AKI 
occurred in 6.4 % of the patients, and most of them were diagnosed more than 24 hours 
after the bite. Four patients died (1.5 %), all of them were children under 14 years old 
(Sezerino et al., 1998). The main factors likely associated with AKI development are 
hemolysis, hypotension/shock, and direct venom nephrotoxicity (Table 2). Pigment-
induced acute tubular necrosis was reported in human necropsies of viscerocutaneous 
loxoscelism (Zambrano et al., 2005). Thus, it was suggested that the pathological effect of 
the venom on the kidney may reflect hematological disturbances, such as intravascular 
hemolysis and disseminated intravascular coagulation (Abdulkader et al., 2008). Although 
only low myotoxic activity has been reported in Loxosceles venom, rhabdomyolysis can also 
occur after envenomation. In this cases, high levels of  serum CK and deposits of 
myoglobin in tubular cells have been observed (França et al., 2002; Lucato-Junior et al., 
2011).  
3.3 Bee and wasp envenomation 
Stings of insects from the order Hymenoptera, which includes several species of bees, 
hornets, wasps and yellow jacks, have also been implicated in cases of human envenomation 
(Vetter et al., 1999). 
In general the victims present only local allergic reactions after one or a few stings. 
However, after a massive attack with hundreds or thousands of stings, a systemic 
envenomation may occur (Abdulkader et al., 2008). The majority of envenomation cases 
with medical importance is caused by the so-called Africanized bees (Apis genus). These 
bees are hybrids between bees of European origin (Apis mellifera mellifera and Apis mellifera 
ligustica) and African bees (Apis mellifera scutellata) which were originated by the 
introduction of different species in Brazil since 1957. Currently, due to the migratory 
behavior and a high reproductive rate they are found throughout South America, Central 
America and parts of North America. Because of their aggressive behavior and the number 
of accidents associated with them, the Africanized bees are also known as “killer bees” 
(Abdulkader et al., 2008; França et al., 1994). 
The main venom activities are hemolytic, myotoxic, cardiotoxic and nephrotoxic (Table 2). 
Clinical manifestations can be divided into allergic and systemic reactions. Allergic reactions 
usually are observed in patients with a history of previous bee stings or asthma or other 
hypersensitivity disease. These reactions occur immediately after a single sting and can lead 
to anaphylaxis and death by laryngeal edema. Systemic reactions usually occur after 
multiple stings and are characterized by pain, erythema, urticaria, release of histamine, 
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reduction in glomerular filtration rate (estimated by the creatinine clearance). AKI patients 
also presented dark-brown urine and a fractional excretion of sodium significantly higher 
than the normal (Pinho et al., 2005). The major kidney pathological alteration is acute 
tubular necrosis, although interstitial nephritis has also been observed (Amaral et al., 1986; 
Azevedo-Marques et al., 1985) (Table 2). In this type of envenomation the occurrence of 
severe rhabdomyolysis is one of the more accepted explanations for the acute tubular 
necrosis. Other factors potentially associated with venom-induced AKI such as shock, 
hypotension and hemolysis are present in some cases, but have not been confirmed in 
Crotalus envenomation (Azevedo-Marques et al., 1987; Pinho et al., 2008). Despite of in vitro 
hemolytic activity of Crotalus venom, it was confirmed that in vivo C.d. terrificus 
envenomation causes myolysis rather than intravascular hemolysis (Azevedo-Marques et 
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induced AKI ranges from 8 to 17 % (Amaral et al., 1986; Pinho et al., 2008; Silveira & 
Nishioka, 1992). Although most risk factors for AKI are very similar to those described for 
bothropic envenomation it was reported that early after Crotalus snakebite the plasma levels 
of CK (higher than 2,000 U/L) were associated with a 12-fold increase in the risk of 
developing AKI (Pinho et al., 2005). 
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Among arthropods, spider and scorpion bites are the most frequent and of medical care 
importance. Although the number of accidents with scorpions often overcome those with 
spiders, reports of AKI after human envenomation with scorpion are scarce (Abdulkader et 
al., 2008). One species of spider that can cause severe renal injury is the brown spider 
(Loxosceles genus). Spiders of the genus Loxosceles have a worldwide distribution, since they 
can live under variable conditions such as temperature ranging from 8 to 43°C and that 
they can stay long time intervals living without food or water (Hogan et al., 2004; 
Swanson and Vetter, 2006). In Brazil, seven species have been described, but some of them 
are the most frequently implicated in bites in humans, namely Loxosceles intermedia, L. 
gaucho and L. laeta. These spiders are commonly found inside the residences both in rural 
and urban areas. They are small, measuring between 8 and 15 mm of body length while 
their legs measure 8-30 mm. Their colour varies from a pale brown (L. laeta) to a dark 
brown (L. gaucho). Loxosceles spiders are not aggressive and the bites usually occur when 
they are pressed against the body, mainly while the victim is sleeping or dressing (da 
Silva et al., 2004).  
The venom has proteolytic, dermonecrotic, hemolytic and nephrotoxic activities (Isbister & 
Fan, 2011) (Table 2). The accident may have local and systemic manifestations that are 
exhibited in two different clinical forms: cutaneous and viscerocutaneous loxoscelism (da 
Silva et al., 2004). Most patients have only the local manifestation or cutaneous 
loxoscelism. In these cases, the accident may cause mild cutaneous inflammatory reaction 
or a local injury characterized by pain, edema and erithrema, later developing to 
dermonecrosis with gravitational spreading. In the minority of cases loxoscelism can 
cause a systemic injury or the viscerocutaneous loxoscelism. This form occurs 
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predominantly in children, and patients can develop AKI, which is considered the main 
cause of death after brown spider envenomation. Viscerocutaneous loxoscelism is 
characterized by fever, malaise, weakness, nausea and vomiting, hemolysis, hematuria, 
jaundice, thrombocytopenia and disseminated intravascular coagulation. This severe 
multisystemic clinical picture can occur as early as 24 hours after the bite (Abdulkader et 
al., 2008; da Silva et al., 2004; Isbister & Fan, 2011).  
Analysis of 267 loxoscelism cases reported in Brazil showed that the viscerocutaneous form 
was diagnosed in 13.1 % of the cases, where L laeta was the main specie implicated in the 
accidents. The investigators reported jaundice in 68.6 %, oliguria in 45.7 %, anuria in 8.6 %, 
dark urine in 28.6 %, hemorrhage in 25.7 %, and shock in 2.9 % of the patients. AKI 
occurred in 6.4 % of the patients, and most of them were diagnosed more than 24 hours 
after the bite. Four patients died (1.5 %), all of them were children under 14 years old 
(Sezerino et al., 1998). The main factors likely associated with AKI development are 
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Clinical manifestations can be divided into allergic and systemic reactions. Allergic reactions 
usually are observed in patients with a history of previous bee stings or asthma or other 
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to anaphylaxis and death by laryngeal edema. Systemic reactions usually occur after 
multiple stings and are characterized by pain, erythema, urticaria, release of histamine, 
 
Renal Failure – The Facts 
 
164 
nausea, vomiting, respiratory failure, hypotension and shock (Abdulkader et al., 2008). 
Rhabdomyolysis and hemolysis can be detected a few hours after the accident (Chao et al., 
2004). Fatalities are typically the result of renal damage or from cardiac arrest due to 
complications of the venom toxicity (Vetter et al., 1999).  
AKI has been observed in cases of massive attacks with 150 stings to more than 1,500 stings. 
Envenomed patients commonly have anuria or oliguria, high levels of serum creatinine (10-
30 mg/dL) and CK (>2,000 U/L), hypotension, tachycardia, myocardial damage and anemia 
(Daher et al., 2003; Gabriel et al., 2004; França et al., 1994; Xuan et al., 2010). Acute tubular 
necrosis is the main histologic finding in human beings, domestic dogs, and in experimental 
animals after bee and wasp envenomations. Allergic interstitial nephritis with concurrent 
pigment tubulopathy resulting from both hemoglobin and myoglobin has also been 
described after wasp stings (Chao et al., 2004; Zhang et al., 2001) (Table 2). A direct 
nephrotoxicity of the venom and/or hypotension caused by anaphylactic reaction are also 
mechanisms implicated in AKI induced by bees of Apis genus (Grisotto et al., 2006). By 
analyzing five cases of severe envenomation by Africanized bees, França et al. (1994) found 
high venom concentrations in serum and urine which remain for more than 50 h after the 
stings in two fatal cases; in one of them the total circulating unbound whole venom 
components was estimated at 27 mg, one hour after the attack. Despite the treatment with 
dialysis, antihistamines, corticosteroids, bronchodilators, vasodilators, bicarbonate, 
mannitol and mechanical ventilation, three out four patients died between 22 and 71 h after 
the attacks. However, in the majority of cases, the renal damage is usually reversible 
responding well to the dialysis. Complete recovery may require 3-6 weeks (Vetter et al., 
1999).  
3.4 Caterpillar envenomation 
The accidental contact with some lepidopteran caterpillars can also cause human 
envenomation cases that vary from simple skin irritation and local allergic reactions to a 
systemic disease characterized by renal damage and hemorrhagic disturbances (Pinto et al., 
2010; Veiga et al., 2009). From the medically important Saturniidae family, Lonomia genus 
has been attributed to cause human envenomations since late 1960’s in Venezuela (Arocha-
Piñango et al., 2000). In Southern Brazil, Lonomia obliqua caterpillar is becoming the most 
important venomous animal responsible for severe injuries, hemorrhagic disorders and 
often fatal outcome since the 1980’s (Duarte et al., 1990). For instance, in the State of Rio 
Grande do Sul, located in this Brazilian region, more than a thousand accidents have been 
registered in the period from 1997 to 2005 (Abella et al., 2006). In fact, based on data from 
the year 2009, the Brazilian Ministry of Health registered an incidence of 7.3 lepidopteran 
envenomations per 100,000 inhabitants in Southern Brazil (Boletim eletrônico 
epidemiológico, 2010) (Table 1). Actually, these numbers are greatly underestimated due to 
the fact that most accidents are occurring in distant rural areas, where the cases are poorly 
reported. Lonomia’s accidents usually occur when the victim, leaning against tree trunks 
containing dozens or hundreds of caterpillars, comes into contact with their bristles. These 
structures are hard and spiny evaginations of the cuticle, underneath which the toxins are 
stored. Often, the whole animal is smashed in the accident, the insect’s chitinous bristles get 
broken and the venomous secretions, including hemolymph, penetrate the human skin and 
enter the circulation (Veiga et al., 2001a). 
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The venom presents procoagulant, fibrinogenolytic, proteolytic and hemolytic activities 
(Table 2). Clinical symptoms of Lonomia envenomation include local pain (burning 
sensation) and inflammatory reaction, which starts immediately after contact; systemic 
reactions such as headache, fever, vomiting and asthenia, which appear a few hours after 
exposure; and bleeding diathesis characterized by hematomas and ecchymosis, gross 
hematuria, hematemesis, melena, pulmonary and intracerebral hemorrhage and AKI (Pinto 
et al., 2010). Intravascular hemolysis has also been described in human envenomation and 
experimental studies (Malaque et al., 2006; Seibert et al., 2004). The activation of blood 
coagulation, fibrinolysis and the systemic inhibition of platelet function are mechanisms that 
seem to contribute to the hemorrhagic syndrome commonly observed in Lonomia 
envenomation (Berger et al., 2010a). In human patients, this hemorrhagic syndrome 
manifests as a consumptive coagulopathy without thrombocytopenia (Berger et al., 2010a; 
Zannin et al., 2003). 
The incidence of AKI varies from 2 to 5 % of envenomation cases reported in the literature 
(Duarte et al., 1990; Gamborgi et al., 2006). Of the 2,067 patients evaluated in southern Brazil 
(period from 1989 to 2003), 39 (1.9 %) developed AKI (serum creatinine levels > 1.5 mg/dL). 
Eleven (32 %) of these patients were treated with dialysis and four (10.3 %) developed 
chronic renal injury (CRI). All victims with AKI presented concomitantly coagulation 
disturbances and hematuria and/or hemoglobinuria. Seven deaths (4%) occurred during the 
period (Gamborgi et al., 2006). The impossibility of conducting early renal biopsies, due the 
coagulation disturbances inherent to the envenomation, has made it difficult to analyze the 
acute anatomopathological alterations. The few reports existing in the literature describe 
thickening of the Bowman’s capsule, focal tubular atrophy and acute tubular necrosis 
(Burdmann et al., 1996; Fan et al., 1998) (Table 2). Similarly, the contribution of other factors 
possibly associated with AKI, such as hypotension or glomerular fibrin deposition, remains 
still obscure in Lonomia envenomation. 
4. Toxins of snake and arthropod venoms and their role in the 
pathophysiology of acute kidney injury 
Animal venoms are mixtures of biologically active proteins and peptides, and also non-
protein toxins, carbohydrates, lipids, amines, and other small molecules. The clinical 
features of envenomation reflect the effects of these different venom components and thus, 
the contribution of the venom toxins to the pathophysiology of renal injury is complex and 
multifactorial (Sitprija, 2006).  
Based on the current knowledge, the hypothesis for pathogenesis of venom-induced AKI 
include both a direct cytotoxic action of the venom on different renal structures, and a 
secondary response of the whole organism resulting from systemic envenomation. The  
secondary response is usually triggered by inflammation, release of cytokines and 
vasoactive substances that leads to changes in renal function and hemodynamics (Fig. 1). In 
fact, there is an increase in plasma concentration of different cytokines and vasoactive 
substances such as TNF-α, interleukins, nitric oxide, histamine, bradykinin and eicosanoids 
following several types of envenomations (Petricevich et al., 2000). The elevation of 
cytokines are mainly due to accumulation of pro-inflammatory cells and immune system 
response. Together, all these mediators can impair renal function ultimately contributing to 
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a decrease in renal perfusion pressure, renal blood flow and glomerular filtration rate. As a 
result in association with the systemic hypotension (Table 2), there will be an inadequate 
tissue and cellular oxygen delivery which can generate an ischemic process. Since the 
intermediary metabolism and energy production have an absolute dependence on oxygen, 
and oxygen cannot be stored intracellularly, the inadequate oxygen availability rapidly 
leads to cellular dysfunction, injury, and cell death by necrosis (Deitch, 1992). Important 
contribution to venom-induced renal ischemia is also derived from the process of hemolysis, 
rhabdomyolysis and/or intravascular deposition of platelets and fibrin in the 
microcirculation (Table 2). The presence of hemoglobin and myoglobin also have a direct 
cytotoxic effect on renal tubules (Fig.1) (Khan, 2009; Zager, 1996). Thus, it seems that 
different, but interrelated processes may contribute to the nephrotoxicity and even to other 
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DIC - Disseminated Intravascular Coagulation; ATN - Acute tubular necrosis, AIN - Allergic interstitial 
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Table 2. Clinical aspects of venom-induced Acute Kidney Injury (AKI).     
Recently, advances in molecular biology, proteomics and transcriptomics, facilitated the 
isolation of toxins and contributed significantly to the study of their mechanisms of action 
on renal tissue. In this subsection, we reviewed the renal physiopathological effects of snake 
and arthropod venoms and their main isolated toxins. Special emphasis was given to 
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experimental studies with venomous animals highly prevalent in Brazil and other regions of 
Latin America. As in the previous subsection the following animals were included: Bothrops 
and Crotalus snakes, the brown spider Loxosceles, africanized bees, wasps and the caterpillars 
of genus Lonomia.   
 
Fig. 1. Schematic summary of pathophysiological phenomena involved in the venom-
induced acute kidney injury (AKI). RBF – Renal Blood Flow; GFR – Glomerular Filtratiton 
Rate; ATN – Acute Tubular Necrosis; ACN – Acute Cortical Necrosis. 
4.1 Snake venoms 
4.1.1 Bothrops venom 
The venom of bothrops snakes can cause prominent local tissue damage usually 
characterized by swelling, blistering, hemorrhage and necrosis of skeletal muscle. Such local 
pathology is mostly due to the venom proteolytic action (Gutiérrez et al., 2006). Snake 
venom metalloproteinases (SVMPs), phospholipases A2, , serine proteinases, esterases, L-
amino acid oxidases, hyaluronidases, C-type lectins-like and bradykinin-potentiating 
peptides (BPPs) are the main venom components that acts inducing cellular injury or 
releasing inflammatory and vasoactive mediators (Warrell, 2010). Transcriptomic and 
proteomic studies have showed that SVMPs and serine proteinases are the major toxins in 
the venom, which explained the high local damage and hemorrhage seen in envenomed 
patients (Table 2) (Cidade et al., 2006; Zelanis et al., 2010). Bothrops toxins are also known for 
their multiple effects on hemostasis. In fact, the venom have thrombin-like enzymes, factor 
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X and prothrombin activators that are able to directly convert fibrinogen into fibrin (Berger 
et al., 2008; White, 2005). These actions produce intravascular coagulation and may lead to 
blood incoagulability by consumption coagulopathy. Systemic inhibition of platelet 
aggregation and thrombocytopenia are common (Rucavado et al., 2005; Santoro & Sano-
Martins, 2004). Moreover, anti-hemostatic principles, such as thrombin and platelet 
aggregation inhibitors, are also found in bothrops venoms (Kamiguti , 2005; Zingali et al., 
2005).    
Regarding renal function, Boer-Lima et al. (1999) observed that the intravenous injection of 
B. moojeni venom in rats, produced renal tubular disturbances including an increase in 
proximal and post-proximal fractional excretion of sodium associated with acute tubular 
necrosis. The glomerular filtration rate decreased significantly, despite the absence of 
systemic hypotension. Severe morphologic disturbances in the renal glomeruli also 
occurred. The changes included mesangiolysis, glomerular microaneurysms, and 
glomerular basement membrane abnormalities. In addition, there was a reduction in the 
number and width of podocyte pedicels, which caused a reduction in the number of 
filtration slits. The morphophysiological changes observed in experimental animals also 
correlated with the levels of proteinuria (Boer-Lima et al., 2002). Similar renal functional 
alterations were observed after intravenous injection of B. jararaca venom into rats. In these 
animals, differently of human envenomation, B. jararaca venom was not able to induce 
systemic hypotension but significantly reduced the renal plasma flow and increased renal 
vascular resistance (Burdmann et al., 1993). There was no increase in CK, indicating that 
rhabdomyolysis is not an important consequence of B. jararaca envenomation. However, the 
venom caused marked fibrinogen consumption and intravascular hemolysis. Indeed, kidney 
of rats and rabbits envenomed with B. jararaca showed an extensive intraglomerular 
deposition of fibrin and platelets (Burdmann et al., 1993; Santoro & Sano-Martins, 2004). 
Contrarily to the findings with B. jararaca venom, Boer-Lima et al. (1999) did not observed 
any glomerular fibrin deposition in the B. moojeni envenomation. They suggested that the 
glomerular injury is more likely to be related to structural disorganization of the glomerular 
capillary tuft, consequent to a direct action of the venom on the mesangial matrix, 
glomerular basement membrane and podocytes rather than to fibrin deposition in the 
capillaries. 
Studying the kinetic of renal distribution of injected B. alternatus venom in rats, Mello et al. 
(2010) detected the highest venom concentration in renal tissue 30 min post-venom injection. 
After this time, venom concentration decreased progressively. Venom components were 
also detected into urine 3, 6 and 24 h post-venom injection. By immunohistochemistry, 
venom proteins were detected in glomeruli, proximal and distal tubules, and vascular and 
perivascular tissue, suggesting that toxins bind to kidney structures where they probably 
exert a direct nephrotoxic action. In accordance to this observation, it was showed that B. 
alternatus venom is cytotoxic to canine renal epithelial cells (MDCK) in culture and causes 
extensive cytoskeletal alterations inducing impairment of the cell-matrix interaction 
(Nascimento et al., 2007). Additionally, it was described that B. jararaca venom also causes in 
vitro injury of isolated renal proximal tubules and that the B. moojeni venom increases cell 
release of lactate dehydrogenase and decreased cellular uptake of the vital neutral red in 
MDCK cells (de Castro et al., 2004; Collares-Buzato et al., 2002). Functionally, B. alternatus 
venom induced oliguria, urine acidification, decreased in glomerular filtration rate and 
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hematuria. Morphologically, the venom caused lobulation of the capillary tufts, dilation of 
Bowman's capsular space, disruption of renal tubule brush border, and fibrosis around 
glomeruli and proximal tubules that persisted 7 days after envenomation (Linardi et al., 
2011; Mello et al., 2010).    
Some purified Bothrops toxins are able to reproduce the renal effects obtained with whole 
venom. Studies on the isolated perfused rat kidney have shown that L-amino acid oxidase 
(Braga et al., 2008), C-type lectins (Braga et al., 2006), phospholipase A2 myotoxins (Barbosa 
et al., 2005; Evangelista et al., 2010) and thrombin-like enzyme (Braga et al., 2007) from 
Bothrops venoms can alter renal function. The isolated perfused kidney technique also 
confirmed the direct acute tubular nephrotoxicity of Bothrops venoms and showed that 
platelet activating factor might play a role in some renal functional disturbances such as the 
decreased in glomerular filtration rate (Monteiro and Fonteles, 1999). However, the systemic 
injection of baltergin, a purified metalloproteinase from B. alternatus venom, only mildly 
affected the kidney structure. At high doses, baltergin causes congestion, subcapsular 
hemorrhage and inflammatory infiltrate (Gay et al., 2009). There was no detection of tubular 
necrosis indicating that different toxins act synergistically to produce the AKI observed in 
animals treated with whole venom.  
4.1.2 Crotalus venom 
The venom of Crotalus rattlesnakes is a complex combination of different enzymes and toxic 
peptides that mainly display neurotoxic and myotoxic activities (Boldrini-França et al., 
2010). Toxins affecting hemostasis, such as thrombin-like enzymes and platelet activators are 
also found. The main protein families identified by proteomics included phospholipases A2, 
serine proteinases, cysteine-rich secretory proteins (CRISP), vascular endothelial growth 
factor-like molecules (VEGF), L-amino acid oxidases, C-type lectins-like, and snake venom 
metalloproteinases (SVMP). Crotoxin, a neurotoxic phospholipase A2, represents more than 
60 % of the proteins in the whole venom and is the major component responsible for its 
neurotoxic and myotoxic effects (Boldrini-França et al., 2010). Additionally, crotoxin also 
exhibits cardiotoxic and direct nephrotoxic activities. Structurally, crotoxin is a 
heterodimeric β-neurotoxin that consists of a toxic basic phospholipase A2 and a 
nonenzymatic, non-toxic acidic component (crotapotin). Crotapotin potentiates the activity 
of crotoxin, since it prevents the basic phospholipase subunit binding to non-specific sites 
(Sampaio et al., 2010; Soares et al., 2001). Crotoxin targets neuromuscular junctions and 
inhibits the release of acetylcholine, which leads to neuromuscular blockade and muscular 
and respiratory paralysis. In the muscle tissue, crotoxin causes selective injury of skeletal 
muscle groups composed of type I and IIa fibers, which are extremely vascularized and rich 
in myoglobin (Sampaio et al., 2010). Other important toxins are crotamine, convulxin and 
gyroxin. Crotamine is a toxic peptide with myonecrotic activity (Martins et al., 2002). 
Convulxin is a C-type lectin-like glycoprotein with high affinity to specific receptors in 
rabbit and human platelets. Convulxin binds to the putative collagen receptor glycoprotein 
VI (GPVI) and mediates platelet adhesion, aggregation and intracellular calcium 
mobilization (Francischetti et al., 1997). Gyroxin is a serine proteinase that displays several 
activities including the induction of blood coagulation (thrombin-like activity), vasodilation 
and neurotoxicity (Alves da Silva et al., 2011). 
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hematuria. Morphologically, the venom caused lobulation of the capillary tufts, dilation of 
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Intraperitoneal injection of C.d. terrificus venom in mice increased plasma creatinine and uric 
acid and caused urinary hypoosmolality. When compared to control groups injected with 
saline, the incidence of hypercreatinemia and hyperuricemia (plasma values higher than 1.8 
mg/dL) occurred in 60 % and 100 % of the experimental animals, respectively (Yamasaki et 
al., 2008). Crotalus experimental envenomation was also associated with significant renal 
blood flow and glomerular filtration rate decreases and ischemia with consequent acute 
tubular necrosis. In isolated perfused rat kidneys treated with crude venom or crotoxin, a 
large amount of protein material was observed in the glomeruli, probably due to a direct 
toxic effect of the venom on the glomeruli and tubules and/or to an increase in vascular 
permeability (Monteiro et al., 2001). Prostaglandins and TNF-α release seems to be 
important since the treatment with indomethacin and pentoxifylline (inhibitors of 
cyclooxygenase and TNF-α synthesis, respectively) were able to blockade the renal effects 
induced by supernatant of macrophages activated with Crotalus venom (Martins et al., 2003; 
Martins et al., 2004). Among the main venom components, crotoxin was able to induce 
significant changes in glomerular filtration rate and electrolyte transport in isolated kidney. 
Gyroxin caused only mild alteration in renal parameters and convulxin had no effects 
(Martins et al., 2002). 
Rhabdomyolysis is a well-known cause of AKI and is commonly observed in envenomed 
patients and envenomed experimental animals. Myoglobin toxicity has been related to renal 
vasoconstriction, intraluminal cast formation and direct heme-protein cytotoxicity. 
Myoglobin can contribute to renal vasoconstriction by directly binding to nitric oxide (NO). 
Thus, acting as NO scavenging molecules, heme-proteins (including myoglobin or 
hemoglobin) lead to renal hypoperfusion, reductions in the storage of ATP, ischemia and 
tissue injury (Zager, 1996). Intraluminal casts are formed due to the precipitation of 
myoglobin inside the renal tubules, forming obstructive casts. Precipitated myoglobin also 
can be degraded resulting in the release of free iron and heme. Once released, free iron and 
heme contribute to renal injury by generate reactive oxygen species (ROS) and lipid 
peroxidation (Khan, 2009; Zager, 1996). Indeed, Yamasaki et al. (2008), showed an increase 
of oxidized glutathione/reduced glutathione ratio (GSSG/GSH) in renal tissue during 
Crotalus envenomation. This data indicates a rise in the ROS generation by consumption of 
reduced glutathione (GSH) and production of oxidized glutathione (GSSH) which are the 
main antioxidant and oxido-reducing agents, respectively. Confirming the participation of 
ROS in Crotalus induced renal injury, envenomed animals treated with lipoic acid (an 
antioxidant molecule) had their GSSG/GSH ratios normalized when compared to control 
groups (Alegre et al., 2010). In addition to deleterious effects of obstructive myoglobin casts 
formation, the high levels of uric acid found in envenomed animals also contribute to 
tubular obstruction (Yamasaki et al., 2008). Marked hyperuricemia is known to cause AKI 
by supersaturation, crystallisation and deposition of crystals inside renal tubules (acute 
urate nephropathy). Moreover, experimental hyperuricemia causes renal vasoconstriction 
and soluble uric acid has been shown to inhibit endothelial NO bioavailability (Ejaz et al., 
2007). Recently, it was observed that systemic inhibition of uric acid synthesis, by 
allopurinol treatment, significantly reduced lethality rate, normalized GSSG/GSH ratio and 
ameliorate the renal histopathological changes. Thus, uric acid also seems to have an 
important role in renal pathophysiology of Crotalus envenomation (Frezzatti & Silveira, 
2011).   
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4.2 Loxosceles venom 
The bites of brown spiders (Loxosceles genus) led to several clinical manifestations such as 
necrotic skin degeneration and gravitational spread at the bite site, renal injury and 
hematological disturbances. Several studies concerning the structural and biological roles of 
various venom components have shown the complex nature of these venomous secretions. 
Likewise, the venom of Loxosceles spiders is a complex mixture of protein-based toxins with 
a molecular mass profile ranging from 5 to 40 kDa. The main components belong to the 
classes of phospholipases D (or dermonecrotic toxins), serine proteinases, venom allergens, 
hyaluronidases, astacin-like metalloproteinases and insecticidal peptides (Gremski et al., 
2010). Dermonecrotic toxins and astacin-like metalloproteinases are considered the major 
components responsible for the clinical profile observed in envenomed victims (Table 2) (da 
Silva et al., 2004). In fact, a transcriptomic study indicated that phospholipases D and 
astacin-like metalloproteinases represent 20.2 % and 22.6 % of total toxin-encoding 
transcripts, respectively. Other toxins also important to envenomation, such as serine 
proteinases, venom allergens and hyaluronidases represent the minority of encoding 
transcripts (Gremski et al., 2010).  
Among all the toxins found in Loxosceles spider venom, dermonecrotic toxin is undoubtedly 
the component most investigated and characterized. This toxin is able to reproduce the 
major biological effects induced by whole venom. It is involved with the development of 
dermonecrotic lesions and can trigger neutrophil migration, complement system activation, 
cytokine and chemokine release, platelet aggregation, lysis of red blood cells, among other 
effects (Abdulkader et al., 2008; da Silva et al., 2004). Dermonecrotic toxin comprises a 
family of toxins with different related isoforms that have biological, amino acid and 
immunological similarities which are found in several Loxosceles species. Only in L. 
intermedia venom, many isoforms were described being 9 out of them already expressed as 
recombinant proteins (Gremski et al., 2010). Loxosceles dermonecrotic toxins belong to 
phospholipases D (30–35 kDa) class of enzymes which was primarily designated as 
sphingomyelinases D due to their ability to convert sphingomyelin to choline and ceramide 
1-phosphate (N-acylsphingosine1-phosphate). As some Loxosceles sphingomyelinases D 
have broad substrate specificity, being able to hydrolyze not only sphingophospholipids but 
also lysoglycerophospholipids, they are now classified as phospholipases D (Lee and Lynch, 
2005). Due to sequence, structural and biochemical differences these toxins are grouped in 
two classes and their structures and substrate specificities have been recently elucidated (de 
Giuseppe et al., 2011; Murakami et al., 2005). Other important components of Loxosceles 
venom are the metalloproteinases. The enzymes have molecular weights ranging from 20 to 
35 kDa displaying gelatinolytic, fibronectinolytic and fibrinogenolytic activities. They are 
zinc endopeptidases homologous to the astacin family of metalloproteinases from the 
crayfish, Astacus astacus. The Loxosceles astacin-like metalloproteinases possess a digestive 
function used to initiate the degradation of prey molecules, facilitating the posterior 
ingestion process (Trevizan-Silva et al., 2010). Furthermore, these enzymes have an 
important role in the pathogenesis observed in envenomation, particularly inducing 
hemorrhage into the dermis, injury of blood vessels, imperfect platelet adhesion, and the 
defective wound healing observed in some cases. Likewise, these metalloproteases can also 
render tissue structures more permeable, facilitating other noxious toxins to spread 
throughout the body of victims (Veiga et al., 2000; Veiga et al., 2001b). 
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The nephrotoxic effect of the L. intermidia spider venom was demonstrated experimentally 
in mice exposed to the whole venom (Luciano et al., 2004). Histhopathological analysis 
showed morphological renal alterations including hyalinization of proximal and distal 
tubules, erythrocytes in Bowman’s space, glomerular collapse, tubule epithelial cell blebs 
and vacuoles, interstitial edema, and deposition of a protein-rich material inside the 
Bowman’s space and tubule lumen. Morphometric analysis showed that 75–80 % of the 
kidney area was affected by the venom and no glomerular or tubule leukocyte infiltration 
was described, suggesting that the involvement of inflammatory process is not important to 
renal injury in this type of envenomation. Despite the presence of erythrocytes and protein 
deposits in glomerular and tubular structures, no signs of intravascular hemolysis or 
hemoglobin were detected in envenomed animals. Supporting the evidence that L. intermidia 
venom has toxins with direct nephrotoxicity, confocal microscopy studies with antibodies 
against venom proteins were able to show direct binding of toxins to renal structures. 
Venom proteins were detected in glomerular and tubular epithelial cells and in renal 
basement membranes. Toxins with molecular weights of 30 kDa were also identified in renal 
tissue extracts by immunoblotting (Luciano et al., 2004). One of these venom proteins that 
can bind to the kidney tissue is the dermonecrotic toxin. Chaim et al. (2006), injecting the 
recombinant dermonecrotic toxin in mice, found glomerular edema and tubular necrosis 
without signs of inflammatory response. Additionally, the dermonecrotic toxin was detected 
in kidney tissue and induced changes in renal function such as urine alkalinization, 
hematuria and elevation of blood urea nitrogen levels. The treatment of renal epithelial cells 
(MDCK) with recombinant dermonecrotic toxin also caused morphological alterations 
and reduced the cell viability, confirming its direct citotoxicity (Chaim et al., 2006). Both 
effects upon renal structures in vivo and renal cells in vitro were dependent of the 
phospholipase D catalytic activity, since a mutated toxin without phospholipase activity 
showed no nephrotoxic effect (Kusma et al., 2008). Another mechanism involved in AKI 
induced by Loxosceles venom is the renal vasoconstriction and rhabdomyolysis. Recently, 
it was reported that L. gaucho caused a sharp and significant drop in glomerular filtration 
rate, renal blood flow and urinary output and increased renal vascular resistance in rats 
(Lucato-Júnior et al., 2011). In this model, the authors also found deposits of myoglobin in 
tubular cells and degenerative lesions indicative of an ischemic process (Lucato-Júnior et 
al., 2011).     
4.3 Bee and wasp venoms 
Bee and wasp venoms are composed of a mixture of proteins, peptides, and small 
molecules, which are related to different mechanisms of envenomation. In the Africanized 
bee (Apis mellifera) venom the most important components are melittin and phospholipase 
A2. Melittin is a highly toxic peptide and the most abundant component of bee venom 
comprising about 50 % of its dry weight. This peptide is able to disrupt biological 
membranes, producing many effects on living cells (Fletcher et al., 1993). Melittin has 
antibacterial activity, induces voltage-gated channel formation and can also produce 
micellization of phospholipids bilayers due to its membrane-interacting effect. This peptide 
is responsible for the direct hemolytic effect of Apis venom (Dempsey, 1990; Terra et al., 
2007). The enzyme phospholipase A2 represents approximately 11 % of whole venom and 
acts synergically with melittin. Once melittin has disrupted the membrane, phospholipase 
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A2 cleaves bonds in the fatty acid portion of the bilipid membrane layer (Vetter et al., 1999; 
Lee et al., 2001). In association, melittin and phospholipase A2, can act on erythrocytes, 
myocytes, hepatocytes, fibroblasts, mast cells, and leukocytes (Abdulkader et al., 2008; 
Fletcher et al., 1993; Habermann, 1972). Additionally, bee venom also has hyaluronidase (an 
enzyme that disrupts the hyaluronic acid in connective-tissue matrix), apamin (a 
neurotoxin), mast cell degranulating peptide (a peptide that releases histamine from mast 
cells) and other small molecules such as histamine, dopamine, and noradrenaline. Among 
all Apis mellifera venom components the main allergens are melittin, phospholipase A2 and 
hyaluronidase (Vetter et al., 1999). In wasp venoms the components are active amines 
(serotonin, histamine, tyramine, catecholamines); wasp kinins (similar in composition to 
bradykinin), which are mostly responsible for pain; and histamine-releasing peptides, which 
are responsible for the inflammatory response. The major allergens identified in wasp 
venoms are phospholipase A1, a hyaluronidase and a serine-protease (Pantera et al., 2003; 
Vetter et al., 1999).  
Despite the current knowledge on the composition of wasp venoms, little is known about 
the participation of its components, and even the whole venom, on the AKI observed in 
envenomed patients. On the other hand, the mechanisms of bee venom-induced AKI have 
been more explored in experimental models in vivo and in vitro. In the case of bee 
envenomation, the experimental injection of venom in rats caused a significant and early 
reduction in glomerular filtration rate and diuresis and an increase in plasma creatinine 
levels (dos Reis et al., 1997; Grisotto et al., 2006). Tubular alterations such as increased 
fractional sodium and potassium excretions and a reduced water transport through 
collecting tubules, were also described (dos Reis et al., 1997). The early glomerular filtration 
rate reduction was concomitant with marked cortical and medullary renal blood flow 
decrease (Grisotto et al., 2006). Neither hypertension and hypotension nor intravascular 
hemolysis were detected in experimental models. Despite of the absence of hemolysis, 
rhabdomyolysis was present with massive myoglobin deposition in the lumen of the tubules 
as well as into the tubular cells (dos Reis et al., 1997; Grisotto et al., 2006). The injection of 
purified melittin or phospholipase A2 also induced rhabdomyolysis, due to their capacity to 
disrupt the membranes of myocytes (Ownby et al., 1997). Additionally, in vitro studies have 
been demonstrated that bee venom is citotoxic to cultured isolated proximal tubule cells 
(Grisotto et al., 2006). Histological analysis showed acute tubular necrosis mainly in cortex 
and outer medulla, and cast formation in the distal and collecting tubules (dos Reis et al., 
1998). These degenerative lesions observed in AKI induced by the bee venom have been 
associated with the ischemic process induced by melittin, phospholipase A2 and histamine 
(Abdulkader et al., 2008; Grisotto et al., 2006). Indeed, melittin and phospholipase A2 may 
be related to impaired renal blood flow by causing direct vasoconstriction, smooth muscle 
cell contraction, increased renal renin secretion and release of vasoconstrictor eicosanoids 
and catecholamines. Histamine and the mast cell degranulating peptides present in the 
venom also play a role in renal blood flow decrease, since histamine can directly induce 
vascular changes (Cerne et al., 2010; Churchill et al., 1990).  
4.4 Lonomia venom 
Caterpillars of the species L. obliqua are well known in Southern Brazil by causing a severe 
hemorrhagic syndrome characterized by coagulation disorders, AKI and generalized 
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is responsible for the direct hemolytic effect of Apis venom (Dempsey, 1990; Terra et al., 
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A2 cleaves bonds in the fatty acid portion of the bilipid membrane layer (Vetter et al., 1999; 
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enzyme that disrupts the hyaluronic acid in connective-tissue matrix), apamin (a 
neurotoxin), mast cell degranulating peptide (a peptide that releases histamine from mast 
cells) and other small molecules such as histamine, dopamine, and noradrenaline. Among 
all Apis mellifera venom components the main allergens are melittin, phospholipase A2 and 
hyaluronidase (Vetter et al., 1999). In wasp venoms the components are active amines 
(serotonin, histamine, tyramine, catecholamines); wasp kinins (similar in composition to 
bradykinin), which are mostly responsible for pain; and histamine-releasing peptides, which 
are responsible for the inflammatory response. The major allergens identified in wasp 
venoms are phospholipase A1, a hyaluronidase and a serine-protease (Pantera et al., 2003; 
Vetter et al., 1999).  
Despite the current knowledge on the composition of wasp venoms, little is known about 
the participation of its components, and even the whole venom, on the AKI observed in 
envenomed patients. On the other hand, the mechanisms of bee venom-induced AKI have 
been more explored in experimental models in vivo and in vitro. In the case of bee 
envenomation, the experimental injection of venom in rats caused a significant and early 
reduction in glomerular filtration rate and diuresis and an increase in plasma creatinine 
levels (dos Reis et al., 1997; Grisotto et al., 2006). Tubular alterations such as increased 
fractional sodium and potassium excretions and a reduced water transport through 
collecting tubules, were also described (dos Reis et al., 1997). The early glomerular filtration 
rate reduction was concomitant with marked cortical and medullary renal blood flow 
decrease (Grisotto et al., 2006). Neither hypertension and hypotension nor intravascular 
hemolysis were detected in experimental models. Despite of the absence of hemolysis, 
rhabdomyolysis was present with massive myoglobin deposition in the lumen of the tubules 
as well as into the tubular cells (dos Reis et al., 1997; Grisotto et al., 2006). The injection of 
purified melittin or phospholipase A2 also induced rhabdomyolysis, due to their capacity to 
disrupt the membranes of myocytes (Ownby et al., 1997). Additionally, in vitro studies have 
been demonstrated that bee venom is citotoxic to cultured isolated proximal tubule cells 
(Grisotto et al., 2006). Histological analysis showed acute tubular necrosis mainly in cortex 
and outer medulla, and cast formation in the distal and collecting tubules (dos Reis et al., 
1998). These degenerative lesions observed in AKI induced by the bee venom have been 
associated with the ischemic process induced by melittin, phospholipase A2 and histamine 
(Abdulkader et al., 2008; Grisotto et al., 2006). Indeed, melittin and phospholipase A2 may 
be related to impaired renal blood flow by causing direct vasoconstriction, smooth muscle 
cell contraction, increased renal renin secretion and release of vasoconstrictor eicosanoids 
and catecholamines. Histamine and the mast cell degranulating peptides present in the 
venom also play a role in renal blood flow decrease, since histamine can directly induce 
vascular changes (Cerne et al., 2010; Churchill et al., 1990).  
4.4 Lonomia venom 
Caterpillars of the species L. obliqua are well known in Southern Brazil by causing a severe 
hemorrhagic syndrome characterized by coagulation disorders, AKI and generalized 
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hemorrhage. The venom is composed of several active principles, including procoagulant 
and fibrinolytic activities (Pinto et al., 2010). Even though many studies have been 
performed with toxic secretions from L. obliqua aiming a better elucidation of the 
hemorrhagic syndrome resulting from this envenomation, few active principles have been 
purified from the venom and fully characterized so far. Thus, most of the molecules 
identified in this caterpillar have been characterized as putative enzymes and other proteins 
based solely on cDNA and amino acid sequences obtained by transcriptomic and proteomic 
methods (Ricci-Silva et al., 2008; Veiga et al., 2005). Through these techniques, the major 
protein found in Lonomia is a biliverdin-binding protein of the lipocalin family, which is 
mainly concentrated in the bristles and plays an important role in the caterpillar’s 
camouflage behavior. Along with the lipocalin and other housekeeping proteins, L. obliqua’s 
integument, hemolymph and bristles produce and store a variety of active principles. 
Among these proteins, the most abundant ones are serine proteases and their inhibitors 
(serpins) in the integument, and serine proteases, kininogen and lectins in the bristles. 
Besides these molecules, cysteine proteinases, phospholipase A2, cystatins, Kazal-type 
inhibitors and other protease inhibitors are also found. Serine proteases are the most 
relevant protein family when considering their potential of interfering with blood 
coagulation. Moreover, serine proteases are an expressive group, representing 16.7 % and 25 
% of the clusters derived from tegument and bristle transcriptome, respectively (Veiga et al., 
2005). This protein group presents coagulation factors-like activities, so it is expected that 
these enzymes participate in the generation of thrombin, by activation of factor X and 
prothrombin (Berger et al., 2010a; Veiga et al., 2003), and in the activation of the fibrinolytic 
system, contributing directly and indirectly to fibrinogen degradation (Pinto et al., 2006) and 
resulting in the hemorrhagic disorder. In fact, proteases with fibrinogenolytic, prothrombin 
and factor X activating activities have been purified and characterized in this venom 
(Alvarez-Flores et al., 2006; Pinto et al., 2004; Reis et al., 2006). The phospholipase A2 
enzyme also has a function in envenomation. This enzyme was isolated and characterized 
as the major component responsible to the in vitro and in vivo hemolytic activity of L. 
obliqua venom (Seibert et al., 2004; Seibert et al., 2006). Additionally, the phospholipase A2 
seems to be involved in platelet aggregation inducing activity present in the venom 
(Berger et al., 2010b). Lectins, particularly c-type lectins, are a relatively well-studied 
group of proteins in snake venoms that may exert an additional function in hemostasis 
modulation by interacting with coagulations factors and/or platelet receptors. Three 
lectin clusters were found in the bristle cDNA library with homology to many snake 
venom lectins being then another important candidate contributing to the hemorrhagic 
disorder (Veiga et al., 2005). 
Although AKI is the leading cause of death in L. obliqua envenomation, the mechanisms 
involved in kidney disorders are poorly understood. In contrast to hemostatic disturbances, 
to date, there is no experimental studies describing the renal effects of L. obliqua venom. 
Current knowledge is based only on a few case reports in which hematuria, high levels of 
serum creatinine and acute tubular necrosis are described as the main features of L. obliqua 
induced AKI. Due to this lack of knowledge, nowadays we are focused on the investigation 
of the effects of L. obliqua venom on renal function in rats. Preliminary results, indicate that 
subcutaneous injection of L. obliqua bristle extract caused severe hematuria with the 
presence of intact erythrocytes and leukocytes in urinary sediment (Berger et al., 
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unpublished data). Envenomed animals also show proteinuria and significant changes in 
glomerular filtration rate and tubular electrolytic transport (Berger et al., unpublished data). 
Currently, the contribution of intravascular coagulation, deposits of hemoglobin in renal 
tubules and hemodynamic changes are under investigation. 
5. Diagnosis and management of acute kidney injury in snake and arthropod 
envenomation 
The early intravenous administration of animal-derived antivenoms is the only specific 
treatment against snake and arthropod envenomations. Antivenoms are concentrated of 
immunoglobulins (usually pepsin-refined F(ab’)2 fragment of whole IgG) purified from the 
plasma of a horse or sheep that has been immunized with the venoms of one or more 
species of venomous animal (WHO, 2010a). The preparation of antivenoms is expensive and 
technically demanding. Around the world different manufacturers, which include public 
and private laboratories of diverse sizes and strengths, are able to produce the antivenoms 
(Gutiérrez et al., 2010; Williams et al., 2010). Some of them are small facilities, mostly located 
in public institutions, which manufacture for the needs of specific countries. Others are 
larger laboratories that manufacture and distribute antivenoms throughout various 
countries or regions. Although some countries or regions manufacture enough antivenom 
for their national and regional needs, as in Europe, USA, Brazil, Central America, Mexico, 
Australia, Thailand and Japan, in other parts of the world, specially in some regions of 
Africa, there are very few antivenom producers (Gutiérrez et al., 2010). In Brazil, three main 
Institutions are responsible for production of antivenoms: Instituto Butantan, Fundação 
Ezequiel Dias and Hospital Vital Brasil. The manufacture is government-subsidized and the 
antivenom is usually provided free to the patients. However, failures in the distribution of 
antivenoms to places where they are needed still contribute to the maintenance of high 
mortality rates (Table 1). In some instances, antivenoms are held in the main cities, where 
envenomations are rare, instead of being distributed to peripheral health clinics in rural 
areas where the accidents are frequent. This reflects defective distribution planning which is 
associated with a lack of coordination between those who understand the epidemiological 
pattern of the disease and those responsible for the antivenom distribution. Also, inadequate 
storage and transportation of antivenoms may result in physical destruction of vials and 
ampoules (e.g. by freezing of liquid antivenom) (WHO, 2010a). Besides the inadequate 
supply, distribution and accessibility to safe and effective antivenoms, another major issue is 
the lack of trained of health workers on how to use these products and how to conduct 
appropriate clinical management of medical emergencies. In fact, it is estimated that in 
Brazil in 2009, 37% of accidents with scorpions and 9% of accidents with spiders received 
inadequate treatment with antivenom, mainly because the health authorities are uninformed 
of the treatment protocols (Boletim eletrônico epidemiológico, 2010).   
The treatment with antivenom is indicated in moderate and severe cases when systemic 
signs of envenomation are observed. In general, patients with hemostatic abnormalities, 
neurotoxic signs, cardiovascular abnormalities, AKI, hemoglobinuria and myoglobinuria 
should receive antivenom therapy (WHO, 2010a). In these cases the time elapsed between 
the occurrence of the accident and administration of a correct dose of antivenom is decisive 
for a sucessful therapy. It was demonstrated that the time interval between the accident and 
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hemorrhage. The venom is composed of several active principles, including procoagulant 
and fibrinolytic activities (Pinto et al., 2010). Even though many studies have been 
performed with toxic secretions from L. obliqua aiming a better elucidation of the 
hemorrhagic syndrome resulting from this envenomation, few active principles have been 
purified from the venom and fully characterized so far. Thus, most of the molecules 
identified in this caterpillar have been characterized as putative enzymes and other proteins 
based solely on cDNA and amino acid sequences obtained by transcriptomic and proteomic 
methods (Ricci-Silva et al., 2008; Veiga et al., 2005). Through these techniques, the major 
protein found in Lonomia is a biliverdin-binding protein of the lipocalin family, which is 
mainly concentrated in the bristles and plays an important role in the caterpillar’s 
camouflage behavior. Along with the lipocalin and other housekeeping proteins, L. obliqua’s 
integument, hemolymph and bristles produce and store a variety of active principles. 
Among these proteins, the most abundant ones are serine proteases and their inhibitors 
(serpins) in the integument, and serine proteases, kininogen and lectins in the bristles. 
Besides these molecules, cysteine proteinases, phospholipase A2, cystatins, Kazal-type 
inhibitors and other protease inhibitors are also found. Serine proteases are the most 
relevant protein family when considering their potential of interfering with blood 
coagulation. Moreover, serine proteases are an expressive group, representing 16.7 % and 25 
% of the clusters derived from tegument and bristle transcriptome, respectively (Veiga et al., 
2005). This protein group presents coagulation factors-like activities, so it is expected that 
these enzymes participate in the generation of thrombin, by activation of factor X and 
prothrombin (Berger et al., 2010a; Veiga et al., 2003), and in the activation of the fibrinolytic 
system, contributing directly and indirectly to fibrinogen degradation (Pinto et al., 2006) and 
resulting in the hemorrhagic disorder. In fact, proteases with fibrinogenolytic, prothrombin 
and factor X activating activities have been purified and characterized in this venom 
(Alvarez-Flores et al., 2006; Pinto et al., 2004; Reis et al., 2006). The phospholipase A2 
enzyme also has a function in envenomation. This enzyme was isolated and characterized 
as the major component responsible to the in vitro and in vivo hemolytic activity of L. 
obliqua venom (Seibert et al., 2004; Seibert et al., 2006). Additionally, the phospholipase A2 
seems to be involved in platelet aggregation inducing activity present in the venom 
(Berger et al., 2010b). Lectins, particularly c-type lectins, are a relatively well-studied 
group of proteins in snake venoms that may exert an additional function in hemostasis 
modulation by interacting with coagulations factors and/or platelet receptors. Three 
lectin clusters were found in the bristle cDNA library with homology to many snake 
venom lectins being then another important candidate contributing to the hemorrhagic 
disorder (Veiga et al., 2005). 
Although AKI is the leading cause of death in L. obliqua envenomation, the mechanisms 
involved in kidney disorders are poorly understood. In contrast to hemostatic disturbances, 
to date, there is no experimental studies describing the renal effects of L. obliqua venom. 
Current knowledge is based only on a few case reports in which hematuria, high levels of 
serum creatinine and acute tubular necrosis are described as the main features of L. obliqua 
induced AKI. Due to this lack of knowledge, nowadays we are focused on the investigation 
of the effects of L. obliqua venom on renal function in rats. Preliminary results, indicate that 
subcutaneous injection of L. obliqua bristle extract caused severe hematuria with the 
presence of intact erythrocytes and leukocytes in urinary sediment (Berger et al., 
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unpublished data). Envenomed animals also show proteinuria and significant changes in 
glomerular filtration rate and tubular electrolytic transport (Berger et al., unpublished data). 
Currently, the contribution of intravascular coagulation, deposits of hemoglobin in renal 
tubules and hemodynamic changes are under investigation. 
5. Diagnosis and management of acute kidney injury in snake and arthropod 
envenomation 
The early intravenous administration of animal-derived antivenoms is the only specific 
treatment against snake and arthropod envenomations. Antivenoms are concentrated of 
immunoglobulins (usually pepsin-refined F(ab’)2 fragment of whole IgG) purified from the 
plasma of a horse or sheep that has been immunized with the venoms of one or more 
species of venomous animal (WHO, 2010a). The preparation of antivenoms is expensive and 
technically demanding. Around the world different manufacturers, which include public 
and private laboratories of diverse sizes and strengths, are able to produce the antivenoms 
(Gutiérrez et al., 2010; Williams et al., 2010). Some of them are small facilities, mostly located 
in public institutions, which manufacture for the needs of specific countries. Others are 
larger laboratories that manufacture and distribute antivenoms throughout various 
countries or regions. Although some countries or regions manufacture enough antivenom 
for their national and regional needs, as in Europe, USA, Brazil, Central America, Mexico, 
Australia, Thailand and Japan, in other parts of the world, specially in some regions of 
Africa, there are very few antivenom producers (Gutiérrez et al., 2010). In Brazil, three main 
Institutions are responsible for production of antivenoms: Instituto Butantan, Fundação 
Ezequiel Dias and Hospital Vital Brasil. The manufacture is government-subsidized and the 
antivenom is usually provided free to the patients. However, failures in the distribution of 
antivenoms to places where they are needed still contribute to the maintenance of high 
mortality rates (Table 1). In some instances, antivenoms are held in the main cities, where 
envenomations are rare, instead of being distributed to peripheral health clinics in rural 
areas where the accidents are frequent. This reflects defective distribution planning which is 
associated with a lack of coordination between those who understand the epidemiological 
pattern of the disease and those responsible for the antivenom distribution. Also, inadequate 
storage and transportation of antivenoms may result in physical destruction of vials and 
ampoules (e.g. by freezing of liquid antivenom) (WHO, 2010a). Besides the inadequate 
supply, distribution and accessibility to safe and effective antivenoms, another major issue is 
the lack of trained of health workers on how to use these products and how to conduct 
appropriate clinical management of medical emergencies. In fact, it is estimated that in 
Brazil in 2009, 37% of accidents with scorpions and 9% of accidents with spiders received 
inadequate treatment with antivenom, mainly because the health authorities are uninformed 
of the treatment protocols (Boletim eletrônico epidemiológico, 2010).   
The treatment with antivenom is indicated in moderate and severe cases when systemic 
signs of envenomation are observed. In general, patients with hemostatic abnormalities, 
neurotoxic signs, cardiovascular abnormalities, AKI, hemoglobinuria and myoglobinuria 
should receive antivenom therapy (WHO, 2010a). In these cases the time elapsed between 
the occurrence of the accident and administration of a correct dose of antivenom is decisive 
for a sucessful therapy. It was demonstrated that the time interval between the accident and 
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administration of the antivenom of more than 2 hours was associated with the development 
of AKI, as well as with the risk of death or permanent injuries after Bothrops and Crotalus 
envenomations (Otero et al., 2002; Pinho et al., 2005). Although the correct use of antivenom 
is an effective form of treatment, the sorotherapy is also associated with the occurrence of 
severe adverse effects. The most serious adverse effect is anaphylactic reactions. Clinical 
features such as urticaria, itching, fever, tachycardia, vomiting, abdominal colic, headache, 
bronchospasm, hypotension and angioedema have been described after antivenom 
treatment (Fan et al., 1999; Ministério da Saúde, 2001). The incidence of adverse effects 
depends on the quality, dose and speed of intravenous injection or infusion. With 
antivenoms of good quality profile, there is a low incidence (less than 10%) of generally mild 
adverse reactions, mostly urticaria and itching. However, for products containing 
contaminant proteins, the incidence of such reactions may be as high as 85 %, including 
potentially life-threatening systemic disturbances such as hypotension and bronchospasm 
(WHO, 2007). Thus the adverse effects are directly associated with lack of good 
manufacturing practices adopted by laboratories that manufacture antivenoms. Recently, in 
an attempt to improve the quality of antivenom production the WHO established the 
guidelines for production, control and regulation of snake antivenom immunoglobulins. 
These guidelines provide detailed information on the recommended steps for antivenom 
manufacture and control (WHO, 2010b).   
A number of additional interventions besides antivenom  may be necessary to restore renal 
function in patients who developed AKI. Special attention should be given to hypotension, 
shock, electrolyte balance and maintenance of an adequate state of hydration. An urinary 
flow of 30 to 40 mL/h/kg is recommended for adults and 1 to 3 mL/h/kg for children to 
prevent AKI after snake envenomations (Ministério da Saúde, 2001; Pinho et al., 2008). 
Patients presenting oliguria or anuria, despite of fluid administration, are usually treated 
with intravenous furosemide or mannitol (WHO, 2010a). In these cases, a higher urinary 
flow may decrease the expousure of tubular cells to venom components and myoglobin or 
hemoglobin, which result in injury attenuation and prevention of tubular lumen obstruction 
(Zager, 1996). Cases that are unresponsive to fluid intake and diuretics are referred to renal 
units for dialysis (Pinho et al., 2008). Early alkalinization of urine by sodium bicarbonate in 
patients with myoglobinuria or hemoglobinuria is also recommended, because in the 
presence of acidic urine, myoglobin and uric acid precipitate and form obstructive cast 
(Khan, 2009). 
6. Conclusion 
Envenomation by different venomous snakes and arthropods is a neglected disease that 
afflicts the most impoverished inhabitants of rural areas in tropical developing countries. In 
this chapter, we reviewed some important aspects related to epidemiology, prevalence, 
clinical manifestations, pathophysiology and treatment of venom-induced AKI, which is one 
of the most significant and lethal effect of animal venoms. Despite of actual knowledge 
discussed here, several aspects involving the renal manifestations remain still unclear. Thus, 
further research are needed to cover the following key points: (i) biochemical composition of 
different animal venoms and their individual contribution to renal injury; (ii) renal 
pathological mechanisms induced by some specific venoms that are still unexplored; (iii) 
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discovery of new and more specific therapeutic alternatives to treat envenomation cases and 
(iv) improvement in the production, distribution and availability of the antivenoms 
currently used. 
7. Acknowledgments 
The authors are grateful to Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, 
Ministério da Educação, Brasil (CAPES-MEC) and Conselho Nacional de Desenvolvimento 
Científico e Tecnológico, Ministério da Ciência e Tecnologia, Brasil (CNPq-MCT) for 
funding and fellowships. 
8. References 
Abella, H.B; Marques, M.G.B.; Silva, K.R.L.M.; Rossoni, M.G. & Torres, J.B. (2006). Acidentes 
com lagartas do gênero Lonomia registrados no Centro de Informação Toxicológica 
do Rio Grande do Sul no período de 1997 a 2005, In: Nicolella, A. (Ed.), 
Toxicovogilância – toxicologia clínica: dados e indicadores selecionados. Secretaria da 
Saúde. Fundação Estadual de Produção e Pesquisa em Saúde. Centro de 
Informação Toxicológica, Porto Alegre, pp. 29-34. 
Abdulkader, R.C.; Barbaro, K.C.; Barros, E.J. & Burdmann, E.A. (2008). Nephrotoxicity of 
insect and spider venoms in Latin America. Seminars in Nephrology. Vol.28, No.4, 
pp. 373-82. 
Alegre, V.S.; Barone, J.M.; Yamasaki, S.C.; Zambotti-Villela, L. & Silveira, P.F. (2010). Lipoic 
acid effects on renal function, aminopeptidase activities and oxidative stress in 
Crotalus durissus terrificus envenomation in mice. Toxicon. Vol.56, No.3, pp.402-10. 
Alvarez-Flores, M.P.; Fritzen, M.; Reis, C.V. & Chudzinski-Tavassi, A.M. (2006). Losac, a 
factor X activator from Lonomia obliqua bristle extract: its role in the 
pathophysiological mechanisms and cell survival. Biochemical and Biophysical 
Research Communications. Vol. 343, No. 4, pp. 1216-23.  
Alves da Silva, J.A.; Oliveira, K.C. & Camillo, M.A. (2011). Gyroxin increases blood-brain 
barrier permeability to Evans blue dye in mice. Toxicon. Vol.57, No.1, pp.162-7. 
Amaral, C.F.; de Rezende, N.A.; da Silva, O.A.; Ribeiro, M.M.; Magalhães, R.A.; dos Reis, 
R.J.; Carneiro, J.G. & Castro, J.R. (1986). Acute kidney failure secondary to ophidian 
bothropic and crotalid accidents. Analysis of 63 cases. Revista do Instituto de 
Medicina Tropical de Sao Paulo. Vol.28, No.4, pp. 220-7. 
Arocha-Piñango, C.L.; Marval, E. & Guerrero, B. (2000). Lonomia genus caterpillar toxins: 
biochemical aspects. Biochimie. Vol.82, No.9-10, pp.937-42. 
Azevedo-Marques, M.M.; Cupo, P.; Coimbra, T.M.; Hering, S.E.; Rossi, M.A. & Laure, C.J. 
(1985). Myonecrosis, myoglobinuria and acute renal failure induced by South 
American rattlesnake (Crotalus durissus terrificus) envenomation in Brazil. Toxicon. 
Vol.23, No.4, pp. 631-6. 
Azevedo-Marques, M.M.; Hering, S.E. & Cupo, P. (1987). Evidence that Crotalus durissus 
terrificus (South American rattlesnake) envenomation in humans causes myolysis 
rather than hemolysis. Toxicon. Vol.25, No.11, pp. 1163-8. 
Barbosa, P.S.; Martins, A.M.; Havt, A.; Toyama, D.O.; Evangelista, J.S.; Ferreira, D.P.; 
Joazeiro, P.P.; Beriam, L.O.; Toyama, M.H.; Fonteles, M.C. & Monteiro, H.S. (2005). 
 
Renal Failure – The Facts 
 
176 
administration of the antivenom of more than 2 hours was associated with the development 
of AKI, as well as with the risk of death or permanent injuries after Bothrops and Crotalus 
envenomations (Otero et al., 2002; Pinho et al., 2005). Although the correct use of antivenom 
is an effective form of treatment, the sorotherapy is also associated with the occurrence of 
severe adverse effects. The most serious adverse effect is anaphylactic reactions. Clinical 
features such as urticaria, itching, fever, tachycardia, vomiting, abdominal colic, headache, 
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hemoglobin, which result in injury attenuation and prevention of tubular lumen obstruction 
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units for dialysis (Pinho et al., 2008). Early alkalinization of urine by sodium bicarbonate in 
patients with myoglobinuria or hemoglobinuria is also recommended, because in the 
presence of acidic urine, myoglobin and uric acid precipitate and form obstructive cast 
(Khan, 2009). 
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of the most significant and lethal effect of animal venoms. Despite of actual knowledge 
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1. Introduction   
Contrast-induced nephropathy (CIN) is defined as acute deterioration of renal function after 
intravascular administration of iodinated contrast agents, in the absence of other causes. 
Laboratory diagnosis is expressed as an increase in serum creatinine levels of 0.5 mg/dL (or 
44 μmol/L) or a 25% or greater relative increase from baseline 48-72 hours after a diagnostic 
or interventional procedure, even if the clinical significance of this definition in the absence 
of pre-existing renal failure is questionable (Thomsen & Morcos, 2006). 
The Acute Kidney Injury (AKI) Network was estabilished in 2007 to study the improvement 
of outcomes associated with various forms of acute renal failure; recently, it has expressed 
the hope that the diagnostic criteria for all cases of acute kidney injury are standardized in 
sudden reduction (within 48 hours) of renal function with a serum creatinine increase ≥ 0.3 
mg/dL or a 50% or greater increase from baseline, or after onset of oligoanuria (urinary 
output < 0.5 mL/kg/hour for 6 hours) (Mehta et al., 2007).  
However, there is no consensus in bringing CIN parameters in AKI criteria, because contrast 
medium damage usually causes a serum creatinine peak on the third-fifth day after contrast 
medium exposure, and rarely occurs with oligoanuria, except in patients with advanced 
impairment of renal function (Detrenis et al., 2007a). Nevertheless, recent literature uses the 
term “radiocontrast-induced acute kidney injury” (RCI-AKI) rather than CIN, although the 
clinical implications of different definitions have never been tested on a large scale 
(Goldfarb et al., 2009). 
2. Epidemiology 
RCI-AKI is today the third nosographic entity related to hospital-acquired acute renal 
failure, after organ hypoperfusion and nephrotoxic drugs (eg, nonsteroidal anti-
inflammatory drugs) (Nash et al, 2002). RCI-AKI incidence is significantly greater in the 
case of intra-arterial (from 10-20% for moderate to 25-70% for high-risk patients; 0.15-
2.30% in general population) compared to intravenous administration (~5%) (Detrenis et 
al., 2007a). 
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The probability of renal replacement therapy is closely related to individual patient 
comorbidities, but it is reasonable to assume that it varies from less than 1% of all patients 
undergoing percutaneous coronary intervention to 10%of those with pre-existing alteration 
in renal function parameters who have RCI-AKI after coronary angiography (Meschi et al., 
2006). In other words, the probability of RCI-AKI requiring dialysis increases from 0.04 to 
48% if measured glomerular filtration rate is reduced from 50 to 10 mL/min; on the other 
hand, 13-50% of subjects undergoing dialysis after RCI-AKI tends to prolong renal 
replacement therapy definitively (Toprak, 2007).    
As in general for nephropatic patients, even for those affected by RCI-AKI the incidence of 
associated cardiovascular events or major adverse cardiac effects was assessed: a study on 
16.000 hospitalized subjects who underwent coronary angiography (Levy et al., 1996) shows 
that those with RCI-AKI develop a risk for complications and death 5-fold higher than in 
controls, even after data correction for any existing comorbidities. Even for the majority of 
cases, with benign clinical course (pre-existing serum creatinine values restoration in 1-3 
weeks, no symptoms or dialysis), there was a significant increase in 1- and 5-years mortality 
(Rihal et al., 2002). This evidence is greater for cases with unfavourable renal prognosis 
requiring temporary renal replacement therapy (McCullough et al., 1997).  
Consequently, even if the pathophysiological relationship between contrast nephropathy, 
morbidity and mortality it is not clear, RCI-AKI is today definitely considered an 
independent predictor for long term mortality. It is possible to hypothesize that the 
pathogenic process underlying RCI-AKI may interfere with pro-atherogenic mechanisms of 
cardiovascular disease, although there are no definitive studies on this issue (Detrenis et al., 
2005). 
3. Risk markers for contrast nephropathy 
The pathogenetic events underlying RCI-AKI are still not completely understood and the 
identification of “risk factors” for disease is difficult, because the term usually refers to a 
medical condition or nosographic entity associated with a therapeutic intervention or 
preventive approach. It is therefore considered that the term “marker” is more useful to 
identify patients predisposed to acute deterioration of renal function in this context, due to 
specific pathophysiological features (Toprak, 2007).  
In one third of cases, these markers do not correspond to changeable conditions. Instead, the 
early recognition of remaining situations becomes a prerequisite to the use of prophylactic 
protocols. Even in the absence of incontrovertible evidence, these protocols have shown a 
variable reduction in the incidence of RCI-AKI during prospective or retrospective studies 
(Toprak, 2007) (Fig. 1). 
3.1 Advancing age, chronic nephropathy and accurate assessment of renal function  
Between markers of risk, the reduction in renal function before the administration of 
iodinated contrast medium plays a predominant significance, particularly if baseline 
glomerular filtration rate values are < 60 mL/min/1.73 m2, that is in the course of 
chronic kidney disease at stage 3, 4, 5 for the National Kidney Foundation (Nelson & 
Tuttle, 2007). 
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The decrease of renal function can not be revealed by routine measurement of  serum 
creatinine, because there is an inverse, non-linear relationship between serum creatinine 
(varying with the muscle mass, age and sex of the patient) and corresponding glomerular 
filtration rate. In any case, glomerular filtration rate tends to decrease progressively with 
increasing age and can be measured indirectly by creatinine clearance (Detrenis et al., 
2007b). A recent analysis of more than 20000 patients undergoing coronary angiography 
showed that there is a significantly higher incidence of RCI-AKI in the elderly, especially 
women, who usually have a net reduction of glomerular filtration rate even when there is an 
apparently normal serum creatinine. Indeed, a relative reduction in muscle mass is 
frequently observed in these subjects (Sidhu et al., 2008) (Fig. 2). 
 
Fig. 1. Risk markers for contrast nephropathy 
When the creatinine clearance (1) is not easily achieved trough the urinary output collection, 
so-called MDRD or Levey equation (from the Modification of Diet in Renal Disease Study) 
(2) can be used to estimate glomerular filtration rate (Levey et al., 1999). However, the 
simple evaluation of creatinine clearance by classical Cockcroft and Gault formula (3), which 
consider daily urinary creatinine and only requires knowledge of body weight, age and sex 
of the patient, it is appropriate to clinical practice (Cockcroft & Gault, 1976). 
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Cystatin C, produced at a constant rate by nucleated cells and released into circulation 
(normal values <0.95 mg/L in subjects aged < 45 years, up to 1.2 mg/L in older), was 
recently identified as a marker of renal injury early and easily measurable. It is freely filtered 
by the glomerulus and completely reabsorbed and metabolized, but not secreted by cells of 
the proximal tubule. Furthermore, it is not subject to significant urinary excretion, and is not 
affected by gender or muscle mass of the patient (Perkins et al., 2005). 
Some studies have used direct measurements of glomerular filtration rate as a gold standard 
to compare the use of cystatin C with serum creatinine and serum creatinine-based 
assessments, demostrating the superiority of the former especially in diabetic patients 
(Perkins et al., 2005). 
The data on clinical use of this method, however, are controversial. The serum 
concentrations of cystatin C identify a condition of preclinical renal damage earlier than 
other laboratory parameters, and are also a possible risk marker for heart failure and other 
cardiovascular events in elderly patients. On the contrary, is not yet clear the real influence 
of other factors (cigarette smoking, thyroid disease, high levels of C-reactive protein, 
corticosteroid therapy) on these measurements (Burkhardt et al., 2002). 
In other words, the accuracy of this diagnostic test has been documented when the 
sensitivity of serum creatinine measurement is reduced. However, cystatin C can be 
interpreted not only as a marker of renal function, but also as generic indicator of 
inflammatory processes (Burkhardt et al., 2002). In addition, quantitative data on extrarenal 
clearance of the molecule are not available. Therefore, because its early serum increase 
(within 24 hours after contrast administration) it could be a useful parameter for RCI-AKI 
after angiographic procedures, but requires further prospective evaluation for large-scale 
use (Detrenis et al., 2007b). 
 
Fig. 2. Serum creatinine, creatinine clearance and age. 1: male, 60 kg, 40 years. 2: female, 60 
kg, 40 years. 3: male, 60 kg, 60 years. 4: male, 60 kg, 80  years. 5: male, 60 kg, 90 years 
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3.2 Impaired fasting glucose, diabetes mellitus and its complications 
Between changes in carbohydrate, lipid and protein profile (dyslipidemia, hyperuricemia, 
metabolic syndrome), diabetes mellitus – according to definition in use, two measurements 
of fasting plasma glucose > 126 mg/dL – does not seem constitute an additional risk for 
RCI-AKI in itself, but only if there is consequent impairment of renal function (Parfrey PS et 
al., 1989). 
Conversely, a prospective evaluation suggests a slight, but significant increase in the 
incidence of RCI-AKI in diabetic, non-nephropatic subjects, and even for those with 
impaired fasting glucose, compared to the general population (Toprak et al., 2007). 
This is consistent with the hypothesis that the so-called endothelial dysfunction contributes 
to development of disease. In fact, it is present in all the above conditions of dysglycemia. At 
the level of the renal glomerulus, it leads to reduced availability of vasodilatory substances, 
such as nitric oxide and prostaglandins, which are synthesized in the endothelium. In this 
way, the renal ischemia associated with administration of iodinated contrast is encouraged, 
through the role of oxygen free radicals, which are able to induce the formation of reactive 
species in enzymes and membrane protein structures, using mechanisms of nitrosylation 
and oxidation (Detrenis et al., 2005). 
3.3 Dehydration and relative hypovolemia 
Even patients with heart failure and low cardiac output leading to reduced renal perfusion 
should be considered at increased risk for RCI-AKI (Thomsen & Morcos, 2003). This 
condition may worsen hypoxia and ischemia of the kidney caused by iodinated contrast 
agents. After an initial vasodilation, contrast media lead to a prolonged vasoconstriction in the 
medulla of the nephron, which already is less perfused than the cortex (Detrenis et al., 2005). 
Subjects with the effective blood volume depletion, peripheral hypoperfusion, hypotension 
can be found under the same conditions. A similar trend is observed during sepsis, liver 
disease with severe hypoalbuminemia and dysproteinaemia, or in severe protein loss from 
any cause (Savazzi et al., 1997). 
Periprocedural hydration and consequent volume expansion of the patient appear as the 
only safe options for RCI-AKI prophylaxis. They stimulate physiological diuresis and dilute 
concentrations of contrast medium and circulating mediators of vasoconstriction (adenosine, 
endothelin, angiotensin II). Therefore, true effectiveness of parenteral infusion protocols 
does not depend on the characteristics of the fluids used, or peculiar infusion rate. The use 
of solutions of sodium bicarbonate (154 mEq/L, 3 mL/kg/hour to 1 hour before the 
procedure, 1 mL/kg/ hour in the next 6 hours) (Merten et al., 2004) or isotonic saline (1 
mL/kg/hour, 12 hours before and 12 hours after the procedure) (Mueller et al., 2002) is 
designed to correct the evident or latent depletion of the extra- and intracellular body 
compartments (Meschi et al., 2006). 
4. Iodinated contrast media and other drugs 
High-osmolal appear to be more nephrotoxic than current low-osmolal contrast media and 
recent iso-osmolal dimers, which did not demonstrate a favorable cost-effectiveness ratio 
(Savazzi et al., 2005; Detrenis et al., 2007c). 
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Although the CM-induced renal damage is dose-dependent, the volume below which the 
risk is reduced has not been identified, particularly when there is a preexisting decrease in 
renal function associated with diabetes (Meschi et al., 2006). 
The intra-arterial route of administration (eg, interventional cardiology) is associated with 
an increased risk of RCI-AKI that the intravenous (eg, computed tomography), especially 
when examinations are repeated in succession at an interval of time less than 72 hours 
(Detrenis et al., 2007a). 
In the case of concomitant use of contrast media, it is mandatory to avoid traditional 
nephrotoxic drugs (eg aminoglycosides), as well as nonsteroidal anti-inflammatory drugs, 
which can reduce the filtrate due to inhibition of intrarenal vasodilatation (Meschi et al., 
2006). 
The continuous treatment with agents that interfere with the renin-angiotensin system 
(angiotensin converting enzyme inhibitors, angiotensin receptor antagonists) contribute to 
the increase in the incidence of RCI-AKI in patients with chronic kidney disease. In fact, they 
cause efferent arteriolar vasodilation and thus the relative reduction of pressure within the 
glomerulus. According to some evidence, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers and diuretics should be discontinued the day before and day 
of the procedure with contrast, and should be taken after 2 days, unless contraindicated 
(Komenda et al., 2007; Cirit et al., 2006). However, more recent studies refute the efficacy of 
withdrawal (Rosenstock et al., 2008); on the contrary, telmisartan may play a protective role, 
at least in animals (Duan et al., 2009). 
Extreme caution must be observed in the administration of contrast media in patients with 
diabetes treated with metformin. In fact, renal failure caused or worsened by concomitant 
AKI-RCI tends to result in a significant accumulation of biguanide, with possible 
development of lactic acidosis (Thomsen & Morcos, 1999). 
5. The myth of monoclonal gammopathies 
Until a few years ago, many clinicians prescribing the so called "screening for Bence Jones 
proteinuria" before performing an examination with contrast medium (Strada et al., 2008).  
Many laboratories provided (and still provide) a report in mg/dL, compared with a normal 
range (0 – 0.8 mg/dL). With this system, “Bence Jones proteinuria” greater than 0.8 mg/dL 
was defined as positive. 
Many criticisms can be conducted in this model. Under normal conditions, immunoglobulin 
light chains (kappa, lambda) are freely filtered by the glomerulus and subsequently 
reabsorbed from the tubule to 99%. A normal urinary excretion of light chains is estimated 
at 20-40 mg per day (Strada et al., 2008). This amount increases significantly in case of 
impaired tubular reabsorption, for example during tubule-interstitial nephropathy, but 
concerns polyclonal light chains that are not of neoplastic origin.  
On the contrary, the real Bence Jones protein was first described in 1962 as "consisting of 
monoclonal light chains" and produced by a single clone of B lymphocytes. It appears in the 
urine when the efficiency of tubular reabsorption is saturated, as in the course of diseases 
such as multiple myeloma, Waldenstrom's macroglobulinemia and lymphoproliferative 
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disorders (Strada et al., 2008).   For this reason, a pathological parameter (M monoclonal 
component), which under normal conditions should not be detected, can not be expressed in 
a range defined as physiological (0 – 0.8 mg/dL). 
Moreover, despite the monoclonal gammopathies have been reported as risk markers for 
RCI-AKI for a long time, all the reviews of the scientific literature indicate that the 
association between the two comorbidities occurs only if a severe depletion of water and 
blood volume of the patient is demonstrated, or when the hematological malignancy has led 
to renal failure or hypercalcemic syndrome. 
Thus, the monoclonal gammopathies should not be considered as primary contributing 
factors of the RCI-AKI, and screening of the so-called Bence Jones proteinuria has no clinical 
significance in patients undergoing contrast media (Meschi et al., 2006; Toprak, 2007). The 
presence of monoclonal gammopathy should be considered critically and the procedure 
with contrast medium, when necessary, can be implemented after evaluating volume, fluid 
and electrolyte status and renal function of the patient (Fig. 3). 
 
Fig. 3. Management of the patient undergoing contrast medium examination. 
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1. Introduction 
Acute kidney injury is a serious clinical problem with significant morbidity and mortality. 
Several factors are recognized to aggravate the outcome including advanced age, gender, 
oliguria and the serum creatinine level. What is currently unknown is whether the presence 
of the human immunodeficiency virus (HIV) aggravates the outcome of patients who 
develop acute kidney injury (AKI). Sub-Saharan Africa currently bears the brunt of the 
global HIV pandemic. In South Africa alone more than 5.7 million people are infected 
((UNAIDS 2008 report on the global AIDS epidemic, 2009), creating substantial additional 
pressure on already inadequate social and healthcare infrastructures. Acute kidney injury 
occurs commonly in HIV-infected patients admitted to hospital and carries with it 
substantial mortality. In a resource-poor environment clinicians are often forced to select 
patients with a better chance of survival for admission to the intensive care unit (ICU). A 
rigorous evaluation of the outcomes of HIV-positive patients admitted to ICU with AKI may 
assist in identifying factors associated with better survival, and thus aid in the cost-effective 
management of these patients. 
2. Description of the conditions involved  
2.1 Acute kidney injury 
Acute kidney injury is characterized by a sudden reduction in glomerular filtration rate and 
is expressed clinically as azotemia with or without accompanying oliguria. Research on the 
outcomes of patients with AKI has been hampered by the absence of uniformity in the 
definition of the condition. With more than 35 different definitions being used before 2002, 
clinicians battled a bewildering array of reports varying in severity and mortality rates for 
patients (Ronco et al, 2010). In order to create some uniformity, the Acute Dialysis Quality 
Initiative formulated a consensus definition, the RIFLE criteria which were published in 
2004. In a subsequent review, The Acute Kidney Injury network (AKIN) proposed minor 
modifications to the RIFLE system. This included the use of the term acute kidney injury instead 
of acute renal failure, recognizing that kidney injure does not always result in failure or the need 
for renal replacement therapy, but that even minor injury can have severe consequences, 
especially in severely ill patients, including HIV-infected patients. 
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The mortality of AKI remains high and is of the order of 50% in hospitalized patients who 
require dialysis (Metcalfe et al, 2002). ICU patients with multi-organ failure have mortality 
rates approaching 90%, despite improvements in the management of these patients (Uchino 
et al, 2005).  
AKI is common in HIV-infected patients admitted to hospital, with a published occurrence 
rate of 5.9 per 100 person years in developed countries (Franceschini et al, 2005).  More than 
50% of episodes are attributed to infection. Most patients have pre-renal failure, often 
resulting in acute tubular necrosis from sepsis and fluid depletion because of vomiting, 
diarrhea and poor intake (Williams et al, 1998). There are little reliable data available on the 
causes and incidence of acute HIV-related kidney injury in Africa, but it is clear that a 
different pattern of presentation from the developed world is observed. Patients are 
frequently previously well young black adults who present with overwhelming 
opportunistic infections. In a Cape Town-based study this has lead to a 500% escalation in 
the provision of acute dialysis to HIV-infected patients over a 6 year period (Arendse et al, 
2011). This study found acute tubular necrosis as the clinical and biopsy-determined cause 
for AKI requiring urgent dialysis in 58% of the HIV-infected patients between 2002 and 
2007. These findings are almost identical to a study by Williams reported in 1998. In 
contrast, the main causes of AKI in HIV patients in developed countries are predominantly 
nephrotoxicity, rhabdomyolysis, ischemia and dehydration (Izzedine et al, 2007). Other 
common causes include interstitial nephritis due to infections and drugs commonly used to 
treat or prevent opportunistic infections, as well as obstructive uropathy, crystalluria and 
other insults from the antiretroviral drugs. 
2.2 Human  Immunodeficiency virus (HIV) infection and the kidney 
The profound immunodeficiency from HIV infection is well described, and results primarily 
from the progressive deficiency of the subset of CD4-helper T cells. The CD4 receptor is 
vital for HIV entry, and the subsequent immune dysfunction, results in a high risk of 
developing opportunistic infections and neoplasms. The progression from infection to 
seroconversion, latent disease, early symptomatic infection and eventually advanced 
AIDS disease is well documented. Human Immunodeficiency Virus-associated nephropathy 
(HIVAN) is a common cause of end-stage renal failure, predominantly in black patients. 
Though timely interventions with antiretroviral (ARV) therapy and angiotensin converting 
enzyme inhibitors (ACEI) can reduce the progression of the disease, this aggressive 
glomerulopathy can advance to endstage kidney disease (ESKD) within weeks to months. 
It may be difficult to distinguish the effects of an acute insult to the kidneys from 
underlying HIVAN.  The kidneys are typically normal or even increased in size even in 
advanced HIVAN, in contrast to the small kidneys found sonographically in most other 
forms of ESKD. To compound the issue, conditions frequently co-exist: in biopsies 
performed in a study on HIV-positive patients with presumed acute renal failure, 20% of 
the patients had HIVAN as the predominant underlying pathology (Arendse et al, 2011).   
Given the complexity of HIV-associated renal failure and the impact of this increasing burden 
of disease on countries in sub-Saharan Africa, it would be important to be able to identify 
patients with potentially better outcomes from the severe case-load of critically ill HIV-positive 
patients, and apply limited resources in such a way that would offer the most benefit.  
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3. Objectives  
With this literature review we planned to assess the survival of HIV-positive patients with 
AKI admitted to ICU, compared to the survival of those who were HIV-negative. If possible, 
we also wanted to identify factors which may predict poorer outcomes. The primary 
outcome to be assessed was survival in ICU, with our secondary outcomes being 30-day and 
90-day post ICU survival, provided that sufficient data were available. 
4. Methods  
We searched the following databases:  Pubmed (incorporating Medline), Web of Science 
(including Science Citation Index), Academic Search Premier, the Cochrane Library and 
Scopus (incorporating Embase) for all relevant literature up to June 2011. We used a 
controlled vocabulary of Medical Subject Headings terms, and free text, appropriately 
modified for the different databases. Included in the string sentence were the terms “acute 
renal failure” OR “ARF” AND “human immunodeficiency virus” OR “HIV” AND 
“Intensive Care Unit” OR “ICU”. The electronic search results yielded a total of 84 articles 
which were screened liberally from titles and abstracts and followed by the selection of full 
papers for inclusion in the review. Particular attention was paid to the possible inclusion of 
duplicate publications or overlap of databases in order to avoid the multiple inclusions of 
the same study.  
All randomised control trials, case-control, and cohort studies investigating the survival of 
HIV-positive patients with acute renal failure compared to the survival of the general 
population with acute renal failure in ICU were to be included. Only studies published in 
the English language were included. In order to include the largest number of published 
articles, the definition of acute renal failure/acute injury was not limited to the 
RIFLE/AKIN criteria. We decided to distinguish clearly on mortality in ARV-naïve patients 
as compared to patients on ARV therapy if possible. Studies correcting for confounding 
factors were to be given preference. 
5. Results 
Our search yielded articles from 1988 to 2010. Of the 84 articles identified by our databases, 
5 were identified by more than one database. One article was written in German and thus 
excluded, 5 were identified as posters, abstracts at congresses or personal correspondence 
and thus not available for scrutiny, and one article could not be accessed by the electronic 
resources from our library. 
Seventy-two articles remained and were scrutinised carefully. Of these, 22 were dismissed 
as not being relevant to our review. Individual case studies numbered 8, all of which were 
discarded reducing the total of relevant articles to 42. Of these 3 dealt with HIV infection 
and respiratory illness; 1 reviewed the survival of HIV-positive paediatric patients in ICU 
without mentioning acute renal failure; 8 addressed HIV-positive patients in ICU due to 
respiratory failure or Pneumocystis jiroveci infection; 2 focused solely on acute respiratory 
failure without addressing HIV infection; 8 articles covered other systemic infections in 
patients with HIV without addressing ICU outcomes or AKI; 6 articles covered aspects of 
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The mortality of AKI remains high and is of the order of 50% in hospitalized patients who 
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The Outcome of HIV-Positive Patients  
Admitted to Intensive Care Units with Acute Kidney Injury 
 
199 
3. Objectives  
With this literature review we planned to assess the survival of HIV-positive patients with 
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modified for the different databases. Included in the string sentence were the terms “acute 
renal failure” OR “ARF” AND “human immunodeficiency virus” OR “HIV” AND 
“Intensive Care Unit” OR “ICU”. The electronic search results yielded a total of 84 articles 
which were screened liberally from titles and abstracts and followed by the selection of full 
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5 were identified by more than one database. One article was written in German and thus 
excluded, 5 were identified as posters, abstracts at congresses or personal correspondence 
and thus not available for scrutiny, and one article could not be accessed by the electronic 
resources from our library. 
Seventy-two articles remained and were scrutinised carefully. Of these, 22 were dismissed 
as not being relevant to our review. Individual case studies numbered 8, all of which were 
discarded reducing the total of relevant articles to 42. Of these 3 dealt with HIV infection 
and respiratory illness; 1 reviewed the survival of HIV-positive paediatric patients in ICU 
without mentioning acute renal failure; 8 addressed HIV-positive patients in ICU due to 
respiratory failure or Pneumocystis jiroveci infection; 2 focused solely on acute respiratory 
failure without addressing HIV infection; 8 articles covered other systemic infections in 
patients with HIV without addressing ICU outcomes or AKI; 6 articles covered aspects of 
HIV infection with AKI but without assessing any Intensive Care aspect; 3 articles dealt with 
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AKI in the ICU but did not address any aspect of HIV infection, and 5 of the identified 
articles dealt with aspects of AKI only without addressing ICU or HIV infection.  
Only 5 articles addressed all three of our key search items: HIV infection, intensive care and 
ARF/AKI. Of these, one listed the number of HIV-positive patients as 1% of their total study 
population without discussing outcome or comparison to the HIV-negative ICU patients 
with renal failure, and was thus discarded (Mehta et al, 2004).  Another assessed the 
application of the RIFLE criteria for acute renal failure in critically ill HIV-infected patients, 
as well as their survival, but failed to compare it to the uninfected patients in their ICU, and 
was discarded as well (Lopes et al, 2007a). An article evaluating long-term risk of mortality 
after AKI in patients with sepsis was discarded because it only assessed the mortality of the 
group surviving ICU admission two years after their discharge (Lopes et al, 2010). The 
remaining two articles assessed the impact of acute renal failure on the HIV population in 
ICU retrospectively as single unit studies and identified it as a cause for increased mortality, 
but failed again to compare their outcomes with outcomes of patients from the general 
population with acute renal failure in ICU (Coquet et al, 2010; Lopes et al, 2007b).  
6. Conclusion 
There are insufficient publications available comparing the outcomes of HIV-positive 
patients with AKI admitted to ICU directly with that of the general population in ICU with 
acute renal failure in randomised control trials, cohort studies or retrospective studies to 
provide clear answers. 
7. Discussion 
Significant progress has been made in the treatment of HIV-disease since the early days of 
the pandemic, when the issues regarding acquired immunodeficiency syndrome patients 
and dialysis were still being debated (Pennel & Bourgoignie, 1988). It is commonly accepted 
that the outcome of patients with HIV is no different to other patients admitted to ICU 
(Rosen et al, 2006). Several publications have reported that critically ill patients with HIV 
infection have similar outcomes to other patients with a comparable severity of illness 
(Casalino et al, 1988; Forrest et al, 1988).  Although outcome studies in patients with HIV 
infection are limited by retrospective analyses and subsequent selection bias a South African 
study (albeit with significant methodological limitations) confirmed this (Bhagwanjee et al, 
1997).  
In the ARV era, ICU survival of critically ill HIV-patients has increased significantly, despite 
unchanged disease severity (Coquet et al, 2010). Whereas ICU management of these patients 
was widely perceived as futile in the 1980s, mortality rates steadily declined as shown by a 
single-centre study, where co-morbidities and organ dysfunctions - but not HIV-variables 
were associated with mortality (Coquet et al, 2010). In this study, AKI was still 
independently associated with death, as it is in non HIV-infected ICU patients (Odds ratio 
4.21; 95% Confidence interval). In a study on the long-term risk of mortality after AKI in 
patients with sepsis, HIV infection was not associated with increased 2-year mortality after 
discharge from the ICU (Lopes et al, 2010). This study, however, made no comparison 
between the in-ICU survival of HIV-infected patients who developed AKI associated with 
sepsis, and HIV non-infected patients.  
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Little prospective data are available on the survival of the subgroup of HIV-infected patients 
in ICU who develop AKI. A small single-centre study demonstrated a significantly higher 
mortality rate in ICU in HIV-infected patients who develop AKI compared to HIV-infected 
patients who do not. Sepsis was the most common associated aetiology (Lopes et al, 2007b). 
In a publication examining the same data, the authors assessed the RIFLE criteria for acute 
renal failure in these patients, and found that mortality increased significantly from normal 
to RIFLE class F (normal, 23.5%; class R, 50%; class I, 66.6% and class F, 72%; P<0.0001). The 
majority of their patients died within one month of ICU admission, but all survivors had 
complete recovery of renal function (Lopes et al, 2007a). When compared to a retrospective 
cohort study in seven intensive care units where the mortality rates for RIFLE class R was 
8.8%, class I, 11.4% and class F 26% (Hoste et al, 2006), it would seem that HIV-infected 
patients have significantly worse outcomes.  This comparison is however problematic, since 
neither differences in the severity of illness of the patients nor their subsequent renal 
management was corrected for.   
In conclusion, there are no prospective studies available comparing the outcomes of HIV-
positive patients with AKI admitted to ICU directly with that of HIV uninfected ICU 
patients with comparable severities of illness. The available literature on patients with HIV 
infection in the ICU is most often confounded by single centre experience, reflecting local 
ICU admission criteria, and management, practice patterns and especially management of 
renal failure. Prospective studies are needed to provide further answers.  
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with Hemodialysis 
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1. Introduction  
Unfractionated heparin is the most commonly used anticoagulant for hemodialysis (HD) 
(Sonawane et al., 2006). It is well-known that heparin can cause immune-mediated 
thrombocytopenia due to immunoglobulin antibody formation against the complex of 
platelet factor 4 (PF4) and heparin. Heparin may also contribute to HD-associated platelet 
activation, thrombocytopenia, and increased PF4 release from platelets during a heparin 
dialytic session (Matsuo et al., 1986). Typically, IgG isotype HIT antibodies develop after 5-
14 days of heparin exposure. The incidence of heparin-induced thrombocytopenia (HIT) was 
estimated at 3.9% in newly treated hemodialysis patients (Yamamoto et al., 1996). Also, 
dialysis is often complicated by clotting of the dialysis lines and/or dialyzer due to 
hypercoagulation regardless of the etiology. When a diagnosis of HIT based on clinical 
symptoms of thrombocytopenia and immunoassay for PF4/heparin complex antibodies is 
employed, it remains unclear whether a few patients have HIT. An antigen-based 
immunoassay to detect the presence of antibodies in a patient’s circulation that binds to the 
PF4/heparin complex is highly sensitive but less specific. Thus, the serological diagnosis of 
HIT needs to be confirmed by employing a functional assay such as 14C-serotonin release 
assay and heparin-induced platelet aggregation test. The enzyme-linked immunosorbent 
assay (ELISA) usually detects antibodies of three classes of isotype (IgG, IgA, and IgM) 
regardless of the capability of these antibodies to activate platelets. There is a way to 
improve the specificity based on only IgG class antibodies having the capability of inducing 
platelet activation by heparin (Chang et al., 2006; Syed & Reilly, 2009). 
There are two kinds of dialysis-related complication: unexpected clotting in the circuit and 
abrupt fistula thrombosis. The former seems to be more frequent in HIT patients than that in 
non-HIT patients. Visible clotting in the extracorporeal circulation can provide a clue to 
suspect HIT. AVF thrombosis is also observed in both HIT and non-HIT patients. After 
starting heparin, the sudden onset of fistula closure is rare as HIT-complicated thrombosis 
(O’Shea et al., 2002; Nakamoto et al., 2005).  
HD patients who develop HIT require not only the discontinuation of heparin, but 
essentially also the introduction of alternative anticoagulant therapy. An alternative 
anticoagulant, such as citric acid, and some therapeutic methods, such as heparin-free 
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dialysis and peritoneal dialysis, have been employed for patients who require dialysis. 
However, these therapeutic modalities are unlikely to be beneficial because of the absence of 
evidence for long-term management. 
Regarding clinical evidence to support HIT, a non-heparin anticoagulant should be started 
with an alternative to heparin. Argatroban rather than lepirudin is recommended as 
elimination is not via the kidneys, but mainly via the billiary system. As the elimination of 
lepirudin mainly depends on the renal function, it is not easy to monitor the optimal dose of 
lepirudin in each session. However, the dose of argatroban in hepato-renal failure is 
recognized variably to reduce while avoiding major bleeding in a critical setting (Hurting & 
Murray et al., 2007). Nafamostat mesilate, a polyvalent protease inhibitor, is sometimes used 
as an alternative to heparin in Japan. Although a few patients showed the effective 
resolution of clotting and a gradual increase of the platelet count to the baseline level in a 
subsequent session receiving nafamostat mesilate, no clinical trial has ever been carried out 
to evaluate the efficacy in the management of HIT (Matsuo & Wanaka, 2008b). Although 
hemodialysis-related HIT appears in an early session after starting HD with heparin, some 
patients with the anti-PF4/heparin complex antibodies have a risk of delayed-onset HIT, 
and they may suffer from HIT after cardiovascular intervention.  
2. Frequency of HIT in dialysis patients 
The frequency of HIT is suggested to be from 1 to 5% of patients exposed to unfractionated 
heparin, and significantly lower in patients exposed to low-molecular-weight heparin. As 
one of the reasons for the various frequencies of HIT, assays used to detect HIT antibodies 
vary in their specificity and sensitivity. An assay for HIT antibody usually detects both non-
pathogenic and pathogenic antibodies irrespective of the presence of thrombocytopenia. The 
clinical significance without thrombocytopenia in which a patient exhibits a stable titer of 
long-term HIT antibodies remains unclear, but there is an ongoing survey on whether or not 
subjects have a risk of thrombosis (Asmis et al., 2008).          
Few reports on the frequency of HIT in dialysis patients are known, although heparin is 
employed as the most useful anticoagulant during dialysis. It was believed that the 
frequency of HIT would be low in a survey targeting to all dialytic patients including both 
acute and chronic stages (Hutchison et al., 2005). Two surveys involving different subjects 
show quite different figures on the frequency of HIT. A relatively high frequency of 3.2% 
was reported for newly treated subjects receiving dialysis in three months (Yamamoto et al., 
1996), and a low rate frequency of 0.6% is described in chronic dialysis patients treated for 
over 3 months (Matsuo et al., 2006). Thus, the frequency of HIT in a dialysis population is 
different between newly treated and chronic maintained dialytic groups. HIT in the former 
shows a similar incidence to the heparin-sensitive group, and HIT in the later group is rarely 
identified as HIT or recurrence of HIT when a patient experiences changes in the 
immunological tolerance brought about by cardiovascular surgery, orthopedic surgery, and 
high-dose administration of erythropoietin with an adverse platelet-stimulating reaction. 
3. Clinical manifestations and laboratory testing in HD-HIT patients 
Major clinical manifestations are primary thrombocytopenia and new thrombosis. The onset 
of thrombocytopenia and/or thrombosis which sometimes complicates before 
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thrombocytopenia usually occurs 5-10 days after starting heparin anticoagulation. Although 
thrombocytopenia is ordinarily defined as a >50% fall in the platelet count and below 
100×109 /L, the definition of HD-HIT is less strict, in the range of a >30% fall in the platelet 
count and below 150×109 /L due to the intermittent use of heparin.  Timing of the fall of 
platelet counts also is likely to delay due to the intermittent heparin use. Thus, no dialytic 
session day may give a chance of recovering the platelet count, and the timing is usually 
delayed over 10 days. However, heparin flushing to maintain the patency of the inserted 
catheter in non-session days sometimes leads to the conventional formation of HIT 
antibodies (Table 1).  
 
Step Clinical and Lab. assessment Action plan 
1 suspicion of HIT  thrombocytopenia (<150×109 /L, unexplained 
decrease of > 30%), timing of over 5 days, no 
other cause of thrombocytopenia or 
thrombosis 
2 ELISA (IgG, A, M) no likelihood of HIT due to a negative 
qualitative assay    
3 specific IgG-ELISA high specificity for platelet-activating 
antibodies   
4 14C serotonin release assay 
(platelet aggregation test) 
confirmation of HIT as a gold standard test 
(not preferable due to being less sensitive) 
5 reassessment of HIT if 
necessary  
recheck other causes of thrombocytopenia and 
thrombosis, assess with alternative therapy   
Table 1. Diagnostic approach to HIT 
HIT symptoms may occur more rapidly within 24 hr or less in patients who have had a 
previous exposure to heparin within the prior 3 months. However, a dialytic patient can 
experience the onset of acute systemic reaction associated with circuit clotting and a marked 
drop in the platelet count immediately after a bolus heparin injection at start of the session. 
In chronic intermittent dialysis, HIT is unlikely to occur after several weeks of heparin 
exposure.  
HIT testing is grouped into two types: 1) detection of immunoglobulin antibody against 
heparin/PF4 complexes by ELISA as a standard technique, and ELISA is simple to perform, 
can be done in a few hours, is highly sensitive and less specific for antibody detection. 
Owing in part to its high sensitivity, ELISA often detects antibodies that would not be 
positive in 14C serotonin release and may be clinically insignificant. ELISA provides much 
information about the likelihood that a patient has HIT (Shaheed et al., 2007; Aster RH. 
2010), and 2) functional assays for the detection of platelet-activating immunoglobulin G by 
14C serotonin release. ELISA permits the identification of three subclasses of 
immunoglobulin: IgG, IgA, and IgM, reacting with PF4/heparin complexes in a solid-phase 
plate. To avoid the overdiagnosis of HIT, the pathogenic impact of HIT antibodies should be 
considered if the optical density is ≥ 0.4 (Warkentin et al., 2008). Therefore, a negative result 
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dialysis and peritoneal dialysis, have been employed for patients who require dialysis. 
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subsequent session receiving nafamostat mesilate, no clinical trial has ever been carried out 
to evaluate the efficacy in the management of HIT (Matsuo & Wanaka, 2008b). Although 
hemodialysis-related HIT appears in an early session after starting HD with heparin, some 
patients with the anti-PF4/heparin complex antibodies have a risk of delayed-onset HIT, 
and they may suffer from HIT after cardiovascular intervention.  
2. Frequency of HIT in dialysis patients 
The frequency of HIT is suggested to be from 1 to 5% of patients exposed to unfractionated 
heparin, and significantly lower in patients exposed to low-molecular-weight heparin. As 
one of the reasons for the various frequencies of HIT, assays used to detect HIT antibodies 
vary in their specificity and sensitivity. An assay for HIT antibody usually detects both non-
pathogenic and pathogenic antibodies irrespective of the presence of thrombocytopenia. The 
clinical significance without thrombocytopenia in which a patient exhibits a stable titer of 
long-term HIT antibodies remains unclear, but there is an ongoing survey on whether or not 
subjects have a risk of thrombosis (Asmis et al., 2008).          
Few reports on the frequency of HIT in dialysis patients are known, although heparin is 
employed as the most useful anticoagulant during dialysis. It was believed that the 
frequency of HIT would be low in a survey targeting to all dialytic patients including both 
acute and chronic stages (Hutchison et al., 2005). Two surveys involving different subjects 
show quite different figures on the frequency of HIT. A relatively high frequency of 3.2% 
was reported for newly treated subjects receiving dialysis in three months (Yamamoto et al., 
1996), and a low rate frequency of 0.6% is described in chronic dialysis patients treated for 
over 3 months (Matsuo et al., 2006). Thus, the frequency of HIT in a dialysis population is 
different between newly treated and chronic maintained dialytic groups. HIT in the former 
shows a similar incidence to the heparin-sensitive group, and HIT in the later group is rarely 
identified as HIT or recurrence of HIT when a patient experiences changes in the 
immunological tolerance brought about by cardiovascular surgery, orthopedic surgery, and 
high-dose administration of erythropoietin with an adverse platelet-stimulating reaction. 
3. Clinical manifestations and laboratory testing in HD-HIT patients 
Major clinical manifestations are primary thrombocytopenia and new thrombosis. The onset 
of thrombocytopenia and/or thrombosis which sometimes complicates before 
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thrombocytopenia usually occurs 5-10 days after starting heparin anticoagulation. Although 
thrombocytopenia is ordinarily defined as a >50% fall in the platelet count and below 
100×109 /L, the definition of HD-HIT is less strict, in the range of a >30% fall in the platelet 
count and below 150×109 /L due to the intermittent use of heparin.  Timing of the fall of 
platelet counts also is likely to delay due to the intermittent heparin use. Thus, no dialytic 
session day may give a chance of recovering the platelet count, and the timing is usually 
delayed over 10 days. However, heparin flushing to maintain the patency of the inserted 
catheter in non-session days sometimes leads to the conventional formation of HIT 
antibodies (Table 1).  
 
Step Clinical and Lab. assessment Action plan 
1 suspicion of HIT  thrombocytopenia (<150×109 /L, unexplained 
decrease of > 30%), timing of over 5 days, no 
other cause of thrombocytopenia or 
thrombosis 
2 ELISA (IgG, A, M) no likelihood of HIT due to a negative 
qualitative assay    
3 specific IgG-ELISA high specificity for platelet-activating 
antibodies   
4 14C serotonin release assay 
(platelet aggregation test) 
confirmation of HIT as a gold standard test 
(not preferable due to being less sensitive) 
5 reassessment of HIT if 
necessary  
recheck other causes of thrombocytopenia and 
thrombosis, assess with alternative therapy   
Table 1. Diagnostic approach to HIT 
HIT symptoms may occur more rapidly within 24 hr or less in patients who have had a 
previous exposure to heparin within the prior 3 months. However, a dialytic patient can 
experience the onset of acute systemic reaction associated with circuit clotting and a marked 
drop in the platelet count immediately after a bolus heparin injection at start of the session. 
In chronic intermittent dialysis, HIT is unlikely to occur after several weeks of heparin 
exposure.  
HIT testing is grouped into two types: 1) detection of immunoglobulin antibody against 
heparin/PF4 complexes by ELISA as a standard technique, and ELISA is simple to perform, 
can be done in a few hours, is highly sensitive and less specific for antibody detection. 
Owing in part to its high sensitivity, ELISA often detects antibodies that would not be 
positive in 14C serotonin release and may be clinically insignificant. ELISA provides much 
information about the likelihood that a patient has HIT (Shaheed et al., 2007; Aster RH. 
2010), and 2) functional assays for the detection of platelet-activating immunoglobulin G by 
14C serotonin release. ELISA permits the identification of three subclasses of 
immunoglobulin: IgG, IgA, and IgM, reacting with PF4/heparin complexes in a solid-phase 
plate. To avoid the overdiagnosis of HIT, the pathogenic impact of HIT antibodies should be 
considered if the optical density is ≥ 0.4 (Warkentin et al., 2008). Therefore, a negative result 
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excludes the diagnosis of HIT. ELISA detects together with IgA and IgM antibodies that do 
not react on FcγIIA-mediated platelet activation. Specific IgG-HIT antibodies can contribute 
to the interaction of the HIT antibody/PF4/heparin complexes with the FcγIIA receptor, 
and subsequently induce platelet activation and the release of microparticles. A high-titer of 
IgG antibodies is accountable for HIT as well (EI-Shahawy et al., 2007; Carrier et al., 2008).  
The 14C serotonin release assay is the gold standard because of its high sensitivity and 
specificity. Thus, the 14C serotonin release assay should be performed to confirm the 
diagnosis if a weak positive result is obtained using ELISA (Sheriden et al., 1986; Pouplard 
et al., 1999). For the assessment of HD-HIT, the pretest probability of the diagnosis of HIT 
(4T’s test) has not been elucidated whether clot formation in the extracorporeal circulation is 
the first sign of HIT (Weiss et al., 2007). Sudden unexpected clotting in the circuit often 
provides an important clue for HIT diagnosis despite of there being many causes of clotting 
during dialysis. After changing the clotted dialyzer and circuit to new ones, dialysis must be 
restarted with an alternative to heparin, and the planned treatment modality can be 
uneventfully completed. Subsequent sessions will never affect re-clotting and the recurrence 
of thrombocytopenia under adequate switching to non-heparin anticoagulation. 
Furthermore, the patient is more likely to have HIT in the presence of a comparable HIT-
antibody seroconversion. Clotting of the extracorporeal circuit seems to be a manifestation 
of HIT in the context of primary thrombocytopenia, the visible resolution of clotting with an 
alternative anticoagulant, HIT antibody formation, and timing within 3 months of starting 
HD. 
 
Step 1. Recognition of HIT is most important:     
1. Unexpected clotting of dialyzer/circuit, and thrombotic occlusion of arteriovenous 
fistula/grafting despite optimal dose of heparin infusion   
2. Absence of other cause of clotting:  
slow blood flows, high hematocrit, high ultrafiltration rate, intradialytic blood and   
blood product transfusion, intradialytic lipid transfusion 
3. Check thrombocytopenia  
 
Step 2. Emergent protocol for suspected HIT patient:  
1. Stop dialysis immediately, and replace whole extracorporeal circuit with a new one 
2. Restart dialysis with argatroban (lepirudin)  
3. Confirm by visible inspection that there is no clot in the circuit once starting an 
alternative to heparin     
4. Avoid heparin flush on non-session days 
 
Table 2. Management strategy for HIT in dialytic patients 
The clinical features of HIT in dialysis patients includes acute thrombocytopenia that is 
associated with renal insufficiency except HIT (Oliveria et al., 2008), and repeated clotting of 
extracorporeal circulation undergoing heparin administration (Lasocki et al., 2008), and the 
clear disappearance of clots on using an alternative anticoagulant to heparin, and/or, rarely, 
thrombotic occlusion in AV fistula/grafting (O’Shea et al., 2002, Nakamoto et al., 2005). 
Circuit clotting occasionally occurs in a routine dialysis procedure, caused by non-HIT 
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factors. The causes of clotting are slow blood flow, high hematocrit, high ultrafiltration rate, 
intradialytic blood and blood product transfusion, intradialytic lipid transfusion. In clinical 
settings, it is difficult to decide whether the clotted circuit is derived from HIT or not.  No 
differences in the platelet count’s fall and timing between clotting-circuit and non-clotting 
circuit groups have been found in clinical settings. However, a higher level of optical 
density in ELISA is noted in the clotting patient group.  This suggests that HIT antibody 
formation may be active in the clotting rather than non-clotting patent group (Table 2). 
 
 
Fig. 1. Algorithm for the diagnosis of HIT in hemodialysis by adding the results of ELISA  
4. Diagnostic approach to HD-HIT patients  
An HD patient associated with HIT is recognized by stepwise assessment. The first step is 
the evaluation of the platelet count with the definition (<150×109 /L and > 30%). If the 
patient shows circuit clotting with no other causes, the next step would be to evaluate the 
timing of thrombocytopenia over days 7-30. The timing of HD-HIT is generally applied over 
a wider range than usual due to the duration of heparin use always being limited in dialysis 
of 4-6 hours per day. Positive ELISA added to platelet reduction, the presence of a clotting 
circuit, and reasonable timing, should be considered as revealing HIT. Thirty six (92.3%) of 
39 patients with four-factor combinations of thrombocytopenia, clotted circuit, optimal 
timing of platelet count fall, and positive ELISA had a positive 14C serotonin release assay 
(Matsuo et al., accepted in Clin Appl Throm/Hemost). According to the algorithm under 
the condition of no circuit clotting, five (71.4%) of 7 patients with thrombocytopenia, 
reasonable timing, and positive ELISA also had a positive 14C serotonin release assay. In the 
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excludes the diagnosis of HIT. ELISA detects together with IgA and IgM antibodies that do 
not react on FcγIIA-mediated platelet activation. Specific IgG-HIT antibodies can contribute 
to the interaction of the HIT antibody/PF4/heparin complexes with the FcγIIA receptor, 
and subsequently induce platelet activation and the release of microparticles. A high-titer of 
IgG antibodies is accountable for HIT as well (EI-Shahawy et al., 2007; Carrier et al., 2008).  
The 14C serotonin release assay is the gold standard because of its high sensitivity and 
specificity. Thus, the 14C serotonin release assay should be performed to confirm the 
diagnosis if a weak positive result is obtained using ELISA (Sheriden et al., 1986; Pouplard 
et al., 1999). For the assessment of HD-HIT, the pretest probability of the diagnosis of HIT 
(4T’s test) has not been elucidated whether clot formation in the extracorporeal circulation is 
the first sign of HIT (Weiss et al., 2007). Sudden unexpected clotting in the circuit often 
provides an important clue for HIT diagnosis despite of there being many causes of clotting 
during dialysis. After changing the clotted dialyzer and circuit to new ones, dialysis must be 
restarted with an alternative to heparin, and the planned treatment modality can be 
uneventfully completed. Subsequent sessions will never affect re-clotting and the recurrence 
of thrombocytopenia under adequate switching to non-heparin anticoagulation. 
Furthermore, the patient is more likely to have HIT in the presence of a comparable HIT-
antibody seroconversion. Clotting of the extracorporeal circuit seems to be a manifestation 
of HIT in the context of primary thrombocytopenia, the visible resolution of clotting with an 
alternative anticoagulant, HIT antibody formation, and timing within 3 months of starting 
HD. 
 
Step 1. Recognition of HIT is most important:     
1. Unexpected clotting of dialyzer/circuit, and thrombotic occlusion of arteriovenous 
fistula/grafting despite optimal dose of heparin infusion   
2. Absence of other cause of clotting:  
slow blood flows, high hematocrit, high ultrafiltration rate, intradialytic blood and   
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Step 2. Emergent protocol for suspected HIT patient:  
1. Stop dialysis immediately, and replace whole extracorporeal circuit with a new one 
2. Restart dialysis with argatroban (lepirudin)  
3. Confirm by visible inspection that there is no clot in the circuit once starting an 
alternative to heparin     
4. Avoid heparin flush on non-session days 
 
Table 2. Management strategy for HIT in dialytic patients 
The clinical features of HIT in dialysis patients includes acute thrombocytopenia that is 
associated with renal insufficiency except HIT (Oliveria et al., 2008), and repeated clotting of 
extracorporeal circulation undergoing heparin administration (Lasocki et al., 2008), and the 
clear disappearance of clots on using an alternative anticoagulant to heparin, and/or, rarely, 
thrombotic occlusion in AV fistula/grafting (O’Shea et al., 2002, Nakamoto et al., 2005). 
Circuit clotting occasionally occurs in a routine dialysis procedure, caused by non-HIT 
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factors. The causes of clotting are slow blood flow, high hematocrit, high ultrafiltration rate, 
intradialytic blood and blood product transfusion, intradialytic lipid transfusion. In clinical 
settings, it is difficult to decide whether the clotted circuit is derived from HIT or not.  No 
differences in the platelet count’s fall and timing between clotting-circuit and non-clotting 
circuit groups have been found in clinical settings. However, a higher level of optical 
density in ELISA is noted in the clotting patient group.  This suggests that HIT antibody 
formation may be active in the clotting rather than non-clotting patent group (Table 2). 
 
 
Fig. 1. Algorithm for the diagnosis of HIT in hemodialysis by adding the results of ELISA  
4. Diagnostic approach to HD-HIT patients  
An HD patient associated with HIT is recognized by stepwise assessment. The first step is 
the evaluation of the platelet count with the definition (<150×109 /L and > 30%). If the 
patient shows circuit clotting with no other causes, the next step would be to evaluate the 
timing of thrombocytopenia over days 7-30. The timing of HD-HIT is generally applied over 
a wider range than usual due to the duration of heparin use always being limited in dialysis 
of 4-6 hours per day. Positive ELISA added to platelet reduction, the presence of a clotting 
circuit, and reasonable timing, should be considered as revealing HIT. Thirty six (92.3%) of 
39 patients with four-factor combinations of thrombocytopenia, clotted circuit, optimal 
timing of platelet count fall, and positive ELISA had a positive 14C serotonin release assay 
(Matsuo et al., accepted in Clin Appl Throm/Hemost). According to the algorithm under 
the condition of no circuit clotting, five (71.4%) of 7 patients with thrombocytopenia, 
reasonable timing, and positive ELISA also had a positive 14C serotonin release assay. In the 
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algorithm (Fig. 1), four groups can be identified: HD-HIT is most likely due to a highest 
positive rate of 14C serotonin release among the four groups, ‘HD-HIT most likely’; 
secondly, HD-HIT is likely to show a relatively high rate on a functional assay, ‘HD-HIT 
likely’. Timing outside the range and a negative ELISA despite the presence of a clotting 
circuit should be identified as ‘unlikely’. ‘HD-HIT less likely’ without any clotting is rare 
even though ELISA is positive. 
The sudden occurrence of clots in the dialyzer and/or circuit with an unexpected fall in the 
platelet count between 7 and 30 days are dramatic symptoms of HIT in HD patients 
undergoing appropriate anticoagulation with heparin. In an HD patient with suspected 
HIT, the clinical implication of clotting in the circuit as HIT can easily be supported in 
combination with thrombocytopenia, timing of the platelet fall, and result of ELISA. 
5. Management of HD-HIT patients 
Visible clotting in the circuit, including blood chambers, tubes, and dialyzer, are easily 
recognized by medical staff in the session, so HIT management can be initiated immediately 
when the clotting is likely to arise from HD-HIT. Once the HIT diagnosis has been 
established from high clinical suspicion alone before laboratory confirmation, it is essential 
that all sources of heparin, including low-molecular-weight-heparin, heparin flushing, and 
heparin-coated catheters or devices, must be discontinued. The early recognition of HIT in 
the presence of clot formation in the extracorporeal circuit is critical, and any additional 
infusion of heparin on the misunderstanding of heparin shortage must be contraindicated to 
resolve the clot. When the dialytic procedure cannot be continued with circuit clotting, a 
new dialyzer and devices of the extracorporeal circuit must be set up, and the session must 
be immediately restarted with an alternative anticoagulant. Then, the diagnosis of HIT can 
be verified using the algorithmic assessment in Fig. 1 and Table 2.  
Established alternative anticoagulation in HD patients with HIT is conducted with 
danaparoid, lepirudin, and argatroban. Danaparoid is a low- molecular-weight heparinoid. 
Although danaparoid is the most widely used for HD-HIT patients, it does not exhibit 
proper anticoagulation for HD-HIT due to clinically relevant cross-reactivity. Lepirudin is a 
recombinant hirudin preparation. Adequate dose adjustment is very difficult in for HD-HIT 
patients, in which it is cleared mainly by the kidneys and its half-life is markedly long in 
uremic patients.  
Argatroban (formerly called MD805), a synthetic direct thrombin inhibitor, is non-
immunogenic and does not show cross-reactivity with HIT antibodies. In contrast to 
lepirudin, argatroban is primarily hepatically metabolized, and its half-life is moderately 
extended in HD patients (Matsuo et al., 1988; Matsuo et al., 1990). Argatroban as an 
alternative anticoagulant is predominantly used for the prevention of extracorporeal circuit 
clotting in HD-HIT patients at the initial dose of 250μg/kg at the start of dialysis, and 
followed by a continuous infusion of at 2μg/kg/min while the hepatic function is normal. 
Dose adjustment is conducted for an empirical target of a 1.5-3.0-fold prolongation of the 
activated partial thromboplastin time (APTT) test, as an equivalent to the prolongation of 
heparin therapy. This dose can be reduced to <2μg/kg/min with a 1.5-2.5-fold prolongation 
of the APTT after the acute phase of HIT has subsided. The dose should also be reduced to 
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<2μg/kg/min depending on the severity hepatic dysfunction to avoid unexpected 
hemorrhagic complications. Only the replacement of heparin with argatroban in dialysis can 
lead to recovery from symptoms of HIT (Gozdzikiewicz et al., 2007; Roncon-Albuquerque et 
al., 2010; Matsuo & Wanaka, 2008a). Despite there being no apparent evidence for the 
systemic administration of argatroban on non-session days, argatroban anticoagulation may 
be useful to prevent the risk of new and worsening thrombotic events. When an HD-HIT 
patient is in a hypercoagulable state, such as with an elevated level of plasma D-dimer, 
argatroban therapy seems to be essential. The empirical dose of the drug is estimated to 
0.7μg/kg/min in patients with a normal liver function and 0.2μg/kg/min in those with 
hepatic dysfunction or a risk of bleeding. Future studies should be done on how to apply the 
drug on non-session days (Hursting & Murray et al., 2008).  
Nafamostat mesilate, a polyvalent synthetic protease inhibitor, is employed as a regional 
anticoagulant in dialysis patients with bleeding risks as an alternative to heparin in Japan. 
The drug has no influence on the systemic blood coagulation cascade due to its very short 
half-life, within 10 min, about 40% of the drug is removed from the dialyzer, and there is no 
cross-reactivity with HIT antibodies. Despite the fact that the HD-HIT session is 
uneventfully completed using nafamostat mesilate, it remains why the drug has a 
therapeutic benefit on the resolution of HIT over the effect of heparin cessation (Matsuo et 
al., 2001; Matsuo & Wanaka, 2008b) 
 
 Age/sex Type of 
surgery 
Thrombocytopenia
(50%fall, 5-10 days 
from pre-op. level)
Immunoassay 




Pre 7days 14days Pre 7days 14days 
1 58/M aortic 
aneurysm 
grafting 
—* —** 1.82 2.39 —*** — 96 
2 67/M aortic 
aneurysm 
grafting 
+ (56.6%) — — — — — — 
3 63/M CABG — — — — — — — 
4 69/M CABG + (69.6%) — — — — — — 
5 55/M CABG — — — — — — — 
6 60/F CABG + (73.5%) — — — — — — 
7 63/M valve op. — — — — — — — 
8 70/M CABG — 1.28 1.87 2.01 − 65 68 
* not consistent with platelet criteria  
**optical density < 0.4 by ELISA 
***radioactive serotonin release under 20% 
Table 3. Seroconversion in cardiac surgery patients with chronic hemodialysis 
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algorithm (Fig. 1), four groups can be identified: HD-HIT is most likely due to a highest 
positive rate of 14C serotonin release among the four groups, ‘HD-HIT most likely’; 
secondly, HD-HIT is likely to show a relatively high rate on a functional assay, ‘HD-HIT 
likely’. Timing outside the range and a negative ELISA despite the presence of a clotting 
circuit should be identified as ‘unlikely’. ‘HD-HIT less likely’ without any clotting is rare 
even though ELISA is positive. 
The sudden occurrence of clots in the dialyzer and/or circuit with an unexpected fall in the 
platelet count between 7 and 30 days are dramatic symptoms of HIT in HD patients 
undergoing appropriate anticoagulation with heparin. In an HD patient with suspected 
HIT, the clinical implication of clotting in the circuit as HIT can easily be supported in 
combination with thrombocytopenia, timing of the platelet fall, and result of ELISA. 
5. Management of HD-HIT patients 
Visible clotting in the circuit, including blood chambers, tubes, and dialyzer, are easily 
recognized by medical staff in the session, so HIT management can be initiated immediately 
when the clotting is likely to arise from HD-HIT. Once the HIT diagnosis has been 
established from high clinical suspicion alone before laboratory confirmation, it is essential 
that all sources of heparin, including low-molecular-weight-heparin, heparin flushing, and 
heparin-coated catheters or devices, must be discontinued. The early recognition of HIT in 
the presence of clot formation in the extracorporeal circuit is critical, and any additional 
infusion of heparin on the misunderstanding of heparin shortage must be contraindicated to 
resolve the clot. When the dialytic procedure cannot be continued with circuit clotting, a 
new dialyzer and devices of the extracorporeal circuit must be set up, and the session must 
be immediately restarted with an alternative anticoagulant. Then, the diagnosis of HIT can 
be verified using the algorithmic assessment in Fig. 1 and Table 2.  
Established alternative anticoagulation in HD patients with HIT is conducted with 
danaparoid, lepirudin, and argatroban. Danaparoid is a low- molecular-weight heparinoid. 
Although danaparoid is the most widely used for HD-HIT patients, it does not exhibit 
proper anticoagulation for HD-HIT due to clinically relevant cross-reactivity. Lepirudin is a 
recombinant hirudin preparation. Adequate dose adjustment is very difficult in for HD-HIT 
patients, in which it is cleared mainly by the kidneys and its half-life is markedly long in 
uremic patients.  
Argatroban (formerly called MD805), a synthetic direct thrombin inhibitor, is non-
immunogenic and does not show cross-reactivity with HIT antibodies. In contrast to 
lepirudin, argatroban is primarily hepatically metabolized, and its half-life is moderately 
extended in HD patients (Matsuo et al., 1988; Matsuo et al., 1990). Argatroban as an 
alternative anticoagulant is predominantly used for the prevention of extracorporeal circuit 
clotting in HD-HIT patients at the initial dose of 250μg/kg at the start of dialysis, and 
followed by a continuous infusion of at 2μg/kg/min while the hepatic function is normal. 
Dose adjustment is conducted for an empirical target of a 1.5-3.0-fold prolongation of the 
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<2μg/kg/min depending on the severity hepatic dysfunction to avoid unexpected 
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 Age/sex Type of 
surgery 
Thrombocytopenia
(50%fall, 5-10 days 
from pre-op. level)
Immunoassay 




Pre 7days 14days Pre 7days 14days 
1 58/M aortic 
aneurysm 
grafting 
—* —** 1.82 2.39 —*** — 96 
2 67/M aortic 
aneurysm 
grafting 
+ (56.6%) — — — — — — 
3 63/M CABG — — — — — — — 
4 69/M CABG + (69.6%) — — — — — — 
5 55/M CABG — — — — — — — 
6 60/F CABG + (73.5%) — — — — — — 
7 63/M valve op. — — — — — — — 
8 70/M CABG — 1.28 1.87 2.01 − 65 68 
* not consistent with platelet criteria  
**optical density < 0.4 by ELISA 
***radioactive serotonin release under 20% 
Table 3. Seroconversion in cardiac surgery patients with chronic hemodialysis 
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6. Cardiovascular surgery with chronic hemodialysis 
Chronic dialysis patients who repeatedly exposed to heparin rarely are at risk of developing 
HIT, show high-level mortality due to atherosclerotic cardiovascular events (Mureebe et al., 
2004). Sometimes they have indications for cardiovascular surgery on non-dialysis sessions. 
There are few data available on whether long-term heparin usage affects post-operative 
seroconversion, and the development of HIT. Surgical procedures usually stimulate the 
release of PF4 from platelets and the endothelium. PF4 does certainly facilitate complex 
formation in the presence of a dynamic equilibrium with external heparin. Macromolecular 
PF4/heparin complexes stimulate the immunomediated production of anti-PF4/heparin 
complex antibodies. Increased levels of immunomediated HIT-antibody production are 
occasionally recognized in the post-operative period. Although a high rate of seroconversion 
appears to be involved in the development of HIT, most seroconversion shows a lack of 
thrombocytopenia, and very few patients with seroconversion develop HIT.  
In cardiovascular patients receiving regular dialysis, the risk of HIT is presumed to increase 
in certain situations, such as cardiac interventions, by the modification of immunological 
tolerance to PF4/heparin complexes. Eight of 79 patients with cardiovascular surgery were 
treated with dialysis (Table 2). Two patients with neither thrombocytopenia nor thrombosis 
experienced seroconversion with the development of positive ELISA and SRA. One patient 
was negative in the pre-operative state despite heparin dialysis for 3.5 years.  He may have 
undergone a resetting of the immunologic response to PF4/heparin complexes due to the 
influence of perioperative surgical procedures (case #1 in Table 3). The other patient had 
pre-existing HIT antibodies on ELISA, and the positive SRA would be induced by 
accelerating the production of HIT antibodies due to cardiac intervention (case #8 in Table 
3). Although no ‘true HIT’ patient could be found in the series, this suggests that 
reactivation of the immune system could be functioning in the perioperative period, and the 
risk of developing HIT may be continuing until subsidence of HIT antibody production. 
Any thrombocytopenia corresponding to HIT criteria could not be detected with the 
monitoring of platelet counts in post-operation, despite a marked fall within 4 postoperative 
days, and steeply increasing platelet counts in the following days were observed regardless 
of whether or not the patients experienced seroconversion.  
Post-operative thrombocytosis, in contrast to HIT-related thrombocytopenia, can influence 
the results of platelet counts, because marked thrombocytosis must compensate for 
thrombocytopenia derived from immune-mediate platelet consumption. When the recovery 
of platelet counts remains low over the 5th post-operative day and an abrupt platelet fall is 
induced by the reuse of heparin, HIT should be considered in patients with no other cause 
of thrombocytopenia.  
HD patients with both positive ELISA and serotonin release assay and without defined 
thrombocytopenia may have a risk of developing HIT through re-exposure to heparin in a 
restarted dialysis session. A clotting circuit recognized as atypical HIT-related thrombosis is 
causally linked to the onset of thrombocytopenia, and the event will be certainly resolved by 
employing an alternative to heparin. HIT may occur even after years of uneventful chronic 
intermittent hemodialysis due to resetting of the immune mechanism triggered in cardiac 
surgery, catheter intervention, and, rarely, a platelet-activating procedures and agents. 
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fall ( days) 
1 Dyspnea, chills, fever +** - 53 85 14 
2 Nausea, vomiting - + 25 88 12 
3* Dyspnea, flushing, chills, 
fever, 
- - 16 90 13 
4 Dyspnea, chest pain + - 28 94 7 
5 Dyspnea, chest pain, 
hypotension, nausea, 
vomiting 
- + 84 72 13 
6* Dyspnea, fever + - 57 67 8 
7*** Dyspnea, chills, nausea + - 92 80 11 
8 Dyspnea, chills, fever, 
chest pain, nausea 
+ - 74 73 11 
*diagnosed with pseudo-pulmonary embolism, ** unexpected closure of hollow fibers of dialyzer with 
fibrin-platelet aggregates in two consecutive sessions, ***heparin flushing on non-session day.  
Table 4. Eight patients with HIT-induced acute systemic reaction from twenty-seven dialytic 
patients who experienced some acute systemic reactions 
7. Characteristics of acute systemic reaction in dialytic patients 
Infrequently, an acute systemic reaction (ASR) as a manifestation of HIT occurs 5-30 min 
after heparin bolus administration at the start of dialysis. The symptoms are fever, chills, 
and flushing as acute inflammatory reactions, and hypertension, tachycardia, dyspnea, chest 
pain, and cardiopulmonary arrest. Although hypertension is usually associated with ASR 
(Warkentin et al., 2009), in contrast, acute hypotension often occurs as a sign of 
cardiovascular collapse during dialysis. When dyspnea as the cardiorespiratory reaction in 
ASR is prominent, it is considered to be a pseudo-pulmonary embolism (Tejedor Alonso et 
al., 2005; Hartman et al., 2006; Matsuo et al., 2007). However, the signs and symptoms are 
very similar to those in dialyzer reactions, dialytic complications as disequilibrium 
syndrome, and circuit clotting during the HD procedure. Except for platelet reduction by 
heparin, it is difficult to determine whether symptoms of ASR are most likely to be due to 
HIT in clinical settings. There are two causes of hypotension: HIT-induced hypotension may 
associate with cardiorespiratory collapse due to pseudo-pulmonary embolism, and HD-
induced hypotension often with nausea and vomiting, and occasionally with back pain and 
syncope.  
As the clinical features of eight patients defined with HIT-induced ASR from twenty-seven 
patients who experienced some ASR, seven of the eight patients suffered from dyspnea, and 
two ASR patients (case #3, #6 in Table 4) showing hypoxia, no radiological evidence, and 
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the quick recovery of symptoms after the cessation of heparin were defined as pseudo-
pulmonary embolism. Hypotension was implicated when pulmonary collapse was noted in 
a patient (case #5 in Table 4). Thus, hypotension was not a primary feature of the HIT-
induced acute systemic reaction. However, no hypertension appeared in eight HIT-induced 
ASR patients. Either complications of circuit clotting or AVF thrombus formation appeared 
in seven patients excluding a case (case #3 in Table 4) of pseudo-pulmonary embolism. The 
platelet fall rate and timing in HIT-induced ASR cannot be differentiated from those of HD-
induced ASR (Table 4). Complications during dialysis including dialyzer reactions, clotting 
circuit, anticoagulation failure, and hypotension may mimic the signs and symptoms of 
HIT-induced ASR except hypotension. Thus, a platelet count and assays for HIT antibodies 
should be considered for diagnosing acute HIT when HD patients show an abrupt fall in 
platelet counts and clinical symptoms of ASR with an unknown cause during dialysis. The 
results of the HIT-antibody assay showed that the differential diagnosis would be 
straightforward regarding whether HD patients with thrombocytopenia suffered from HIT-
induced or HD-complicated ASR. 
  
Fig. 2. Reduction in optical density of ELISA after heparin cessation in HD-HIT 
8. Reexposure to heparin 
The principal of heparin reexposure is based on a characteristic immune response in T-cell 
independent B-cell activation because of lack of a strong memory response, perhaps 
explaining transience and lack of anamnesis of the anti PF4/heparin immune response 
(Selleng et al., 2010). The reexposure can be carried out with lack of immune memory for the 
PF4/heparin complex antigen in patients with previous episodes of HIT when their HIT 
antibodies become negative. Currently, there is no clinical consensus regarding reexposure 
to heparin for HIT. However, it reexposure is needed at least 100 days after no detection of 
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HIT antibodies by ELISA. Reductions in the optical density of ELISA are quite variable after 
the cessation of heparin (Fig. 2).  While a positive ELISA continues long-term over years 
marked as positive ELISA is also recognizable in Fig.2, a short span type is also contained. 
Since the various half-life of HIT antibodies may reflect the existence of different properties 
of HIT antibodies, each patient should be followed by ELISA until there is no longer a 
detection of HIT antibodies. Reexposure to heparin should be introduced under negative 
ELISA where adequate emergent measures are adopted including platelet counting tests 
(Matsuo et al., 2003; Davenport et al., 2009; Wanaka et al., 2010). A majority of heparin-
reexposure patients show no recurrence of HIT unless they undergo cardiovascular surgery, 
catheter intervention, and, rarely, receive platelet-stimulating drugs. Reexposure to heparin 
in HD patients carrying a stable titer with an optical density over 0.4 may not be allowed 
because the risk of recurrence of HIT is likely to increase on heparin reuse.  
9. Conclusion    
HD-HIT is a drug-induced, immunoglobulin-mediated disorder that it is suspected in 
dialytic patients with an unexpected fall in the platelet count, and/or unexplained 
thrombotic events, particularly visible clotting in the circuit under an adequate heparin 
dose, and that begins between 5 and 10 days (nadir between 7 and 30 days, mostly by the 
third to fifth session) after heparin initiation. Although a positive result of HIT antibodies is 
presumably detected by sensitive ELISA, the diagnosis should be confirmed, whenever 
possible, using a functional assay. Immediately after the clinical suspicion of HIT, all sources 
of heparin should be discontinued including heparin used to flush or lock catheters. 
Alternative non-heparin anticoagulants, preferentially in a direct thrombin inhibitor, should 
be restarted for dialysis. Early treatment is important as thrombus formation including a 
clotting circuit may complicate at a high rate in 30 days after the cessation of heparin. 
Argatroban as an alternative to heparin must contribute to the quick recovery of the platelet 
count and immediate disappearance of circuit clotting. A steady decrease of the ELISA titers 
can be expected after heparin discontinuation. A negative seroconversion of HIT antibodies 
is usually observed by ~30 to more than 100 days after the discontinuation. Reexposure to 
heparin can be selected at the same dose of heparin as used before the onset of HIT. Small 
peak of HIT antibodies may often appear after exposure, but a follow-up of the antibody 
titers does not reach a threshold to induce the recurrence of HIT. When HD-HIT patients 
exhibit a high risk of thrombotic formation or worsening thrombosis, the same alternative 
anticoagulant therapy may be needed in non-session days. 
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1. Introduction 
Renal disease is common throughout the world. In the United States alone, almost 100,000 
people began renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 
2001(Kimmel & Peterson, 2005); by 2008, this number had increased to 485,000 patients 
(Collins et al., 2009). More than 90% of these patients were started on hemodialysis (HD), 
while only 8.5% began RRT with peritoneal dialysis (PD)(Kimmel & Peterson, 2005). In 
Korea, the number of dialysis centers and machines has continuously increased, and 62.1% 
of patients receiving RRT were being treated with HD (Son et al., 2009). An international 
comparison showed that Taiwan has the greatest incidence and second-greatest prevalence 
of ESRD (Kuo et al., 2007). Furthermore, renal disease is one of the top 10 causes of death in 
Taiwan, and roughly 95% of ESRD patients are on HD (Hsieh et al., 2007). 
While HD does not cure renal disease, its use does allow patients with ESRD to survive 
(Weisbord et al., 2007a). Nevertheless, HD is a lifelong treatment that significantly and 
sometimes adversely affects patients both physically and mentally (Kimmel, 2001). Common 
psychological effects include depression, anxiety, fatigue, decreased quality of life (QoL) 
and increased suicide risk (Chen et al., 2010). The global effects of continual treatment lead 
to changes in patients’ family roles and ability to work, with feelings of loss of control and 
fear of death. These very real psychological consequences of treatment may affect survival 
in HD patients (Chilcot et al., 2011; Kimmel & Peterson, 2005). Therefore, it is imperative to 
identify and treat these psychological symptoms among HD patients. 
2. Depression  
2.1 Prevalence and influence of depression  
Depression is one of the most common psychological problems among HD patients. We still 
lack reliable data that can be used to directly compare the prevalence of depression between 
HD patients and the general population. However, extant investigations generally agree 
that the rate of depression is high among HD patients.  
In the general population, the lifetime prevalence of major depressive disorder is about 
16.2% (Kessler et al., 2003). However, the rates vary widely across countries, ranging from 
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1.5% in Taiwan to 19% in Beirut, Lebanon (Weissman et al., 1996). Chilcot et al. (2008) 
reported that the prevalence of major depression among ESRD patients is approximately 
20% to 30%. When we reviewed the recent literature, depression rates among HD patients 
ranged from 19.3% (Araujo et al., 2011) to 60.5% (Kao et al., 2009). These studies are 
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KEY: BDI: Beck Depression Inventory; CCI: Charlson Comorbidity Index; CESD: Center of 
Epidemiological Studies Depression Scale; CFS: Chalder Fatigue Scale; CKD: chronic kidney disease; 
COPE: Coping Orientation to Problems Experienced Inventory; CRP: C-reactive protein; DSI: Dialysis 
Symptom Index; HADS: Hospital Anxiety and Depression Rating Scale; ESRD: end-stage renal disease; 
HARS: Hamilton Anxiety Rating Scale; HD: hemodialysis; HDRS: Hamilton Depression Rating Scale; 
IL: interleukin; KDQoL: Kidney Disease Quality of Life; KDQoL-SF: Kidney Disease and Quality of Life 
Short Form; MINI: Mini International Neuropsychiatric Interview; MIS: Malnutrition-Inflammation 
Score; MMSE: Mini Mental State Examination; PD: peritoneal dialysis; PHQ-9: Patient Health 
Questionnaire; PRIME-MD: Primary Care Evaluation of Mental Disorders; SBQ: Suicide Behaviours 
Questionnaire; SCID: Structured Clinical Interview for DSM; SCL-90-R: Hopkins Symptom Checklist 90 
Revised; SF-36: The Short-form Health-related Quality of Life; TNF: tumor necrosis factor 
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The variation in prevalence rates of depression might be accounted for by differences in 
sample sizes and assessment tools (Watnick et al., 2005). Despite such discrepancies, 
depression is unquestionably one of the most important mental illnesses among HD 
patients. Strong correlations have been noted between depression and longitudinal outcome 
among HD patients, including poor treatment adherence and higher mortality rates (Drayer 
et al., 2006; Kimmel et al., 1993). In addition, depression in HD patients is associated with 
higher rates of hospital admission, and a greater likelihood of emergency department visits 
(Abbas Tavallaii et al., 2009; Hedayati et al., 2008).  
2.2 Biological factors underlying depression 
The etiology of dialysis-related depression is multifactorial, and is related to biological, 
psychological, and social mechanisms (Chilcot et al., 2008). Some of the biological 
mechanisms include increased cytokine levels, possible genetic predisposition, and 
neurotransmitters affected by uremia (Kimmel, 2001; Smogorzewski et al., 1995).  
For decades it’s been known that immunologic factors have potent influences on 
neurotransmitter metabolism and neuroendocrine function (Irwin & Miller, 2007; Wichers & 
Maes, 2002). A growing number of studies have investigated the relationships between 
cytokines and depression (Howren et al., 2009; Loftis et al., 2010; Sonikian et al., 2010). 
During hemodialysis, the blood-dialyzer interaction has the potential to activate 
mononuclear and dendritic cells, leading to production of inflammatory cytokines (Agrawal 
et al., 2010; Pertosa et al., 2000). Several researchers support the supposition that pro-
inflammatory cytokines are involved with depression in renal patients. In particular, there is 
evidence that depression is associated with interleukin (IL)-1, IL-6, tumor necrosis factor-
alpha (TNF-α), and C-reactive protein (CRP) in both the general and ESRD populations (Gill 
et al., 2010; Simic Ogrizovic et al., 2009; Sonikian et al., 2010). These pro-inflammatory 
cytokines also appear to be associated with survival rate in HD patients (Kimmel et al., 
1998). The underlying biological mechanisms have been proposed as a defect in serotonergic 
function and hypercortisolemia associated with stimulation of the hypothalamic-pituitary-
adrenal (HPA) axis (Capuron & Miller, 2011; Leonard, 2010), thus leading to depression and 
affecting mortality.  
Malnutrition, which is commonly observed in dialysis patients, is related to chronic 
inflammation (Pertosa et al., 2000). It has also been reported that malnutrition is associated 
with emotional symptoms among HD patients (Bossola et al., 2009; Czira et al., 2011; Huang 
& Lee, 2007; Ibrahim & El Salamony, 2008; Koo et al., 2003). These authors also determined 
that patients with depression had lower-than-normal body mass indices (BMI) (Chen et al., 
2010).  
There is evidence of an association between malnutrition, inflammation, and atherosclerosis 
(MIA) in ESRD patients, and some researchers have suggested that depression might be 
involved in the MIA syndrome (Simic Ogrizovic et al., 2009). Others have demonstrated 
frequent and close relationships between serum albumin levels and depression (Huang & 
Lee, 2007; Hung et al., 2011; Koo et al., 2003). However, a correlation between hemoglobin, 
ferritin, and emotional symptoms is less clear-cut (Bossola et al., 2009; Czira et al., 2011; 
Huang & Lee, 2007). Hopefully the causal relationships in the complexity of 
psychoneuroimmune mechanisms will be further elucidated in future studies.  
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Racial effects on depression and anxiety have been studied in HD patients, once again with 
conflicting results (Feroze et al., 2010). Higher prevalence rates of major depressive 
disorders have been noted among Caucasians than among African-Americans or Mexican-
Americans (Riolo et al., 2005). In contrast, the results of some studies revealed no differences 
in the prevalence of depression among races (Chen et al., 2011; Weisbord et al., 2007b). 
Balakrishnan et al. (2004) demonstrated that single nucleotide polymorphisms in the 
promoter region of the proinflammatory cytokines appear to have a strong association with 
indices of comorbidity, biological and nutritional markers. Whether depression is associated 
with a genetic predisposition for racial differences or cytokine gene polymorphisms 
warrants further investigation. 
Other studies have evaluated the possible effects of dialysis materials on depression. 
Peritoneal dialysis (PD) patients have been noted to have less severe anxiety, insomnia, and 
depression than do HD patients (Ginieri-Coccossis et al., 2008; Noshad et al., 2009). It has 
been suggested that the rate of depression is greater among patients using cellulose-
derivative dialyzers than among those using polysulfone dialyzers (Hsu et al., 2009). Using 
PD or more biocompatible dialyzers thus might be associated with better mental health in 
HD patients. 
2.3 Psychological and social factors for depression 
A number of studies have focused upon the effects of HD patients, including feelings of 
hopelessness, perceptions of loss and lack of control, job loss, and altered family and social 
relationships (Kimmel, 2001). Because ESRD is a lifelong disease, feelings of lack of control 
and perceptions of overwhelming illness might be inevitable. The intrusiveness of these 
thoughts is related to depression (Christensen & Ehlers, 2002; Devins et al., 1997). 
More recent work has focused upon the possible effects of underlying illness upon 
depressive symptoms among ESRD patients (Guzman & Nicassio, 2003). Perception of loss 
has been regarded as a strong predictor of depression (Chan et al., 2009), which in turn 
predicts mortality (Chilcot et al., 2011). In terms of the risk by demographic characteristics, 
results have been inconsistent (Taskapan et al., 2005). It was reported that depression among 
dialysis patients increased with increasing age and lower educational levels (Keskin & 
Engin, 2011). In some studies, depressive symptoms were more common among women, 
and increased with unemployment and also rose among patients with higher comorbidity of 
physical diseases (Araujo et al., 2011; Chen et al., 2010; Ibrahim & El Salamony, 2008). Thus, 
negative cognition and lack of social support might exacerbate patients’ negative feelings, 
and thus further contribute to depression.  
3. Anxiety 
Anxiety is also commonly seen in HD patients (Kring & Crane, 2009). Cukor et al. 
demonstrated a 27% incidence of anxiety among 70 urban HD patients, which was 
somewhat higher than the 18% incidence reported in a national survey (Kessler et al., 2005). 
During a 16-month follow-up study, 9% of patients had both anxiety and depression at 
baseline; the incidence of both conditions rose to 13% by the end of the study. At the end of 
the study, two-thirds of individuals with comorbid depression and anxiety at baseline had 
both diagnoses (Cukor et al., 2008b). Furthermore, Cukor et al. (2008a) reported that 45.7% 
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of a group of dialysis patients recruited from a single center met criteria for an anxiety 
disorder. The most prevalent disorders were specific phobias (26.6%) and panic disorder 
(21.0%). Bossola et al. (2010) indicated that 47.5% of 80 HD patients had mild symptoms of 
anxiety, while 48.7% had moderate or severe symptoms of anxiety. In addition, the anxiety 
scores correlated significantly with age and comorbidities, and anxiety were commonly 
noted in patients with poor appetite (Bossola et al., 2011). A review of 55 studies that 
investigated symptoms of anxiety in ESRD patients found that 12% to 52% of patients with 
ESRD had substantial anxiety (Murtagh et al., 2007). 
In one of our previous studies, 21% of dialysis patients had symptoms of anxiety. In 
addition, 15.5% of these subjects had comorbid depression and anxiety, and 44.3% of 
depressed patients had comorbid anxiety (Chen et al., 2010). Furthermore, suicide risk was 
not only attributed to depression, but also to anxiety.  
The call for depression screening in HD patients is growing, but screening for anxiety in 
patients with ESRD population is relatively disregarded. This is an indication that many 
clinicians underestimate the importance of anxiety among HD patients. O'Donovan et al. 
(2010) reported that clinically anxious participants exhibited significantly lower levels of 
morning cortisol and significantly higher levels of IL-6, compared with non-anxious 
participants. Uncertainty about the future and fear of losing control of one’s life are 
important factors associated with anxiety that adversely impact emotional stability (Haenel 
et al., 1980).  Notably, anxiety is a common psychological problem that may emerge during 
the initial course of dialysis (Cukor et al., 2008b), and is a reminder to clinicians to pay close 
attention to this issue.  
4. Fatigue 
Fatigue is a subjective symptom characterized by tiredness, weakness, and lack of 
energy.(Lee et al., 1991) Fatigue is also one of the most debilitating symptoms reported by 
HD patients, and roughly 60% to 97% of patients on HD experience some degree of it 
(Jhamb et al., 2008). People with chronic renal disease, regardless of whether they are pre-
dialysis or receiving either HD or PD, are reported having high levels of fatigue and are 
often unable to engage in normal daily activities (Bonner et al., 2010). In addition, fatigue is 
positively correlated with depression (Chen et al., 2010; Sklar et al., 1996), and negatively 
correlated with QoL (Lee et al., 2007). In one study, researchers noted a significant 
relationship between the duration of treatment and the level of fatigue. The experience of 
fatigue was more commonly reported in respondents who had been receiving treatment for 
more than 2 years, compared to those treated for less than 2 years (Letchmi et al., 2011). In a 
longitudinal analysis of 917 incident HD and PD patients, those with lower levels of fatigue 
at baseline survived longer (Jhamb et al., 2009).  
Factors that may contribute to fatigue in dialysis patients include anemia, malnutrition, 
inflammation, depression and/or sleep disorders (Jhamb et al., 2008). Anemia resulting 
from reduced erythropoietin production has been cited as an important cause of fatigue in 
this population (Singh et al., 2006). Additionally, patients undergoing chronic HD show 
evidence of accelerated protein catabolism, which might be due to the significant loss of 
amino acids induced by dialysis (Pertosa et al., 2000). Thus, it is reasonable to presume that 
lower levels of albumin can be significantly correlated with greater levels of fatigue (Bonner 
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Racial effects on depression and anxiety have been studied in HD patients, once again with 
conflicting results (Feroze et al., 2010). Higher prevalence rates of major depressive 
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Americans (Riolo et al., 2005). In contrast, the results of some studies revealed no differences 
in the prevalence of depression among races (Chen et al., 2011; Weisbord et al., 2007b). 
Balakrishnan et al. (2004) demonstrated that single nucleotide polymorphisms in the 
promoter region of the proinflammatory cytokines appear to have a strong association with 
indices of comorbidity, biological and nutritional markers. Whether depression is associated 
with a genetic predisposition for racial differences or cytokine gene polymorphisms 
warrants further investigation. 
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Peritoneal dialysis (PD) patients have been noted to have less severe anxiety, insomnia, and 
depression than do HD patients (Ginieri-Coccossis et al., 2008; Noshad et al., 2009). It has 
been suggested that the rate of depression is greater among patients using cellulose-
derivative dialyzers than among those using polysulfone dialyzers (Hsu et al., 2009). Using 
PD or more biocompatible dialyzers thus might be associated with better mental health in 
HD patients. 
2.3 Psychological and social factors for depression 
A number of studies have focused upon the effects of HD patients, including feelings of 
hopelessness, perceptions of loss and lack of control, job loss, and altered family and social 
relationships (Kimmel, 2001). Because ESRD is a lifelong disease, feelings of lack of control 
and perceptions of overwhelming illness might be inevitable. The intrusiveness of these 
thoughts is related to depression (Christensen & Ehlers, 2002; Devins et al., 1997). 
More recent work has focused upon the possible effects of underlying illness upon 
depressive symptoms among ESRD patients (Guzman & Nicassio, 2003). Perception of loss 
has been regarded as a strong predictor of depression (Chan et al., 2009), which in turn 
predicts mortality (Chilcot et al., 2011). In terms of the risk by demographic characteristics, 
results have been inconsistent (Taskapan et al., 2005). It was reported that depression among 
dialysis patients increased with increasing age and lower educational levels (Keskin & 
Engin, 2011). In some studies, depressive symptoms were more common among women, 
and increased with unemployment and also rose among patients with higher comorbidity of 
physical diseases (Araujo et al., 2011; Chen et al., 2010; Ibrahim & El Salamony, 2008). Thus, 
negative cognition and lack of social support might exacerbate patients’ negative feelings, 
and thus further contribute to depression.  
3. Anxiety 
Anxiety is also commonly seen in HD patients (Kring & Crane, 2009). Cukor et al. 
demonstrated a 27% incidence of anxiety among 70 urban HD patients, which was 
somewhat higher than the 18% incidence reported in a national survey (Kessler et al., 2005). 
During a 16-month follow-up study, 9% of patients had both anxiety and depression at 
baseline; the incidence of both conditions rose to 13% by the end of the study. At the end of 
the study, two-thirds of individuals with comorbid depression and anxiety at baseline had 
both diagnoses (Cukor et al., 2008b). Furthermore, Cukor et al. (2008a) reported that 45.7% 
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of a group of dialysis patients recruited from a single center met criteria for an anxiety 
disorder. The most prevalent disorders were specific phobias (26.6%) and panic disorder 
(21.0%). Bossola et al. (2010) indicated that 47.5% of 80 HD patients had mild symptoms of 
anxiety, while 48.7% had moderate or severe symptoms of anxiety. In addition, the anxiety 
scores correlated significantly with age and comorbidities, and anxiety were commonly 
noted in patients with poor appetite (Bossola et al., 2011). A review of 55 studies that 
investigated symptoms of anxiety in ESRD patients found that 12% to 52% of patients with 
ESRD had substantial anxiety (Murtagh et al., 2007). 
In one of our previous studies, 21% of dialysis patients had symptoms of anxiety. In 
addition, 15.5% of these subjects had comorbid depression and anxiety, and 44.3% of 
depressed patients had comorbid anxiety (Chen et al., 2010). Furthermore, suicide risk was 
not only attributed to depression, but also to anxiety.  
The call for depression screening in HD patients is growing, but screening for anxiety in 
patients with ESRD population is relatively disregarded. This is an indication that many 
clinicians underestimate the importance of anxiety among HD patients. O'Donovan et al. 
(2010) reported that clinically anxious participants exhibited significantly lower levels of 
morning cortisol and significantly higher levels of IL-6, compared with non-anxious 
participants. Uncertainty about the future and fear of losing control of one’s life are 
important factors associated with anxiety that adversely impact emotional stability (Haenel 
et al., 1980).  Notably, anxiety is a common psychological problem that may emerge during 
the initial course of dialysis (Cukor et al., 2008b), and is a reminder to clinicians to pay close 
attention to this issue.  
4. Fatigue 
Fatigue is a subjective symptom characterized by tiredness, weakness, and lack of 
energy.(Lee et al., 1991) Fatigue is also one of the most debilitating symptoms reported by 
HD patients, and roughly 60% to 97% of patients on HD experience some degree of it 
(Jhamb et al., 2008). People with chronic renal disease, regardless of whether they are pre-
dialysis or receiving either HD or PD, are reported having high levels of fatigue and are 
often unable to engage in normal daily activities (Bonner et al., 2010). In addition, fatigue is 
positively correlated with depression (Chen et al., 2010; Sklar et al., 1996), and negatively 
correlated with QoL (Lee et al., 2007). In one study, researchers noted a significant 
relationship between the duration of treatment and the level of fatigue. The experience of 
fatigue was more commonly reported in respondents who had been receiving treatment for 
more than 2 years, compared to those treated for less than 2 years (Letchmi et al., 2011). In a 
longitudinal analysis of 917 incident HD and PD patients, those with lower levels of fatigue 
at baseline survived longer (Jhamb et al., 2009).  
Factors that may contribute to fatigue in dialysis patients include anemia, malnutrition, 
inflammation, depression and/or sleep disorders (Jhamb et al., 2008). Anemia resulting 
from reduced erythropoietin production has been cited as an important cause of fatigue in 
this population (Singh et al., 2006). Additionally, patients undergoing chronic HD show 
evidence of accelerated protein catabolism, which might be due to the significant loss of 
amino acids induced by dialysis (Pertosa et al., 2000). Thus, it is reasonable to presume that 
lower levels of albumin can be significantly correlated with greater levels of fatigue (Bonner 
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et al., 2010). Malnutrition in dialysis patients might also be related to poor intake, or the 
result of chronic inflammation (Stenvinkel et al., 1999). Cytokines productions, particularly 
IL-6, might induce protein catabolism and lipolysis (Memoli et al., 2002), and cytokines have 
a strong negative correlation with serum albumin levels in HD patients (Montinaro et al., 
2010). Thus, chronic inflammation and malnutrition might result in fatigue by either directly 
activating the central nervous system through adrenal axis or by indirectly triggering 
multisystem deregulation (Jhamb et al., 2008).  
5. Decreased Quality of Life (QoL) 
Health-related QoL is an important measure of how a disease affects the lives of patients. 
The QoL domains include physical, psychological, and social functioning and general 
satisfaction with life (Tsay & Healstead, 2002). Once patients with ESRD start to receive HD, 
they must face the chronic stress related to restrictions on their time, the economical and 
vocational costs related to treatment, functional limitations, dietary constraints, and possible 
adverse effects of medications (Son et al., 2009). Numerous studies have demonstrated that 
these patients have a lower QoL than that of healthy populations (Kao et al., 2009; Perlman 
et al., 2005; Wolcott et al., 1988). Depression is strongly correlated with decreased health-
related QoL, especially in mental dimensions (Chen et al., 2010; Kao et al., 2009). 
Furthermore, several studies have shown that patients with poorer QoL had a higher 
incidence of anxiety and fatigue (Kring & Crane, 2009), and longitudinal follow-up showed 
increased mortality (Drayer et al., 2006; Wolcott et al., 1988). 
Biological function, mental illnesses, general health perception, and characteristics of the 
individual and environment may contribute to the variability in patients’ QoL (Kring & 
Crane, 2009). Biological factors that have been associated with QoL include altered 
hemoglobin, albumin, ferritin, CRP, IL-6, IL-8, and TNF-α levels (Farag et al., 2011; Kalender 
et al., 2007a; Montinaro et al., 2010; Perlman et al., 2005). Poor exercise tolerance and muscle 
weakness may limit daily activity, again causing poor QoL (Hsieh et al., 2007; Sakkas et al., 
2003). However, Barros et al. (2011) suggested there was no association of nutritional status 
with malnutrition-inflammation, QoL, or depressive symptoms. There is still debate about 
whether patients’ QoL can be directly correlated to malnutrition-inflammation markers.  
  Among psychological issues, uncertainty about the future and lack of energy emerged as 
the major contributors to poor QoL (Tsay & Healstead, 2002). A patient’s dependency on 
treatment may negatively impact his or her QoL and exacerbate feelings of a loss of control 
(Chilcot et al., 2008). Improved QoL is correlated with higher self-esteem and lower levels of 
mood disturbances (Wolcott et al., 1988). Furthermore, time of diagnosis of chronic renal 
failure may be an important factor related to the QoL of patients receiving dialysis. Late 
diagnosis of renal failure and the consequent lack of predialysis care adversely affect QoL 
among these patients (Sesso & Yoshihiro, 1997). Therefore, early detection of renal failure 
and identification of underlying mental illnesses might be important issues for establishing 
better QoL in HD patients.  
6. Suicide 
Suicide may be the most serious result of mental illness among HD patients. Kurella et al. 
(2005) reported the death rate from suicide was 0.24% per 1000 dialysis patients-years at 
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risk. Patients with ESRD had a significantly higher rate of suicide compared with the 
general population in the United States. Chen et al. (2010) demonstrated that among 200 
patients with HD, 21.5% had suicidal ideation; 3.5% had planned a suicide attempt in prior 
months; and 3.5% had attempted suicide during their lifetime. It is noteworthy that an 
increased number of patients with ESRD had withdrawn from dialysis before their death. 
Nevertheless, only a small proportion (12%) of the respondents were unsure or believed that 
discontinuing dialysis was the equivalent of suicide (Cohen et al., 2002). If the data on 
withdrawal from dialysis were factored into current epidemiologic investigations, the 
suicide rate among HD patients might be much greater.  
Suicide was associated with several demographic characteristics among HD patients. 
Independent predictors of suicide included old age, male gender, lower educational status, 
alcohol or drug dependence, and recent hospitalization for mental illness (Keskin & Engin, 
2011; Kurella et al., 2005). Having strong religious beliefs has been suggested as one 
protective factor of suicide risk among HD patients (Martiny et al., 2011). Preexisting 
depression and anxiety disorders have been identified as independent risk factors for 
subsequent onset of suicidal ideation and attempts in the general population (Martiny et al., 
2011; Sareen et al., 2005). Specific for HD patients, suicide risk was also significantly 
predicted by anxiety and depression. On the other hand, fatigue and QoL may not directly 
affect suicide risk (Chen et al., 2010). Because suicide might be preventable via early 
detection of warning signs, it is crucial to identify the psychological impact and possible risk 
of suicide among dialysis patients. 
7. Managing the psychological impact on dialysis patients 
Numerous studies investigated the managements for mental illness in HD patients, 
including pharmacological and non-pharmacological interventions (Table 2).  
7.1 Pharmacological interventions 
Today, selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice for HD 
patients with depression or anxiety (Raymond et al., 2008). Fluoxetine has been effective and 
safe in HD patients, although trials have thus far involved only small numbers of patients 
(Blumenfield et al., 1997). Citalpram, which is similar to fluoxetine in treatment effects, is 
thought to be safe (Cohen et al., 2004), and it has been beneficial for improving QoL in HD 
patients (Kalender et al., 2007b). Paroxetine, combined with supportive psychotherapy, has 
been shown to be not only successful for treating depression, but also for improving 
nutritional status in chronic HD patients with depression (Koo et al., 2005). Sertraline has 
safe pharmacokinetics in patients with ESRD, and treatment with sertraline in PD patients is 
associated with improved of QoL and fewer symptoms of depression (Atalay et al., 2010). 
Duloxetine and venlafaxine, which are categorized as serotonin-norepinephrine reuptake 
inhibitors, are beneficial for patients with major depressive disorder (Ye et al., 2011). 
However, these agents’ safety and efficacy have not been specifically established for HD 
patients. Bupropion, a dopamine-norepinephrine reuptake inhibitor, and mirtazapine, a 
noradrenergic and specific serotonergic, have also been widely used for patients with 
depression. However, once again, it is not clear whether the beneficial effects of these agents 
can be generalized to dialysis patients. Generally, older tricyclic medications have an 
adverse cardiac profile and anticholinergic effects, which limits their use for HD patients 
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et al., 2010). Malnutrition in dialysis patients might also be related to poor intake, or the 
result of chronic inflammation (Stenvinkel et al., 1999). Cytokines productions, particularly 
IL-6, might induce protein catabolism and lipolysis (Memoli et al., 2002), and cytokines have 
a strong negative correlation with serum albumin levels in HD patients (Montinaro et al., 
2010). Thus, chronic inflammation and malnutrition might result in fatigue by either directly 
activating the central nervous system through adrenal axis or by indirectly triggering 
multisystem deregulation (Jhamb et al., 2008).  
5. Decreased Quality of Life (QoL) 
Health-related QoL is an important measure of how a disease affects the lives of patients. 
The QoL domains include physical, psychological, and social functioning and general 
satisfaction with life (Tsay & Healstead, 2002). Once patients with ESRD start to receive HD, 
they must face the chronic stress related to restrictions on their time, the economical and 
vocational costs related to treatment, functional limitations, dietary constraints, and possible 
adverse effects of medications (Son et al., 2009). Numerous studies have demonstrated that 
these patients have a lower QoL than that of healthy populations (Kao et al., 2009; Perlman 
et al., 2005; Wolcott et al., 1988). Depression is strongly correlated with decreased health-
related QoL, especially in mental dimensions (Chen et al., 2010; Kao et al., 2009). 
Furthermore, several studies have shown that patients with poorer QoL had a higher 
incidence of anxiety and fatigue (Kring & Crane, 2009), and longitudinal follow-up showed 
increased mortality (Drayer et al., 2006; Wolcott et al., 1988). 
Biological function, mental illnesses, general health perception, and characteristics of the 
individual and environment may contribute to the variability in patients’ QoL (Kring & 
Crane, 2009). Biological factors that have been associated with QoL include altered 
hemoglobin, albumin, ferritin, CRP, IL-6, IL-8, and TNF-α levels (Farag et al., 2011; Kalender 
et al., 2007a; Montinaro et al., 2010; Perlman et al., 2005). Poor exercise tolerance and muscle 
weakness may limit daily activity, again causing poor QoL (Hsieh et al., 2007; Sakkas et al., 
2003). However, Barros et al. (2011) suggested there was no association of nutritional status 
with malnutrition-inflammation, QoL, or depressive symptoms. There is still debate about 
whether patients’ QoL can be directly correlated to malnutrition-inflammation markers.  
  Among psychological issues, uncertainty about the future and lack of energy emerged as 
the major contributors to poor QoL (Tsay & Healstead, 2002). A patient’s dependency on 
treatment may negatively impact his or her QoL and exacerbate feelings of a loss of control 
(Chilcot et al., 2008). Improved QoL is correlated with higher self-esteem and lower levels of 
mood disturbances (Wolcott et al., 1988). Furthermore, time of diagnosis of chronic renal 
failure may be an important factor related to the QoL of patients receiving dialysis. Late 
diagnosis of renal failure and the consequent lack of predialysis care adversely affect QoL 
among these patients (Sesso & Yoshihiro, 1997). Therefore, early detection of renal failure 
and identification of underlying mental illnesses might be important issues for establishing 
better QoL in HD patients.  
6. Suicide 
Suicide may be the most serious result of mental illness among HD patients. Kurella et al. 
(2005) reported the death rate from suicide was 0.24% per 1000 dialysis patients-years at 
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risk. Patients with ESRD had a significantly higher rate of suicide compared with the 
general population in the United States. Chen et al. (2010) demonstrated that among 200 
patients with HD, 21.5% had suicidal ideation; 3.5% had planned a suicide attempt in prior 
months; and 3.5% had attempted suicide during their lifetime. It is noteworthy that an 
increased number of patients with ESRD had withdrawn from dialysis before their death. 
Nevertheless, only a small proportion (12%) of the respondents were unsure or believed that 
discontinuing dialysis was the equivalent of suicide (Cohen et al., 2002). If the data on 
withdrawal from dialysis were factored into current epidemiologic investigations, the 
suicide rate among HD patients might be much greater.  
Suicide was associated with several demographic characteristics among HD patients. 
Independent predictors of suicide included old age, male gender, lower educational status, 
alcohol or drug dependence, and recent hospitalization for mental illness (Keskin & Engin, 
2011; Kurella et al., 2005). Having strong religious beliefs has been suggested as one 
protective factor of suicide risk among HD patients (Martiny et al., 2011). Preexisting 
depression and anxiety disorders have been identified as independent risk factors for 
subsequent onset of suicidal ideation and attempts in the general population (Martiny et al., 
2011; Sareen et al., 2005). Specific for HD patients, suicide risk was also significantly 
predicted by anxiety and depression. On the other hand, fatigue and QoL may not directly 
affect suicide risk (Chen et al., 2010). Because suicide might be preventable via early 
detection of warning signs, it is crucial to identify the psychological impact and possible risk 
of suicide among dialysis patients. 
7. Managing the psychological impact on dialysis patients 
Numerous studies investigated the managements for mental illness in HD patients, 
including pharmacological and non-pharmacological interventions (Table 2).  
7.1 Pharmacological interventions 
Today, selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice for HD 
patients with depression or anxiety (Raymond et al., 2008). Fluoxetine has been effective and 
safe in HD patients, although trials have thus far involved only small numbers of patients 
(Blumenfield et al., 1997). Citalpram, which is similar to fluoxetine in treatment effects, is 
thought to be safe (Cohen et al., 2004), and it has been beneficial for improving QoL in HD 
patients (Kalender et al., 2007b). Paroxetine, combined with supportive psychotherapy, has 
been shown to be not only successful for treating depression, but also for improving 
nutritional status in chronic HD patients with depression (Koo et al., 2005). Sertraline has 
safe pharmacokinetics in patients with ESRD, and treatment with sertraline in PD patients is 
associated with improved of QoL and fewer symptoms of depression (Atalay et al., 2010). 
Duloxetine and venlafaxine, which are categorized as serotonin-norepinephrine reuptake 
inhibitors, are beneficial for patients with major depressive disorder (Ye et al., 2011). 
However, these agents’ safety and efficacy have not been specifically established for HD 
patients. Bupropion, a dopamine-norepinephrine reuptake inhibitor, and mirtazapine, a 
noradrenergic and specific serotonergic, have also been widely used for patients with 
depression. However, once again, it is not clear whether the beneficial effects of these agents 
can be generalized to dialysis patients. Generally, older tricyclic medications have an 
adverse cardiac profile and anticholinergic effects, which limits their use for HD patients 
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(Cohen et al., 2004). In the case of trazodone and nefazodone, treatment effects have only 
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(Cohen et al., 2004). In the case of trazodone and nefazodone, treatment effects have only 
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In summary, with the exception of the SSRIs, the efficacy and safety of antidepressant drug 
therapy in dialysis patients have not been clearly established, although these medications 
are believed to improve depression empirically. Notably, the relative activity and mode of 
excretion of metabolites of antidepressants in dialysis patients are as yet unknown and may 
complicate the use of these drugs if adverse events occur. It also remains unclear whether 
there are potential drug-drug interactions between antidepressants and other drugs 
commonly used in HD patients. Therefore, the general rule for prescribing antidepressants 
among HD patients is to start at a lower dose and increase the dosage gradually (Cohen et 
al., 2004). 
There is evidence that the use of erythropoietin-stimulating agents might reduce fatigue and 
improve QoL among ESRD patients (Jones et al., 2004). Benzodiazepines (BZD), such as 
diazepam, alprazolam, and lorazepam, have been successfully used to relieve acute 
episodes of panic and anxiety. In addition, BZD are also widely prescribed for HD patients 
with insomnia (Wyne et al., 2011). In recent years, the use of non-BZD drugs such as 
zolpidem, zopiclone, and zaleplon for insomnia patients has rapidly increased. However, it 
is noteworthy that the liability for abuse and dependence exist in both BZD and non-BZD 
drugs, especially with long-term use (Victorri-Vigneau et al., 2007). Buspirone, a partial 
serotonin agonist that acts on the 5HT(1A) receptor, is often recommended for patients with 
anxiety, and it is generally is considered to have fewer unfavorable side effects than does 
BZD. Generally, it is not necessary to adjust the dosage of most of the erythropoietin-
stimulating agents we have mentioned for the level of the glomerular filtation rate, for these 
agents are metabolized in the liver (Hedayati & Finkelstein, 2009). However, buspirone and 
lorazepam may take longer to be eliminated in ESRD patients, and thus the dosage of these 
two drugs should be carefully titrated. Notably, Winkelmayer et al. (2007) reported that 
BZD or zolpidem are commonly used for incident dialysis patients and may be associated 
with greater mortality in this group. Although the causal reference to this effect warrants 
further investigation, it is also a warning that clinicians need to consider the necessity of 
long-term use of BZD in dialysis patients.  
7.2 Non-pharmacological interventions 
Psychotherapy has been used for a wide range of chronic illnesses, including patients with 
HD (Hedayati & Finkelstein, 2009). Of these approaches, cognitive behavioral therapy 
(CBT), a well-documented evidence-based therapy for depression, has been shown to be 
effective (Chen et al., 2011; Duarte et al., 2009). CBT is based on the assumption that one’s 
dysfunctional “automatic thoughts” in response to a situation can result in strong negative 
feelings/emotions, and thus lead to depression. Correction of those faulty dysfunctional 
constructs can lead to clinical improvement. Duarte et al. (2009) demonstrated that CBT 
performed during 3-month-long group therapy is effective for improving depression and 
many dimensions of QoL in chronic HD patients. Chen et al. (2011) conducted a randomized 
controlled interventional study of 72 sleep-disturbed HD patients. Compared with the 
control group (who received sleep health education), patients who received CBT had 
significant improvements in sleep quality, fatigue, depression, and anxiety. Interestingly, 
CRP, IL-18, and oxidized low-density lipoprotein levels also significantly declined among 
those receiving CBT in comparison to those in the control group (Chen et al., 2011). Thus, 
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these studies suggest that CBT might be effective for improving mental health, and for 
reducing inflammation and oxidative stress in HD patients. 
Exercise programs may have a beneficial effect on depressive symptoms in patients with 
ESRD. Ouzouni et al. (2009) reported that 10-month intradialytic exercise training improved 
QoL in both physical functioning and psychological status in HD patients, and decreased 
in self-reported depression. In another study, a 1-year exercise training program reduced 
emotional distress and concomitantly improved cardiac autonomic modulation measured 
by heart rate variability (HRV) indices (Kouidi et al., 2010). For alternative therapy, Kim et 
al. (2011) reported that 24 HD patients who received individualized acupuncture 
treatments over 6 consecutive weeks showed significant improvements in some QoL 
subscales.  
Social support has been shown to help improve emotional disturbances in a variety of 
chronic illnesses. Support and education, either individually to patients or including their 
caregivers and family members, may be helpful (Symister & Friend, 2003). A patient’s 
depression could be influenced by the psychosocial status of his or her spouse, and the 
spouse might be amenable to interventions that could improve patient outcome (Daneker 
et al., 2001). Social support has been shown to decrease depression by improving the self-
esteem of patients with ESRD, which led to increased optimism (Symister & Friend, 2003). 
Treatment programs that address problems with social interactions of patients need to be 
comprehensive, and should explore use of family and marital counseling, and 
involvement of the community, along with consideration of the patient’s social life (Cohen 
et al., 2007). 
8. Conclusion 
HD is a life-sustaining treatment for patients with ESRD; however, it adversely affects 
patients’ mental status. Increasingly, depression is being recognized as a substantial 
comorbid illness in these patients. Anxiety, feelings of fatigue, and decreasing QoL are also 
significant psychological symptoms, and they may be interrelated. Depression and anxiety 
particularly increase patients’ suicide risk. Mental illnesses may have underlying biological 
and psychological causes. There is considerable evidence that these psychological effects are 
associated with adverse outcomes in HD patients with ESRD. It is important, therefore, to 
develop systematic approaches to screening patients for mental illness, and then planning 
treatment strategies. To improve treatment outcome and patient Qol, a comprehensive 
management plan that includes pharmacological and psychosocial interventions, is 
essential.  
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al. (2011) reported that 24 HD patients who received individualized acupuncture 
treatments over 6 consecutive weeks showed significant improvements in some QoL 
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Social support has been shown to help improve emotional disturbances in a variety of 
chronic illnesses. Support and education, either individually to patients or including their 
caregivers and family members, may be helpful (Symister & Friend, 2003). A patient’s 
depression could be influenced by the psychosocial status of his or her spouse, and the 
spouse might be amenable to interventions that could improve patient outcome (Daneker 
et al., 2001). Social support has been shown to decrease depression by improving the self-
esteem of patients with ESRD, which led to increased optimism (Symister & Friend, 2003). 
Treatment programs that address problems with social interactions of patients need to be 
comprehensive, and should explore use of family and marital counseling, and 
involvement of the community, along with consideration of the patient’s social life (Cohen 
et al., 2007). 
8. Conclusion 
HD is a life-sustaining treatment for patients with ESRD; however, it adversely affects 
patients’ mental status. Increasingly, depression is being recognized as a substantial 
comorbid illness in these patients. Anxiety, feelings of fatigue, and decreasing QoL are also 
significant psychological symptoms, and they may be interrelated. Depression and anxiety 
particularly increase patients’ suicide risk. Mental illnesses may have underlying biological 
and psychological causes. There is considerable evidence that these psychological effects are 
associated with adverse outcomes in HD patients with ESRD. It is important, therefore, to 
develop systematic approaches to screening patients for mental illness, and then planning 
treatment strategies. To improve treatment outcome and patient Qol, a comprehensive 
management plan that includes pharmacological and psychosocial interventions, is 
essential.  
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1. Introduction 
In many countries, diabetic renal disease has become, or will soon become, the single most 
common cause of end-stage renal disease (ESRD). End stage renal failure (ESRF) in type 2 
diabetic patients is increasing worldwide (1).  
Diabetic nephropathy (DN) is the most prevalent cause of ESRD in the USA. The proportion 
of ESRD patients who are diabetic is increasing by more than 1% each year in the USA. The 
rate of admission of uraemic patients with diabetes as a co-morbid condition in the USA was 
107 per million population (p.m.p.) per year in 1994 (2) and is currently approximately 120 
p.m.p. The corresponding figures in other countries are lower: 66 p.m.p. in Japan and 52 
p.m.p. in southwestern Germany (1). The incidence of ESRD in Europe due to diabetes, 
hypertension and renal vascular disease has nearly doubled over 10 years; in 1998–99, it 
varied between countries from 10.2 to 39.3 p.m.p. for diabetes, from 5.8 to 21.0 for 
hypertension, and from 1.0 to 15.5 for renal vascular disease (3). The figures are lower in the 
Mediterranean countries, as well as in Macedonia (4), although an increase has recently been 
reported from Spain (5) and Italy (6). ESRD and ESRF caused by DN was 10%, 5–15% in 
different haemodialysis 
Centres for adults in 2000 in the Republic of Macedonia (4), as well as 22% in 2006 (4a).  
The great majority of diabetic patients admitted suffer from type 2 diabetes. 
The increasing trend may be explained by a number of factors: 
1. the increasing prevalence of type II diabetes in the general population; 
2. improved survival of diabetic patients, particularly diabetic patients with nephropathy, 
because of better treatment of hypertension and coronary heart disease, so that they live 
long enough to experience renal failure; 
3. less restriction of admission to renal replacement therapy. 
One major problem continues to be late referral. 
The poor prognosis of patients with diabetic nephropathy is well known in both in type 1 
and type 2 diabetes. The high mortality and morbidity, especially in type 2 diabetic patients 
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with nephropathy, are mainly caused by coronary artery, cerebrovascular and peripheral 
vascular disease (7). 
The survival of type 1 diabetic patients requiring renal replacement therapy has been 
dramatically improved during the last decade; however, prognosis for type 2 diabetic 
patients with ESRD continues to be extremely poor (1). 
2. Evaluation of the diabetic patient with preterminal renal failure 
Evaluation of the diabetic patients with preterminal renal failure has the following aims: 
1. to assess the course of renal failure (progression); 
2. to recognize the presence of acute renal failure, or acute or chronic renal failure; 
3. to recognize renal problems other than diabetic nephropathy, for example ischaemic 
nephropathy, diabetic cystopathy, urinary tract infection; 
4. to monitor the patient for clinical evidence of extrarenal microvascular and 
macrovascular complications, for example retinopathy or polyneuropathy and coronary 
heart disease or arterioocclusive disease. 
Some of these coincident kidney diseases are listed below. 
2.1 Ischaemic renal disease 
Renal ischaemia or atherosclerotic renal artery stenosis is much more common in diabetics 
than previously assumed (8). In this case one should be cautious regarding ACE-inhibitors 
or angiotensin receptor blocking antihypertensives. Frequent control of s-creatinin, s-
potassium and bodyweight are mandatory. A two-fold increase in s-creatinine should 
prompt the physician to stop this type of medication. 
2.2 Urinary tract infection 
Urinary tract infection (UTI) has frequently led to renal parenchymatous infection with 
purulent papillary necrosis and intrarenal abscess formation. UTI may be frequent in 
diabetics, especially when residual urine is present.  
2.3 Glomerulonephritis 
Glomerulonephritis (GN), particularly membranous GN, is thought to be more frequent in 
diabetics, but this has not been supported by other studies. 
2.4 Acute renal failure 
Diabetic patients with nephropathy are exceptionally susceptible to acute renal failure (ARF) 
after the administration of radiocontrast media, the risk being similar with ionic and non-
ionic materials. The risk may be reduced by fluid administration and a temporary withdrawal 
of diuretics. In patients with severely elevated serum-creatinine a dialysis procedure 
immediately after the radiographic procedure is warranted, without any delay in time.  
Hydroxyethyl starch and ACE inhibitors also cause deterioration of renal function in 
diabetic patients, especially in those with congestive heart failure. 
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The points relating to treatment strategies and decision-making in diabetic patients with 
renal failure present are: evaluation (and treatment) of risk factors for progression, 
monitoring of progression, evaluation of patient for renal replacement therapy (dialysis, 
transplantation), informing patient both and care about renal replacement therapy, 
preparing patients for renal replacement therapy (vascular access, check-up for 
transplantation) and adjustment of diet and insulin or oral hypoglycaemic agents. 
In the table 1 is a check-list for management of diabetic patients with preterminal renal 
failure. 
 
• Reversible causes of renal failure present? (contrast media, urinary tract infection, 
angiotensin converting enzyme inhibitors, congestive heart failure) 
• Hypovolaemia present? 
• Coronary heart disease present (percutaneous transluminal angioplasty or coronary 
bypass surgery required? 
• Cardiomyopathy or congestive heart failure present? 
• Congestion due to hypervolaemia or heart failure? 
• Early vascular access? 
• Hypoglycemic episodes present? Adequate nutrient intake? 
• Eye (examined and treated?) 
• Foot (neuropathic? ischaemic? foot ulcers? infection?) 
• Residual urine present, urinary tract infection? 
• Normotension or antihypertensive treatment achieved? 
• Orthostatic blood pressure drop? 
• Gastroparesis or diarrhoeal episodes? 
Table 1. Check-list for management of diabetic patients with preterminal renal failure 
3. Option in uremia therapy 
Determination of which treatment option is "best" for a particular diabetic ESRD patient, 
however, is an individualized judgment (table 2) depending on the patient's age, education, 
geographic location, family and social support systems, and the extent of co-morbid 
conditions, most importantly, of cardiovascular integrity. Major subjects which must be 
apprised when devising a longterm plan for ESRD management include anticipated patient 
compliance and potential to participate in self-treatment. Each ESRD treatment option must 
be explained in understandable terms covering the probable survival rate, the degree of 
rehabilitation and the expected stabilisation of extrarenal diabetics complications. Ideally, 
what has been termed a "life plan" should be constructed for every ESRD patient after 
consultation between the health care team, the patient, and the members of the patient's 
social support system. 
While the best rehabilitation of diabetic ESRD patients is achieved in recipients of living 
related donor renal transplants, this superior outcome may reflect a selection bias in which 
younger, healthier patients are chosen for a transplant leaving a residual pool of more 
morbid dialysis patients. Morbidity from blindness and neuropathy (but not coronary artery 
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or peripheral vascular disease) is decreased in diabetic kidney transplant recipients (9). 
Lacking randomized prospective trials of diabetics treated with dialytic therapy versus a 
kidney transplant, controlled for age, race, gender, and severity of extrarenal complication, 
caution must be exercised when assessing one ESRD therapy against another. A reasonable 
policy can be based on the premise that while the best rehabilitation is effected by renal 
transplantation, there is no distinctly superior treatment for the uraemic diabetic, and 
therefore, assessment and treatment of diabetic with ESRD must be highly individualized 
(10). 
 
1. Passive suicide which is the consequence of declining dialysis or kidney 
transplantation 
2. Haemodialysis 
- Facility haemodialysis 
- Home haemodialysis 
3. Peritoneal dialysis 
- Intermittent peritoneal dialysis (IPD) 
- Continuous ambulatory peritoneal dialysis (CAPD) 
- Continuous cyclic peritoneal dialysis (CCPD) 
4. Renal transplantation 
- Cadaver donor kidney 
- Living donor kidney 
5. Pancreas, plus kidney transplantation 
- IDDM 
- ? NIDDM 
- islet-cell transplantation (type 1) 
Table 2. Options in uremia therapy for diabetic ESRD patients 
4. Timing the start of dialytic therapy 
As residual creatinine clearance falls to about 20–30 ml/min, available ESRD options should 
be discussed and a selection made. In practice, bias by the patient's most trusted physician 
usually is the major factor determining which renal replacement therapy is chosen. 
Diabetic complications which persist and/or progress during ESRD and on dialysis are: 
retinopathy, glaucoma, cataracts; coronary artery disease, cardiomyopathy; cerebrovascular 
disease; hypertension; peripheral vascular disease: limb amputation; motor neuropathy, 
sensory neuropathy; autonomic dysfunction: diarrhoea, constipation, hypotension; 
myopathy; depression; infections; bladder neuropathy; sexual disorders; impotence; eating 
disorders; gastroparesis with vomiting and food retention; alteration in the metabolic 
control and dyslipidaemias; ion imbalance and metabolic acidosis. 
For the 80% of uraemic diabetic selecting haemodialysis (HD), the construction of a vascular 
access is of great importance. Once it is clear that uraemia is a near term probability (less 
than one year), an arteriovenous access should be constructed. 
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The first choice in HD access in diabetics is an autologous a-v fistula of the Cimino-Brescia 
type. 
When peritoneal dialysis (PD) is selected advance planning should ensure that a suitable 
peritoneal catheter is in situ 2–4 weeks before starting dialysis.  
Option for a kidney or a kidney plus pancreas transplant obviously demands referral to and 
evaluation by a transplant team. In the case of an intended living related donor transplant, 
interim dialysis can be avoided by proper planning, performing the transplant at an early 
stage of uraemic symptoms. A long wait is usual for a cadaver kidney. 
Accordingly, patients should be entered on waiting lists when the creatinin clearance is 
about 10–15 ml/min. 
5. Haemodialysis in diabetics 
Haemodialysis has emerged as the most common treatment for all forms of renal failure 
including diabetic nephropathy. It is generally accepted that renal replacement therapy 
should be considered as a creatinine clearance of approximately 9–14 ml/min in non-
diabetic uraemia patients (11). 
In diabetic patients with ESRD, dialysis is started at creatinine clearance as high as 15–20 
ml/min, at serum creatinine levels as low as 3–5 mg/dl. 
In any case, HD should be started before the clinical status deteriorates, secondary to fluid 
overload, malnutrition, hyperkalaemia and infection. This is usually the case when the GFR 
declines below 20 ml/min. 
Vascular access surgery (usually autologous arteriovenous fistula of the Cimino-Brescia 
type) some month before the initiation of the dialysis treatment helps to avoid central 
venous lines and their concomitant complications. Blood drawing for regular serum 
chemistry is restricted to the dorsal hand veins only. 
5.1 Prognosis in patients with diabetic nephropathy on haemodialysis and in 
assessing the adequacy of haemodialysis 
In the past, the prognosis for DN was discouraging, with 77% of patients dying within 10 
years after the onset of persistent proteinuria. The survival of dialysed diabetics has 
improved over the past decade. No single factor is credited with reducing the death rate 
of haemodialysed diabetics, though better control of hypertension, a reduction in 
intravascular volume overload, better nutrition, and better vascular access surgery have 
contributed. 
Table 3 compares actuarial 5-year survival of non-diabetic and diabetic patients on 
maintenance haemodialysis in different countries. It is obvious that in countries with a low 
prevalence of cardiovascular deaths in the general population, e.g. East Asian countries and, 
to a lesser extent, the Mediterranean countries, survival of diabetic patients on RRT is 
significantly better than that in countries with notoriously high cardiovascular death rates, 
e.g. USA and Germany. 
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 No diabetes Diabetes 
Australia 60 42/27 a 
Japan b 64/73 50/40 
Taiwan 65 37 
Hong Kong 70 20 
Italy (Lombardy) 61 28 
Spain (Catalonia) c 65 30 
Germany – 38/5 
USA d 35 21 
Values are expressed as percentage of surviving patients. 
a Reported as type 1 / type 2 diabetes. 
b Reported as haemodialysis / continuous ambulatory peritoneal dialysis. 
c Includes renal transplantation. 
d Censored at first transplantation. 
Table 3. Comparison of actuarial 5 year survival of non-diabetic and diabetic patients on 
dialysis treatment in different countries (1). 
In table 4 are the causes of death in diabetic patients on HD. 
 
 Type 1 diabetes (n = 67)
Type 2 diabetes 
(n = 129)
Myocardial infarction  8 12 
Sudden death  7 13 
Cardiac other 3 17 
Stroke 0 6 
Septicaemia 7 11 
Interruption of treatment 2 8 
Other 2 13 
Total 29 (40%) 80 (43%) 
Total cardiovascular mortality was 62% in type 1 and 60% in type 2 diabetes. 
Table 4. Causes of death in diabetic patients 57 months after start of haemodialysis (12). 
Cardiovascular disease and serious infections are the major causes of death in 
haemodialysed and transplanted diabetics. Despite recent improvement, rehabilitation of 
haemodialysed diabetics continues to be inferior to that of nondiabetics. Improvement of 
survival is a matter of reduction of cardiovascular death and infection. 
5.2 Cardiovascular death and adequacy of dialysis 
Cardiac death is strongly predicted by a history of vascular disease (peripheral vascular 
and/or carotid), myocardial infarction and angina pectoris. Proliferative retinopathy and 
polyneuropathy were associated with an increased cardiac risk, in the latter possibly due to an 
imbalance of autonomic cardiac innervation. Hypotensive cardiac episodes during dialysis are 
also predictive of cardiac death. 
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Haemodialysis procedures should be with low ultrafiltration rates and prolonged duration 
of dialysis sessions (13). In practice, ultrafiltration in diabetics should not exceed more than 
500–600 ml/h on haemodialysis. This means dialysis sessions of more than 4h and, in larger 
patients, of more than 5h haemodialysis three times per week. 
Guidelines have been created to assure adequate dialysis – "dose of dialysis". 
According to DOQI (Dialysis Outcomes Quality Initiative), a Kt/V (indicator for adequacy of 
dialysis, where K is the dialyser clearance rate, t the net duration of dialysis and V the 
corrected body volume) of above 1.2 (e.g. a 70-kg patient dialysed for 5h) is adequate (14). 
Lower Kt/V, especially below 1, is associated with a higher mortality rate and this is 
particularly true of the patient with diabetic nephropathy. 
Optimal dialysis in diabetic patients: 
Need for a dialysis technique which will provide 
- – absence of acetate 
- – good cardiovascular stability 
- – good acid-base correction 
- – good solute removal 
- – good biocompatibility 
5.3 Special problems of diabetic patients on haemodialysis 
5.3.1 Vascular access 
In a diabetic patient it is often more difficult to establish vascular access because of a poor 
arterial inflow (atherosclerosis, media calcification of the artery) and venous run-off 
(hypoplasia or thrombosed veins) in chronically ill patients, with numerous stays in 
hospital. Arterio-venous anastomosis should be placed in the upper forearm to maintain 
adequate shunt blood flow. It is therefore advisable to establish vascular access early, 
when creatinine clearance is above 20-25 ml/min (14, 15). In malnourished, older 
individuals, this level of GFR impairment can be reached even at a serum-creatinine of 
2 mg/dl. 
One should patiently wait for maturing of the fistula: early puncture tends to be associated 
with haematoma formation, scarring, stenosis and thrombosis, and should be avoided, even 
if dialysis has to be performed by a central venous catheter. Some authors have reported 
poor functioning of the vascular access in diabetics, with only 64% of fistula functioning 
after 1 year compared to 83% in non-diabetic. 
Radial steal syndrome, venous hypertension, infection/thrombosis (15, 16), and ischaemic 
monomelic neuropathy could be problems related to vascular access. 
5.3.2 Metabolic control 
In clinical practice, the need for insulin decreases upon the institution of maintenance HD. 
The fall in insulin requirements in no way signifies any improvement in the underlying 
disease. Also, good glucose control should remain a goal even after initiation of dialysis. It 
remains important to protect further injury to other organs such as the eyes. Glycaemic 
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a Reported as type 1 / type 2 diabetes. 
b Reported as haemodialysis / continuous ambulatory peritoneal dialysis. 
c Includes renal transplantation. 
d Censored at first transplantation. 
Table 3. Comparison of actuarial 5 year survival of non-diabetic and diabetic patients on 
dialysis treatment in different countries (1). 
In table 4 are the causes of death in diabetic patients on HD. 
 
 Type 1 diabetes (n = 67)
Type 2 diabetes 
(n = 129)
Myocardial infarction  8 12 
Sudden death  7 13 
Cardiac other 3 17 
Stroke 0 6 
Septicaemia 7 11 
Interruption of treatment 2 8 
Other 2 13 
Total 29 (40%) 80 (43%) 
Total cardiovascular mortality was 62% in type 1 and 60% in type 2 diabetes. 
Table 4. Causes of death in diabetic patients 57 months after start of haemodialysis (12). 
Cardiovascular disease and serious infections are the major causes of death in 
haemodialysed and transplanted diabetics. Despite recent improvement, rehabilitation of 
haemodialysed diabetics continues to be inferior to that of nondiabetics. Improvement of 
survival is a matter of reduction of cardiovascular death and infection. 
5.2 Cardiovascular death and adequacy of dialysis 
Cardiac death is strongly predicted by a history of vascular disease (peripheral vascular 
and/or carotid), myocardial infarction and angina pectoris. Proliferative retinopathy and 
polyneuropathy were associated with an increased cardiac risk, in the latter possibly due to an 
imbalance of autonomic cardiac innervation. Hypotensive cardiac episodes during dialysis are 
also predictive of cardiac death. 
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Haemodialysis procedures should be with low ultrafiltration rates and prolonged duration 
of dialysis sessions (13). In practice, ultrafiltration in diabetics should not exceed more than 
500–600 ml/h on haemodialysis. This means dialysis sessions of more than 4h and, in larger 
patients, of more than 5h haemodialysis three times per week. 
Guidelines have been created to assure adequate dialysis – "dose of dialysis". 
According to DOQI (Dialysis Outcomes Quality Initiative), a Kt/V (indicator for adequacy of 
dialysis, where K is the dialyser clearance rate, t the net duration of dialysis and V the 
corrected body volume) of above 1.2 (e.g. a 70-kg patient dialysed for 5h) is adequate (14). 
Lower Kt/V, especially below 1, is associated with a higher mortality rate and this is 
particularly true of the patient with diabetic nephropathy. 
Optimal dialysis in diabetic patients: 
Need for a dialysis technique which will provide 
- – absence of acetate 
- – good cardiovascular stability 
- – good acid-base correction 
- – good solute removal 
- – good biocompatibility 
5.3 Special problems of diabetic patients on haemodialysis 
5.3.1 Vascular access 
In a diabetic patient it is often more difficult to establish vascular access because of a poor 
arterial inflow (atherosclerosis, media calcification of the artery) and venous run-off 
(hypoplasia or thrombosed veins) in chronically ill patients, with numerous stays in 
hospital. Arterio-venous anastomosis should be placed in the upper forearm to maintain 
adequate shunt blood flow. It is therefore advisable to establish vascular access early, 
when creatinine clearance is above 20-25 ml/min (14, 15). In malnourished, older 
individuals, this level of GFR impairment can be reached even at a serum-creatinine of 
2 mg/dl. 
One should patiently wait for maturing of the fistula: early puncture tends to be associated 
with haematoma formation, scarring, stenosis and thrombosis, and should be avoided, even 
if dialysis has to be performed by a central venous catheter. Some authors have reported 
poor functioning of the vascular access in diabetics, with only 64% of fistula functioning 
after 1 year compared to 83% in non-diabetic. 
Radial steal syndrome, venous hypertension, infection/thrombosis (15, 16), and ischaemic 
monomelic neuropathy could be problems related to vascular access. 
5.3.2 Metabolic control 
In clinical practice, the need for insulin decreases upon the institution of maintenance HD. 
The fall in insulin requirements in no way signifies any improvement in the underlying 
disease. Also, good glucose control should remain a goal even after initiation of dialysis. It 
remains important to protect further injury to other organs such as the eyes. Glycaemic 
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control may also be important for preserving residual renal function for as long as possible 
(17). 
Most nephrologists prefer to dialyse against glucose (200 mg/dl) to achieve better 
stabilization of plasma glucose concentrations. One must consider, however, that glucose-
containing dialysate does not guarantee normoglycaemia if the prescribed insulin dose is 
too high (18,19). "Tight" metabolic control – a key component in diabetic management – 
risks potentially fatal hypoglycaemic episodes in haemodialysed patients (14). Oral 
sulphonylurea must be avoided, in fact is strictly forbidden, because of prolonged 
hypoglycaemia in endstage renal failure (20). 
If glucose-free dialysate is used, glucose loss (amounting to 80-100 g per dialysis session) 
may occur. It has been argued that the glucose loss into the dialysate contributes to 
catabolism but no convincing evidence for this was produced in a control trial (20). 
Diabetic control is occasionally rendered difficult by diabetic gastroparesis and the tendency 
of gastric motility to deteriorate acutely during dialysis sessions. 
Adequate control of glycaemia is important: hyperglycaemia causes intense thirst and 
subsequent increased fluid intake, as well as osmotic water shift and shift of potassium from 
the intracellular to the extracellular space, with the attendant risk of circulatory and 
pulmonary congestion and hyperkalaemia. 
Poorly controlled diabetics are also more susceptible to infection. 
The HbA1c should be < 8.0% (18, 19, 22). 
5.3.3 Intradialytic and interdialytic blood pressure 
Blood pressure in the diabetic is primarily volume-dependent. Consequently, hypertension 
tends to be more common in dialysed diabetics, who have higher predialytic blood 
pressures, require multidrug therapy more often than non-diabetic uraemic patients. About 
one-half of haemodialysed diabetics require antihypertensive medications, compared to 
27.7% of non-diabetics (23). Betablockers should not be used in diabetics as they exacerbate 
hypertriglyceridemia, worsen glucose control and mask symptoms of severe 
hypoglycaemia. Improvement is typical in volumen-dependent hypertension after 
intradialytic fluid extraction. The problem is compounded by the fact that intradialytic 
hypotension is more frequent in diabetics; as a consequence it is often difficult to reach the target 
dry weight. 
Hypotension is more prevalent in diabetic than in non-diabetic haemodialysis patients. 
Episodic hypotension is at least 20% greater in incidence while nausea and vomiting are 
three times more prevalent (23). Episodes of hypotension are highly predictive of cardiac 
death (24). Severe or sustained hypotension may precipitate angina pectoris culminating in 
acute myocardial infarction. 
Intradialytic hypotension is a multi-factorial problem; inadequate circulatory adjustment to 
volume subtraction (as a consequence of autonomous polyneuropathy) and left ventricular 
diastolic malfunction (necessitating higher left ventricular filling pressures) have both been 
implicated in its genesis. 
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Hypotensive episodes have been associated with an increased risk of sudden cardiac death, 
acute myocardial ischaemia, deterioration of maculopathy and non-thrombotic mesenteric 
ischaemia. 
The following suggestions could be useful for minimizing haemodialysis-induced 
hypotension in diabetics (9): 
• bicarbonate rather than acetate dialysate, 
• acetate free biofiltration, 
• high sodium concentration (140–145 mmol/l) in dialysate, 
• slow rate of ultrafiltration, 
• schedule sequential ultrafiltration and dialysis in patients who are grossly 
• oedematous, 
• prime dialysis circuit with hypertonic albumin solution, 
• maintain hematocrit at or above 30 vol% with erythropoietin, 
• omit antihypertensive medications on morning of dialysis, 
• leg toning exercises to improve venous return, and 
• decrease dialysate temperature (particularly near conclusion of treatment). 
High interdialytic weight gain. Diabetics gain near 30% more weight between haemodialysis 
than non-diabetics. 
Intensified metabolic control facilitated by dietary counselling plus sodium modeling of 
dialysis, and sequential ultrafiltration curtails weight swings and their deleterious 
consequences. 
5.3.4 Lipid abnormalities in diabetic patients with renal failure 
Hypercholesterolaemia and hypertriglyceridaemia are strong predictors of coronary heart 
disease (25). Major dyslipidaemia is seen only in untreated type-1 diabetic patients. A strong 
correlation exists between HbA1c and plasma cholesterol, triglyceride and high-density 
lipoproteins (26). In type-2 diabetes, dyslipidaemia persists even when glycosaemia is well 
controlled, presumably due to an underlying genetic defect which predisposes to both 
diabetes and disturbed lipid metabolism (27, 28). 
In a prospective study (29), a relationship between coronary risk and cholesterol 
concentrations in diabetics admitted for haemodialysis has been established. 
Non-accumulating fibrates or HMG Co-reductase inhibitors are indicated for the treatment 
of dyslipidaemia which does not respond to dietary manipulation. Regular control of 
creatinin kinase (rhabdomyolysis) is recommended. 
5.3.5 Erythropoietin and iron substitution in uraemic diabetic patients 
Len venticular hypertrophy (LVH) is more prevalent in diabetics compared to non-diabetics 
with end-stage renal disease, and it is possible that the beneficial effects of erythropoietin on 
LVH could be particularly relevant for diabetic patients (30, 31). 
Currently, there is no reason to recommend a different target haemoglobin for diabetic and non-
diabetic patients; a haemoglobin of 11–12 g/dl is therefore also appropriate for diabetic patients. 
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hypoglycaemia. Improvement is typical in volumen-dependent hypertension after 
intradialytic fluid extraction. The problem is compounded by the fact that intradialytic 
hypotension is more frequent in diabetics; as a consequence it is often difficult to reach the target 
dry weight. 
Hypotension is more prevalent in diabetic than in non-diabetic haemodialysis patients. 
Episodic hypotension is at least 20% greater in incidence while nausea and vomiting are 
three times more prevalent (23). Episodes of hypotension are highly predictive of cardiac 
death (24). Severe or sustained hypotension may precipitate angina pectoris culminating in 
acute myocardial infarction. 
Intradialytic hypotension is a multi-factorial problem; inadequate circulatory adjustment to 
volume subtraction (as a consequence of autonomous polyneuropathy) and left ventricular 
diastolic malfunction (necessitating higher left ventricular filling pressures) have both been 
implicated in its genesis. 
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Hypotensive episodes have been associated with an increased risk of sudden cardiac death, 
acute myocardial ischaemia, deterioration of maculopathy and non-thrombotic mesenteric 
ischaemia. 
The following suggestions could be useful for minimizing haemodialysis-induced 
hypotension in diabetics (9): 
• bicarbonate rather than acetate dialysate, 
• acetate free biofiltration, 
• high sodium concentration (140–145 mmol/l) in dialysate, 
• slow rate of ultrafiltration, 
• schedule sequential ultrafiltration and dialysis in patients who are grossly 
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• prime dialysis circuit with hypertonic albumin solution, 
• maintain hematocrit at or above 30 vol% with erythropoietin, 
• omit antihypertensive medications on morning of dialysis, 
• leg toning exercises to improve venous return, and 
• decrease dialysate temperature (particularly near conclusion of treatment). 
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Intensified metabolic control facilitated by dietary counselling plus sodium modeling of 
dialysis, and sequential ultrafiltration curtails weight swings and their deleterious 
consequences. 
5.3.4 Lipid abnormalities in diabetic patients with renal failure 
Hypercholesterolaemia and hypertriglyceridaemia are strong predictors of coronary heart 
disease (25). Major dyslipidaemia is seen only in untreated type-1 diabetic patients. A strong 
correlation exists between HbA1c and plasma cholesterol, triglyceride and high-density 
lipoproteins (26). In type-2 diabetes, dyslipidaemia persists even when glycosaemia is well 
controlled, presumably due to an underlying genetic defect which predisposes to both 
diabetes and disturbed lipid metabolism (27, 28). 
In a prospective study (29), a relationship between coronary risk and cholesterol 
concentrations in diabetics admitted for haemodialysis has been established. 
Non-accumulating fibrates or HMG Co-reductase inhibitors are indicated for the treatment 
of dyslipidaemia which does not respond to dietary manipulation. Regular control of 
creatinin kinase (rhabdomyolysis) is recommended. 
5.3.5 Erythropoietin and iron substitution in uraemic diabetic patients 
Len venticular hypertrophy (LVH) is more prevalent in diabetics compared to non-diabetics 
with end-stage renal disease, and it is possible that the beneficial effects of erythropoietin on 
LVH could be particularly relevant for diabetic patients (30, 31). 
Currently, there is no reason to recommend a different target haemoglobin for diabetic and non-
diabetic patients; a haemoglobin of 11–12 g/dl is therefore also appropriate for diabetic patients. 
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Increases in blood pressure, vascular access clotting and even seizures have been observed 
more frequently in diabetic dialysis patients when haemoglobin was increased too rapidly. 
A suggested mode of correction of anaemia in diabetic patients is as follows: a cautious 
dosage of erythropoietin (initial dose of 2000 three times weekly s.c., followed by increments 
of 2000 at monthly intervals) and careful adjustment of heparinisation during dialysis. If 
haemoglobin increases by > 1.3 g/dl over two weeks, the erythropoietin dose should be 
reduced. Once the target haemoglobin has been reached, the weekly dosage should be 
reduced and haemoglobin monitored at regular intervals. 
It is important to establish adequate iron substitution in erythropoietin treated dialysed 
diabetic patients. In clinical practice intravenous iron substitution, at the end of the dialysis 
procedure, is safe and effective. A target ferritin level of above 250 mg/dl is advisable. 
During infection episodes, however, iron substitution should be temporarily stopped. 
5.4 Malnutrition in dialysis – dependent diabetics 
It is important that diabetic patients on dialysis maintain adequate energy (35–40 
kcal/kg/day). In addition, protein intake should not be below 1.3 g/kg a day because of the 
known higher protein requirements of dialysis patients. Anorexia and prolonged 
habituation to dietary restrictions are important reasons for malnutrition of the diabetic 
patient on dialysis. Malnutrition is a common concern in dialysed diabetic patients. 
5.5 Infections in uraemic diabetic patients 
Bacterial infections are common complications in uraemic diabetic patients (32), in whom 
the polymorphnuclear leukocyte function is depressed, particularly when acidosis is 
present. Leukocyte adherence, chemotaxis and phagocytosis may be affected. 
Uraemic diabetics have several particular sites where infections can occur: arteriovenous 
fistula and central venous catheters, CAPD catheter, the urinary tract, the sinus and diabetic 
foot ulcer. Infections of the dialysis access, either HD or CAPD, are mostly caused by 
Staphylococcus as a result of increased skin and mucosal colonization with these organisms 
and need specific therapy. Diabetic patients with prolonged hospital stay should be 
screened for methicillinresistant Staphylococcus. Diabetics are more prone to urinary tract 
infections due to diminishing residual diuresis, incomplete bladder emptying because of 
autonomic neuropathy and following diagnostic or therapeutical instrumentation of the 
urethra or bladder. Foot ulcer infections often progress to septic gangrene and amputation. 
6. Microvascular complications 
6.1 Diabetic retinopathy 
Diabetic retinopathy occurs in 97% of uraemic diabetic patients and 25–30% are blind (33). 
Visual loss results from proliferative retinopathy, cataracts, glaucoma,or vitreous 
haemorrhage. 
Diabetic uraemic patients need regular ophthalmologic controls at a frequency of 3–6 
months. Laser photocoagulation and other intervention are very frequent in all diabetics 
either prior to or during treatment for ESRD. 
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Anticoagulation (heparin) during the haemodialysis procedure and the application of 
platelet aggregation inhibitors (e.g. aspirin) can cause severe retinal bleeding and blindness. 
6.2 Diabetic neuropathy 
Many patients suffer from the consequences of a peripheral sensorimotor neuropathy, or 
from gastroparesis or other bowel disturbances caused by autonomic neuropathy. 
These are very difficult to treat and respond poorly to conventional treatments. Neuropathy is 
less likely to progress in a renal transplant recipient. It also tends to be less severe in patients 
treated with PD, theoretically because of improved clearance of medium-sized molecules (33). 
Many patients may also suffer from impotence caused by neuropathy, vascular disease, or 
medication. These patients may require specialist investigation and treatment. 
7. Macrovascular complication 
7.1 Peripheral vascular disease 
Problems related to the diabetic foot are a major cause of hospital admission, and 50–70% of 
all nontraumatic amputations occur in diabetics. One UK study reported that 6.8% of 
diabetics receiving renal replacement therapy had a major amputation (34, 35). 
There is no reported difference between CAPD and HD (34). The major contributory 
etiologic factors in diabetic foot problems are peripheral vascular disease, diabetic 
neuropathy and stress caused by inappropriate footwear. 
To prevent diabetic foot complications, patients at risk, should be identified should perform 
education about foot care, have regular examination of the feet at clinic, provision of 
appropriate footwear and of podiatry services. 
Some studies have reported a symptomatic deterioration in the lower limbs that correlates 
with falls in blood pressure. Therefore, care should be taken to avoid excessive 
ultrafiltration in diabetic patients undergoing dialysis. In type 2 diabetics, better glycaemic 
control is associated with fewer amputations. 
The treatment of this condition requires a multidisciplinary approach, ideally in a combined 
clinic with a nephrologist, diabetologist, and a podiatrist. At the first sign of lower limb 
ischaemia, patients should be assessed by a vascular surgeon. 
7.2 Hyperparathyroidism 
Diabetics undergoing dialysis developed secondary hyperparathyroidism at a slower rate 
than nondiabetics and this may predispose to adynamic bone disease in which there is a 
reduced rate of bone turnover without an excess of unmineralized osteoid. The reduced 
bone formation may lead to enhanced deposition of aluminium at the ossification front. 
Diabetics appear to accumulate aluminium more readily and are more susceptible to bone 
pain and fractures related to aluminium bone disease, which may also be unmasked by 
parathyroidectomy. 
The diabetic uraemic should be treated with calcium-containing phosphate binders, which 
are ingested with every meal (500–1000 mg according to the amount of food). Aluminium-
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screened for methicillinresistant Staphylococcus. Diabetics are more prone to urinary tract 
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containing phosphate binders should be avoided because of possible aluminium intoxication. 
Vitamin D supplementation (e.g. 10000 U 25-(OH) vitamin D3 once weekly) is recommended. 
Serumphosphate control is important not only to prevent renal bone disease, but to prevent 
stiffness of the large arterial vessels. Increased stiffness of the aorta (36) is associated with 
reduced survival in end-stage renal disease and vascular stiffness is correlated with the 
increase in serumphosphate. 
8. Peritoneal dialysis (PD) 
8.1 Continuous ambulatory peritoneal dialysis (CAPD), continuous cycling peritoneal 
dialysis (CCPD), in diabetic patients 
CAPD has both medical and social benefits and most patients with diabetes are eligible for 
it. This technique enable patients to stay at home, where they can rapidly be taught the 
home dialysis regime and allows flexibility in treatment. The medical benefits of CAPD 
include slow and sustained ultrafiltration and a relative absence of rapid fluid and 
electrolyte changes and preservation of residual renal function. 
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Table 5. Comparison of dialysis options for the diabetic patient (37, 38) 
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In CAPD the major osmotic agent for water removal is glucose. It is therefore of note to 
consider an extra amount of glucose (approximately 600–800 kcal) per treatment-day in the 
uraemic diabetic. Insulin dosage has to be adjusted. 
Some authors propose that insulin be administred via the CAPD fluid. This route of 
application is not without difficulties, because adsorption of insulin into the CAPD bag and 
possible infection by installation of insulin into the bag are possible.  
In table 6 are given a comparison of dialysis options for the diabetic patient. 
8.2 Assessing the quality of dialysis in CAPD 
Adequacy of dialysis is an important issue in CAPD as well as in HD. According to the 
DOQI guidelines, which are based on numerous studies (37), a weekly Kt/V of 2 or even 
more (weekly peritoneal creatinine clearance of more than 70 l) is nowadays considered an 
adequate dose of dialysis. In most patients this is only achievable when a certain amount of 
peritoneal fluid (more than 50 l/week) and a considerable residual renal function are 
combined. This has two implications: a) CAPD in diabetic patients should be started early 
(as in haemodialysis, at a creatinine clearance of approximately 20 ml/min); and b) residual 
renal function has to be monitored vigorously. If there is substantial fall in residual renal 
function (below 5 ml/min), in many cases adequate peritoneal dialysis is impossible. 
Inadequate PD, has a high mortality rate and patients must be taken off PD and either 
transferred to HD or, if possible, transplanted. 
8.3 Outcome of patients on PD (CAPD / CCPD) 
CAPD / CCPD appears to be associated in different evaluations with different outcomes in 
diabetics. The data from the United States Renal Data System (USRDS) registry indicate that, 
within the first 2 years of therapy, outcomes were superior to those for patients on HD. The 
risk of all-cause death for female diabetics aged >55 years in contrast, was 1.21 (confidence 
interval 1.17–1.24) for CAPD / CCPD, and in cause-specific analyses, these patients had a 
significantly higher risk of infectious death (39). This was confirmed by data from the 
Lombardy Registry but interpreted as a result of a hidden negative selection of patients (40). 
In a single-centre evaluation, HD and PD patients had similar survival, whereas the elderly 
(> 75 years) had a better survival on CAPD (41). Data from a Canadian Registry did not 
show any difference between the modalities, but a better survival for patients on PD (42). 
These discrepancies relate most probably to differences in clinical and demographic setting, 
patient populations, study design, statistical methods, and interactions between the dialytic 
modality effect and various other covariables. 
8.4 Renal and pancreas transplantation 
Renal transplantation is a safe and effective treatment modality for diabetic subjects with 
ESRD. Studies have shown that besides the improvement in quality of life, there is also 
posttransplantation better survival in uraemic patients (43, 44, 45). Simultaneous pancreas 
and kidney transplantation can be recommended as it prolongs survival in patients with 
diabetes and end-stage renal failure (46, 47) compared with kidney transplantation alone. In 
another series, patient or graft survival in diabetic patients receiving living-related donor 
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containing phosphate binders should be avoided because of possible aluminium intoxication. 
Vitamin D supplementation (e.g. 10000 U 25-(OH) vitamin D3 once weekly) is recommended. 
Serumphosphate control is important not only to prevent renal bone disease, but to prevent 
stiffness of the large arterial vessels. Increased stiffness of the aorta (36) is associated with 
reduced survival in end-stage renal disease and vascular stiffness is correlated with the 
increase in serumphosphate. 
8. Peritoneal dialysis (PD) 
8.1 Continuous ambulatory peritoneal dialysis (CAPD), continuous cycling peritoneal 
dialysis (CCPD), in diabetic patients 
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In CAPD the major osmotic agent for water removal is glucose. It is therefore of note to 
consider an extra amount of glucose (approximately 600–800 kcal) per treatment-day in the 
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application is not without difficulties, because adsorption of insulin into the CAPD bag and 
possible infection by installation of insulin into the bag are possible.  
In table 6 are given a comparison of dialysis options for the diabetic patient. 
8.2 Assessing the quality of dialysis in CAPD 
Adequacy of dialysis is an important issue in CAPD as well as in HD. According to the 
DOQI guidelines, which are based on numerous studies (37), a weekly Kt/V of 2 or even 
more (weekly peritoneal creatinine clearance of more than 70 l) is nowadays considered an 
adequate dose of dialysis. In most patients this is only achievable when a certain amount of 
peritoneal fluid (more than 50 l/week) and a considerable residual renal function are 
combined. This has two implications: a) CAPD in diabetic patients should be started early 
(as in haemodialysis, at a creatinine clearance of approximately 20 ml/min); and b) residual 
renal function has to be monitored vigorously. If there is substantial fall in residual renal 
function (below 5 ml/min), in many cases adequate peritoneal dialysis is impossible. 
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8.3 Outcome of patients on PD (CAPD / CCPD) 
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diabetics. The data from the United States Renal Data System (USRDS) registry indicate that, 
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8.4 Renal and pancreas transplantation 
Renal transplantation is a safe and effective treatment modality for diabetic subjects with 
ESRD. Studies have shown that besides the improvement in quality of life, there is also 
posttransplantation better survival in uraemic patients (43, 44, 45). Simultaneous pancreas 
and kidney transplantation can be recommended as it prolongs survival in patients with 
diabetes and end-stage renal failure (46, 47) compared with kidney transplantation alone. In 
another series, patient or graft survival in diabetic patients receiving living-related donor 
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kidney transplants or simultaneous pancreas and kidney transplants were not different, 
whereas unadjusted graft and patient survival rates in diabetic recipients (older and longer 
on dialysis) of cadaveric renal transplant were significantly lower than in the other group 
(48). 
Despite these encouraging data, acturarial patient survival post-transplant is less favourable 
in diabetes compared to other primary renal diseases. It is indispensable to examine a 
diabetic uraemic thoroughly for vascular complications and infectious foci before the patient 
qualifies for the transplant waiting list (49). 
Living related donor graft survival is superior to cadaveric donor grafts in diabetics (80 
versus 64%, 5-year survival) as in nondiabetics. The higher mortality rate seen in cadaveric 
graft recipients is probably a consequence of a higher cumulative burden of 
immunosuppression and co-morbidities (50, 51). The introduction of improved 
immunosuppressive agents should further improve patient and graft survival both in the 
diabetic and nondiabetic population. 
Survival of the diabetic patient ranges from 45 to 75% at 5 years. This is significantly lower 
than in nondiabetic renal transplant recipients and is a consequence of cardiovascular 
disease: 36% of diabetic transplant recipients die from cardiovascular disease (51, 52). There 
is also an increased risk of death from infection, cerebrovascular disease, and peripheral 
vascular disease compared with nondiabetic graft recipients. The pretransplant presence of 
any vascular disease is reported to have a significant effect on mortality in diabetis 
transplant recipients, especially preexisting cardiac or peripheral vascular disease. Although 
patient survival is still suboptimal compared with nondiabetic subjects, it is better than that 
seen with dialysis. Transplantation is also associated with improved rehabilitation and a 
better quality of life than dialysis. 
8.5 Pretransplant assessment 
Most important is the vascular tree evaluation, the Achilles’ heel of every successful 
transplantation procedure. Careful evaluation of pelvic and lower extremily arteries must be 
performed. Non-invasive methods (e.g. Doppler and Duplex techniques) as well as invasive 
procedures (e.g. angiography) may be applied. Plain radiography on the pelvis documents 
the magnitude of media calcification in the uraemic diabetic. 
Coronary artery disease is an important issue in diabetic patients on dialysis. Non-invasive 
testing is often non substantial and coronary angiography is still the most helpful procedure 
to rule out severe coronary stenosis in this patient population. 
Additional information on cardiac valves are no less important, since aortic stenosis is a 
common problem in dialysis patients. 
Before transplantation, peripheral vascular surgery is mandatory, particularly on the 
ipsilateral side of the graft, to avoid post-transplant circulatory complications of the lower 
extremities. 
Cardiac surgery (bypass or valve replacement) is nowadays a common procedure in non-
diabetic and diabetic patients with an in-hospital mortality rate of 5.4%, which is roughly 
comparable to those of non-uraemic cardiac patients. 
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Chronic infections are common in diabetic patients and several sites of infections in diabetic 
patients have to be considered. Infection of the native kidneys may be due to renal calculi or 
papillary necrosis and secondary obstruction, and infection of the bladder is often due to 
multiresistant bacteria. 
Cholecystolithiasis is common in diabetics and recurrent cholecystitis should be an 
indication for cholecystectomy. Uraemic patients often suffer from chronic constipation and 
colonic diverticula are common in female diabetic patients, gynaecological infections or 
tumours must be excluded by bacteriological work-up and cytology. 
9. Post-transplantation in diabetics 
9.1 Hypertension 
Approximately 80–90% of adult renal transplant recipients develop hypertension post-
transplantation (52, 53). This incidence is no different in diabetics. Hypertension is a major 
risk factor for post-transplant cardiovascular disease and should be very well controlled in 
the diabetic. 
9.2 Hyperlipidemia 
Hypercholesterolaemia and hypertriglyceridaemia following renal transplantation have 
been reported. Increased total serum cholesterol is usually from increases in low-density 
lipoprotein (LDL) cholesterol (74% of patients) (53.) Many patients also have elevated levels 
of triglyceride (29%) and very low-density lipoprotein (VLDL) cholesterol, especially in the 
presence of proteinuria and graft dysfunction. High density lipoprotein (HDL) cholesterol 
levels are normal or may be reduced in up to 10% of transplant recipients and the 
composition of HDL may be abnormal, leading to a reduced cardioprotective effect. The use 
of diet and pharmacologic approaches to treat hyperlipidemia is reasonable. 
9.3 Infection 
Diabetics are at increased risk of infection following transplantation. As well as the effects of 
immunosuppression, which are similar to those in nondiabetic patients, factors specific to 
diabetics include impaired chemotaxis, increased colonization, and the effects of 
hyperglycaemia on host defences. Cell-mediated immunity is essentially normal in 
diabetics. Diabetics are at increased risk of foot infections and fungal infections, especially 
candidiasis and mucormycosis. Urinary tract infections are more common in diabetic 
transplant recipients and often associated with glycosuria and urinary stasis as a result of 
poor bladder emptying. In this situation, antibiotic prophylaxis is often required. 
9.4 Diabetic control and continuing complication of diabetes 
Glycaemic control remains an important post-transplantation factor affecting the 
development of macrovascular disease and the development of recurrent disease. A number 
of factors result in altered blood glucose homeostasis. Corticosteroid therapy and 
cyclosporin (cyclosporin A) alter blood glucose control and insulin requirements. 
Cyclosporine and, particularly, tacrolimus may lead to de novo diabetes. Improved renal 
clearances may also change post-transplantation insulin requirements. 
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9.5 Recurrent diabetic nephropathy 
Lesions consistent with diabetic nephropathy develop in almost all grafts, with basement 
membrane thickening and mesangial expansion reported after 2 years and hyalinization of 
arterioles after 4 years. The development of nodular glomerulosclerosis is, however, rare in 
the transplant. 
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In the future, new techniques such as insulin gene manipulation in autologous cells (e.g. 
myoblasts, hepatocytes or fibroblasts) or islet cell transplantation will be the procedure of 
choice. Such a graft is currently technically feasible in patients who are recipients of other, 
usually renal, grafts. Another possibility is to graft encapsulated xeno-islets, protected 
against immune attack by encapsulation in a biocompatible membrane. 
Comparison of ESRD options for diabetics patients are given in table 6 (54). 
11. Diabetics on dialysis in the Republic of Macedonia 
Today the nephrologists are challenged both to control the underlying diabetic disease and 
also to provide an adequate renal replacement therapy. On the other hand, it has to be 
stressed that treatment of these patients and DM complications is very expensive. For 
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example, in USA the cost of treatment of these patients per year was estimated to about 100 
billion dollars, which is more than the whole health budget of a country like Italy (health 
budget estimated for 2001). Moreover, in USA around 2 billion dollars are being spent on 
dialysis treatments [55]. Recently performed, large epidemiological studies have 
demonstrated that CV morbidity and all cause mortality can be reduced with strict 
glycaemic and blood pressure control and with the use of anti-angiotensine agents and also 
lipid lowering agents [56-60]. Certain factors like age, time on dialysis, vascular access 
complications, co morbidities, type of dialysis membrane, time of dialysis and others have 
been identified to correlate with the survival of the patients on dialysis [61, 62]. These factors 
assume even greater importance in diabetics. Biocompatible membranes, ultrapure dialysis 
fluid and diffuse - convective techniques have also been promoted to reduce cardiovascular 
instability [63, 64] and to minimize the injuries of the excessive oxidative stress inherent in 
uremia and the dialysis treatment.     
In Republic of Macedonia (RM) in last two decades there was an increase of number of 
diabetic patients. The number of patients with diabetic nephropathy progressing to the 
point of need for renal replacement therapy and renal transplantation is also increasing [65- 
67]. Given the fact of lack of data and valuable epidemiological studies in these patients, we 
performed a nation wide study with the aim of defining prevalence of these patients in RM, 
determining the standards of care in diabetics in term of methodological approach, dialysis 
and drug treatment and analysis of these patients on dialysis. The aim of the study was to 
make a closer observation in all dialysis centers in 2002 in the country and to compare data 
with those obtained 2006. 
11.1 Patients and methods 
Data were collected from medical histories of diabetic patients on dialysis in all dialysis 
centers in Republic of Macedonia by using a specially developed questionnaire for this 
purpose. Date of 31 December for 2002 and 2006 year was selected as a “critical day” for 
data collection. Besides demographic data (name, surname, sex, date of birth and 
profession), data for cigarette smoking and alcohol consuming were collected as well as type 
of diabetes (family history for diabetes, therapy, dose and type of the insulin intake, 
duration of diabetes and kidney disease), hypertension (family history, duration, therapy), 
other renal diseases including diabetic nephropathy, as well as laboratory findings (residual 
diuresis, blood glucose level, HbA1C, microalbuminuria, proteinuria, urea, creatinin blood 
level, creatinin clearance, thryglycerides (TG) blood level, cholesterol, HDL and LDL 
cholesterol, hepatitis B virus serological markers (HBs Ag, anti HBc-Ig G) , hepatitis C virus 
serological markers (anti HCV) and human imunodeficiency virus antibodies (anti-HIV); 
type of dialysis (bicarbonate or acetate); duration and frequency of dialysis sessions, 
medications used, hypoglycemic events, number of hospitalizations, complications: 
cardiovascular events (pectoral angina, heart attack, cerebrovascular insult), hypertension, 
peripherial vascular artheriopathy (diabetic foot), diabetic retinopathy, infection of the 
urinary system); cause of death – if patient died. The progression of other diabetic 
complications was obtained by roentgenograms, ECG, echocardiography and examination 
of eye fundus. Special attention was paid to data on vascular access (type of central venous 
catheter, A-V fistula, graft, complications on vascular accesses infection/thrombosis, other 
complications, as well as number of created vascular accesses). 
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Patients were treated according to the recommendations introduced by University 
Nephrology Clinic - Skopje, Faculty of Medicine, “Ss. Cyril and Methodius” University in 
Skopje, as a reference center for dialysis patients in Republic of Macedonia [68]. Duration of 
dialysis sessions was approximately three times four hours per week divided into three day 
sessions in same week. Low flux polysulphonic membranes, were used. Water was prepared 
by a reverse osmosis and blood flow in most of the cases was 250-280ml/min, whereas 
dialysis flow was usually 500 ml/min. Dialysis machines used were GAMBRO types AK 10, 
AK 100 and AK 95. There was no reuse of the dialysis filters. A low salt intake diet and 
malnutrition protective protein intake of 1gr/kg diet were recommended to all patients. 
11.2 Results  
Total number of dialysis patients in RM was 1114 and 1074 in 2002 and 2006 year, 
respectively (Figure 1, Table 7). There were 109 (9.78%) diabetic patients on dialysis, 60 
(55%) male and 49 (45%) female in 2002. A slight increase of diabetics was determined in 
2006, namely there were 115 (10.7%) diabetic patients on dialysis, 74 (64.35 %) male and 41 
(35.65%) female in 2006 year, as to compare with 2000 when total number of dialysis 
patients was 1010 and number of diabetics on dialysis was 103 (10.19%) [65, 66] (Figure 2). 
There was a difference in distribution of diabetics on dialysis trough different dialysis 
centers in RM for 2002 and 2006 year (Table 8 and Table 9), respectively. Diabetics on 
dialysis were from 3% in Veles, to 21 % in Kavadarci for 2002. Similar diversity was 
obtained in 2006:  from 2.43% in Skopje Military Hospital Dialysis Center to 22.07% in 
University Nephrology Clinic - Skopje. In 2002 most of the diabetics on dialysis (31 patients) 
were registered in University Nephrology Clinic - Skopje and in the Nephrology Institute - 
Struga (15 patients) similarly like 2006 when most of diabetics on dialysis (34 patients) were 
in University Nephrology Clinic - Skopje and in Nephrology Institute - Struga (16 patients). 
The mean age of all diabetics on dialysis in 2002 was 58±10.29 years (56±10.49 for males and 
60±9.56 for females), and in all diabetics on dialysis in 2006 it was 56.5±10.71 years 
(55.06±8.82 for males and 57.92±12.56 for females) (Table 1). In 2002, 19 (17.43%) patients 
had DM1, while 90 (82.57%) patients had DM2. 28 (25.68%) patients were treated with oral 
anti-diabetic drugs and 62 (57.21%) patients were on insulin. In 2006, 15 (13.04%) patients 
had DM1 while 100 (86.96%) patients had DM2. 31 (26,96 %) of diabetics were treated with 
oral anti-diabetic drugs and 69 (60%) were on insulin. The mean age of DM1 patients in 2002 
was 47±11.6 years, with a diabetic history of 16.2±9.7 years, while the mean age of DM1 
patients in 2006 was 45±7.32 years, with a diabetic history of 24.07±11.07 years. The mean 
age of DM2 patients in 2002 was 60.37±8.33 with a diabetic history of 13.4±8.1 years and the 
mean age of DM2 patients in 2006 was 61.14±10.23 years with a diabetic history of 
14.18±8.42 (Table 1). The mean dose of insulin intake was 9.5±6.63IU and 10.85±9.29IU, for 
2002 and 2006 respectively. In 2002, 21% of diabetics on dialysis were smokers, 13% 
consumed alcohol, while 15% were engaged in sport, as compared to 2006 when 17.39% of 
diabetics on dialysis were smokers, 5.22% consumed alcohol and 3.48% were doing sport.  
The mean duration of dialysis therapy in 2002 for DM type 1 patients was 54.3±44.4 months, 
whereas in DM type 2 was 34.3±36.3 months. The mean duration of dialysis therapy in 2006 
for DM 1 patients was 76.29±74.96 months, whereas in DM 2 was 33.68±43.24. The mean 
body mass index (BMI) in 2002 was 26.4±3.28  kg/m2 and 25.5±2.92 kg/m2 in DM1 and DM2 
patients, respectively. In 2006 BMI was 23.49±4.74 kg/m2 and 24.77±3.70 kg/m2 in DM1 and 
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DM2 patients, respectively. There was a need for urgent dialysis treatment and a first 
dialysis session a trough femoral venous catheter in 90.1% and 94.4% of diabetics on dialysis 
in 2002 and 2006, respectively.  After a period of patient adaptation to dialysis procedure 
and in order to eliminate possible bacterial infection trough the femoral venous catheter, an 
arterio venous fistula (AVF) was created as a permanent vascular access for dialysis. 
Preventive AVF was created in 9.9% and in 5.6% of diabetics on dialysis in 2002 and 2006 
respectively. Thrombosis of the newly created AVF was detected in 41% and 24.35% in 2002 
and 2006 respectively, whereas AVF infection was detected in 58.6% of the patients in 2002. 
In 2002 there were 19.26% of patients on acetate dialysis and 80.74% on bicarbonate dialysis 
while in 2006 there were no patients on acetate dialysis, and all 110 diabetic patients 
(95.65%) were on bicarbonate dialysis modality (Figure 3). 
It has to be stressed that a high rate of HCV infection was noticed in diabetics on dialysis, 
57% and 37.39% of these patients were anti HCV positive in 2002 and in 2006, respectively. 
81% and 86.09% of the patients were treated with erytropoethin in 2002 and 2006, 
respectively. In both years hypertension (HTA) was the most frequent co-morbid state: in 
2002, 91% diabetics on dialysis had a HTA before dialysis program and following the start of 
dialysis sessions 40.54% (Table 10). Furthermore, in 2006 HTA was registered in 47.74% of 
diabetics before dialysis, and in 60% of patients during dialysis. Finally, family history for 
HTA was noticed in 43% and 29.57% patients, in 2002 and 2006, respectively. The most 
frequent cardiovascular co-morbidity in these patients for the year 2002 and 2006 are shown 
in Table 10. 
 
Fig. 1. Total number of patients on dialysis and diabetics on dialysis. 
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 2002 year 2006 year 
N° dialysis patients 1114 1074 
N° of diabetics 109 (9.78%) 115 (10.7%) 
Male Pts 60 (55%) 74 (64.35%) 
Female Pts 49 (45%) 41 (35.65%) 
Mean age 58±10.29 56.5±10.71 
Mean age male 56±10.49 55.06±8.82 
Mean age female 60±9.56 57.92±12.56 
Patients with DM1 19 (17.43%) 15 (13.04%) 
Mean age DM1 47±11.6 45±7.32 
DM history DM1 (years) 16.2±9.7 24.07±11.7 
DM1 dialysis history (months) 54.3±44.4 76.29±74.96 
Patients with DM2 90 (82.57%) 100 (86.96%) 
Mean age DM2 60.4±8.33 61.14±10.23 
DM history DM2 (years) 13.4±8.1 14.18±8.42 
DM2 dialysis history (months) 34.3±36.3 33.68±43.24 
On OADD 28 (25.68%) 31 (26.96%) 
On insulin 62 (57.21%) 69 (60%) 
Dose of insulin (IU) 9.5±6.63 10.85±9.29 
BMI in DM1 kg/m2 26.4 25.5 
BMI in DM2 kg/m2 23.49±4.74 24.77±3.70 
First dialysis on FVC (%) 90.1 94.4 
Preventive AVF (%) 9.9 5.6 
Thrombosis of first AVF (%) 41 24.35 
Anti HCV positive (%) 57 37.39 
DM1 - Diabetes mellitus type 1, DM2 -  Diabetes mellitus type 2 ; OADD – Oral antidiabetic drugs ;  
BMI – Body mass index; FVC – femoral vascular cathether ; AVF – Arterio venouse fistula 
Table 7. Characteristics of diabetics on dialysis in Republic of Macedonia 
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Fig. 2. Oscillations in the total number of dialysis patients and diabetics on dialysis period 
2001 – 2006 in RM 
 
 Dialysis center N° of Dialysis pts N° of Diabetics % DM 
University Clinic of Nephrology, Skopje 201 31 15.42 
Institute of Nephrology, Struga 204 15 7.35 
Тetovo 63 9 14.28 
Gevgelija 28 1 3.57 
Debar 15 2 13.30 
Gostivar 53 4 7.54 
Кočani 24 3 12.50 
Kumanovo 60 6 10.00 
Delčevo 31 4 12.90 
Strumica 46 4 8.69 
Prilep 60 6 10.00 
Renal Replacement Therapy  
in Uremic Diabetic Patients – Experience from The Republic of Macedonia 
 
259 
Bitola 38 4 10.52 
Štip 49 3 12.50 
Železara 125 5 4.00 
Military hospital, Skopje  40 3 7.5 
Veles 39 1 2.56 
Kavadarci 38 8 21.50 
 Total 1114 109 9.78 
Table 8. Distribution of dialysis patients by dialysis centers in RM, year 2002 
 
 Dialysis center N° of Dialysis pts N° of Diabetics % DM 
University Nephrology Clinic, Skopje 171 32 19.88 
Nephrology Institute, Struga 171 16 9,36 
Тetovo 69 11 15,94 
Gevgelija 30 2 6,67 
Кriva Palanka 26 3 11,54 
Gostivar 46 4 8,70 
Кočani 31 1 3,23 
Kumanovo 49 7 14,29 
Delčevo 32 7 21,88 
Strumica 47 3 6,38 
Prilep 56 6 10,71 
Bitola 43 2 4,65 
Štip 60 4 6,67 
Železara 162 12 7,41 
Military hospital 40 2 5 
Veles 41 1 2,44 
 Total 1074 115 10,71 
Table 9. Distribution of dialysis patients by dialysis centers in RM, year 2006 
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Fig. 3. Use of acetate and bicarbonate haemodialysis (HD) in 2002 and 2006 
 








Pectoral angina 7.2% 19% 1.12% 3.4% 
Heart attack 5.4% 5.4% 1.12% 4.43% 
Intermitent 
claudication 
10% 10% 2.25% 11.3% 
Cerebrovascular 
attack 
7% 8% 8.7% 9.57% 
Hypertension 
(HTA) 
91% 40.54% 47.74% 60% 
Table 10. Distribution of the most frequent cardiovascular co-morbidity in diabetics on 
dialysis in 2002 and 2006. 
11.3 Discussion 
In the present analysis we have demonstrated an increase in the prevalence on diabetic 
dialysis patients in certain dialysis centers of RM. It has been reported before that the annual 
incidence of patients who initiate dialysis is constantly increasing in all industrialized 
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countries and a significant part of this increase is explained by the influx of diabetic patients 
on dialysis [68, 69]. This study shows the importance of the need to increase the number of 
specialists nephrologists in RM who will take an important role in healthcare of these 
patients in collaboration with endocrinologists and other specialists practitioners.  
We have previously shown that the number of diabetics on dialysis in RM enlarges slowly 
but progresively [65-68]. In current analysis, beside the fact that mean total prevalence of 
DM was just slightly increased as compared to our previous studies [66], we show that there 
is an important difference in prevalence of diabetics on dialysis between different dialysis 
centres. In certain dialysis in RM the prevalence of diabetics reached a level similar with that 
of Northern European countries [69] while in others it was lower than expected. This 
diversity in the number of diabetics on dialysis could be explained by the fact that RM is a 
developing country, geographically European with predominance of Mediterranean diet, 
and this difference could be due to a numerous economical, sociological, genetic, 
environmental and nutritional factors in different parts of the country.  
We included in the study all diabetic patients on dialysis in RM, without differentiating 
diabetics who started dialysis because of diabetic nephropathy from those who started 
dialysis with other renal pathology. We show that diabetics with CKD in most of the cases 
were diagnosed at the University Nephrology Clinic - Skopje, and diagnosis most often was 
in developed phase of CKD. It has been shown that these patients present an extraordinary 
acceleration of all clinical complications and it is a well known fact that accelerated 
development of terminal uraemia constitutes a devastating clinical event [1, 55, 69, 70, 71]. 
Phase of the disease when diabetes is installed is accompanied usually with a certain variety 
of cardiovascular complications, predominatelly as a result of a long-term hypertension, 
nephrotic syndrome and infections. Metabolic and blood vessels modifications induce 
constant overweight and problems with vascular access leading to quality of life decrease in 
these patents. Consequently, as it has been showen by the others and us, the survival rate 
of diabetics on dialysis is significantly reduced, Figure 4 [72, 73]. When compared with 
other dialisys patients it has been shown that the best survival rate was observed in those 
with balkan endemic nephropathy and adult polycystic kidney disease. This observation 
goes in line with other studies confirming that in diabetics on dialysis the quality of life is 
impaired and survival is significantly curtailed [1, 74, 26]. It has been shown also that the 
clinical results depend on both the severity of complications present at the initiation of 
dialysis and on capacity to slow its evolution during dialysis [74]. In current analysis we 
did not evaluate the effect of patient therapies on the incidence of complications and on 
patient mortality. 
Besides the fact that most of the nephrologists and internal medicine specialists in RM are 
aware of the importance of the timely initiation of dialysis for diabetic patients, this analysis 
underlines the fact that dialysis initiation often starts in emergency conditions and most of 
the patients start dialysis program at University Nephrology Clinic – Skopje trough urgently 
and temporary placed femoral venous catheter. We found that almost 90% of first dialysis 
sessions in 2002 as well as in 2006 were started in emergency conditions, confirming that 
diabetics are reffered to the nephrologists late in the course of CKD. Analysing why this 
happens, we think that a part of responsibility for the delay of dialysis initiation could be 
explained by patient mentality but it is also important to stress the important role of medical 
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countries and a significant part of this increase is explained by the influx of diabetic patients 
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personnel in preparing the patient for dialysis. We have to underline insufficient 
coordination between physicians such as general practitioners, internists, endocrinologists 
and nephrologists, and lack of their influence on patient dialysis reality acceptance. It is also 
important to notice that in two dialysis centres where the prevalence in diabetics on dialysis 
is much higher, dialysis patients are followed by educated and well trained nephrologists. 
In these centres accessibility of other specialties practitioners is higher as compared to 
dialysis centres where patients are followed by internal medicine specialists and other 
specialized doctors are also accessible. This might explain the high difference in number of 
diabetic’s among different dialysis centers and it also underlines the need for more trained 
nephrologists in the country and their more important implication in follow up of diabetics 
on dialysis.  
 
Fig. 4. Distribution of survival (Kaplan Meier test) of dialysis patients, distribution by basic 
renal disease (University Clinic of Nephrology - Skopje); abbrevations: Diabetes Mellitus 
Insulin Independent – DM1,  Diabetes Mellitus Insulin Dependent DM2, Arterial 
Hypertension – HTA, Malignant HTA – HTA mal., Adult Polycystic Renal Diseases-APKD, 
Balkan Endemic Nephropathy – BEN). 
It has been shown previously that a very large difference exists in the ratio of DM2 to DM1 
on dialyisis in different European countries and among different regions in a same country 
[1]. A recent study of Italian population showed that most diabetics on dialysis were DM2 
patients, probably because of high prevalence of this disease among the general population 
[75]. In our study we found that the ratio of DM2 to DM1 patients was approximately 4,3 : 1. 
As expected, patients with DM2 were older, with higher body weight and body mass index. 
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Epidemiological studies has also shown that cardiovascular morbidity and mortality can be 
reduced with pharmacological therapy that normalizes blood pressure values and controls 
hyperglicemia, hyperlipidemia, platelet agreggation and hypercoagulability [56-58]. 
Proportion of diabetics od dialysis treated with ACE inhibitors and / or angiotensin 
receptor blockers (ARB), beta blockers and antiplatelat drugs was still quite low as 
compared to propositions of the guidelines. There was a negligible number of patients 
treated with lipid lowering agents.  
In conclusion, the present study underline the importance of an interdisciplinary 
approach in early diagnosis and treatment of diabetes, diabetic nephropathy and 
treatment of diabetics on dialysis, as well as importance of introducting preventive 
measures for progression of CKD in these patients. In most dialysis centres in the 
Republic of Macedonia prevalence of diabetics on dialysis did not increase in the period 
from 2002 to 2006 where these patients were followed mostly by internal medicine 
specialists. Frequency of complications was increased in DM2 compared to DM1 dialysis 
patients. Blood glucose level control is important as well as a strict control of the blood 
preasure. Bicarbonate dialysis is a dialysis of choice with an optimal duration of 
minimun 12 hours per week. More nephrologists need to be involved in the dialysis 
centres and together with an improvement of colaboration between general practitioners, 
internternal medicine doctors, endocrinologists, nephrologists, cardiologists, 
ophtalmologists, neurologists in order to improve health care for these patients. This 
kind of studies should be carried out on a regular basis in Republic of Macedonia. 
12. Could we prevent or postpone diabetic kidney disease and development 
of chronic renal failure? 
The World Kidney Day, 11 March 2010 was devoted to diabetic kidney disease, under the 
auspices of the International Society of Nephrology (ISN) and the International Federation 
of Kidney Foundations (IFKF), together with the International Diabetic Federation (IDF).  
R.C. Atkins and P. Zimmet in their paper: Diabetic kidney disease: act now or pay later [76] 
point out the importance of a better understanding of the global pandemic of type 2 diabetes 
and diabetic kidney disease. They suggest that it is necessary to alert governments, health 
organizations, providers, doctors and patients to the increasing health and socioeconomic 
problems due to diabetic kidney disease and its sequels: end-stage kidney disease requiring 
dialysis, and cardiovascular death. It should be emphasized that its management involves 
prevention, recognition and treatment of its complications. 
The most important measure is primary prevention of type 2 diabetes. It will require 
massive lifestyle changes in the developing world, supported by strong governmental 
commitment to promote lifestyle and societal change. 
In the Republic of Macedonia there are about 100,000 patients with diabetes mellitus type 1 
and 2; 85–95% have diabetes mellitus type 2. Around 28,000–30,000 patients are on therapy 
with insulin. 
Some of them are candidates for development of diabetic kidney disease. 
We should develop a strategy to detect early diabetic kidney disease by screening for 
albuminuria as well as reduced glomerular filtration rate. It is very important to introduce 
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approach in early diagnosis and treatment of diabetes, diabetic nephropathy and 
treatment of diabetics on dialysis, as well as importance of introducting preventive 
measures for progression of CKD in these patients. In most dialysis centres in the 
Republic of Macedonia prevalence of diabetics on dialysis did not increase in the period 
from 2002 to 2006 where these patients were followed mostly by internal medicine 
specialists. Frequency of complications was increased in DM2 compared to DM1 dialysis 
patients. Blood glucose level control is important as well as a strict control of the blood 
preasure. Bicarbonate dialysis is a dialysis of choice with an optimal duration of 
minimun 12 hours per week. More nephrologists need to be involved in the dialysis 
centres and together with an improvement of colaboration between general practitioners, 
internternal medicine doctors, endocrinologists, nephrologists, cardiologists, 
ophtalmologists, neurologists in order to improve health care for these patients. This 
kind of studies should be carried out on a regular basis in Republic of Macedonia. 
12. Could we prevent or postpone diabetic kidney disease and development 
of chronic renal failure? 
The World Kidney Day, 11 March 2010 was devoted to diabetic kidney disease, under the 
auspices of the International Society of Nephrology (ISN) and the International Federation 
of Kidney Foundations (IFKF), together with the International Diabetic Federation (IDF).  
R.C. Atkins and P. Zimmet in their paper: Diabetic kidney disease: act now or pay later [76] 
point out the importance of a better understanding of the global pandemic of type 2 diabetes 
and diabetic kidney disease. They suggest that it is necessary to alert governments, health 
organizations, providers, doctors and patients to the increasing health and socioeconomic 
problems due to diabetic kidney disease and its sequels: end-stage kidney disease requiring 
dialysis, and cardiovascular death. It should be emphasized that its management involves 
prevention, recognition and treatment of its complications. 
The most important measure is primary prevention of type 2 diabetes. It will require 
massive lifestyle changes in the developing world, supported by strong governmental 
commitment to promote lifestyle and societal change. 
In the Republic of Macedonia there are about 100,000 patients with diabetes mellitus type 1 
and 2; 85–95% have diabetes mellitus type 2. Around 28,000–30,000 patients are on therapy 
with insulin. 
Some of them are candidates for development of diabetic kidney disease. 
We should develop a strategy to detect early diabetic kidney disease by screening for 
albuminuria as well as reduced glomerular filtration rate. It is very important to introduce 
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public education about the relationship between diabetes and kidney disease. There is a 
remarkable lack of awareness among patients about their condition. 
In our papers: Chronic Kidney Disease: a Hidden Epidemic [77] and Public Health Aspects of Renal 
Disease in the Republic of Macedonia 1983–2007 [78] we have shown a continuous increase in 
end-stage renal disease and renal replacement therapy (RRT) in the Republic of Macedonia. 
In 2002, we had 1,056 patients on RRT compared to 1,216 in 2005. In some dialysis centres 
20% of the patients on haemodialysis are diabetics. Our message was that there is an urgent 
need for a screening programme for the detection of Chronic Kidney Disease (CKD) in the 
Republic of Macedonia. Health authorities, nephrologists and general physicians should 
collaborate on the detection of CKD. 
“There is evidence that early therapeutic intervention in patients with chronic kidney 
disease or diabetes can delay the onset of complications and improve outcomes. For 
example, the UKPDS [79, 80], STENO-2 [81] and ADVANCE studies [82, 83, 84] all 
demonstrated that tight control of blood glucose level and blood pressure (and lipids in 
STENO-2) significantly reduced the incidence and progression of diabetic kidney disease. In 
people with type 2 diabetes, inhibition of the renin-angiotensin-aldosterone system using an 
angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) 
decreased the progression from normoalbuminuria to microalbuminuria [85] and slowed 
the development of ESRD [86]. Thus the use of an ACE inhibitor or ARB is now standard 
therapy for patients with diabetic nephropathy, as well as glucose, lipid and blood pressure 
control.” [76] 
12.1 How should we act now? 
We are going to repeat our message from 2008 [77]: “there is an urgent need for a screening 
programme for the detection of CKD” and we will add as well as of diabetic kidney disease 
in the Republic of Macedonia. 
We can follow the steps suggested by Atkins and Zimmet (76): 
“i.  prevention of type 2 diabetes; 
ii. screening for early diabetic kidney disease; 
iii. increasing patient awareness of kidney disease; 
iv. using medications of proven strategy” 
"The ultimate challenge is to get action from primary health care to all higher levels, from 
the individual patient, to those at risk, in various health jurisdictions, in all countries despite 
varying economic circumstances and priorities. The problem is a global one and yet requires 
action at a local level; prevention screening and treatment strategies; education, including 
increasing awareness both in diabetic patients and those at risk of developing diabetes; and 
health priorities and governments. Basic research and clinical trials searching for a new 
understanding and therapies must be supported." [76] 
In our country we should work harder on the prevention of diabetic kidney diseases, to stop 
or postpone the development of CKD and chronic renal failure with modern therapy and 
the need for RRT. 
Renal Replacement Therapy  
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